ahead curve annual report 2017 ahead curve environment constant technological disruption success hinge ability stay ahead curve strike ahead biocon broke pack 02 ahead curve annual report 2017 biocon limited w e evaluated prospect pitfall technology pioneer took eclectic scientific face market skepticism encouraged culture experimentation constantly acquired bet generate new knowledge new knowhow focused breakthrough plunged uncharted water innovation ran rd program innovationled biotechnology research bring new drug potential believed audacious wager change course disease making today would pay disproportionately tomorrow evenly spread risk reward sought right partner forged path chose capital intensive enduring relationship pursued researchintensive ipintensive incisive ip strategy create robust inherently long gestational time intellectual capital line product commercialization undaunted made countercyclical market place leadership investment took proactive step transient innovation king futureready equipped biocon stand ahead curve manage uncertainty committed make difference economic cycle global healthcare ahead curve 03 biocons strength derived r e g c c l r n n v e e n co e n robust infrastructure capability expertise proprietary technology based talent pool extensive global array expression platform pichia pastoris platform product development experience include microbial mammalian expression recombinant system protein robust analytical capability scientifically rigorous ethically 400member strong scientific anchored cuttingedge tool compliant stage gatebased team including md phd latest orthogonal approach structured preclinical clinical master degree holder drawn world class technology development strategy within india global biopharma organization product approved key strategic global regional globalscale complex biologics regulatory agency u partnership across novel manufacturing capability eu japan france brazil mexico molecule biosimilars turkey gulf country 04 ahead curve annual report 2017 biocon limited strong foundation process science enables development biologics economical scalability high productivity comprehensive presentation biologics across drug substance drug product liquid vial lyophilized vial cartridge prefilled syrinx delivery device reusable disposable prefilled pen wide presence marketing footprint across 120 country key strength 05 06 ahead curve annual report 2017 biocon limited b c n di f f e r e n tiat e p l e r n h e g l ba l p h ar c e uti c l pa c e among handful indian first listed pure play globally recognized pharma company working biopharmaceuticals company biopharmaceuticals enterprise area biologics india unique business model straddle product service extensive experience diversified portfolio biosimilar rd strategy cover early mid demonstrated expertise taking insulin analog antibody latestage novel asset two novel biologics five advanced stage development biosimilars lab market inhouse expertise across incisive intellectual property experience multiple global drug value chain pipeline strategy recognized several regulatory filing insulin includes proprietary national international award biosimilar antibody partnered program complex generic formulation key differentiator 07 motivation enter niche area strategy perceive potential collaborative model profitably smart moderate cost allows u share socially good widen patient access risk reward drug provide affordable development access advanced research partnership biopharmaceuticals extend global global patient footprint local population marketing alliance biocons business model woven around business philosophy unwavering commitment built around core commitment stringent value quality core quality control affordability reliability value compliance bestin innovation class global standard relentless focus obligation develop chronic disease space portfolio approach affordable blockbuster like diabetes cancer focused chronic drug potential autoimmune disease segment benefit billion inflammation integrating well validated patient targettoclinictocounter capability 08 ahead curve annual report 2017 biocon limited global biologics landscape present good opportunity biocon top 15 worldwide worldwide global pharma prescription drug biotechnology drug brand revenue market 2022 market 2022 projected 2016 forecasted grow grow 10 biologics u 11 trillion u 337 billion global biosimilars market 2020 projected u 25 billion u 35 billion emerging market market u action historically seen u eu japan payer regulatory high penetration defined regulatory level increased generic drug similar requirement political noise around trend could apply registration biosimilar drug pricing biosimilars product payer encouraging towards pushing contain cost acceptance biosimilars source genetic engineering biotechnology news evaluate pharma allied market research key opportunity 09 first indian company manufacture 1979 export enzyme u europe first biotechnology company india get iso 9001 1993 certification german authority rwtuv india first custom research service 1994 organization syngene set india first clinical research 2000 biocon organization clinigene set grown first indian company get u fda 2001 year approval manufacturing lovastatin c n e n ly investing 2004 first indian company submit dmf drug master file rhinsulin api u fda planning ahead first company globally commercialize rhinsulin curve 2004 manufactured pichia fermentation technology first biotech company india 2004 list indian stock exchange india first indigenously produced novel monoclonal antibody 2006 head neck cancer biomab egfr launched india 10 ahead curve annual report 2017 biocon park india first private corporate 2006 biotechnology sez became operational signed mylan one earliest partnership global 2009 pharma industry codevelopment biosimilars evertor india first generic everolimus treatment 2010 advanced renal cell carcinoma launched world first novel anticd6 monoclonal antibody psoriasis 2013 alzumab itolizumab launched india first indian biopharmaceuticals company venture 2013 exciting space sirnabased small interfering rna therapeutic partnership quark pharma first biosimilar trastuzumab approved anywhere 2014 world launched canmab india first biosimilar approved mexico per 2015 biocomparable approval pathway biocons insulin glargine first indian company launch biosimilar insulin glargine 2016 pen japan biocons insugen first locally manufactured biosimilar product 2017 approved sale malaysian drug regulator key achievement 11 f 1 7 g l n c e revenue profit year ebitda margin 40787 6121 28 h million h million rd spend gross eps employee 4019 31 9000 h million h business revenue mix geographic distribution 4 30 28 40 70 14 14 small molecule h16330 million international biologics h5793 million domestic branded formulation h5489 million research service h11604 million others h1571 million 12 ahead curve annual report 2017 biocon limited content chairperson review 14 branded formulation 54 qa ceo 22 global marketing 57 financial review cfo 28 research service 59 board director 34 enablers scientific advisory board 38 research development 62 core committee 39 quality 68 vision mission value 40 supply chain management 69 financial highlight 41 human resource 74 business segment review 44 environment health safety 77 biologics 46 corporate social responsibility biosimilars 47 biocon foundation 81 novel biologics 50 biocon academy 90 small molecule 52 financial report 93 content 13 chairperson review kiran mazumdarshaw chairperson 14 ahead curve annual report 2017 biocon limited dear shareholder era biologics global pharmaceutical industry noteworthy 10 top 15 drug sale 2016 biologics witnessing transformative change forecast 2022 biologics contribute 50 value biologic drug protein therapeutic top 100 drug product sold globally global sale biotechnology like antibody interleukin vaccine drug projected grow usd 337 billion 2022 derived microbial mammalian cell ushered paradigm shift getting ahead curve treating chronic disease targeted turn millennium biocon chose embark biologicsled therapy precision medicine pharmaceutical journey differentiated business strategy invested poised disrupt future disease ahead curve promising future targeted biologics management revolutionizing treatment chronic disease recognized indian pharmaceutical sector built company size audacious plan took plunge global scale leadership reverse believed would provide u head start overcrowded generic engineering expensive chemically market place decided take complex development manufacturing synthesized small molecule drug regulatory challenge inherent biologics confident produce cost effective generic capability stemmed knowledge expertize enzyme alternative earned technology started biotechnology business pursued label pharmacy innovation strategy rooted affordability leveraging india cost base world dominating traditional generic drug industry decade many set address unfolding opportunity choosing lead rather indian company race follow able transform scientific discovery advance create generic version biologic human healthcare generate incremental value shareholder drug biosimilars far biologics cutting edge complex make offer large global opportunity 2006 biocon earned distinction first company india launch novel biologic nimotuzumab humanized antiegfr epidermal biocon ahead pursuit develop growth factor receptor monoclonal antibody mab head neck cancer first wave biosimilars global patient market expand access number essential lifesaving biologic drug followed launch second novel biologic itolizumab facing patent expiry 2013 psoriasis patient india pathbreaking anticd6 mab also developing pipeline patented offered less aggressive dosing regimen longer treatment free biologics address unmet medical period need entered codevelopment partnership usbased mylan source portfolio biosimilars 2009 collaboration led launch genetic engineering biotechnology news world first biosimilar trastuzumab 2014 patient suffering evaluate pharma world preview 2016 chairperson review 15 her2positive metastatic breast cancer india gained access affordable version lifesaving drug rest emerging world put three recourse expensive innovator product advanced biocon mylan one longeststanding partnership global biosimilar asset biosimilars space leveraged mutual strength build one track anticipated largest diverse biosimilar pipeline spanning insulin analog regulatory approval monoclonal antibody developed market first block early mover biosimilars space put three advanced biosimilar asset track anticipated regulatory approval developed market address aggregate market opportunity usd 20 billion fy17 filed two biologics license application blas u three marketing authorization application maas eu first file regulatory application proposed biosimilar trastuzumab u eu positioned biocon mylan among first company able address critical need highquality biosimilar treat certain her2positive breast cancer u eu application biosimilar pegfilgrastim also accepted review u eu submitted marketing authorization application biosimilar bevacizumab indian drug regulator completing emerging markettargeted india clinical trial maa recently granted global clinical trial biosimilar adalimumab plaque psoriasis completed expect regulatory submission various geography start fy18 biosimilars development capability endorsed year publication heritage study prestigious journal american medical association jama study result confirmed efficacy safety 16 ahead curve annual report 2017 biocon limited immunogenicity proposed biosimilar trastuzumab codeveloped biocon mylan comparison reference product moving presentation study result american society clinical steadfastly towards oncology asco annual meeting chicago u european society aspiration medical oncology esmo congress copenhagen denmark 2016 providing insulin dr hope rugo appreciated immensely scientific community one five insulindependent consolidating market leadership people diabetes built market leadership insulin back global around world manufacturing scale moving steadfastly towards aspiration providing insulin one five insulindependent people diabetes around world achieved key milestone journey towards visionary goal launched readytouse disposable insulin glargine pen japan partner fujifilm pharma insulin glargine first biosimilar india launched japan also first biosimilar developed market confidence product gained among prescribers patient japan endorsed quality efficacy product enhanced brand biocons reputation across world also started commercial supply first overseas insulin manufacturing facility malaysia year recombinant human insulin rhinsulin became malaysia first locally manufactured biosimilar product sold southeast asian nation signed threeyear myr 300 million offtake agreement malaysian government looking forward insulin foray larger developed market following submission acceptance filing insulin glargine european medicine agency ema u fda commercialization malaysia facility fy17 strengthen position among top 3 biosimilar player globally insulin term volume market shareunits source ims year end 2016 chairperson review 17 novel molecule poised leap practitioner frontier science built pipeline novel biologics successful address local well global unmet medical need diabetes cancer journey itolizumab autoimmune disease basket novel asset clinical development laboratory represents interesting combination early advanced stage asset market india believe insulin tregopil firstinclass oral prandial insulin put u ahead advanced program global oral insulin space promise transform race anticd6 diabetes management set stage pivotal study insulin antibody unlock tregopil different diabetic population india form potential foundation broad global program envisioned novel molecular entity unique mechanism action multiple successful journey itolizumab laboratory market india autoimmune put u ahead race unlock potential unique mechanism indication action multiple autoimmune indication fy17 reported encouraging progress test patientfriendly subcutaneous form itolizumab small molecule enabling partner significant brand equity built worldwide fermentationderived small molecule apis across statin immunosuppresants specialty product made u leading global supplier product built reputation emerge among first wave supplier rosuvastatin api partner u launch upon patent expiry 2016 year received first generic formulation approval rosuvastatin calcium u fda become vertically integrated player niche space difficultto make generic formulation leveraged strength fermentation technology molecular characterization branded formulation india uae initiated branded formulation business india 2004 launch country first indigenously developed rhinsulin brought cost insulin therapy third since aimed staying ahead curve deftly balancing innovation affordability 18 ahead curve annual report 2017 biocon limited intent bring costeffective biologics differentiated small molecule formulation chronic condition patient india uae frontrunner select market contract year business reported overall growth 24 like like research service basis segment marginally compared last year though sale space syngene india sluggish continued improve prescription share expanded key brand insugen basalog canmab robust growth role fy17 uae placed u among top 15 pharma company year innovation partner product ranked among top 5 brand respective segment recently announced leadership change across india branded formulation business provide u ability pursue strong growth trajectory syngene integrated research service provider syngene research service subsidiary publicly listed contract research organization cro india offer endtoend drug discovery development service novel molecular entity global life science sector front runner contract research space syngene expanded role fy17 innovation partner new strategic partnership amgen herbalife nutrition dedicated rd center december 2016 fire accident one syngenes research block bengaluru affected strong revenue momentum business syngenes value proposition customer remains strong expanded capacity acquired new capability year important acquisition effect bioinformatics business bengaluru based genomics company strand lifesciences standalone basis reported revenue growth 14 healthy ebitda margin quality unwavering focus culture quality excellence helped biocon maintain strong compliance track record regulatory inspection year fy17 underwent multiple regulatory audit various international regulator chairperson review 19 best employer brand continue asian company global best biotech continue employer list brought prestigious science career magazine asian believe great testament work culture opportunity company scientist get within company 2016 featured among top 10 global best biotech employer globally employer list financial highlight matched operational performance fy17 equally strong financial performance grew topline 18 h40787 million simultaneously improving quality earnings ebitda margin year expanded 28 24 year ago adjusting exceptional item boosted bottomline fy16 net profit fy17 jumped 54 h6199 million declaration bonus share final dividend board director company recommended issue two bonus share every one share held biocon subsequently approved shareholder board also recommended final dividend h3 per share fy17 pre bonus work h1 per share post approval socially responsible strongly believe use technology address several challenge associated public health delivery country biocon foundation csr arm biocon taken ahead belief develop unique ehealthcare model introduced elaj smart clinic year ago clinic designed facilitate effective preventive primary healthcare intervention rural area india benefit community poor access healthcare foundation currently run 14 elaj smart clinic covering 30 gram panchayat across karnataka rajasthan elaj smart clinic paving way evidencebased public health intervention location enabling multiple diagnostic test generation electronic medical record emrs patient 20 ahead curve annual report 2017 biocon limited past year patient footfall elaj clinic gone 50 9000 month elaj elaj model facilitating ontime treatment helping reduce outofpocket smart clinic healthcare spending cutting need trip tertiary hospital paving line commitment enable right healthcare way evidence every citizen based public health intervention using biocon academy oneofakind initiative area skill development technology delivered commitment prepare industryready student biotech sector fy17 saw successful completion three batch multiple diagnostic biocon kgi certificate program bioscience second batch bit test generation biocon program applied industrial microbiology academy maintained electronic medical 100 placement record year even 35 company record emrs visited recruiting fresh talent 60 student patient employed outside biocon syngene looking ahead fy18 promise exciting year biocon developed market regulatory submission biosimilars could translate marketing approval opening immense growth opportunity company finally would like thank shareholder trust placed u humanitarian business making difference people life mission spurred u fight way year credibility challenge market skepticism emerge leading indian company working cuttingedge sphere biosimilars best wish kiran mazumdarshaw chairperson managing director june 8 2017 chairperson review 21 qa ceo dr arun chandavarkar ceo joint managing director 22 ahead curve annual report 2017 biocon limited biocon consistently stayed ahead curve biocons focus innovation differentiation predates entry pharmaceutical sector entrepreneurial culture rooted building strength nascent field biotechnology instrumental u identifying opportunity based market technology trend initial year enzyme company subsequent foray biopharmaceuticals led u proactively invest capability aligned opportunity ahead curve biocon commenced pharma journey 1999 leveraging capability fermentation technology derived long experience manufacturing enzyme unlike company india largely focused generic made chemical synthesis furthermore amongst early mover developing portfolio fermentation derived statin gave u leadership position segment simultaneously chose expand strategic option small molecule like statin recombinant protein like insulin address growing healthcare challenge associated diabetes hesitate exploit differentiated technology proprietary yeast platform based pichia pastoris create portfolio insulin 2003 initiated work mammalian cell culture based expression system develop monoclonal antibody mabs targeting cancer autoimmune disease product portfolio limited generic biosimilars sought opportunity ahead curve addressing unmet need therapeutic segment novel biologics novel target marked high entry barrier wherein early anticipation required make significant investment full range rd increasing capability spanning process analytical development preclinical dominance clinical research biologics global early anticipation increasing dominance biologics global development development pipeline helped u ahead curve crafting pipeline helped u differentiated product portfolio based fermentation recombinant ahead technology believe would provide u sustainable competitive curve advantage year ahead ceo qa 23 ahead curve translate tangible achievement biocon strategic choice focusing biotech fermentationderived biopharmaceuticals resulted unique differentiated product portfolio straddling fermentationderived small molecule recombinant protein including insulin mabs biocons growth mid 2000s triggered first approval statin api facility u fda driven early mover advantage lovastatin pravastatin simvastatin amongst company approved apis fermentationderived statin helped lower competitive intensity otherwise typical chemistrybased apis expanded portfolio fermentationderived apis establish strong competitive position immunosuppressant certain speciality apis likewise one among two nonoriginator company commercialize recombinant human insulin india 2004 subsequently rapidly expand footprint multiple emerging market year followed launch insulin glargine india 2009 recently gone important endorsement product quality account demonstrated approval launch glargine disposable pen japan 2016 capability also pioneer developing manufacturing launching couple dossier novel biologics india namely antiegfr mab nimotuzumab head submission neck cancer 2006 anticd6 mab itolizumab psoriasis europe 2013 partner mylan three biosimilar embarked biosimilar journey anticipated product based risk long gestation period development evolving regulatory diverse technology landscape significant financial outlay rd manufacturing platform scale infrastructure proactively mitigated risk entering operation regional global partnering agreement one mylan 24 ahead curve annual report 2017 biocon limited biosimilar mabs 2009 expanded insulin analog 2013 partnership structured sharing risk reward leveraged complementary strength partner forerunner many global partnership exist today biosimilar space including involving many innovator company believe partnering strategic choice early investment cycle biosimilars another example ahead curve tangible outcome partnership mylan launch biosimilar trastuzumab 2014 india emerging market collaboration also reached important milestone fy17 trastuzumab pegfilgrastim dossier accepted review u fda ema followed glargine filing europe biocons ahead curve strategy mean prospect biocons annual report shareholder fy16 highlighted effort initial success credibly capable based first approval biosimilar product namely insulin glargine demanding developed market like japan progress made advancing biosimilar program clinic year gone demonstrated capability dossier submission europe partner mylan three biosimilar product based diverse technology platform scale operation namely trastuzumab pegfilgrastim insulin glargine last year also u fda accept dossier trastuzumab pegfilgrastim review insulin glargine follow early fy18 three product target market opportunity usd 1820 billion current innovator pricing continue develop biosimilar asset collaboration mylan nearterm growth biosimilars driven expanding footprint key emerging market strong local partnership product approval ceo qa 25 commercial success developed market u europe would significant milestone help company reinvent lay strong foundation stay ahead curve next decade supported capacity expansion needed phased manner addition product portfolio cater next wave opportunity continue adopt riskbalanced approach advance promising firstinclass novel biologics target critical unmet need strive remain ahead curve developing fermentation derived complex potent niche small molecule generic apis forward integrate finished dosage form believe strategy ahead curve well diversified portfolio small molecule biosimilars novel biologics help u overcome headwind facing generic pharmaceutical sector today term pricing pressure tougher regulatory expectation increased competition biocons key priority fy18 fy18 position u key inflection point journey amongst successful first wave successful entrant global biosimilar arena look commissioning forward receiving approval u europe biosimilar filing malaysian facility done fy17 launch product market also insulin fy17 expect couple additional filing fy18 market threeyear myr 300 million successful commissioning malaysian facility insulin fy17 contract threeyear myr 300 million contract malaysian ministry malaysian ministry health augur well seek approval key emerging market health augur well approval commercial launch thereafter expected seek approval latter part fy18 would help partly defray annual fixed cost key emerging usd 48 million associated malaysian facility approval also debottleneck capacity constraint insulin indian facility market 26 ahead curve annual report 2017 biocon limited continue seek approval expand commercial footprint biosimilars key emerging market latam mena ci southeast asia unlock value first set asset whilst waiting developed market open expect break ground new brownfield mabs facility bengaluru rd front continue invest progressing biosimilars novel biologics whilst completed rowfocused phase iii trial metastatic colorectal cancer proposed biosimilar bevacizumab fy17 separate global phase iii trial nonsmall cell lung cancer track patient recruitment continue develop rapidacting insulin analog enable progress clinical stage shortly initiate significant clinical study novel insulin tregopil oral insulin validate positioning orallydelivered rapidacting prandial insulin establish safety efficacy type 2 diabetes patient expect conclude stage 2 study novel anticd6 mab itolizumab australia provide valuable data term subcutaneous route administration small molecule segment expected see steady growth back increased volume offtake base product comprising statin small molecule immunosuppressant continue invest developing segment expected next portfolio small molecule forward integrating apis see steady growth finished dosage form expect newly constructed oral solid back formulation facility operational latter part fy18 increased volume reduce current dependence outsourced manufacturing offtake base key focus fy18 rebooting branded formulation business product comprising recently revamped leadership team intent gaining market statin share profitably anchor brand augmented immunosuppressant new launch inhouse inlicensed product ceo qa 27 financial review cfo siddharth mittal presidentfinance cfo revenue ebitda h40787 million h11366 million 18 34 net profit ebitda margin h6121 million 28 11 4 28 ahead curve annual report 2017 biocon limited comment transition new indian accounting standard fy17 biocon amongst early adopter new indian accounting standard referred commonly ind transition older standard ind starting april 1 2016 applied standalone consolidated financial statement line ind changed segment reporting better reflect way view measure overall business started reporting four segment small molecule biologics branded formulation research service instead two biopharmaceuticals research service used report previous accounting standard line growth strategy represented four business segment provides clearer picture segment shareholder earlier rate performance year overall financial performance year satisfactory line expectation fy17 consolidated revenue h40787 million grew 18 net profit h6121 million reported 11 growth adjusting exceptional income fy16 net profit actually jumped 54 h6199 million year earnings interest tax depreciation amortization ebitda year rose 34 h11366 million ebitda margin markedly improved 28 24 last year extraordinary gain recorded previous year account deferred revenue recognition pertaining rhinsulin development impairment intangible asset biocon sa adjusting company strong performance year led small exceptional income molecule business reporting growth 12 h16330 million fy16 net profit biologics business h5793 million reporting growth 43 branded actually jumped 54 formulation business includes sale uae reported growth h6199 million 24 h5489 million research service syngene contributed year h11604 million biocons sale financial review 29 operating margin trajectory look like medium term company core operating margin operating margin adjusted licensing income rd expense forex gain loss continue remain healthy spite increased operational expense like salary cost fy17 ebitda margin 28 core operating margin stood 32 resulting growth small molecule business biosimilars business emerging market mediumterm endeavor maintain core operating margin 30 level despite increase rd expense inclusion malaysian expense pl anticipate margin improve launch biosimilar product developed market enjoy reasonable penetration reflects optimum utilization manufacturing asset good service tax gst expected rolled nationwide july 1 2017 would anticipated impact biocon longterm perspective gst good nation replace number different tax company deal currently single nationwide tax would simplify operation expect shortterm impact branded formulation india business anticipated distribution channel could destock market inventory gst rollout hence sale q1 fy18 could impacted impact could rollover q2 fy18 well depending quickly channel becomes gstready compliant expect thing normalize second half fiscal mediumterm gst company claim input credit certain item endeavor possible earlier tax structure however saving would maintain core ultimately passed customer given antiprofiteering operating margin clause gst bill 30 level despite increase expected tax rate biocon consolidated level rd expense fy18 inclusion consolidated level effective tax rate fy17 19 malaysian expense adjusting onetime deferred tax benefit company availed pl effective tax rate 22 year 30 ahead curve annual report 2017 biocon limited rate expected go 200300 bps 100 bps 1 fy18 due expiry 10year tax holiday manufacturing facility government gradually phasing rd tax benefit availed biocon thus far 200 weighted deduction reduce 150 fy18 completely eliminated next couple year biocon stopped capitalization expense malaysia plant end fy17 affect bottomline fy18 stopped capitalizing preoperating expense relating malaysia plant end fy17 consequently depreciation fixed expense related malaysia plant charged pl account starting q1 fy18 estimate annual depreciation approximately usd 18 million fixed plant operating expense includes finance cost approximately usd 30 million already commenced commercialization malaysia plant supply rhinsulin domestic market fy18 also anticipate approval followed commercial supply emerging market previously india plant qualified lastly partly utilize plant development pipeline insulin product wherein cost shared partner mylan accounted rd expense result expect adverse impact bottomline malaysian operation fy18 however endeavour minimize impact trajectory rd expenditure across foreseeable future company continue focus development biosimilars complex generic novel biologics program require intensive rd effort long gestation period guided gross annual rd expense range 1215 sale excluding syngene expect rd expense fy18 line guidance financial review 31 rationale behind capitalization rd expense select biosimilar product accordance requirement ind 38 intangible asset development cost capitalized intangible asset based recognition parameter summarized product technically commercially feasible ie future economic benefit probable group intends complete development intent use sell asset establish technical feasibility demonstrated biosimilarity product term safety efficacy various preclinical clinical activity occurs upon receipt regulatory approval product major territory establish commercial feasibility demonstrated intangible asset generate probable future economic benefit occurs probable able successfully commercialize product intended market technical commercial feasibility established believe adequate technical financial resource complete development activity capitalize future development cost incurred also sufficient leverage b expenditure measured reliably balance cost development identified product level hence sheet raise development cost eligible capitalization measured reliably additional debt broad category expense capitalized include cost material fund remaining salary appropriate overhead used product validation cost portion capex conducting clinical trial etc foresee raising fresh equity biocons capex plan fy18 funding nearing completion two capex project oral solid dosage capital market facility biologics fillfinish line bengaluru expected fund commissioned fy18 commence qualification shortterm capex process maintenance capex estimated h750 million requirement h1 billion year 32 ahead curve annual report 2017 biocon limited term new large project expect start construction second monoclonal antibody facility bengaluru fy18 receipt regulatory approval investment phased period three four year associated capex shared partner mylan debt position company biocon plan fund upcoming capex would biocon need raise fund market fund future growth plan biocon consolidated gross debt long term plus short term debt h23025 million march 31 2017 corresponding cash liquid investment h22551 million excluding syngene gross debt cash liquid investment stood h14961 million h11875 million respectively cash liquid investment balance sheet coupled free cash flow operation used fund significant portion capex also sufficient leverage balance sheet raise additional debt fund remaining portion capex foresee raising fresh equity funding capital market fund shortterm capex requirement longterm perspective restructured legal entity reflect key business segment new structure provides u flexibility unlock value raise capital required business segment future biocon specific dividend policy yes biocon dividend policy dividend distributed shareholder depending upon multiple factor including limited future earnings financial condition cash flow planned capital expenditure working capital requirement declaration payment dividend recommended board director approved shareholder discretion subject provision article association company act detail please read page 107 financial review 33 board director sitting left dr vijay kuchroo john shaw mary harney kiran mazumdarshaw russell wall daniel bradbury standing left dr jeremy levin damodaran dr arun chandavarkar prof ravi mazumdar 34 ahead curve annual report 2017 biocon limited kiran mazumdarshaw people across globe played pivotal role evolution chairperson managing director field medicine recognized biocon last 27 year first generation entrepreneur consecutively third year since phd biochemical engineering nearly 42 year experience 2015 massachusetts institute biotechnology conferred highest french technology mit cambridge usa well recognized global business distinction chevalier de lordre btech chemical engineering leader national de la légion dhonneur indian institute technology knight legion honour independent member board mumbai 2016 infosys limited chairman confederation indian recently bestowed chairperson board industry national committee advancing woman science governor indian institute biotechnology medicine awsm award management bangalore excellence 2017 feinstein prof ravi mazumdar recipient two prestigious institute medical research usa nonexecutive director national award padma shri university research chair professor john shaw padma bhushan department electrical vice chairman wholetime recipient othmer gold medal computer engineering university director 2014 u based chemical waterloo canada foreign promoter wholetime heritage foundation jd gandhi distinguished visiting director recipient 2014 global economy professor iit mumbai master degree art economic prize business germany member several advisory hons history political kiel institute committee working group economy glasgow university featured 100 powerful uk including u congress sub woman asiapacifics 48 committee science served finance managing hero philanthropy forbes technology director coat viyella group magazine fellow royal statistical served senior corporate position recognized 100 leading society around world global thinker 2014 u 150 referred publication based foreign policy magazine former chairman madura coat ltd ph university fortune magazine top 25 dr arun chandavarkar california los angeles ucla powerful woman asiapacific chief executive officer joint msc dic imperial college 2014 managing director london featured among top 10 core member biocons leadership team btech electrical engineering medicine maker power list iit mumbai index 100 influential board director 35 russell wall daniel bradbury independent director independent director chairman aviva life holding ltd board trustee keck experience 47 year graduate institute california usa field finance member san diegos rady school fellow member association management advisory council chartered certified accountant uk member miami innovation board mytrah energy ltd aviva corporate advisory council italia holding spa signet life science executive jeweler ltd 30 year experience creating mary harney implementing strategy independent director transforming business tánaiste deputy prime minister honoured corporate irish republic 1997 2006 director forum director year award enhancing economic longest serving woman ever value 2012 irish parliament 30 year ernst young entrepreneur member board crann year finalist trinity college dublin largest research institute hold postgraduate diploma management study chair amber advanced material bioengineering diploma chartered institute research centre trinity joint marketing harrow ealing research enterprise university college higher education uk college cork royal college bachelor degree pharmacy surgeon ireland industry hons nottingham university honorary member uk international womens forum dr jeremy levin economics graduate trinity independent director college dublin former president ceo teva pharmaceutical 36 ahead curve annual report 2017 biocon limited former executive committee center immunologic disease chairing government india task member bristolmyers squibb harvard medical school usa force set resolution corporation india responsible global codirector center infection strategy alliance operational immunity brigham research former chairman security transaction institute boston exchange board india sebi unit trust india uti industrial led string pearl strategy named distinguished eberly development bank india idbi bm helped transform lecturer 2014 company pipeline former chief secretary government obtained nobel laureate peter tripura served global head strategic doherty lecture prize 2014 alliance novartis set excellence enablers private hold 25 patent limited eepl corporate recognized among top 25 founded 5 different biotech governance board advisory influential people company including costim consultancy firm biopharmaceutical industry pharmaceutical tempero board leading indian recipient kermode prize work pharmaceutical corporates well novel hypertension drug published 325 original research advisory board foreign albert einstein award leadership paper field immunology entity life science awarded mr costimulation role th17 shimon peres cell officer cross order merit fred z eager research prize republic hungary medal phd research work university queensland bachelor degree zoology master art doctorate phil specialization pathology university oxford university queensland brisbane australia obtained phd degree bachelor medicine bachelor surgery mb b chir damodaran university cambridge independent director dr vijay kuchroo founder chairman indian institute independent director management tiruchirappalli samuel l wasserstrom professor chairman glocal healthcare system neurology director evergrande private limited board director 37 scientific advisory board prof alan cherrington dr brian kotzin phd professor chairman molecular physiology medical degree postdoctoral fellowship biophysics professor medicine diabetes immunology rheumatology stanford university research vanderbilt university past president vice president global clinical development head american diabetes association inflammation therapeutic area amgen vice president head medical science member dr david essayan advisory council national institute arthritis md key research interest clinical regulatory musculoskeletal skin disease nih associate editor development small molecule biologics clinical clinical investigation immunologist former fda supervisory medical officer former executive director amgen dr brian daniel md m b mit venture partner 5am dr g alexander fleming venture management llc former svp bm directed md president ceo kinexum llc member conducted clinical research merck research numerous scientific advisory board expert laboratory genentech extensive experience committee clinical development medical affair corporate strategy across broad range therapeutic area dr harold e lebovitz md face professor medicine endocrinology dr jugnu jain diabetes division state university new york health phd cambridge university launched sapien science center brooklyn saarum india molecular geneticist cell biologist led vertex global immune inflammation team dr lawrence steinman research cytokine gene regulation harvard md key research interest remission relapse m published 30 paper 2 patent vaccine m brain inflammation coinventor leading m drug natalizumab several new therapy prof huub schellekens autoimmune disease md phd professor medical biotechnology utrecht university published 300 paper dr vijay kuchroo development therapeutic protein member dvm phd key research interest multiple sclerosis dutch medicine evaluation board national expert costimulation th17 currently scientific review ema board national multiple sclerosis society new york 38 ahead curve annual report 2017 biocon limited core committee 1 2 3 5 4 6 7 1 kiran mazumdarshaw 4 dr narendra chirmule chairperson managing director sr vice president head rd founder biocon limited 5 siddharth mittal 2 john shaw president finance cfo vice chairman 6 ravi limaye 3 dr arun chandavarkar president marketing chief executive officer 7 amitava saha joint managing director sr vice president head human resource scientific advisory board core committee 39 vision mission value vision discovery research management research development business partnership enhance global healthcare stateoftheart manufacturing innovative affordable capability value biopharmaceuticals patient partner healthcare system integrity ethical behaviour internationally benchmarked across globe quality regulatory system performance driven work culture new medical insight value creation innovation mission disease specific clinical research differentiation integrated biotechnology customer relationship quality compliance enterprise global distinction outstanding product service best practice essential mission human resource development collaboration team work excellence training mentoring mutual respect intellectual asset creation empowering 40 ahead curve annual report 2017 biocon limited financial highlight segmentwise revenue small molecule biologics branded formulation h million h million h million 13240 14475 14432 14546 16330 2244 2788 2857 4046 5793 3684 4242 5212 4409 5489 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 research service others total revenue h million h million h million 5722 7346 8514 10809 11604 490 481 414 792 1571 25380 29332 31429 34602 40787 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2016 2017 figure per ind financial highlight 41 profit debt equity h million h million 5089 4138 4974 5504 6121 2488 8497 10350 24777 23025 26946 30267 32706 40338 48377 debt equity 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 total asset current ratio h million h million 44161 57506 63754 84581 93943 226 191 165 238 241 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 includes exceptional income year 2013 2015 2016 2016 2017 figure per ind 42 ahead curve annual report 2017 biocon limited net worth eps book value per share eps dividend per share h million h million h million 26946 30267 32706 40338 48377 26 21 25 28 31 26 21 25 28 31 135 151 164 202 242 75 5 5 5 3 eps dividend per share book value per share eps 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 gross rd spend return net asset return net equity h million h million h million 1860 1580 3284 4267 4019 15 9 10 8 8 20 14 16 15 14 34262 43710 48207 67924 77159 24835 28607 31487 36480 44358 5089 4138 4974 5504 6121 5089 4138 4974 5504 6121 return net asset return equity net asset average equity pat pat 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 includes exceptional income year 2013 2015 2016 2016 2017 figure per ind financial highlight 43 sitting left suresh subramanian sr vice president head branded formulation india dr narendra chirmule sr vice president head rd novel biologics standing left paul thomas vice president head biosimilars mabs prasad bsv sr vice president head small molecule shreehas tambe sr vice president head insulin 44 ahead curve annual report 2017 biocon limited business segment review biologics total small branded research biosimilars revenue molecule formulation service novel 18 43 12 24 7 growth growth growth growth growth h40787 h5793 h16330 h5489 h11604 million million million million million biocons greenfield audit conducted canmab featured expanded business insulin manufacturing u fda mexico among top 10 two additional facility malaysia cofepris korean oncology brand dedicated rd center commercialized fda country amgen herbalife nutrition regulatory filing continued work oral paper biosimilar trastuzumab development niche presentation expanded capability pegfilgrastim marginaccretive alzumab bioinformatics accepted review api molecule international purchase asset u fda ema conference psoriasis strand life science development u related system heritage study laboratory oncology biology heptox data biosimilar apis commissioned initiated physician pharma bioinformatics trastuzumab published centric registry progressed service jama program construction biocons alzumab progressed first oral solid dosage cytosorb key clinical study facility subcutaneous version neobiocon jumped itolizumab australia five place ranked among top 15 pharma company uae segmental review 45 biologics biocons innovationled strategy aligned global trend increased 43 growth use biologics address unmet medical need one earliest h5793 million player realm biologics india created rich pipeline novel biosimilar asset available patient india emerging market revenue biocon poised enter developed market biosimilar product time increasing acceptance biosimilars u pharmacy benefit manager pbms taken step exclude originator product formulary favour biosimilars group european regulator published paper supporting appropriateness switching patient originator biosimilar study conducted norwegian government established evidence supporting safety biosimilar source biodrugs 2017 interchangeability scandinavian country also taken apr3128391 doi 101007 s4025901702100 strong national level step encourage biosimilar uptake time lancet volume 389 issue emerging market also showing inclination wider biosimilars use 10086 1016 june 2017 page 23042316 expected launch pilot project prequalifying biosimilars 46 ahead curve annual report 2017 biocon limited step towards making expensive pen business recorded strong treatment cancer doubledigit growth year chronic disease widely available low middleincome led higher offtake existing market expansion one leading global player insulin committed deliver affordable country commercial presence diabetes therapy option market worldwide including japan range basal rapid fy17 biologics segment intermediate acting generic reported strong growth 43 revenue growth emerging insulin insulin portfolio h5793 million driven largely market propelled robust complemented highend patientfriendly device sale biosimilars including sale rhinsulin cartridge offer ease use people rhinsulin insulin glargine reusable insulin pen ministry diabetes resulting improved trastuzumab global market health moh malaysia compliance therapy novel biologics also advanced threeyear myr 300 million contract clinical development year shreehas tambe sr vice president head insulin program year besides malaysia also launched insulin glargine rhinsulin augur well insulin glargine biosimilars emerging market region latin america africa address usd 64 billion global biocon portfolio 10 market opportunity current middle east biosimilars spanning insulin innovator pricing monoclonal antibody japan readytouse prefilled disposable insulin glargine pen marketing authorization recombinant protein address well accepted prescribers application maa insulin critical chronic disease patient second glargine submitted european diabetes cancer autoimmune player received regulatory medicine agency first disorder collectively target approval sell biosimilar insulin filing developed market global market opportunity glargine estimated usd 118 incorporates product validated usd 60 billion million source ims year end 2016 new stateoftheart malaysia facility insulin analog market successful japan launch molecule insulin biocon among top 3 biosimilar enhanced credibility expand analog portfolio insulin aspart player globally insulin term footprint developed insulin lispro preclinical volume market share measured market european union development number unit sold source ims year end 2016 company canada australia accepted commercialization malaysia diversified portfolio spanning review regulatory submission insulin facility recombinant human insulin insulin glargine codeveloped important milestone longacting insulin analog glargine mylan expect file fiscal commercialization complemented comprehensive marketing authorization application greenfield insulin product presentation across vial insulin glargine u fda manufacturing facility malaysia cartridge disposable reusable shortly key development biologics 47 one largest asia diabetes management pegfilgrastim accepted malaysian government contract affordable biosimilar insulin review u fda ema enabled u start supplying inulin analog mark key milestone product overseas facility business fy17 india made significant invested nearly investment capacity global addressable market usd 250 million debottlenecking meet projected opportunity trastuzumab rhinsulin malaysia first demand insulin drug indicated treating her2positive locally manufactured biosimilar substance drug product breast gastric cancer product approved emerging market usd 69 billion pegfilgrastim commercial sale country administered patient insulin glargine manufactured monoclonal antibody undergoing chemotherapy india also approved recombinant market opportunity usd 46 sale malaysia protein billion biocon distributing insulin biocon mylan codeveloping biocon mylan first file insulin delivery device highvalue portfolio six regulatory approval biosimilar leading local pharmaceutical player biosimilar mabs recombinant trastuzumab u eu extensive supply protein trastuzumab bevacizumab fda target action date chain network service primary adalimumab pegfilgrastim trastuzumab pegfilgrastim healthcare clinic hospital etanercept filgrastim targeting september october 2017 across malaysia chronic disease cancer respectively indicates range autoimmune disorder could one first biosimilar product enabling entrant product u malaysian government expand commenced sale eu market access affordable insulin therapy biosimilar trastuzumab emerging nearly 33 million people market fy16 year regulatory submission diabetes southeast asian took product newer biosimilar pegfilgrastim also country geography including accepted australia larger emerging market canada several regulatory filing audit underway malaysian trastuzumab boosted biologics bevacizumab adalimumab manufacturing facility expect business revenue well fy17 completed emerging facility qualified licensing income year market targeted clinical trial emerging market continue seek regulatory proposed biosimilar bevacizumab ramp commercial sale approval trastuzumab metastatic colorectal cancer patient site fy18 increase presence submitted marketing emerging market unlocking additional capacity authorization application india malaysia emerging market trastuzumab pegfilgrastim additional global phase iii approval would help accelerate regulatory submission trial nonsmall cell lung cancer journey making global impact proposed biosimilar trastuzumab commenced late fy17 48 ahead curve annual report 2017 biocon limited global clinical trial biosimilar result trial first conjunction chemotherapy adalimumab plaque psoriasis presented american society patient treated her2 patient complete begin clinical oncology asco annual positive metastatic breast cancer regulatory submission meeting chicago u completion sample data analysis european society medical expect submission various oncology esmo congress geography start fy18 copenhagen denmark 2016 presentation made biocon mylan study published dr hope rugo chair jama steering committee year result heritage study biosimilar heritage study appreciated immensely scientific b iocon vision global leader field biosimilars several year ago trastuzumab published community manifesting prestigious journal american several biosimilar asset jama recognized result track anticipated regulatory medical association jama heritage study approval developed market flagship publication real tribute last major step multiphased american medical association team biocon able program demonstrate accomplish complex area significant development bioconmylans proposed biosimilar relatively short period considering study published time trastuzumab meet criterion jama highly respected equivalence comparison undergo rigorous peer review paul thomas reference product used vice president head biosimilarmabs process global generic insulin biosimilars portfolio category molecule status regular acting insulin recombinant human insulin preclinical u market marketed emerging market long acting insulin analog insulin glargine filed eu australia canada u filing h1 fy18 marketed japan since july 2016 emerging market rapid acting insulin analog insulin aspart preclinical rapid acting insulin analog insulin lispro preclinical cancer trastuzumab filed u eu marketed emerging market autoimmune adalimumab global phase iii completed neutropenia pegfilgrastim filed u eu canada australia cancer bevacizumab indiaemerging market phase iii completed global phase iii commenced neutropenia filgrastim early development autoimmune etanercept early development biologics 49 novel biologics insulin tregopil treating type 1 type 2 biocons lead program diabetes diabetes pivotal phase iii study biocon developing novel type 2 diabetes expected insulin tregopil firstinclass biologics aimed addressing local start india fy18 clinical trial oral insulin molecule post well global unmet medical application cta filed prandial glycaemic control need area diabetes indian regulator announced successful result autoimmune inflammation study multiple ascending dose phase clinical study oncology basket novel study type 1 diabetes patient drug candidate concluded asset clinical development population also planned fy18 u fy16 study represents interesting collaboration juvenile established target product combination early advanced diabetes research foundation profile molecule including stage asset combined study different food effect drugdrug interaction program generating diabetes population form pkpd profile fy17 encouraging exciting data foundation broad global followed positive ultimate success program program envisioned insulin phase data continue bring transformational growth tregopil development program business 50 ahead curve annual report 2017 biocon limited itolizumab organization india anticd20 autoimmune inflammatory forayed exciting space second generation disease space novel first sirnabased small interfering rna humanized antibody targeting cd20 inclass anticd6 humanized therapeutic path ind monoclonal antibody itolizumab fy17 made progress one mapped plan advance marketed alzumab high potential novel asset asset neuroinflammatory treatment chronic plaque qpi1007 developing disease eg multiple sclerosis psoriasis india since 2013 biocon asset sirna platform first company quark pharma rare world clinically validate cd6 ophthalmology indication target autoimmune disease pivotal global phase iiiii study fy17 progressed nonarteritic ischemic optic key clinical study using sub neuropathy naion initiated cutaneous version itolizumab quark pharma fy17 u australia evaluation multiple includes patient randomized indication bridging phase pk india safety study normal healthy fmab2 fusion protein volunteer australia seek immunooncology lead evaluate pharmacokinetics molecule fmab2 combine pharmacodynamics sub monoclonal antibody egfr cutaneous route administration tgf receptor fragment itolizumab comparison bind neutralizes tgf intravenous route fusion antibody currently company marketing preclinical development work approval india stage 1 concept preferentially dosing subcutaneous route delivering immune modulators administration showed equivalent tumor site thus enhancing efficacy bioavailability drug plan delivering larger dos tgf initiate stage 2 dosing shortly w tumor microenvironment e developing novel understanding cd6 pathway ind molecule planned biologics aimed led scientist biocon addressing local well fy18 currently ready potential developing novel global unmet medical need pharmacology mechanism area diabetes therapy patient immune action moa established autoimmune inflammation dysfunction vitro invivo tumor model oncology qpi1007 sirna provides u potentially broad dr narendra chirmule biocon first biopharma clinical opportunity multiple sr vice president head rd novel biologics tumor type biologics 51 small molecule audit entrenched presence complex immunosuppressant 12 growth chronic therapy space recently generic h16330 million made u preferred partner pharma customer india overseas formulation strategy hinge leveraging strength revenue characterization manufacturing lovastatin went patent biologics build robust biocon one leading global 2001 biocon one pipeline difficulttomake niche supplier complex small molecule three company world formulation chronic condition active pharmaceutical ingredient get u fda approval supply order address global need apis spanning cardiovasculars anti api drug since affordable therapy obesity agent immunosuppressant emerged world narrowspectrum antibiotic largest statin manufacturer apis antifungal drug substance used biocons ability stay ahead unique strength fermentation produce one every three statin curve placed among first wave technology complex chemistry pill globally year supplier rosuvastatin api successful track record regulatory also emerged leading player partner acquisition new 52 ahead curve annual report 2017 biocon limited customer statin generic made progress immunosuppressant apis helped construction first oral solid formulation drive healthy performance dosage facility play business year part strategy sustain important role generic longterm growth small formulation strategy work sale rosuvastatin api molecule business working facility track u start key customer targeting u building robust pipeline exhibit batch various post patent expiry 2016 differentiated generic finished product qualification activity supplemented higher offtake dosage global market fy18 immunosuppressant apis especially commercial perspective latin american market strategy give biocon competitive maintained momentum advantage enable u regulatory filing 10 drug integrated player offering master file dmfs submitted drug substance drug u key regulated market product niche area year successfully generic formulation business completed audit u fda obtained first anda approval mexico cofepris korean fda u fda rosuvastatin calcium tablet 2016 going ahead regulatory submission eight approval plan leverage experience received key apis scale regulatory u eu augur well submission u fda business file andas launch generic formulation u differentiated apis player focus provide partner meet increase demand add profitability best class statin complex expanded capacity statin business already enjoys immunosuppressant immunosuppressant specialty molecule thus healthy operating margin year enabling formulation completion fullcycle business committed endeavour expand exploit new opportunity development generic drug small molecule oncology within small molecule product positioned u file space niche portfolio portfolio development regulatory approval five generic formulation laboratory oncology api six molecule every year across enhance access affordable commissioned therapy chronic disease emerging market developed investment towards enhancing market u eu prasad bsv manufacturing capability sr vice president head small molecule progress small molecule 53 branded formulation biocons branded formulation 24 growth business ahead curve h5489 million anticipating critical need affordable therapy chronic b iocons unique combination world class product personalized patient support disease india physician engagement revenue emerging market accordingly initiative enabled u prepared address make impact therapeutic area diabetology challenge differentiated oncology immunology world class biopharmaceuticals india focused execution personalized medical support new launch enable u deliver superior result year branded company going forward formulation business enabled biocon carve niche suresh subramanian sr vice president head branded biologicsled specialty formulation india pharmaceutical company 54 ahead curve annual report 2017 biocon limited india enabled biocons brand 30 publication result assume leadership position heritage trial involving pioneer bringing fy17 15 brand featured biosimilar trastuzumab journal innovative globally benchmarked among top 3 brand american medical association biologics patient india respective category india helped build additional strategy highest quality top 10 brand india portfolio confidence product among lowest cost enabled u accounted 70 medical fraternity india build premium brand chronic revenue year stopped offering abraxane key therapeutic area diabetes inlicensed oncology molecule cancer endstage renal disease fy17 witnessed significant patient fy17 due decision immune disorder life increase prescription share taken licensor discontinue threatening condition insugen basalog supply flagship brand metabolics year extended division basalog ranked tacrograf key presence niche area number two insulin glargine immunosuppressant brand reported saw potential moderate brand india registered strong double digit growth fy17 cost widen patient access doubledigit sale growth number three tacrolimus brand introduced patientcentric initiative year insugen retained position india disease awareness prevention among top 3 brand rhinsulin management partnered psorid one key available india key stakeholder like government immunotherapy brand continued healthcare professional biomab egfr canmab prescribed brand advocacy group increase access evertor nufil cyclosporine india lifesaving medicine licensed oncotherapeutics portfolio featured novel biologic alzumab product global innovator among top 3 brand itolizumab made psoriasis core therapeutic area bring respective category continuing management easier several latest therapeutic advance make significant impact hundred patient india since india engaged physician realm cancer care india launch 2013 fy17 oral targeted educational biomab egfr novel biologic paper role itolizumab program related best treatment head neck cancer witnessed psoriasis management practice complex medical 1000 new enrollment presented international condition adopted evidence fy17 canmab biosimilar conference psoriasis skin based engagement strategy trastuzumab brand helped treat specialist meeting dallas u key opinion leader leveraging several thousand her2positive data generated 155 patient clinical experience novel metastatic breast cancer patient treated alzumab also biologics biosimilars india since launch 2014 accepted publication unique combination specialty fy17 canmab continued gain indian dermatology online journal product patient support traction featured among top multicenter panindia study physician engagement program 10 oncology brand country initiated identify potential volume market share nearly biomarkers treating subgroup branded formulation 55 jumped five place ranked among top 15 pharma company uae uae business supported 27 brand sale diversified across portfolio includes cardiovascular drug anti histamine proton pump inhibitor oral antidiabetic chronic plaque psoriasis patient based approach abide helped several brand ranked alzumab physician improve practice among top 3 respective enriched patient connect cytosorb firstinclass therapy segment uae market enhanced clinical outcome since extracorporeal cytokine filter used one key product statix inception abide empowered manage wide range life atorvastatin generic nearly 3000 physician spread threatening condition seen brand feature among uaes top across 300 townscities across india intensive care unit underwent 5 cardiovascular brand segment panindia study evaluate clinical abide conferred award dominated innovator product outcome administered recognition prestigious research society study jalra jalram two patient suffering sepsis diabetes india rssdi licensed innovator brand septic shock benefit coverage impeccable novartis made significant inroad also initiated physiciancentric antidiabetes space since quality delivery 44th registry program alzumab launch fy16 positioning u one annual conference rssdi held cytosorb year key player segment hyderabad 2016 abide awarded rssdi uae recognition rssdi 2012 biocon introduced largest organization diabetes strengthened alliance abide unique education initiative researcher healthcare novartis fy17 medical practitioner treat professional asia validation transaction inlicense diabetes regular basis positive impact biocon company second brand exforge conduct basic course primary enrich healthcare ecosystem high blood pressure medication care physician advanced india launched shortly course consultant physician launch expected diabetologists course uae strengthen position uae delivered noncommercial branded formulation business cardiovascular market setting offer learning uae represented neobiocon currently rank among top 10 opportunity experience sustained momentum company sharing small group engagement 25 increase sale fy17 pragmatic application source ims fy16 fy17 56 ahead curve annual report 2017 biocon limited global marketing biocons global marketing team sale asiapacific apac ahead curve commonwealth independent anticipating growing worldwide state ci region almost doubled need affordable high quality previous year revenue drug address increasing africa middle east burden noncommunicable turkey afmet latin america disease consistently latam region witnessed strong aligned increasing doubledigit growth started trend among government adopt executing strategic roadmap generic formulation cut enter top 10 emerging healthcare spends market insulin mabs portfolio multiple licensing fy17 70 revenue agreement came international market global marketing 57 increasing global biosimilars widening scope furthered mission footprint differentiated small molecule provide affordable access worldwide biocons expertise biologics portfolio therapy chronic disease given firstmover advantage scaled leadership position biosimilars portfolio statin immunosuppressant enable partner launch following success biocons formulation nafta afmet insulin glargine launch japan latam region made inroad emerging market position biocon emerged among first u greater play addressing wave supplier rosuvastatin market opportunity usd 220 api partner u million also introduced brand market upon patent expiry insugen one ci market 2016 enabled partner currently market capture double digit share leader generic rhinsulin rosuvastatin market also space experienced revival sale fidaxomicin api increased apac region strengthened traction tacrolimus api position successfully winning u year antiobesity exclusive malaysian government product orlistat api made contract supply insugen significant inroad emerging also introduced insulin glargine market due safety profile also introduced rhinsulin insulin glargine highend quality ur ability make impact global market strong portfolio another differentiated complex latam nafta market cuttingedge chronic api product glatiramer acetate therapeutic hold key fy17 multiple sclerosis introduced unlocking next level significantly benefited key emerging market nafta growth biocon plan breast cancer patient india address market region partner synergistic alliance biosimilar trastuzumab diversified portfolio year built strong increased product penetration reflects strong global regional partnership orientation towards difficult algeria thus capturing dominant provide affordable small molecule tomake small molecule market share also prepared speciality apis generic insulin generic biosimilars market entry biosimilars thus giving payer licensing partnership ravi limaye physician patient greater president marketing latam apac country choice treatment option fy17 58 ahead curve annual report 2017 biocon limited research service syngene began journey 13 million sq ft syngene 7 growth early 1990s india first contract positioned address global research organization cro drug discovery outsourcing market h11604 million time industry country still infancy opportunity expected grow compounded annual rate 7 revenue year evolved usd 29 billion 2022 integrated discovery research service business development service provider syngene reported revenue new molecular entity across h11604 million fy17 multiple platform like small standalone basis syngenes total large molecule antibody drug revenue rose 14 h12716 conjugate oligonucleotides million growth broad today syngene publicly based across three business listed pure play cro india vertical dedicated rd center talented pool discovery service development 3000 scientist worldclass manufacturing service infrastructure spread across research service 59 capability expansion also help meet customer u fda audit without growing need bioinformatics observation last three year year company data analytics support expanded business include company also received two new dedicated rd center stateofthe art gmp good environmental clearance one amgen herbalife manufacturing practice commercialscale manufacturing nutrition syngene glp good laboratory practice facility setting five dedicated rd center compliant viral testing facility mangalore manufacture novel including bm abbott also set address need small molecule innovator nutrition baxter several pharma biotech client company area growth business driven fire incident addition new customer key rd program number syngenes client december 2016 well extension ongoing move advanced phase fire one syngenes research collaboration development open new facility bengaluru facility syngene amgen research including office laboratory opportunity expanding development center sarc space contributed approximately scope work line staffed team 100 20 total revenue strategy syngene commissioned highly qualified syngene scientist fire caused due chemical first phase new work closely amgen reaction conducted formulation facility researcher around world facility injury loss capable manufacturing clinical discovery development life part business commercial supply small innovative medicine dedicated continuity plan client volume niche technology product nutrition research center set related project redeployed complies regulatory herbalife develop formulate lab enhanced shift requirement u fda ema worldclass nutrition product working introduced minimize health authority indian consumer enable revenue impact lead healthier life syngene year company also also extended collaboration commissioned first phase abbott nutrition till end cy 2017 syngene research center spread year company also added new capability across 50000 sq ft fully commissioned center w e made good progress year strategic priority total area 200000 sq ft bioinformatics acquiring syngenes track record support integrated discovery building successful longterm asset related system biology development program relationship client heptox pharma bioinformatics newly expanded capability service bengalurubased strand syngenes clinical development worldclass scientist life science deal also brought facility successfully underwent infrastructure look forward onboard team highly skilled u fda ema audit accelerating growth coming year data scientist year company commitment complement syngenes existing quality compliance reflected jonathan hunt scientific intellectual capability track record clearing six chief executive officer syngene 60 ahead curve annual report 2017 biocon limited enablers r e e ar c h development supp ly c h ai n n g e e n hu n r e ur c e e n v ir n e n h e lt h sa f e c rp rat e c ia l r e p n ibi l enablers 61 research development biocon rd poised lead advent genomics future biotechnology heralded future therapy several successful regulatory filing difficulttotreat human disease biologics dossier ich regulated region biocon established biocon one leading player developing manufacturing r esearch development form bedrock biocons endeavour deliver affordable wellrecognized significant analytical process small therapeutic globally address unmet patient need biocons player drug development interfering rna sirna technology unique rd story built led way development unique method treatment worldclass competence biosimilars worked interferes nuclear capability robust infrastructure leading edge science top machinery cell enable talent pool extensive global product global regulatory agency development novel molecule development experience u fda ema exemplified target many disease unmet firsttosubmit biosimilar medical need dr narendra chirmule sr vice president head rd trastuzumab antiher2 monoclonal biocon leveraged cuttingedge antibody treatment breast technology since inception cancer 62 ahead curve annual report 2017 biocon limited first set biologics rd capability enablers v regulatory science helped commercial bioreactor india driven passion impact u position biocon ahead many today country largest global health built pharma player india bioreactors developing protein differentiated rd capability process product development therapeutic ability create year area biologics global scale made biocon one expertise array development novel top insulin manufacturer expression platform biosimilars leveraged world time include microbial capability among first established india mammalian system biocons successfully complete submission foremost innovative science pichia pastoris platform key biosimilars several technology driven organization expression recombinant protein jurisdiction across world constantly working address proprietary technology including u eu global disease burden consistent scalable mammalian structured approach incorporate cho nso cellbased expression biocon rd nurtured pool cuttingedge science technology platform used deliver highly talented scientist order deliver exciting novel biosimilar monoclonal expert field ranging portfolio biologics brought antibody bacterial host bioengineering molecular u reliability credibility system utilized numerous small biology analytical science clinical innovationled organization focussed molecule apis peptide science regulatory science providing affordable healthcare intellectual property management impressive pipeline approved highly robust process science biocons reputation enabled indevelopment biosimilars significantly augment ability collaboration leading academic novel molecule testimony develop worldclass biologics institution across world biocon rds vision ahead economical scalability combination high technology curve high productivity coupled high talent culture deep science quality upstream process support exciting deliverable biocon potential involving fermentation technology molecule pipeline transform field biotechnology downstream process technological enablers world protein purification develop capability rd always bulk drug substance india top biotech company strength excellence established decade effort constant focus platform technology spanning prepare next decade ahead curve process product development exponential growth working instrumental establishing ii analytical bioanalytical improving process efficiency india among top 12 biotech capability iii preclinical novel approach destination world clinical development strength flexible continuous second asia iv intellectual property research development 63 manufacturing high quality consistency formulation transferred working collaboration leading product learning vial cartridge make drug academic institution extensive regulatory interaction product process requires indian institute technology previous year evolved extensive science complex iit national institute process development technology understanding pharmaceutical educational process resulted exponential protein structure product stability research niper india well improvement ahead extractableleachables study harvard university massachusetts curve future process expertise formulation institute technology mit product science enabled u formulation product science several reputed international manufacture high quality drug essential part drug university analytical capability product patient worldwide development process biologics anchored cuttingedge biosimilars bulk tool latest orthogonal approach drug substance converted world class technology ensure biological process science molecular upstream formulation biology cell culture development recombinant clone process development scaleup development scaleup liquid gene knockout pcr based analytical perfusion fed batch technology suspension high concentration method control post translational lyophilized formulation modification cell culture purification upstream purification cell culture microbial microbial development purification process process development scaleup scaling high pressure match characteristic biosimiliar bacteria fungi yeast primary chromatography large column protein secondary metabolite recombinant protein peptide fermentation 64 ahead curve annual report 2017 biocon limited analytical bioanalytical science pioneer process product development turn result biocons stateoftheart equipment deep technical expertise nearly 20 year experience analytical bioanalytical science physicochemical functional analytical technology key component process product analytical tool applied inprocess well finished drug substance drug product analysis additionally major percentage method routed towards quality group manufacturing utilized product release assay analytical science characterization bioanalytical molecular method mass characterization development spectrometry characterization protein small method development peptide development method quantifying molecule nlinked olinked quality control expertise method peptide small molecule glycosylation glycations post development showing clearance biological fluid translation modification identification process related impurity characterization low abundance impurity establishing similarity analytics rd strength biosimilar primary structure higher order structure biologics development focused strategic qbd driven approach variant charge orthogonal technique glycosylation size sequence fingerprint similarity functional characteristic fab physiochemical fc function mabs characteristic research development 65 drug discovery preclinical able achieve structure moreover science relevant pharmacokinetic introducing innovative way selecting right molecule pharmacodynamic endpoint predictive toxicology adaptive clinical development establish safety efficacy clinical trial design hopefully prerequisite drug development product courtesy would significantly reduce cost successful regulatory approval scientifically rigorous ethically increase quality trial compliant stage gatebased future translational research development science cell based binding bioanalytical assay assay development qualification valuation potency assay insulin peptide development validation using pk immunogenicity measure mab mab conjugate biacore radioligand binding flow using elisa msd format cell based cytometry potency assay neutralizing antibody determination drug invivo toxicology discovery pharmacology preclinical mechanism action moa study protocol development glp moa pkpd clinical pd patient development invitro assay proof nonglp study evaluation selection marker assay enable concept animal model study histopathology animal tissue pharmacodynamic response diabetes autoimmune disease interpretation pk pd ihc biomarkers development companion oncology preclinical clinical sample diagnostics 66 ahead curve annual report 2017 biocon limited intellectual property process country strong regulatory capability biocon understands importance formidable task drug regulator rd coupled focused team ip biopharmaceutical u fda european union effort resulted u sector ip assumes much greater ema australia tga canada first file proposed biosimilar significance guide rd health canada brazil anvisa trastuzumab u fda ema commercialization strategy japan pmda etc unique regulatory filing two key company enables protection country specific process biosimilar mabs trastuzumab invention innovation followed mandatorily pegfilgrastim reviewed also help build credibility patent expiring novel u fda ema insulin enabling first mover advantage biologics several country glargine review europe many case ip also enables product articulated guideline launch insulin glargine positioning lifecycle management ensuring biosimilarity field japan major milestone well asset monetization evolving new regulatory since country reputed valuation biocon rd submission industry player stringent highly regulated market consistently created intellectual regulator payer physician scientific culture rd wealth incisive ip pharmacist learning biocons rd regulatory culture science strategy recognizes team playing key role dna always valued innovative potential product knowledge exchange cherished role part process till date filed evolution regulatory pathway rich scientific ecosystem nearly 1300 patent application establishing comparability rd employee access hold 1050 patent interchangeability extrapolation special club statistic 555 trademark registration indication among biosimilars medical writing forum access globally ip team brought international journal journal recognition biocon various award biocon indian biopharma company make prestigious asia ip elite list 2016 also awarded 9th national ip award 2017 category top indian company creating global brand along prestigious wipo user trophy regulatory science regulatory science team large number talented individual interface company regulator understanding guideline rule research development 67 club focus learning product approval launch quality curve put u ahead curve country excellence quality manufacturing facility small collaboration compliance essence molecule apis also underwent biocon belief strength biocons strategy ahead number regulatory audit strategic partnership curve rigorously follow including inspection u fda invested various partnership good manufacturing practice good fy17 underwent global pharma company like laboratory practice good 10 international regulatory mylan quark pharma several documentation practice throughout audit receive respective cgmp project since imperative operation compromise approval agency collaborate academia compliance turn ensures approved site include anvisa government institution highest standard quality brazil cofepris mexico mcc biocon rd lay lot emphasis time south africa ministry industry establishing relationship fy17 biocons manufacturing trade russian federation npra national international site underwent several regulatory malaysia ministry health institution collaboration inspection agency different ukraine include trinity country across world part college ireland queensland expect see increase new product approval process institute medical research regulatory inspection account verification compliance australia indian institute new product submission technology among others scope strong regulatory quality well periodic verification collaborative research includes manufacturing capability gmp compliance agency process development preclinical ensured continued global jurisdiction supply animal model exploratory acceptance complex small quality team fully geared meet biomarker study fundamental molecule biosimilar product intensified quality scrutiny science research project successful conclusion address increasingly demanding collaboration happen regulatory audit biologics benchmark regulatory agency different level critical drug substance drug product around globe growth robust rd organization manufacturing site facilitated 68 ahead curve annual report 2017 biocon limited supply chain management supply chain management scm year scm function demand biocons biologic function put biocon ahead enabled u build product also partnered curve focusing operational reputation trusted established global logistic excellence space characterized partner global pharmaceutical company meet need complex manufacturing process company rely apis effective cold chain system stringent regulatory norm formulation scm enabled ensure shipment safety built global scale end successful foray biologic created dedicated toend supply chain process product several emerging logistics team ensure business encompassing multiple business market readiness new market vertical several manufacturing strengthening scm practice enabled u shipping location diverse product channel ready ahead business portfolio meticulous planning smart scm function focused initiation new key sourcing disciplined monitoring building regulatory compliant market enabled u ensure ontime system process meet delivery customer demand imposed supply fy17 initiated implementation 100 country chain increased global ctpat custom trade supply chain management 69 strategic leverage supplier position global reach create competitive advantage develop supplier new strategic region lead industry bestinclass practice focus supply assurance mapping critical material financial cost management initiative predict market price trend buildup strategic inventory address price fluctuation price benchmarking strategy key cost driver functional operational p e r v e cultivate dynamic planning capability enhance performance reduce transactional complexity identify scope improvement extend supplier performance meet customer satisfaction focus green initiative integrated malaysia uniform sourcing operation platform training development promote employee engagement encourage disruptive idea identify meet training need employee certificate program high performing employee inclusive talent pool malaysia maintaining diversity partnership terrorism priority custom clearance increased complexity logistics guideline published u requirement implemented malaysia made good custom border protection system check balance progress tying local ensure aligned area packaging sustainability vendor helped reduce enhanced drug supply security terrainspecific transportation logistical challenge well requirement key u mode material safety delivery bridge sociocultural difference market simplify logistics efficiency procedure help biocon obtain address rising market diversity 70 ahead curve annual report 2017 biocon limited also ensured seamless operation key product using best class logistics service provider packaging vendor warehouse facility consolidation one site helped enhance capacity 20 better align business requirement functioning responsibility singleminded focus achieving business goal target biocons scm maintains high level ethic integrity sourcing vendor consolidation iii periodic vendor evaluation process orientation enabled u maintain spotless record reduce multiplicity biocon developed process meeting mandatory compliance transaction minimize periodically evaluate level process operational load vendor critical material internal external audit consolidated vendor basis selected metric year warehouse team plant bengaluru also contributing local supported facilitated 30 helped better planning economy facility audit including u effective negotiation biocon always strived create fda ema completed ii green supply chain strong local ecosystem procuring without critical observation moving animalorigin good availing service also working continuously recombinant supply base small medium size vendor improving operation key product based around manufacturing six sigma practice ensure better contributed significantly location 1520 working condition improved effort ensuring ecofriendly total supplier base small safety standard supply chain sourcing team medium enterprise local sourcing also focusing use green capability earn u multiple benefit sustainable sourcing initiative solvent eg ethanol majority term shorter turnaround time creation stable sourcing business unit thereby delivery quicker resolution platform critical biologics reducing dependence non issue pertaining material quality portfolio scm taken renewable form energy return help vendor step ensure longterm supply consolidating vendor solvent plan long term capacity sharing sustainability space delivery reduced forecast 12 month initiative taken include fuel cost per unit solvent contributing local economy consumed biocon also enhance sustainability operation supply chain management 71 g l ba l ur c n g fra e w rk strategic sourcing procurement ops vendor risk mitigation sourcing process execution operational dedicated team created compliance discipline managing sourcing risk drug substance drug cost management securing logistics product alignment budgetary timely delivery constraint geographic risk mapped coordinating vendor development crossfunctional interface supporting global vendor platform address longterm supply development plan risk sourcing constraint supply assurance monthly procurement review vendor sustainability org level procurement data integrated planning evaluation builtin analytics procurement crossfunctional team identify mitigate operational dynamism activated review progress sourcing risk riskmitigation activity top house risk mapped corporate level continuous improvement program review performance compliance award biocon conferred award overall excellence procurement sourcing excellence procurement transformation cpo forum india 72 ahead curve annual report 2017 biocon limited u n g n c w rk f r c e p u h n g h e e n v e l p k e e p b c n h e ad f h e cur v e human resource 73 human resource biocon innovative spirit put excellence high degree helping bring key u ahead competitor empowerment instilled project closer realization believe employing fostering confidence high sense best talent believe ownership people global employee base vital health driven make difference 9234 5245 497 3492 company year quality led u attracted brightest recognized among top 10 global mind challenged biotech employer annual survey status quo pushed conducted science science boundary science develop career magazine ranked u 9 affordable therapy 2016 13 previous impact global health skill year distinction helped transform goal company asia reality create new model feature prestigious list success sustain high level growth work culture past 12 month hr total india malaysia syngene unconventional thinking focus team played significant role biocon march 2017 74 ahead curve annual report 2017 biocon limited attracting talent fy17 increased hiring year used social 30 last fiscal within pool new hire 65 b medium extensively attract iocon wellrecognized best talent today techsavvy rise seniorlevel appointment among top global generation hold highest increase workplace diversity biotech employer highly also recruited country like regarded scientific talent brand index linkedin community u amongst peer making u u hong kong uae germany europe performance employer choice following malaysia driven work culture encourages digital integration recruitment unconventional thinking modified internship incubation exciting new idea tool receiving program year target young pursuit excellence 2500 application per month promising life science talent making biocon innovationled linkedin social medium international university organization comparable best world platform enabled u target addition various indian academic talent group almost zero cost institute niper iit amitava saha offered internship student sr vice president head hr biocons positioning world class employer brand enabled u university college cork recruit top talent ireland university glasgow country premier institute several imperial college london university candidate indian school california san diego university business accepted biocons offer melbourne university priority campus queensland among 650 recruitment candidate interned u offered job nearly 150 fy17 learning development manage lead change several addition program learning development play employee underwent focussed close 3000 employee attended critical role knowledgedriven group training program various training program organized organization like biocon isurge year learning development leadership development program team 30000 learning people biowin isurge womens implemented several initiative hour clocked year leadership program also conducted around business excellence focussed workshop several interpersonal excellence designed woman leader human resource 75 young organization checkup practice introduced biocon malaysia joined biocon preferred free thyroid health checkup industryacademia panel destination young aspiring woman employee universiti teknologi malaysia biotech professional fact utm universiti kebangsaan intent provide employee reflected age profile malaysia ukm industry platform pursue interest employee almost half size academia collaboration enable beyond work connect like human capital 34 year university tailor curriculum minded people launched make biocon incubator emerging industry trend biocon adventure sport club exciting new idea talent requirement industrial basc various event ideated visit new integrated insulin executed employee employee age profile manufacturing facility malaysia received good response across student several public organization private malaysian university invivo 2016 annual day provided practical 14 celebration biocon syngene insight working 4 marked great fanfare biopharmaceutical industry runup invivo 2016 21 61 several event conducted effective performance employee showcase talent management 250 employee felicitated robust performance long service several others management program designed recognized valuable encourage reward talent 1824 2534 3544 45 contribution organization harmonizes achievement organizational goal personal employee engagement initiative biocon malaysia growing aspiration milestone employee engagement strength comprehensive talent management initiative year biocon malaysia manpower framework identifies develops aimed motivating employee strength gone 12 critical talent crucial biocons give best stay committed nearly 500 employee last growth strategy organizational goal year learning initiative value enhanced sense intensified leveraging award wellbeing biocon academy program biocon recognized best address specific technical corporate hr practice apart regular employee functional training need nhrd comprehensive engagement activity year talent management framework conducted customized program biocon malaysia also company also felicitated aimed addressing early burnout making significant contribution world hrd congress 2016 healthy living build biotechnology industry excellence human resource wellness initiative biopulse ecosystem southeast asian management extension annual health nation three senior leader 76 ahead curve annual report 2017 biocon limited environment health safety biocon staying ahead safety integral part received iso 140012015 ohsas curve extends beyond business broader environment core 180012007 accreditation tüv adopting best global practice leadership decision process nord successful transition environment health focused providing safe earlier 2004 standard safety ehs comprehensive healthy work environment biocon line new globally governance system bolstered singleminded pursuit harmonized system ghs hazard bestinclass infrastructure philosophy ensured communication migrated specialized ehs system competent reportable incident safety data sheet sd team comprehensive program biocon year review ehs risk assessment sustainable thinking ehs management system ehs risk assessment program cornerstone corporate responsible corporate methodically detect evaluate responsibility biocon organization established risk various parameter ranging helped u move beyond statutory best class environment effect full organization compliance create responsible management system minimize potential impact individual business practice guarantee ecological footprint fy17 biocon employee also help efficiently environmental sustainability health environment health safety 77 prioritize risk determine industrial hygiene management resource yielded significant best way remove transfer committed industrial cost saving year mitigate risk based hygiene excellence aligning biocon believe small assessment define practice global standard step yield big result document ehs role strengthening achieved power saving 32900 responsibility employee part new biocon integrated kwh year operating facility fy17 industrial hygiene system installation ie3 motor switching conducted comprehensive implementation initiative carried led light improving efficiency enterprise risk assessment productwise industrial hygiene filter press reduction block addition evaluation study exposure reduction operation hour project line business continuity drive also upgraded reduce chemical consumption management existing sewage treatment unit effluent treatment led cost new bioremediation technology saving year ehs training introduced dspa dry ehs training program multiple plant operating sprinkler powder aerosol fire emphasizes safety practice simultaneously round year suppression system chemical enables employee identify imperative effectively synthesis block mitigate workplace safety manage environmental impact hazard ensure zero reportable energy conservation find way reduce carbon incident fy17 12000 energy conservation initiative footprint successfully cut carbon person hour invested ehs helped u restrict rise energy dioxide emission 36000 ton training consumption 10 despite year sourcing 44 nearly 20 yoy growth business million unit green power today employee actively participated fy17 identification low green power account 28 several external training cost power source optimization total energy consumption program covering safety aspect pharmaceutical industry prevention dust explosion best practice storage transportation hazardous chemical onsite also organized lead auditor internal auditor training iso 140012015 well symposium leadership safety management additionally steered various activity event across biocon facility mark national safety week fire service week chemical disaster prevention week 78 ahead curve annual report 2017 biocon limited award recognition fy17 received recognition state national level progressive ehs practice initiative included first prize best fuel efficient industrial boiler category adopting best safe practice karnataka state safety institute 4star rating ehs best practice confederation indian industry biocon volunteer revive dense vegetation lake resulted shrinking waterbody water inlet hebbagodi lake cleaned covered screen included biocon taken initiative contribute prevent debris washed lake lake revival mission bengaluru biocon foundation land cleared make place childrens took lead sign expression interest playground fencing cleared stretch eoi rejuvenation hebbagodi lake undertaken information board streetlight bring back lake workshop organized installed karnataka lake conservation development result effort water catchment area authority klcda detailed project report grown seen bird return submitted team working closely habitat motivates u push klcda relevant administrative body stakeholder enable fullfledged lake revival like district commissioner govt karnataka plan hebbagodi hebbagodi city municipal corporation cmc obtain necessary approval implementing also engaged local community detailed lake revival plan sensitize importance water body role preserving best civic meanwhile biocon cleaned area removed behaviour critical local community play debris weed around lake including active role lake conservation revival environment health safety 79 community program team hope biocon accord high importance health safety stakeholder including neighboring community fy17 biocon employee came together aegis namma biocommunity community connect initiative biocon make difference people life urban rural area focus ensuring clean green safe environment 40 member strong team biocon volunteer men woman spearheaded several drive year clean renovate number underpass around hosur road hebbagodi huskur hennagara bommasandra etc poor state thus making impossible use public added safety hazard namma biocommunity encouraged pedestrian area use underpass avert road accident namma biocommunity volunteer also helped renovate government high school neighboring area encouraged community participate tree plantation drive 80 ahead curve annual report 2017 biocon limited corporate social responsibility biocon foundation sustainable solution area treatment centre systematic basic health addressing documentation patient data biocon foundation csr arm burden chronic disease like biocon engaged cancer diabetes hypertension elaj smart clinic developing innovative solution elaj clinic technologyenabled given propensity address critical gap healthcare smart clinic equipped multi stay ahead curve education sanitation make parameter monitoring device extensively leveraged information enduring impact amongst enables multiple diagnostic test communication technology marginalized community india generation electronic medical develop unique ehealthcare various initiative record emrs patient model 2015 bring healthcare foundation aim empowering elaj model designed service doorstep integrating underprivileged deliver databased healthcare need social economic mainstream basis sociodemographic designed elaj smart clinic strengthen primary healthcare health indicator obtained healthcare delivery india converting communitybased screening public health initiative primary health center phcs innovative health delivery model successful providing comprehensive singlepoint facilitating effective preventive corporate social responsibility 81 primary healthcare intervention software connected secure secure server elaj emr system rural area karnataka server introduction elaj mapped unique id ensure rajasthan benefit model phcs provide access continuum care community poor access affordable healthcare service providing clinical consultation quality healthcare remote rural area essential diagnostic service clinic staffed diagnostic centre elaj fair price patient elaj doctor technician pharmacist smart clinic perform 50 clinic reduce outofpocket trained handle test result available expense improved diagnostics stateoftheart diagnostic hour patient record elaj clinic also reduce equipment clinic management digitized stored central burden tertiary hospital objective elaj continuum care quality monitor disease protocol examine generation healthcare profile trigger care delivery prevalence risk report alert case followed factor initiate stakeholder disease outbreak preventive health different level education 82 ahead curve annual report 2017 biocon limited biocons elaj model addressing gap public health delivery india infrastructure training data entry operator quality care improving upgrading collect health information ensured iphs norm infrastructure phcs efficiently related infrastructure training anms health worker manpower facility renovating toilet labor room data collection immunization followed installing diagnostic centre antenatal checkup upgraded labor room ensure phc institutional delivery electronic medical record providing laptop phc patient record digitized ensured proper power backup proper documentation mapped unique id ensure water supply staffing continuum care provided laptop pregnancy recruiting doctor auxiliary child tracking health service secure server store data nurse midwife anms general management system pct data patient privacy maintained nurse midwife gnms data entry entry operator pharmacist lab multiparameter monitor installed record vitals ensured water sanitation technician support staff hygiene wash practice ensuring vacancy three interconnected module followed filled registration clinical consultation diagnostics working government ensuring phcs running set biomedical waste disposal per indian public health dashboard capture data protocol standard iphs norm disease profile community staffing notification help tackle seasonal disease outbreak training capacity building training lab technician use dashboard ensure followup semiautomatic lab device disease surveillance patient treatment insurance profile community disease bengaluru 2015 scheme trend dashboard sends disease pilot huskur provided notification alert organic workflow pattern proof concept scale administrator enables forward start baseline indicator model elsewhere end planning implementation preventive health culminates 2016 elaj smart clinic model needbased healthcare program treatment enables surveillance installed eight clinic moreover notification help monitoring evaluation karnataka run exclusively healthcare provider plan health status population biocon foundation seasonal disease outbreak data individual clinic group clinic available elaj smart clinic scaling health administrator live biocon foundation set first dashboard capture patient elaj smart clinic huskur footfall vital parameter disease corporate social responsibility 83 smart clinic patient doctor interface elaj smart clinic patient registration ehr vitals mpm620 doctor pharmacy diagnostics test report referral secondarytertiary care smart clinic footprint 84 ahead curve annual report 2017 biocon limited 2016 biocon foundation smart clinic model 15 government secondary healthcare completed adoption five run phcs karnataka first effective use technology biocon government phcs rajasthan flagged foundation recognized widely public private partnership ppp february 2017 implementing innovative healthcare government rajasthan ppp biocon foundation aim model create sustainable strengthening present public health ecosystem joining hand january 2017 biocon foundation healthcare system karnataka government aspire government karnataka providing solution around primary benefit many village signed mou install elaj disease profile patient visiting elaj smart clinic fy17 past year patient footfall elaj smart clinic gone 50 9000 7 month patient footfall spiked july october 4 9 seasonal illness hitting peak 13330 35 september 2016 overall data show majority 16 patient visit elaj clinic prompted infectious disease 35 fever pain 29 29 rajasthan run five elaj smart clinic also saw jump patient footfall julyoctober period patient diagnosed clinic mostly suffering pyrexia 31 diarrhoea 27 also infectious disease fever pain seeing good traction laboratory test conducted non communicable disease elaj clinic rajasthan number soaring 13 trauma orthopedics time april 2016 february 2017 ent others corporate social responsibility 85 karnataka elaj model per government requirement officer health department combine good infrastructure collect data monitor hrps latest technology best elaj phcs collaborate dashboard help available medical expertise private doctor part monitor hrp case ensure foundation currently run 14 pmsma proper preparation done elaj clinic covering 30 gram case referral phcs provided fetal panchayat across karnataka doppler foundation case highrisk pregnancy case rajasthan check fetal heart rate elaj phcs follow action plan pradhan mantri surakshit glucometers strip referral higher institution matritva abhiyaan anc camp provided phcs track blood delivery hrps whose india rank first list 10 sugar level pregnant woman delivery due next two country account 60 month referred higher creating monthly action plan preterm birth yet india little institution health centre smooth 50 antenatal care management highrisk birth emergency coverage order tackle issue pregnancy hrp case preparedness plan pregnant premature birth low birth weight woman expected deliver baby stillbirth essential recommended hrps next two month special increase coverage antenatal pmsma guideline elaj health focus high risk case care country enable centre use red sticker ministry health family highrisk individual mamta card referral higher institution welfare government india iron sucrose severe anaemia elaj phcs provide vehicle launched program called pradhan case referred either pick drop pregnant mantri surakshit matritva abhiyaan inpatient phc facility woman antenatal checkup pmsma available higher elaj dashboard given institution aim program provide medical officer senior comprehensive package antenatal care service pregnant woman second third trimester government health institution biocon foundation helping rajasthan government implement pmsma efficiently elaj phcs biocon foundation ensuring smooth implementation pmsma elaj phcs use unique prescription form designed 86 ahead curve annual report 2017 biocon limited referral higher institution multipronged approach ncd breast cancer treatment pregnant management elaj smart clinic biocon foundation run breast woman identified includes cancer screening program clinical condition association ue life science health promotion prevention treatment cant provided phc screening includes clinical strategy healthy lifestyle fy17 nearly 2500 pregnant prevent ncds associated breast examination examination woman attended pmsma camp risk factor handheld device 350 found intelligent breast examination ibe garner evidence action high risk pregnancy case novel u fda approved medical disease surveillance 34000 ironfolic acid tablet instrument prescreening monitoring research distributed anaemic woman breast lesion found biocon foundation also identified psychosocial counselling meet lesion referred 450 woman family emotional social mental ultrasoundmammography planning counselling need patient device able identify high priority patient require human resource non communicable capacity building prevention ultrasound mammography disease treatment ncds first level therefore reducing risk developing breast cancer noncommunicable disease ncds early diagnosis periodic also known chronic disease 1755 person screened opportunistic screening passed person person breast cancer year 185 population long duration found lesion breast treatment care ncd among 90 underwent generally slow progression patient special health camp mammography india transiting speedily handholding referral lifestyle disease ncds contribute required around 587 million death account 60 death india urgent need put ncds centre country health policy plan program biocon foundation believe integrated community based risk factor management program costeffective efficient approach tackling ncds conducting populationbased screening oral cervical breast cancer corporate social responsibility 87 oral cancer risk profiling data generated malnutrition early detection prevention help characterize health status 2015 global hunger index ghi oral cancer drastically reduce community identify new ncd report ranked india 20th amongst mortality economic burden case assess vulnerability leading country serious community nearly associated risk factor year hunger situation one major 6900 patient screened 1200 individual cause malnutrition india year third tested positive screened economic inequality due low potentially malignant lesion ncd health camp social status population fortunately positive case oral biocon foundation also conduct group diet often lack cancer detected monthly health camp type 2 quality quantity woman cervical cancer diabetes hypertension suffer malnutrition less phcs located across karnataka likely healthy baby cervical cancer often early diagnosis carried india mother generally lack good successfully treated diagnosed along health screening nutritional knowledge consequently early nearly 1000 woman camp health checkup newborn infant unable get screened 133 tested positive free medicine lab adequate amount nutrition reproductive tract infection 21 investigation subsidized mother abnormal pap smear one case cervical cancer detected year year witnessed total footfall well baby clinic 8000 ncd health diabetes hypertension malnutrition prevented camp 2300 diabetes adequate primary healthcare biocon foundation developed hypertension case managed community education comprehensive program camp year behavior change order detection management type camp also provide test hypothesis biocon 2 diabetes hypertension psychosocial counselling stress foundation established pediatric phcs foundation routinely management blood glucose control clinic austin town bengaluru conduct survey community quitting tobacco use collaboration st john community health department 2016 clinic provides general pediatric consultative service followup ill child support physical emotional wellbeing child family adopted communitybased management acute malnutrition cmam approach enables u identify initiate treatment 88 ahead curve annual report 2017 biocon limited child severe acute progress monthly health fy13 role supplementary malnutrition sam camp organized clinic government integrated become seriously ill four also provide home counselling child development service icds main component approach program developed referral required comprehensive strategy curb community mobilization child medical complication malnutrition area community health worker chws referred inpatient medical sensitize community treatment year organized total child anthropometric assessment 190 health camp managed year organized eight health identify acute malnutrition case total 834 case malnutrition camp malnutrition 216 sam case showed supplementary feeding program 155 case managed improvement upward growth sfp provide readytouse total five sam case identified trend 92 recorded 14 therapeutic food rutf child balaspandandana bagalkot reduction anemia case rutf energy dense program micronutrient enhanced paste used therapeutic feeding biocon foundation started nutrition intervention child outpatient therapeutic program five year bagalkot district otp monitor childrens education selfreliance child government school karnataka closely aligned directorate year 100000 biocon foundation keenly secondary research training student across 1400 school aware fact quality curriculum standard vii karnataka received workbook education child receive since 2006 distributed also trained 1200 teacher school determines quality workbook initiative future critical gap learning underserved child various language numeracy skill could affect ability attain sustainable livelihood lead productive healthy life biocon foundation attempted plug critical gap mathematics learning chinnara ganitha workbook developed collaboration macmillan publisher india workbook approach mathematics activity game local language thereby inculcating corporate social responsibility 89 biocon academy biocon took leadership role career biotech industry producing highly skilled bio field biotechnology forward collaborated leading scientist year talented establish biocon academy global institute like keck graduate pool 100 student graduated premier center excellence institute kgi california u bit biocon academy advanced applied learning pilani india offer global quality successfully placed bioscience bengaluru 2014 learning indian student leading life science company graduate academy biocon academy csr initiative short span three year biocon hired diverse role production leveraged rich industry academy instrumental quality assurance regulatory affair experience biocon domain shaping career research development knowledge international 300 aspiring bioscientists marketing academic partner empower imparting requisite experiential experienced well recent life learning serf bridge 35 company science graduate translational existing industryacademia gap participated academy education industrial proficiency campus placement program academy jobskills development year 60 contributed immensely enrich essential build promising graduate found job outside life science ecosystem india 90 ahead curve annual report 2017 biocon limited biocon rest placed training biocons quality control global life science industry various department biocon production laboratory opportunity bioscientists syngene cgmp training biocon widen india abroad scope handson training biocon kgi certificate program bit biocon program applied student academy bioscience industrial microbiology collaborated bengalurubased academy flagship program biopharmaceutical service company building success offered collaboration keck biozeen new horizon first batch bit biocon program graduate institute premier college engineering offer quality control microbiology american school bioscience practical training session academy broadened education saw successful facility course curriculum modified completion three batch program rename bit academy also introduced fy17 fulltime certificate biocon program applied industrial special mentorship session program spread 18 week microbiology student faculty includes classroom session best alumnus kgi california exclusive program designed application biotechnology enhance knowledge skill well industry assignment fy17 90 student successfully aspiring microbiologist pharmacy handson training completed program including biotech graduate seek eight malaysia classroom session involve accelerate learning fast placed leading pharma synchronous transmission course growing field microbiology biopharma company learning material developed boost job prospect student offered faculty kgi alumnus meet microbiology bioscience california session highly program offer experiential learning biocon kgi program alumnus interactive create personalized combining real world insight introduced kgi connect learning environment kgi classroom learning various aspect alumnus portal kgi student faculty member student microbiology intensive california portal give biocon engage real time conversation curriculum delivered renowned academy graduate opportunity faculty bit pilani biocon broadbased international network kgi alumnus well academy subject matter expert curriculum program provide access extensive smes biocon addition encompasses domain rd learning resource honing technical skill program production quality assurance academy also organized also sharpens professional regulatory science product second alumnus meet skill candidate provides development additionally attended 100 graduate opportunity holistic development professional skill training prepares event chaired kiran mazumdar biotech student necessary fy17 batch 20 student shaw chief mentor biocon academy knowledge skill make completed bit biocon program dr sheldon schuster president employable industry placed kgi california provided interesting leading pharma biopharma student undergo functional insight new trend company biocon academy 91 international event event witnessed faculty development program biocon academy association participation 95 scientist seek empower biotech american chemical society 11 organization globally faculty various educational medicinal chemistry division institute helping upgrade new program pharma innovation sourcing knowledge emerging biocon academy developed industryspecific technology center u organized medicinal two new program biocon program rolled fy18 chemistry drug discovery kgi certificate program clinical development india 2017 mcaddi biocon offer scholarship upto development biocon 2017 residential course 75 student take academyfaculty development medicinal chemistry drug care major portion cost program expand offering discovery campus bengaluru expensive international biotech world clinical mcaddi 2017 presented program development program principle medicinal chemistry designed equip pharmacy drug discovery development graduate postgraduate format designed industrial diploma holder skill academic participant needed build successful career currently working area plan realm clinical development 92 ahead curve annual report 2017 financial report board report 93 management discussion analysis 130 corporate governance report 142 business responsibility report 156 standalone financial statement 167 consolidated financial statement 217 board report 91 biocon limited biocon limited board report dear shareholder present thirtyninth annual report business operation along audited financial statement auditor report company financial year ended march 31 2017 financial highlight million except eps particular standalone result consolidated result fy17 fy16 fy17 fy16 total revenue 27172 25085 40787 34602 expense 21810 20552 32453 28912 share net profit joint venture 163 217 profit tax exceptional item 5362 4533 8497 5907 exceptional item 1061 1606 profit tax 5362 5594 8497 7513 income tax 1211 845 1538 1299 income tax exceptional item 1042 1063 78 123 noncontrolling interest 760 587 profit year 5193 3686 6121 5504 comprehensive income net 84 10 764 58 total comprehensive income 5277 3676 6885 5446 earnings per share eps exceptional item 2115 1879 3159 2048 earnings per share eps exceptional item 2645 1878 3118 2804 standalone consolidated financial statement standalone consolidated financial statement company prepared accordance indian accounting standard ind notified company indian accounting standard rule 2015 period including year ended march 31 2016 company along subsidiary associate joint venture prepared financial statement accordance accounting standard notified section 133 company act 2013 read together paragraph 7 company account rule 2014 indian gaap financial statement year ended march 31 2017 first prepared company subsidiary associate accordance ind statement containing salient feature financial statement subsidiary pursuant subsection 3 section 129 company act 2013 prescribed form aoc1 appended annexure 1 board report statement also provides detail performance financial position subsidiary board report 93 state affair highlight company standalone performance revenue operation grew 12 26184 mn 23354 mn fy16 income fy17 988 mn fy16 1731 mn primarily due foreign exchange gain 160 mn dividend subsidiary 487 mn fy16 core operating margin ebidta excluding rd forex dividend subsidiary remained similar level compared fy16 exceptional item previous year company gain net tax sale equity share company subsidiary syngene international limited syngene mat credit gain recorded previous year due uncertainty utilization current year pursuant change income tax law business restructuring company belief able utilize mat credit entitlement accordingly year ended march 31 2017 company recorded mat credit entitlement 1042 mn standalone financial statement however consolidated financial statement entitlement recognised credit equity along underlying dilution gain sale equity stake syngene impact group control profit year stood 5193 mn 41 fy16 pat excluding exceptional income net tax 5193 mn fy16 3688 mn effective tax rate etr year 3 due mat credit recorded exceptional income fy16 etr exceptional item 23 year consolidated revenue registered growth 18 40787 mn 34602 mn fy16 segment perspective small molecule recorded growth 12 research service business registered yearonyear increase 7 biologics branded formulation recorded annual growth 43 24 respectively consolidated profit year grew 11 6121 mn 5504 mn profit fy17 included tax exceptional income 78 mn exceptional gain 1483 mn net tax fy16 explained detail section management discussion analysis bonus view encouraging participation small investor making equity share company affordable increasing liquidity equity share expand retail shareholder base director meeting held april 27 2017 recommended issue bonus share two equity share every one equity share held member record date determined board director board consequent proposal issue bonus share authorised share capital company proposed increased 110 crore 22 crore equity share 5 300 crore 60 crore equity share 5 director decided seek approval shareholder proposal way postal ballot dividend director pleased recommend final dividend 3 prebonus per equity share face value 5 per equity share financial year ended march 31 2017 amounting 600 mn view net cash generated operation substantially deployed capex taking account future capital commitment director consider prudent propose dividend dividend payout subject approval member ensuing annual general meeting agm dividend paid member whose name appear register member record date determined board respect share held dematerialised form paid member whose name furnished national security depository limited central depository service india limited beneficial owner record date dividend distribution policy per provision regulation 43a sebi lodr top 500 listed company shall formulate dividend distribution policy accordingly policy adopted set parameter circumstance taken account board determining distribution dividend shareholder retaining profit earned company policy appended herewith annexure 2 board report also available company website httpwwwbioconcomdocsdividend_distribution_policypdf transfer unpaid unclaimed amount iepf pursuant provision section 1245 company act 2013 dividend remains unpaid unclaimed period seven year date transfer unpaid dividend account required transferred company investor education protection fund iepf established central government provision section 125 company act 2013 year review company credited unpaid unclaimed dividend financial year 200809 amounting 648003 lying unpaid dividend account investor education protection fund iepf subsidiary joint venture company formulated policy determining material subsidiary pursuant provision listing agreement said policy available company website httpwwwbioconcomdocspolicydocument_materialsubsidiarypdf year biocon biologics india limited incorporated june 08 2016 wholly owned subsidiary biocon biologics limited uk buk march 31 2017 company 10 subsidiary report performance financial position subsidiary presented 94 ahead curve annual report 2017 biocon limited syngene international limited india syngene international limited syngene one india leading contract research organisation offering suite integrated endtoend discovery development service novel molecular entity nmes across industrial sector including pharmaceutical biopharmaceutical biotechnology amongst others syngene help client conducting discovery hit candidate selection development including preclinical clinical study analytical bioanalytical evaluation formulation development stability study pilot manufacturing scaleup preclinical clinical supply distinctive economic advantage unlike traditional business model service offered flexible business model ranging fulltime equivalent fte feeforservice ffs model combination customized client specific requirement year ended march 31 2017 syngene registered revenue growth 14 12716 mn fy17 fy16 11133 mn ebidta margin year 38 operating margin 4783 mn fy16 3867 mn registering growth 3 pursuant fire incident december 12 2016 syngene certain fixed asset inventory content one building damaged syngene lodged initial estimate loss insurance company survey currently ongoing year ended march 31 2017 syngene written net book value asset aggregating 795 mn recognised minimum amount insurance claim receivable equivalent amount addition group process determining claim business interruption accordingly recorded claim arising therefrom stage april 27 2017 board director syngene recommended dividend 1 10 per equity share fy17 entailing payout 200 mn dividend payout subject approval member ensuing annual general meeting agm biocon research limited india biocon research limited brl 100 subsidiary company undertakes discovery development research work biologics provides scientific support various development programme group brls current business largely directed towards rd service monoclonal antibody molecule protein mabs insulin tregopil formally referred in105 insulin product behalf group company research program undertaken brl made significant inroad next level global clinical trial brl continues hold 093 shareholding syngene fy17 brl registered turnover 1657 mn reported net profit 661 mn compared turnover 4100 mn net profit 832 mn fy16 fy16 turnover included outlicensing development commercialisation right mabs buk consideration 2820 mn biocon pharma limited india biocon pharma limited bpl wholly owned subsidiary company bpl would engaged development manufacture generic formulation sale global market especially opportunity u eu bpl process setting formulation manufacturing facility oral solid dosage biocon sez bengaluru fy17 7 mn equity share face value 10 issued biocon limited face value march 31 2017 bpl commenced commercial operation capital workinprogress 1130 mn fy16 150 mn biocon pharma inc usa biocon pharma inc bpi wholly owned subsidiary biocon pharma limited incorporated july 2015 united state america bpi engaged commercialization generic formulation united state march 31 2017 bpi commenced commercial operation biocon biologics limited uk biocon biologics limited buk wholly owned subsidiary company incorporated united kingdom march 2016 buk house biocons biosimilar biologics business biocon sdn bhd wholly owned subsidiary buk year ended march 31 2017 buk earned 1826 mn revenue reported net loss 189 mn biocon sdn bhd malaysia biocon sdn bhd malaysia step subsidiary company wholly owned buk biocon sdn bhd established objective set group first overseas manufacturing facility malaysia facility located within bioxcell biotechnology park nusajaya johor promoted malaysian government manufacturing facility designed manufacture recombinant human insulin insulin analog received local cgmp certification national pharmaceutical control bureau plant capitalised 16851 mn end current year based readiness start commercial supply average useful life plant expected 16 year biocon sdn bhd seek approval leading regulatory agency across globe marketing product rest world fy 18 approval developed market expected coming year biocon sdn bhd also continue research development activity pertaining human insulin analogue acquired biocon sa biocon sdn bhd reported total revenue 998 mn net profit 5 mn fy17 biocon biologics india limited india biocon biologics india limited bbil step subsidiary company wholly owned buk bbil incorporated june 08 2016 india objective set green field biosimilar biologics facility march 31 2017 bbil commenced commercial operation board report 95 biocon sa switzerland biocon sa wholly owned subsidiary company primarily engaged identifying developing novel molecule commercial product licensable asset strategic partnership current year biocon sa registered net profit 684 mn 1229 mn fy16 exceptional gain explained resulted increased net profit fy16 exceptional item comprises amount 2561 mn net tax released deferred balance pursuant contract laboratory pisa sa de cv pisa mexico codevelopment commercialization generic recombinant human insulin rhinsulin u market b impairment charge 1078 mn marketing right t1h product u canada region territory due uncertainty commercialisation product territory owing ofac sanction c year ended march 31 2017 biocon sa biocon sdn bhd entered assignment license agreement pursuant biocon sa transferred right interest obligation insulin analog ipr biocon sdn bhd consequent transfer bsa recorded gain 1150 mn net tax 78 mn biocon fz llc uae biocon fz llc wholly owned subsidiary company based dubai incorporated june 2015 biocon fz llc established marketing entity pharmaceutical product target market middle east gcc year ended march 31 2017 biocon fz llc earned 1328 mn revenue reported net loss 21 mn biocon academy india biocon academy spearhead biocons csr initiative technical professional education segment academy established centre excellence advanced learning bioscience 2014 biocon academy leverage rich industry experience biocon subject matter expertise international education partner keck graduate institute claremont california usa academy dedicated exclusively industry oriented bioscience education program offered academy aim empower biotechnology engineering graduate advanced learning industrial proficiency jobskills development essential build promising career biotech industry management discussion analysis term provision regulation 34 sebi listing obligation disclosure requirement regulation 2015 sebi lodr management discussion analysis set annual report corporate governance company committed maintain highest standard corporate governance believe sound corporate governance critical enhance retain investor trust disclosure seek attain best practice corporate governance prevalent globally implemented several best corporate governance practice company enhance longterm shareholder value respect minority right business decision corporate governance report fy 201617 form part annual report requisite certificate auditor company confirming compliance condition corporate governance stipulated sebi lodr annexed corporate governance report business responsibility report business responsibility report brr company year 201617 form part annual report required regulation 342f sebi listing obligation disclosure requirement regulation 2015 employee stock option plan esop nomination remuneration committee board inter alia administers monitor company employee stock option plan plan accordance sebi share based employee benefit regulation 2014 sbeb regulation plan implemented biocon india limited employee welfare trust esop trust year ended march 31 2017 total 499689 share transferred esop trust eligible employee company prevailing esop plan march 31 2017 esop trust held 3529870 equity share company year ended march 31 2017 material change company existing plan plan compliance sbeb regulation information required sbeb regulation read sebi circular circfdpolicy cell22015 dated june 16 2015 uploaded company website accessed weblink httpwwwbioconcombiocon_invrelation_annualreportsaspsublinkfinance applicable disclosure stipulated sbeb regulation march 31 2017 appended herewith annexure 3 board report company received certificate statutory auditor scheme implemented accordance sbeb regulation resolution passed shareholder certificate would placed agm inspection member 96 ahead curve annual report 2017 biocon limited deposit company accepted deposit amount principal interest outstanding balance sheet date loan guarantee investment detail loan guarantee investment covered provision section 186 company act 2013 form part note financial statement policy director appointment remuneration company current policy appropriate mix executive independent director maintain independence board separate function governance management march 31 2017 board consists 10 director majority independent director besides chairperson managing director promoter board comprises vice chairman wholetime director ceo joint managing director non executive director 6 independent director board periodically evaluates need change composition size policy company director appointment remuneration including criterion determining qualification positive attribute independence director matter required subsection 3 section 178 company act 2013 formulated nomination remuneration committee policy company director appointment remuneration appended herewith annexure 4 board report board diversity diverse board enables efficient functioning difference perspective skill also foster differentiated thought process back varied industrial management expertise gender knowledge geographical background board recognises importance diverse composition adopted board diversity policy set approach diversity policy available weblink httpwwwbiocon comdocspolicydocument_boarddiversitypdf declaration independent director company received necessary declaration independent director section 1497 company act 2013 heshe meet criterion independence laid section 1496 company act 2013 regulation 25 sebi lodr board evaluation pursuant provision company act 2013 regulation 19 sebi lodr board carried annual performance evaluation performance director individually well evaluation working various committee structured questionnaire prepared taking consideration input received director covering various aspect board functioning adequacy composition board committee board culture execution performance specific duty obligation independence governance ethic value adherence corporate governance norm interpersonal relationship attendance contribution meeting etc separate exercise carried evaluate performance individual director including chairperson board evaluated parameter participation contribution commitment including guidance provided senior management outside board committee meeting effective deployment knowledge expertise effective management relationship various stakeholder independence behaviour judgment etc performance evaluation independent director carried entire board performance evaluation chairperson managing director carried independent director evaluation process explained corporate governance report board reviewed evaluation result collated nomination remuneration committee appointment director key managerial personnel member 38th agm held june 30 2016 appointed mr damodaran independent director period three consecutive year term upto conclusion 41st agm company calendar year 2019 member said agm also appointed dr arun chandavarkar ceo joint managing director director liable retire rotation thank member support confirming mentioned appointment board recommendation nomination remuneration committee appointed mr rajiv balakrishnan company secretary compliance officer effective january 24 2017 place mr kiran kumar g relinquished post company secretary company pursue interest within group board place record appreciation service rendered mr kiran kumar g tenure company secretary retirement reappointment per provision section 1526 company act 2013 prof ravi mazumdar retires rotation ensuing agm eligible seek appointment board recommends reappointment current term appointment mr russell wall m mary harney mr daniel bradbury independent director company shall come end ensuing agm based outcome performance evaluation nomination remuneration committee recommended continue term appointment independent director nominated board reappointment mr russell wall m mary harney mr daniel bradbury independent director additional term five consecutive year company received declaration three independent director confirming meet criterion independence prescribed subsection 6 section 149 company act 2013 regulation 25 sebi lodr company also received requisite notice writing member proposing mr russell wall m mary harney mr board report 97 daniel bradbury independent director company board recommends appointment mr russell wall m mary harney mr daniel bradbury independent director committee board currently board four committee audit risk committee nomination remuneration committee corporate social responsibility committee stakeholder relationship committee required provision section 177 8 company act 2013 composition audit committee disclosed mr russell wall chairman mr daniel bradbury dr jeremy levin mr damodaran detailed note composition board committee provided corporate governance report section annual report meeting board meeting board scheduled regular interval decide discus business performance policy strategy matter significance schedule meeting circulated advance ensure proper planning effective participation meeting certain exigency decision board also accorded circulation board financial year 201617 met four time maximum interval two meeting exceed 120 day prescribed company act 2013 detailed information regarding meeting board included report corporate governance form part board report related party contract arrangement transaction entered related party defined company act 2013 year ordinary course business arm length basis company formulated policy materiality related party transaction process dealing transaction line provision company act 2013 sebi lodr also available weblink httpwwwbioconcomdocs policydocument_relatedpartytransaction_2015pdf prior omnibus approval audit risk committee obtained transaction repetitive also normal nature disclosure related party contract arrangement made audit risk committee board quarterly basis year review material related party transaction regulation 23 4 sebi lodr entered company necessitates approval shareholder particular contract arrangement related party referred section 188 1 company act 2013 prescribed form aoc 2 appended herewith annexure 5 board report credit rating crisil icra continued reaffirm rating aa stable a1 various banking facility throughout year enabling company avail facility bank attractive rate indicating strong degree safety timely payment financial obligation conservation energy technology absorption foreign exchange earnings outgo particular prescribed subsection 3m section 134 company act 2013 read company account rule 2014 appended herewith annexure 6 board report auditor statutory auditor messrs b r co llp chartered accountant icai registration 101248ww100022 appointed statutory auditor company hold office conclusion 38th agm held june 30 2016 conclusion 43rd agm company held calendar year 2021 subject ratification appointment member every agm required provision section 1391 company act 2013 company received written consent b r co llp chartered accountant appointment certificate effect appointment made would accordance company act 2013 rule framed thereunder satisfy criterion provided section 141 company act 2013 member requested ratify appointment statutory auditor ensuing agm auditor report financial statement company year ending march 31 2017 unmodified ie contain qualification reservation adverse remark auditor report enclosed financial statement forming part annual report cost auditor board director recommendation audit risk committee appointed messrs rao murthy cost accountant firm registration number 000065 cost auditor company fy 201718 section 148 company act 2013 messrs rao murthy cost accountant confirmed appointment within limit section 1413 g company act 2013 also certified free disqualification specified section 1413 proviso section 1483 read section 1414 company act 2013 audit risk committee also received certificate cost auditor certifying independence arm length relationship company 98 ahead curve annual report 2017 biocon limited per provision company act 2013 remuneration payable cost auditor required placed member general meeting ratification accordingly resolution seeking member ratification remuneration payable messrs rao murthy cost accountant included notice convening 39th agm secretarial auditor pursuant provision section 204 company act 2013 rule thereunder m sreedharan co practicing company secretary appointed conduct secretarial audit company fy 201617 secretarial audit report fy 201617 appended herewith annexure 7 board report secretarial audit report contain qualification reservation adverse remark board appointed mr damodaran m damodaran associate practising company secretary secretarial auditor company financial year 201718 risk management policy company put place enterprise wide risk management framework object timely identification risk assessment evaluation line overall business objective define adequate mitigation strategy quarterly basis audit risk committee review critical risk rotation basis line mitigation progress effectiveness impact overall risk exposure company critical risk area covered least year annually critical risk area identified reevaluated internal financial control company laid certain guideline process structure enable implementation appropriate internal financial control across organisation internal financial control encompasses policy procedure adopted company ensuring orderly efficient conduct business including adherence policy safeguarding asset prevention detection fraud error accuracy completeness accounting record timely preparation reliable financial information include control process manual application including erp application wherein transaction approved recorded appropriate review control mechanism built place ensure control system adequate operating effectively inherent limitation internal financial control including possibility collusion improper management override control material misstatement financial reporting due error fraud may occur detected also evaluation internal financial control subject risk internal financial control may become inadequate change condition compliance policy procedure may deteriorate company material respect adequate internal financial control system internal financial control operating effectively based internal control criterion established company considering essential component internal control stated guidance note audit internal control financial reporting issued institute chartered accountant india vigil mechanism vigil mechanism envisaged company act 2013 rule prescribed thereunder sebi lodr implemented company whistle blower policy enable director employee stakeholder company report genuine concern provide adequate safeguard victimisation person use mechanism make provision direct access chairman audit risk committee whistle blower policy company available company website accessed weblinkhttpwwwbioconcomdocsbiocon_ group_integrity_whistle_blower_policypdf director responsibility statement pursuant requirement section 134 3 c company act 2013 director confirm preparation annual account applicable accounting standard followed along proper explanation relating material departure b selected accounting policy applied consistently made judgement estimate reasonable prudent give true fair view state affair company end financial year profit loss company period c taken proper sufficient care maintenance adequate accounting record accordance provision act safeguarding asset company preventing detecting fraud irregularity prepared annual account going concern basis e laid internal financial control based internal control framework established company adequate operating effectively f devised proper system ensure compliance provision applicable law system adequate operating effectively particular employee statement containing particular term section 197 12 company act 2013 read rule 51 company appointment remuneration managerial personnel rule 2014 form part report appended herewith annexure 8 board report board report 99 statement containing particular term section 19712 company act 2013 read rule 52 53 company appointment remuneration managerial personnel rule 2014 form part report considering first proviso section 1361 company act 2013 annual report excluding aforesaid information sent member company others entitled thereto said information available inspection registered office company business hour working day company date ensuing annual general meeting shareholder interested obtaining copy thereof may write company secretary regard corporate social responsibility csr biocon csr integral part business since inception incorporation biocon foundation 2004 company formally structured csr activity today company span csr effort biocon foundation biocon academy partnership program like minded private organization government company promotes social economic inclusion marginalized community integrated system focussing largely following area health care service company firmly belief use technology make healthcare delivery rural area efficient therefore developed integrated holistic healthcare delivery service seek address critical gap delivery healthcare rural india effort targeted enabling last mile reach preventive primary health service rural area education company project address experiential learning basic math computer skill language skill underserved young people rural area also imparts advanced training necessary skill required gainful employment biopharma sector young graduate biocon academy promote art culture india rich heritage art culture across land need preserved promoted various form music dance style painting sculpture intrigued many across globe yet large pool artiste gained enough recognition biocon foundation belief creating platform promote art culture encourage artist share knowledge marginalized community various initiative help develop keen sense appreciating fine art safety woman child biocon belief safety woman child collective responsibility society company provides safe transport pregnant woman come primary health centre ante natal checkup child attending aata paata wadi also provides vehicle police support work managing safety citizen gender equality gender equality equity basic human right company work towards community company work towards gender equality providing vocational skill assisting employment opportunity company counsel mentor protect young woman risk sexual trafficking assist woman girl life skill coaching employment opportunity rural development company working build township school sanitation water supply system fulfil basic need underprivileged rural urban community company adopted township north karnataka also providing support infrastructure including school safe drinking water health centre community hall village company installed solar light rain water harvesting system household community toilet enable clean sanitation facility rural community compliance provision section 135 company act 2013 board formed corporate social responsibility committee monitor oversees various csr initiative activity company csr committee comprises m mary harney chairperson dr vijay kuchroo prof ravi mazumdar detailed report regarding corporate social responsibility appended herewith annexure 9 board report sexual harassment woman workplace prevention prohibition redressal act 2013 company place antisexual harassment policy line requirement sexual harassment woman workplace prevention prohibition redressal act 2013 internal complaint committee icc set redress complaint received regarding sexual harassment employee permanent contractual temporary trainee covered policy policy gender neutral year review 7 complaint allegation sexual harassment filed disposedoff per provision sexual harassment woman workplace prevention prohibition redressal act 2013 significant material order significant material order passed year regulator court tribunal impacting going concern status company operation future statutory disclosure none director company disqualified per provision section 1642 company act 2013 director made necessary disclosure required various provision act sebi lodr material change commitment material change commitment affecting financial position company occurred march 31 2017 date report 100 ahead curve annual report 2017 biocon limited change nature business change nature business company company continues pioneer biopharmaceutical company engaged manufacturing active pharmaceutical ingredient formulation including biosimilar drug diabetic oncology autoimmune disease sale market across globe extract annual return accordance provision section 1343 company act 2013 extract annual return prescribed format appended herewith annexure 10 board report acknowledgement place record appreciation committed service every member biocon family globally whose contribution significant growth success company would like thank client partner vendor investor banker business associate continued support encouragement year also thank government india malaysia government karnataka government telangana ministry information technology biotechnology ministry commerce industry ministry finance department scientific industrial research ministry corporate affair custom excise department income tax department csez ltu bengaluru regulatory agency assistance cooperation year look forward continued support future behalf board bengaluru kiran mazumdar shaw april 27 2017 chairperson managing director space intentionally left blank board report 101 annexure 1 statement containing salient feature financial statement 102 subsidiary associate company joint venture pursuant first proviso subsection 3 section 129 company act 2013 read rule 5 company account rule 2014 aoc1 million part subsidiary sl name subsidiary date since subsidiary reporting reporting share reserve total total liability investment turnover profit loss provision profit proposed acquired period currency capital surplus asset excl capital excluding year dividend shareholding incorporated equity reserve subsidiary taxation taxation company 1 syngene international limited india november 18 1993 apr mar 2000 12131 27738 13607 5404 12716 3465 592 2873 200 7354 2 biocon research limited india may 28 2008 apr mar 1 403 2773 2369 1657 391 270 661 10000 3 biocon academy india december 03 2013 apr mar 1 16 15 10000 4 biocon pharma limited india october 31 2014 apr mar 121 10 1761 1630 60 9 4 5 10000 5 biocon sa switzerland april 21 2008 apr mar usd 6 4430 5422 986 1336 762 78 684 10000 6 biocon biologics limited uk march 02 2016 apr mar usd 4342 113 6446 2217 1826 189 189 10000 7 biocon sdn bhd malaysia january 19 2011 apr mar usd 3543 12 21856 18325 998 5 5 refer note 4 8 biocon pharma inc u july 27 2015 jan dec usd 91 98 38 45 98 98 refer note 5 9 biocon fz llc uae june 16 2015 apr mar aed 3 18 658 673 1328 21 21 10000 ahead curve annual report 2017 10 biocon biologics india limited india june 08 2016 apr mar 1 1 refer note 6 exchange rate considered case foreign subsidiary 1 usd 6481 1 aed 1765 part b associate joint venture statement pursuant section 1293 company act 2013 related associate company joint venture sl name joint venture date latest share joint venture held description reason net worth attributable profit year joint venture audited company year end significant influence joint venture share holding per latest associatedacquired balance number amount extent consolidated audited balance sheet considered sheet date share investment considered joint venture holding consolidation consolidation 1 neobiocon uae april 29 2007 march 31 147000 422 mn 49 way control na 422 mn 163 mn 2017 twenty percent total share capital note 1 none subsidiary proposed dividend march 31 2017 except syngene international limited 2 biocon research limited hold 093 equity stake syngene international limited 3 biocon pharma limited biocon pharma inc yet commence commercial operation march 31 2017 4 biocon biologics limited uk hold 100 equity stake biocon sdn bhd malaysia reporting currency biocon sdn bhd myr however usd disclosed since functional currency 5 biocon pharma limited india hold 100 equity stake biocon pharma inc u 6 biocon biologics india limited india pending share application money biocon biologics limited uk behalf board kiran mazumdarshaw arun chandavarkar siddharth mittal rajiv balakrishnan chairperson managing director ceo joint managing director president finance chief financial officer company secretary bengaluru april 27 2017 biocon limited annexure 2 dividend distribution policy pursuant regulation 43a sebi listing obligation disclosure requirement regulation 2015 dividend distribution policy policy establishes principle ascertain amount distributed equity shareholder dividend company well enable company strike balance payout retained earnings order address future need company policy shall come force accounting period beginning april 01 2016 preamble profit earned company may either retained business used acquisition expansion diversification distributed shareholder dividend policy company would endeavor maintain consistent approach dividend payout plan reconciling need company currently one class share ordinary equity share therefore dividend declared distributed amongst shareholder based shareholding record date dividend generally recommended board year announcement full year result annual general meeting agm shareholder may permitted company act board may also declare interim dividend may permitted company act company consistent dividend policy balance objective appropriately rewarding shareholder dividend support future growth company would ensure strike right balance quantum dividend paid amount profit retained business various purpose past subject provision applicable law company dividend payout determined based available financial resource investment requirement taking account optimal shareholder return board director refer policy declaring recommending dividend behalf company company shall comply provision section 123 company act 2013 pertaining recommendation declaration payment dividend category dividend company act provides two form dividend final interim final dividend final dividend paid financial year annual account prepared board director company power recommend payment final dividend shareholder general meeting b interim dividend interim dividend may declared board director one time financial year may deemed fit board board director company would declare interim dividend considered appropriate line policy normally board could consider declaring interim dividend finalization quarterly half yearly financial result board discretion may additionally recommend special dividend certain circumstance extraordinary profit sale investment etc factor considered declaring dividend determining nature quantum dividend payout board would take account following factor internal factor profitable growth company specifically profit earned financial year compared previous year b internal budget ii cash flow position company iii accumulated reserve iv earnings stability v future cash requirement organic growthexpansion andor inorganic growth vi brand acquisition vii current future leverage exceptional circumstance amount contingent liability viii deployment fund short term marketable investment ix long term investment x capital expenditure board report 103 external factor business cycle ii economic environment iii cost external financing iv applicable tax including tax dividend v industry outlook future year vi inflation rate vii change government policy industry specific ruling regulatory provision apart board also considers past dividend history determining rate dividend board may consider declaring dividend may recommend lower payout given financial year analyzing prospective opportunity threat event challenging circumstance regulatory financial environment event board provide rationale annual report retained earnings company may used following way capital expenditure working capital ii organic inorganic growth iii investment new business e andor additional investment existing business e iv declaration dividend v capitalisation share vi buy back share vii general corporate purpose including contingency viii correcting capital structure ix permitted usage per company act 2013 policy review policy reviewed periodically board amended appropriate change revision policy communicated shareholder timely manner policy available company website disclosed company annual report space intentionally left blank 104 ahead curve annual report 2017 biocon limited annexure 3 disclosure respect employee stock option plan company summary status esop sl particular 1 date shareholder approval september 27 2001 2 total number option approved esos 11423820 3 vesting requirement 4 exercise price pricing formula refer note 31 standalone financial statement 5 maximum term option granted 6 source share primary secondary combination combination 7 variation term option variation 8 method used account esos intrinsic fair value refer note 31 standalone financial statement 9 impact profit eps company number option approved esop 2000 adjusted subdivision face value equity share fy 200102 fy 200304 issue bonus share fy 200304 fy 200809 b option movement year 201617 sl particular grant iv grant v grant vi grant vii grant viii grant ix grant x 1 number option outstanding beginning 3500 791875 1185839 1275500 312500 period 2 number option granted year 95000 200000 55000 472500 255000 3 number option forfeited lapsed 1000 74625 61600 238500 105000 5000 51250 year 4 number option vested year 215889 260338 26250 28250 5 number option exercised year 2500 221388 258001 16800 1000 6 number share arising result exercise 2500 221388 258001 16800 1000 option 7 money realized exercise option inr scheme implemented directly company 8 loan repaid trust year exercise price received 9 number option outstanding end 495862 961238 1220200 261500 467500 203750 year 10 number option exercisable end 135175 125026 9450 16750 year 11 weightedaverage exercise price option 357 471 482 460 496 392 outstanding end year 12 weightedaverage fair value option granted 156 251 149 617 442 c option granted employee company year option granted senior managerial personnel year sl name employee designation grant option exercise price granted 1 suresh subramanian senior vice president grant ix 25000 467 2 prasad deshpande vice president grant x 20000 415 3 paul vazhayil thomas vice president grant x 20000 415 4 sandeep nilkanth athalye senior vice president grant ix 25000 566 b employee received grant year option amounting 5 option granted year nil c identified employee granted option year equal exceeding 1 issued capital excluding outstanding warrant conversion company time grant nil board report 105 description method significant assumption used year estimate fair value option including following information 1 weightedaverage value share price exercise price expected volatility expected option life expected dividend riskfree interest rate input model 2 method used assumption made incorporate effect refer note 31 standalone financial statement expected early exercise 3 expected volatility determined including explanation extent expected volatility based historical volatility 4 whether feature option grant incorporated none measurement fair value market condition behalf board bengaluru kiran mazumdarshaw april 27 2017 chairperson managing director space intentionally left blank 106 ahead curve annual report 2017 biocon limited annexure 4 policy director appointment remuneration policy appointment remuneration director key management personnel provides underlying basis guide human resource management thereby aligning plan strategic growth company policy pursuant section 1784 company act 2013 regulation 19 sebi listing obligation disclosure requirement regulation 2015 brief summary policy relation objective appointment criterion remuneration general matter administered nomination remuneration committee reproduced herewith background section key objective committee policy would guide board relation appointment retention removal director key managerial personnel senior management evaluate performance member board provide necessary report board evaluation board recommend board remuneration payable director key managerial personnel retain motivate promote talent ensure long term sustainability talented managerial person create competitive advantage devise policy board diversity develop succession plan board regularly review plan composition meeting board constituted nomination remuneration committee nrc line requirement company act 2013 oversees function related appointment remuneration director key managerial personnel senior management personnel term composition requirement meeting committee committee shall consist minimum 3 nonexecutive director atleast one half composition shall independent minimum two 2 member shall constitute quorum committee meeting nrc shall meet atleast twice year membership committee shall disclosed annual report definition act mean company act 2013 rule framed thereunder amended time time board mean board director company committee mean nomination remuneration committee director mean director company key managerial personnel mean chief executive officer managing director wholetime director chief financial officer company secretary officer may prescribed act senior management mean personnel company member core management team excluding board director including functional head section ii section cover duty committee relation various matter recommendation made committee board duty role committee matter dealt perused recommended board committee shall include formulating criterion determining qualification positive attribute independence director identifying person qualified become director person may appointed key managerial position accordance criterion laid policy recommending board appointment removal director key managerial personnel senior management personnel specifically duty include nomination matter determining appropriate size diversity composition board board report 107 setting formal transparent procedure selecting new director appointment board ensuring appropriate induction place new director reviewing effectiveness identifying recommending director put forward retirement rotation developing succession plan board senior management regularly reviewing plan evaluating performance board member senior management context company performance industry benchmark compliance making recommendation board concerning matter relating continuation office director time including suspension termination service executive director employee company subject provision law service contract recommend necessary change board line board diversity policy considering matter may requested board b remuneration matter considering determining remuneration policy based performance reasonable sufficient need attract retain motivate member board approve remuneration key managerial personnel company maintaining balance fixed incentive pay reflecting short long term performance objective appropriate working company growth strategy manage administer employee stock option plan company consider matter may requested board section iii section cover policy appointment term retirement director key managerial personnel committee appointment criterion qualification committee shall identify ascertain integrity qualification expertise experience person appointment director key managerial personnel recommend board hisher appointment person possess adequate qualification expertise experience position heshe considered appointment committee discretion decide whether qualification expertise experience possessed person sufficientsatisfactory concerned position company shall appoint person wholetime director attained age seventy year provided term person holding position may extended beyond age seventy year approval shareholder passing special resolution based explanatory statement annexed notice motion indicating justification extension appointment beyond seventy year termtenure managing directorwholetime director company shall appoint reappoint person executive chairman managing director executive director term exceeding term may specified act reappointment shall made earlier one year expiry term shall done approval shareholder company independent director independent director shall hold office term five consecutive year board company eligible reappointment passing special resolution company disclosure appointment board report independent director shall hold office two consecutive term independent director shall eligible appointment expiry three year ceasing become independent director provided independent director shall said period three year appointed associated company capacity either directly indirectly evaluation committee shall carry evaluation performance every director regular interval least annual basis removal due reason disqualification mentioned act applicable act rule regulation thereunder committee may recommend board reason recorded writing removal director key managerial personnel subject provision compliance said act rule regulation retirement director key managerial personnel shall retire per applicable provision act prevailing policy company board discretion retain director key managerial personnel position remuneration otherwise even attaining retirement age benefit company 108 ahead curve annual report 2017 biocon limited section iv section policy cover provision relating remuneration wholetime director key managerial personnel senior management personnel general remuneration wholetime director key managerial personnel determined committee recommended board approval wherever required remuneration compensation commission etc shall subject approval shareholder company central government remuneration commission including increment recommended paid wholetime director shall accordance percentage slab condition laid per provision act would subject approval shareholder company remuneration wholetime executive managing director key managerial personnel fixed pay wholetime director managing director shall eligible monthly remuneration may approved board recommendation committee breakup pay scale quantum perquisite including employer contribution provident fund pension scheme medical expense club fee etc shall decided approved board approved shareholder central government wherever required committee shall approve remuneration key managerial personnel b minimum remuneration financial year company profit profit inadequate company shall pay remuneration wholetime director accordance provision schedule v act able comply provision previous approval central government c longterm reward longterm reward linked contribution performance company based relative position personnel organisation reward could form nature stock option based level employee criticality provision excess remuneration wholetime director draw receives directly indirectly way remuneration sum excess limit prescribed act without prior sanction central government required shall refund sum company sum refunded hold trust company company shall waive recovery sum refundable unless permitted central government remuneration non executive independent director remuneration commission remuneration commission shall fixed per limit mentioned act subject approval shareholder applicable b sitting fee non executive independent director shall receive remuneration way fee attending meeting board committee thereof provided amount fee shall exceed amount may prescribed central government time time c stock option independent director shall entitled stock option company remuneration structure independent director per meeting board committee effective april 1 2014 follows particular currency amount board sitting fee inr 100000 board remuneration u 5000 travel allowance overseas directorsnon u u 3000 travel allowance overseas director u u 4000 chairperson audit risk committee u 6000 chairperson committee u 2000 member audit risk committee u 3000 member committee u 1000 revised u 5000 u 6000 effect january 21 2016 revised u 2000 u 3000 effect january 21 2016 amendment update nomination remuneration committee periodically shall review policy may recommend amendment policy time time deems appropriate shall accordance provision company act 2013 case modification amendment inconsistency act provision act rule made thereunder would prevail policy behalf board bengaluru kiran mazumdarshaw april 27 2017 chairperson managing director board report 109 annexure 5 particular contractsarrangements made related party pursuant clause h subsection 3 section 134 act rule 82 company account rule 2014 aoc 2 form disclosure particular contractsarrangements entered company related party referred subsection 1 section 188 company act 2013 including certain arm length transaction third proviso thereto 1 detail contract arrangement transaction arm length basis sl particular detail name related party nature relationship b nature contractsarrangementstransactions c duration contractsarrangementstransactions applicable since contract salient term contract arrangement transaction including value arrangement transaction entered e justification entering contract arrangement transaction company year ended march f date approval board 31 2017 arm length basis g amount paid advance h date special resolution passed general meeting required first proviso section 188 2 detail material contract arrangement transaction arm length basis sl particular detail name related party nature relationship b nature contractsarrangementstransactions applicable since material c duration contractsarrangementstransactions contract arrangement transaction salient term contract arrangement transaction including value entered company year e date approval board ended march 31 2017 f amount paid advance behalf board bengaluru kiran mazumdarshaw april 27 2017 chairperson managing director space intentionally left blank 110 ahead curve annual report 2017 biocon limited annexure 6 conservation energy technology absorption foreign exchange earnings outgo particular pursuant section 1343 company act 2013 read rule 83 company account rule 2014 conservation energy step taken impact conservation power consumption fy17 179 mn unit 161 mn unit fy16 account energy increased consumption 11 yoy unit consumption increased total energy cost reduced 6 1456 mn fy17 1551 mn fy16 reduction overall energy cost attributable procurement power alternate source ii step taken company company started procuring wind power october 2016 total wind power procured utilizing alternate source energy fy17 43 mn unit corresponding reduction c02 emission approx 35000 ton iii capital investment energy 93 mn conservation equipment sl power fuel consumption detail fy 17 fy 16 1 electricity purchased million unit 168 145 total amount mn 930 894 rate unit 55 62 b captive generation hsd quantity kl 3300 4674 million unit 11 16 unit litre 34 34 cost litre 343 418 generation cost rate unit 99 124 2 steam furnace oil quantity kl 15302 14262 total amount mn 413 463 average rate 270 324 sl energy conservation measure investment energy saved per annum mn unit amount mn 1 conversion conventional motor energy efficient motor 2 conversion cfl light energy efficient led light 93 950000 54 3 installation energy efficient brine chiller 4 optimisation hvac system brc continuous monitoring high energy consumption areasequipment taking appropriate corrective measure required resulted energy saving maintained marginal increment power consumption production growth b technology absorption effort made towards technology absorption ii benefit derived like product improvement cost reduction product development import substitution iii case imported technology imported last three year reckoned beginning technology imported financial year company year detail technology imported b year import c whether technology fully absorbed fully absorbed area absorption taken place reason thereof iv expenditure incurred research development rd detailed disclosure rd provided board report 111 research development specific area rd work carried company 1 development synthetic fermentation based generic small molecule antiinfective oncology cardiovascular nephrology transplantation segment 2 formulation development abbreviated new drug application andas 3 generation intellectual property development process patent manufacture key generic small molecule biotherapeutics 4 clinical development pertaining novel program benefit derived result rd activity 1 global presence supply fermentation based small molecule generic industry regulated market 2 rich pipeline generic small molecule catering varied therapeutic area 3 internationally competitive price product quality 4 established intellectual property 1286 patent pct application filed indian international market company granted 1053 patent various jurisdiction 5 safe environment friendly process 6 first anda molecule approval received future plan action 1 strategic collaboration increased speed cost competitiveness drug discovery 2 inhouse rd scale generic formulation 3 collaborate global academia industry build value visibility portfolio expenditure incurred research development million fy 17 fy 16 capital 250 35 b recurring 1461 1480 total 1711 1515 less recharge 4 48 net rd expense 1707 1467 c foreign exchange earnings outgo million foreign exchange earned used year fy17 fy16 gross earnings 12988 11614 outflow 7899 8182 net foreign exchange earnings 5090 3432 behalf board bengaluru kiran mazumdarshaw april 27 2017 chairperson managing director 112 ahead curve annual report 2017 biocon limited annexure 7 secretarial audit report financial year ended march 31 2017 pursuant sub section 1 section 204 company act 2013 rule 9 company appointment remuneration managerial personnel rule 2014 member biocon limited bengaluru conducted secretarial audit compliance applicable statutory provision adherence good corporate practice biocon limited hereinafter called company secretarial audit conducted manner provided u reasonable basis evaluating corporate conductsstatutory compliance expressing opinion thereon based verification company book paper minute book form return filed record maintained company also information provided company officer agent authorized representative conduct secretarial audit hereby report opinion company financial year ended march 31 2017 audit period complied statutory provision listed hereunder also company proper boardprocesses compliancemechanism place extent manner subject reporting made hereinafter examined book paper minute book form return filed record maintained company audit period according provision company act 2013 act rule made thereunder ii security contract regulation act 1956 scra rule made thereunder iii depository act 1996 regulation byelaws framed thereunder iv foreign exchange management act 1999 rule regulation made thereunder extent foreign direct investment overseas direct investment external commercial borrowing v following regulation guideline prescribed security exchange board india act 1992 sebi act security exchange board india substantial acquisition share takeover regulation 2011 b security exchange board india prohibition insider trading regulation 2015 c security exchange board india issue capital disclosure requirement regulation 2009 applicable company audit period security exchange board india share based employee benefit regulation 2014 e security exchange board india issue listing debt security regulation 2008 applicable company audit period f security exchange board india registrar issue share transfer agent regulation 1993 regarding company act dealing client g security exchange board india delisting equity share regulation 2009 applicable company audit period h security exchange board india buyback security regulation 1998 applicable company audit period security exchange board india listing obligation disclosure requirement regulation 2015 vi law applicable specifically company namely drug cosmetic act 1940 b bio medical waste management handling rule 1998 c ich guidelinesthis base u fda eu guideline etc created ucpmp currently voluntary however proposed made mandatory e national biodiversity act 2002 f drug magical remediesobjectionable advertisement rule 1955 g narcotic drug psychotropic substance act board report 113 also examined compliance applicable clause following secretarial standard issued institute company secretary india meeting board director general meeting b listing agreement entered company bse limited national stock exchange india limited period review company complied provision act rule regulation guideline standard etc mentioned examined compliance applicable financial law like direct indirect tax law since subject review statutory financial audit designated professional report board director company duly constituted proper balance executive director nonexecutive director independent director change composition board director took place period review carried compliance provision act adequate notice given director schedule board meeting agenda detailed note agenda sent least seven day advance system exists seeking obtaining information clarification agenda item meeting meaningful participation meeting per minute meeting duly recorded signed chairman decision board unanimous dissenting view recorded report based review compliance report certificate chief executive officer ceo company taken record board director adequate system process company commensurate size operation company monitor ensure compliance applicable law rule regulation guideline report audit period event action major bearing company affair pursuance referred law rule regulation guideline etc v sreedharan associate company secretary pradeep b kulkarni bengaluru partner april 24 2017 fcs 7260 cp 7835 space intentionally left blank 114 ahead curve annual report 2017 biocon limited annexure 8 particular remuneration detail pertaining remuneration required section 19712 read rule 51 company appointment remuneration managerial personnel rule 2014 sl name directorkey managerial personnel remuneration director percentage increase ratio remuneration designation key managerial personnel remuneration director year ended march directorcfocs fy median remuneration 31 2017 201617 employee million 1 m kiran mazumdar shaw 2037 27 498 chairperson managing director 2 mr john shaw 1723 10 421 vice chairman 3 mr arun chandavarkar 3304 7 808 ceo joint managing director 4 m mary harney 281 14 69 independent director 5 mr russell wall 375 5 92 independent director 6 mr daniel bradbury 221 0 54 independent director 7 dr jeremy levin 322 24 79 independent director 8 dr vijay kumar kuchroo 214 13 52 independent director 9 mr damodaran 195 na 48 independent director 10 mr siddharth mittal 1965 25 na chief financial officer 11 mr rajiv balakrishnan 077 na na company secretary 12 mr kiran kumar 655 7 na company secretary mr rajiv balakrishnan appointed company secretary effective january 24 2017 place mr kiran kumar g relinquished post december 15 2016 hence remuneration disclosed period holding title note remuneration independent director excluding sitting fee remuneration include perquisite value account stock option exercised year percentage increase decrease median median remuneration employee increased 369820 408871 representing remuneration employee financial increase 11 computing increase median remuneration employee considered year employee march 31 2017 march 31 2016 ii number permanent employee 4832 permanent employee march 31 2017 roll company iii average percentile increase salary average increase employee remuneration managerial personnel 178 employee managerial personnel marginally higher managerial personnel increase managerial comparison percentile remuneration line measure attract retain best talent company also us increase managerial remuneration mix fixed variable esop based compensation midtolong term basis align middle justification thereof senior management compensation enhance shareholder value hereby affirmed remuneration paid financial year 201617 per policy remuneration director key managerial personnel employee behalf board bengaluru kiran mazumdarshaw april 27 2017 chairperson managing director board report 115 annexure 9 annual report corporate social responsibility activity financial year 201617 pursuant provision section 135 company act 2013 biocon belief making difference life million people underprivileged promotes social economic inclusion ensuring marginalized community equal access health care service educational opportunity proper civic infrastructure company csr activity implemented biocon foundation work towards development implementation healthcare education infrastructure project marginalized section society biocon academy aim address skill deficit biotechnology space external partner partner reliable csr player work towards development society csr vision company promote social economic inclusion ensuring marginalized community equal access healthcare service educational opportunity proper civic infrastructure create globally competitive biotech ecosystem india skill development bridge gap gender disparity education healthcare employment create platform promoting rich art culture country sensitizing community appreciate fine art please refer httpwwwbioconcombiocon_csr_about_policyasp detail related company csr policy csr committee csr committee board provides oversight csr policy monitor execution various activity meet set csr objective member csr committee m mary harney chairperson b dr vijay kumar kuchroo c prof ravi mazumdar financial detail provision pertaining corporate social responsibility prescribed section 135 company act 2013 applicable company summary financial detail company follows particular million average net profit tax company last three financial year 4501 prescribed csr expenditure 2 average net profit computed 90 detail csr spent financial year 201617 total amount spent financial year 90 total amount spent 90 amount unspent nil 116 ahead curve annual report 2017 biocon limited detail amount spent financial year detailed million sl csr project program sector location project program amount amount cumulative amount spent name district state outlay spent spend direct budget external agency project reporting program period expenditure project program 1 ary primary healthcare medical karnataka nine arogya 1276 1264 1264 biocon foundation healthcare clinic facility raksha yojana primary healthcare outpatient clinic 2 cancer screening healthcare medical various district karnataka 343 298 298 biocon foundation program facility 3 ehealth rajasthan healthcare medical rajasthan karnataka 1274 1513 1513 direct biocon karnataka facility foundation 4 project one clean drinking water bengaluru huskur karnataka 130 076 076 biocon foundation rain water harvesting 5 lake development rural development hebbagudi bengaluru 406 240 240 biocon foundation project karnataka 6 rural development rural development karnataka 913 849 849 biocon foundation project 7 international school improving quality hyderabad telangana 325 325 325 biocon foundation business education 8 grant ngo healthcare medical karnataka telengana 487 427 427 biocon foundation facility 9 biotechnology training improving quality bengaluru karnataka 3487 3093 3093 biocon academy education 10 contribution biocon funding activity bengaluru karnataka 337 337 biocon foundation foundation approved csr programme ii administrative expense 1 project excluding office expense bengaluru karnataka 363 582 582 biocon foundation sl 10 9004 9004 9004 responsibility statement hereby confirm implementation policy monitoring csr project activity compliance csr objective csr policy company behalf board bengaluru kiran mazumdarshaw mary harney april 27 2017 chairperson managing director chairperson csr committee board report 117 annexure 10 extract annual return financial year ended march 31 2017 pursuant section 923 company act 2013 rule 121 company management administration rule 2014 form mgt09 registration detail 1 cin l24234ka1978plc003417 2 registration date november 29 1978 3 name company biocon limited 4 category subcategory company category company limited share sub category indian non government company 5 address registered office contact detail 20th km hosur road electronic city bengaluru 560 100 contact tel 91 80 2808 2808 email cosecretarybioconcom 6 whether listed company yes 7 name address contact detail registrar transfer agent karvy computershare private limited plot 3132 karvy selenium tower b gachibowli financial district nanakramguda hyderabad 500 032 contact tel 91 40 67161500 email einwardriskarvycom ii principal business activity company sl name description main product service nic code product service total turnover company 1 manufacture pharmaceutical medicinal chemical 21 10000 botanical product iii particular holding subsidiary associate company sl name address company cingln holdingsubsidiary share held applicable section 1 syngene international limited l85110ka1993plc014937 subsidiary 7354 287 2 biocon research limited u73100ka2008plc046583 subsidiary 100 287 3 biocon pharma limited u24232ka2014plc077036 subsidiary 100 287 4 biocon biologics india limited u24119ka2016flc093936 subsidiary 100 287 5 biocon academy u80301ka2013npl072272 subsidiary 100 287 6 biocon sa na subsidiary 100 287 7 biocon sdn bhd na subsidiary 100 287 8 biocon biologics limited na subsidiary 100 287 9 biocon pharma inc na subsidiary 100 287 10 biocon fz llc na subsidiary 100 287 11 neo biocon fz llc na associate 49 26 including 093 held biocon research limited iv share holding pattern equity share capital breakup percentage total equity 1 categorywise shareholding category category shareholder share held beginning year share held end year code 31032016 31032017 change demat physical total demat physical total total total share share year promoter promoter group 1 indian individualhuf 79838266 79838266 3992 79766766 79766766 3988 004 b central govtstate govts c body corporate financial institutionsbanks e others subtotal a1 79838266 79838266 3992 79766766 79766766 3988 004 118 ahead curve annual report 2017 biocon limited category category shareholder share held beginning year share held end year code 31032016 31032017 change demat physical total demat physical total total total share share year 2 foreign individual nrisforeign 2058986 2058986 103 2058986 2058986 103 000 individual b body corporate 39535194 39535194 1977 39535194 39535194 1977 000 c institution qualified foreign investor e others subtotal a2 41594180 41594180 2080 41594180 41594180 2080 000 total aa1a2 121432446 121432446 6072 121360946 121360946 6068 004 b public shareholding 1 institution mutual fundsuti 5647569 5647569 282 4296869 4296869 215 068 b financial institutionsbanks 5044830 5044830 252 2429062 2429062 121 131 c central governmentstate government venture capital fund e insurance company f foreign institutional 27264626 27264626 1363 35427957 35427957 1771 408 investor g foreign venture capital investor h qualified foreign investor others subtotal b1 37957025 37957025 1898 42153888 42153888 2108 210 2 noninstitutions body corporate 2889920 2889920 144 4099910 4099910 205 060 b individual individual holding nominal share capital upto 1 lakh 15649334 23468 15672802 784 13860069 24064 13884133 694 089 ii individual holding nominal share capital excess 1 lakh 11291220 11291220 565 8184669 8184669 409 155 c others clearing member 138067 138067 007 127359 127359 006 001 foreign national 459818 289902 749720 037 450818 264434 715252 036 002 non resident indian 1358428 172394 1530822 077 1296201 172394 1468595 073 003 nri nonrepatriation 193072 193072 010 010 employee esop trust 3876828 3876828 194 3529870 3529870 176 017 trust 4461150 4461150 223 4282306 4282306 214 009 qualified foreign investor subtotal b2 40124765 485764 40610529 2031 36024274 460892 36485166 1824 206 total bb1b2 78081790 485764 78567554 3928 78178162 460892 78639054 3932 004 total ab 199514236 485764 200000000 10000 199539108 460892 200000000 10000 c share held custodian gdrs adrs grand total abc 199514236 485764 200000000 10000 199539108 460892 200000000 10000 board report 119 2 shareholding promoter sl shareholder name shareholding beginning year shareholding end year change share total share share total share shareholding share pledged share pledged company encumbered encumbered year total share company total share 1 kiran mazumdarshaw 79287564 3964 79287564 3964 2 glentec international limited 39535194 1977 39535194 1977 3 john shaw 1407558 070 1407558 070 4 ravi rasandra mazumdar 565014 028 565014 028 5 yamini r mazumdar 550702 028 003 479202 024 003 004 6 dev mazumdar 86414 004 86414 004 total 121432446 6072 003 121360946 6068 003 004 3 change promoter shareholding sl particular shareholding beginning year cumulative shareholding year share total share share total share company company 1 kiran mazumdarshaw beginning year 79287564 3964 79287564 3964 increase decrease shareholding year end year 79287564 3964 2 glentec international beginning year 39535194 1977 39535194 1977 increase decrease shareholding year end year 39535194 1977 3 john shaw beginning year 1407558 070 1407558 070 increase decrease shareholding year end year 1407558 070 4 ravi rasendra mazumdar beginning year 565014 028 565014 028 increase decrease shareholding year end year 565014 028 5 yamini r mazumdar beginning year 550702 028 550702 028 increase decrease shareholding year 71500 004 479202 024 end year 479202 024 6 dev mazumdar beginning year 86414 004 86414 004 increase decrease shareholding year end year 86414 004 120 ahead curve annual report 2017 biocon limited 4 shareholding pattern top ten shareholder director promoter holder gdrs adrs 1 franklin templeton investment fund increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 6048588 302 6048588 302 01042016 22042016 decreasesold 96956 5951632 298 03062016 decreasesold 192686 5758946 288 10062016 decreasesold 423500 5335446 267 17062016 decreasesold 58283 5277163 264 30062016 decreasesold 127000 5150163 258 01072016 decreasesold 84500 5065663 253 08072016 decreasesold 65242 5000421 250 15072016 decreasesold 2500 4997921 250 29072016 decreasesold 122546 4875375 244 05082016 decreasesold 23657 4851718 243 12082016 decreasesold 343618 4508100 225 19082016 decreasesold 286717 4221383 211 26082016 decreasesold 112407 4108976 205 21102016 decreasesold 142584 3966392 198 02122016 decreasesold 141260 3825132 191 09122016 decreasesold 76233 3748899 187 16122016 decreasesold 55560 3693339 185 23122016 decreasesold 76136 3617203 181 06012017 decreasesold 144345 3472858 174 13012017 decreasesold 44856 3428002 171 03032017 decreasesold 7293 3420709 171 end year 3420709 171 31032017 2 oppenheimer developing market fund increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 0 000 0 000 01042016 21102016 increasebought 438196 438196 022 28102016 increasebought 358524 796720 040 04112016 increasebought 438395 1235115 062 11112016 increasebought 892326 2127441 106 18112016 increasebought 212682 2340123 117 25112016 increasebought 490655 2830778 142 02122016 increasebought 454232 3285010 164 09122016 increasebought 392417 3677427 184 16122016 increasebought 318685 3996112 200 23122016 increasebought 34166 4030278 202 13012017 increasebought 272033 4302311 215 03022017 increasebought 80450 4382761 219 end year 4382761 219 31032017 board report 121 3 life insurance corporation india increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 3707822 185 3707822 185 01042016 08042016 decreasesold 25000 3682822 184 22042016 decreasesold 137355 3545467 177 29042016 decreasesold 556571 2988896 149 06052016 decreasesold 472117 2516779 126 13052016 decreasesold 459591 2057188 103 20052016 decreasesold 110654 1946534 097 27052016 decreasesold 76818 1869716 093 10062016 decreasesold 15000 1854716 093 17062016 decreasesold 20000 1834716 092 24062016 decreasesold 29775 1804941 090 08072016 decreasesold 55561 1749380 087 09092016 decreasesold 12640 1736740 087 end year 1736740 087 31032017 4 templeton developing market trust increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 2497396 125 2497396 125 01042016 03062016 decreasesold 33500 2463896 123 10062016 decreasesold 147500 2316396 116 17062016 decreasesold 89322 2227074 111 30062016 decreasesold 152000 2075074 104 01072016 decreasesold 5000 2070074 104 08072016 decreasesold 7500 2062574 103 15072016 decreasesold 5500 2057074 103 29072016 decreasesold 313500 1743574 087 05082016 decreasesold 61007 1682567 084 21102016 decreasesold 306219 1376348 069 13012017 decreasesold 58727 1317621 066 03032017 decreasesold 15200 1302421 065 end year 1302421 065 31032017 122 ahead curve annual report 2017 biocon limited 5 reliance capital trustee co ltd ac reliancepharm increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 2452018 123 2452018 123 01042016 15042016 decreasesold 18700 2433318 122 22042016 decreasesold 13200 2420118 121 06052016 decreasesold 107800 2312318 116 27052016 decreasesold 100000 2212318 111 17062016 increasebought 19800 2232118 112 24062016 decreasesold 13200 2218918 111 30062016 decreasesold 6600 2212318 111 08072016 decreasesold 15000 2197318 110 15072016 decreasesold 385000 1812318 091 22072016 increasebought 20900 1833218 092 22072016 decreasesold 600000 1233218 062 29072016 decreasesold 33000 1200218 060 05082016 increasebought 58300 1258518 063 19082016 increasebought 15400 1273918 064 26082016 increasebought 166100 1440018 072 02092016 increasebought 99000 1539018 077 09092016 decreasesold 6600 1532418 077 16092016 decreasesold 50600 1481818 074 23092016 decreasesold 1100 1480718 074 07102016 decreasesold 11000 1469718 073 14102016 decreasesold 100000 1369718 068 21102016 decreasesold 167200 1202518 060 28102016 increasebought 19800 1222318 061 28102016 decreasesold 200000 1022318 051 04112016 decreasesold 101100 921218 046 11112016 decreasesold 321218 600000 030 02122016 increasebought 11000 611000 031 09122016 decreasesold 11000 600000 030 24022017 increasebought 3000 603000 030 03032017 increasebought 153600 756600 038 03032017 decreasesold 505673 250927 013 10032017 increasebought 199800 450727 023 10032017 decreasesold 94327 356400 018 17032017 decreasesold 21600 334800 017 31032017 decreasesold 3000 331800 017 end year 331800 017 31032017 6 murali krishnan k n increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 2120342 106 2120342 106 01042016 17032017 increasebought 2100342 4220684 211 17032017 decreasesold 2100342 2120342 106 31032017 decreasesold 2000000 120342 006 end year 120342 006 31032017 board report 123 7 swiss finance corporation mauritius limited increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 1961900 098 1961900 098 01042016 08042016 increasebought 58479 2020379 101 15042016 increasebought 101774 2122153 106 22042016 increasebought 51493 2173646 109 29042016 increasebought 40535 2214181 111 06052016 decreasesold 148435 2065746 103 13052016 increasebought 161199 2226945 111 20052016 increasebought 33501 2260446 113 27052016 increasebought 24099 2284545 114 03062016 increasebought 38500 2323045 116 10062016 increasebought 88768 2411813 121 17062016 increasebought 221212 2633025 132 24062016 increasebought 47731 2680756 134 30062016 decreasesold 137026 2543730 127 08072016 decreasesold 1566 2542164 127 15072016 increasebought 4400 2546564 127 22072016 increasebought 5500 2552064 128 29072016 decreasesold 257577 2294487 115 05082016 increasebought 85518 2380005 119 12082016 increasebought 25097 2405102 120 19082016 increasebought 11100 2416202 121 26082016 decreasesold 670411 1745791 087 02092016 increasebought 3906 1749697 087 09092016 decreasesold 160668 1589029 079 16092016 decreasesold 289555 1299474 065 23092016 increasebought 39600 1339074 067 30092016 decreasesold 84690 1254384 063 07102016 decreasesold 86840 1167544 058 14102016 decreasesold 134893 1032651 052 21102016 decreasesold 48206 984445 049 28102016 increasebought 38500 1022945 051 04112016 decreasesold 2200 1020745 051 11112016 decreasesold 222793 797952 040 18112016 decreasesold 27069 770883 039 25112016 decreasesold 22782 748101 037 02122016 increasebought 9524 757625 038 16122016 decreasesold 38718 718907 036 23122016 decreasesold 51793 667114 033 30122016 increasebought 19800 686914 034 06012017 increasebought 110000 796914 040 13012017 decreasesold 51540 745374 037 20012017 decreasesold 37819 707555 035 27012017 decreasesold 16174 691381 035 10022017 decreasesold 3600 687781 034 17022017 decreasesold 2400 685381 034 24022017 increasebought 8431 693812 035 17032017 increasebought 4800 698612 035 24032017 increasebought 5400 704012 035 31032017 increasebought 600 704612 035 end year 704612 035 31032017 124 ahead curve annual report 2017 biocon limited 8 national westminster bank plc trustee jupiter india fund increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 0 000 0 000 01042016 29072016 increasebought 835019 835019 042 05082016 increasebought 114981 950000 048 23122016 increasebought 182173 1132173 057 27012017 increasebought 58608 1190781 060 03022017 increasebought 250889 1441670 072 10022017 increasebought 288099 1729769 086 31032017 increasebought 40618 1770387 089 end year 1770387 089 31032017 9 icici prudential equity arbitrage fund increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 149600 007 149600 007 01042016 22042016 increasebought 96800 246400 012 22042016 decreasesold 96800 149600 007 06052016 decreasesold 19800 129800 006 13052016 decreasesold 7700 122100 006 03062016 decreasesold 62700 59400 003 30062016 increasebought 163681 223081 011 01072016 increasebought 66713 289794 014 08072016 increasebought 90745 380539 019 15072016 increasebought 370244 750783 038 12082016 increasebought 698550 1449333 072 19082016 increasebought 58866 1508199 075 16092016 increasebought 102603 1610802 081 30092016 decreasesold 59400 1551402 078 07102016 increasebought 2200 1553602 078 14102016 increasebought 41800 1595402 080 28102016 increasebought 95700 1691102 085 28102016 decreasesold 74863 1616239 081 25112016 decreasesold 9900 1606339 080 02122016 increasebought 196112 1802451 090 23122016 decreasesold 129800 1672651 084 13012017 increasebought 119400 1792051 090 13012017 decreasesold 146744 1645307 082 27012017 decreasesold 11039 1634268 082 10022017 decreasesold 46804 1587464 079 03032017 decreasesold 66486 1520978 076 end year 1520978 076 31032017 board report 125 10 credit suisse singapore limited increase decrease shareholding beginning increase cumulative shareholding reason year 01042016 decrease year 31032017 share total shareholding share total share share company company beginning year 316163 016 01042016 08042016 decreasesold 6009 310154 016 15042016 increasebought 85091 395245 020 22042016 increasebought 261762 657007 033 29042016 decreasesold 22577 634430 032 06052016 increasebought 138726 773156 039 13052016 increasebought 311973 1085129 054 20052016 increasebought 121447 1206576 060 27052016 increasebought 111098 1317674 066 03062016 increasebought 90779 1408453 070 10062016 increasebought 55576 1464029 073 17062016 increasebought 31847 1495876 075 24062016 increasebought 9314 1505190 075 30062016 decreasesold 1537 1503653 075 01072016 decreasesold 1100 1502553 075 08072016 increasebought 59475 1562028 078 15072016 increasebought 2828 1564856 078 29072016 increasebought 24157 1589013 079 05082016 increasebought 54963 1643976 082 12082016 increasebought 58931 1702907 085 19082016 increasebought 18775 1721682 086 26082016 decreasesold 19200 1702482 085 02092016 increasebought 63125 1765607 088 09092016 decreasesold 26887 1738720 087 16092016 decreasesold 230 1738490 087 23092016 increasebought 29902 1768392 088 30092016 decreasesold 10682 1757710 088 07102016 decreasesold 31406 1726304 086 14102016 decreasesold 18160 1708144 085 21102016 decreasesold 15332 1692812 085 28102016 decreasesold 1100 1691712 085 04112016 decreasesold 43 1691669 085 18112016 decreasesold 11000 1680669 084 25112016 decreasesold 33000 1647669 082 02122016 increasebought 19602 1667271 083 09122016 increasebought 15988 1683259 084 16122016 decreasesold 21728 1661531 083 23122016 decreasesold 257447 1404084 070 30122016 decreasesold 35700 1368384 068 06012017 increasebought 120800 1489184 074 13012017 increasebought 100344 1589528 079 20012017 decreasesold 61682 1527846 076 27012017 decreasesold 35735 1492111 075 03022017 increasebought 10439 1502550 075 10022017 decreasesold 70800 1431750 072 10032017 decreasesold 300 1431450 072 17032017 increasebought 41392 1472842 074 31032017 increasebought 12850 1485692 074 end year 1485692 074 31032017 126 ahead curve annual report 2017 biocon limited v shareholding director key managerial personnel sl director kmp shareholding beginning cumulative shareholding year year share total share share total share company company 1 kiran mazumdarshaw beginning year 79287564 3964 79287564 3964 increase decrease shareholding year end year 79287564 3964 2 john shaw beginning year 1407558 070 1407558 070 increase decrease shareholding year end year 1407558 070 3 arun suresh chandavarkar beginning year 2200000 110 2200000 110 increase decrease shareholding year end year 2200000 110 4 ravi rasendra mazumdar beginning year 565014 028 565014 028 increase decrease shareholding year end year 565014 028 5 siddharth mittal beginning year increase decrease shareholding year 7750 000 7750 000 end year 7750 000 6 rajiv balakrishnan beginning year increase decrease shareholding year end year 7 kiran kumar g beginning year increase decrease shareholding year end year 5 indebtedness indebtedness company including interest outstandingaccrued due payment million secured loan unsecured loan deposit total excluding indebtedness deposit indebtedness beginning financial year principal amount 1328 2367 3696 ii interest due paid iii interest accrued due total iiiiii 1328 2367 3696 change indebtedness financial year addition 501 501 reduction 32 2830 2862 net change 32 2329 2361 indebtedness end financial year principal amount 1296 39 1335 ii interest due paid iii interest accrued due total iiiiii 1296 39 1335 board report 127 6 remuneration director key managerial personnel remuneration managing director wholetime director andor manager million sl particular remuneration total amount name mdwtd manager 1 gross salary kiran mazumdar john shaw arun shaw cmd wtd chandavarkar ceo jt md salary per provision contained section 171 2034 1720 3301 7055 incometax act 1961 b value perquisite u 172 incometax act 1961 003 003 003 009 c profit lieu salary section 173 income tax act 1961 2 stock option 330 3 sweat equity 4 commission profit others specify others please specify 5 total 2037 1723 3634 7394 ceiling per act 54487 amount indicates perquisite value stock option exercised year b remuneration director million sl particular remuneration name director total amount 1 independent director russell daniel jeremy mary harney vijay k damodaran wall bradbury levin kuchroo fee attending boardcommittee 040 040 040 040 030 040 230 meeting commission 375 221 322 281 214 195 1608 others please specify total 1 415 261 362 321 244 235 1838 2 nonexecutive director ravi mazumdar fee attending board committee 040 040 meeting commission others please specify total 2 040 040 total b12 1878 total managerial remuneration ab 8942 overall ceiling per act 5449 128 ahead curve annual report 2017 biocon limited c remuneration key managerial personnel mdmanagerwholetime director million sl particular key managerial personnel chief financial officer company secretary total 1 gross salary salary per provision contained section 171 incometax act 1961 1962 729 2691 b value perquisite u 172 incometax act 1961 003 003 006 c profit lieu salary section 173 incometax act 1961 2 stock option 631 631 3 sweat equity 4 commission profit others specify 5 others please specify total 2596 732 3328 amount indicates perquisite value stock option exercised year note 1 remuneration ceo included since joint managing director detail already included section 2 remuneration company secretary includes remuneration paid year mr kiran kumar g mr rajiv balakrishnan period holding title 7 penalty punishment compounding offence material penaltiespunishmentcompounding offence year ended march 31 2017 behalf board bengaluru kiran mazumdarshaw april 27 2017 chairperson managing director space intentionally left blank board report 129 management discussion analysis global life science industry fared well amidst past economic downturn light today volatile marketplace faced economic political social challenge industry faced reformdriven pricing pressure increased demand value innovation significant global unmet need aided favourable demographic trend make likely industry would enjoy long term growth driven recent wave innovative therapy approved regulator report suggest global drug spending could reach 11 trillion 2022 globally spending healthcare correlate well general economic strength country given high contribution usa russia brazil china global growth healthcare spending coupled pricing pressure united state unstable economic condition large emerging market led slowdown global marketplace strict measure taken government regard health care budget reduction ofpocket expenditure country impacted spending aging population rise chronic disease introduction innovative frequently expensive treatment eg cancer hepatitis c main factor would continue drive growth health care spending however many country taken step contain health care cost includes price control valuebased pricing reimbursement along progeneric probiosimilar policy company responding current changing market dynamic trying position continued growth portfolio transformation merger acquisition costcutting sharpened focus highperforming therapeutic area ta key geographic market global biologics market continues grow growth pharmaceutical company driven specialty product focus personalized medicine includes biologic drug increased number biologics approved compared nonbiologics synthetic molecule recent time antibody drug become increasingly significant component therapeutic landscape antibody exhibit high specificity selectivity reducing risk offtarget toxicity typical synthetic molecule enabling personalized treatment top 15 pharma drug sale 2016 10 drug biologics figure 1 figure 1 biologics comprised 10 top 15 drug revenue 2016 sl drug sponsor biologic yn sale 2016 1 humira adalimumab abbvie 161 2 harvoni ledipasvir 90 mgsofosbuvir 400 mg gilead science n 91 3 enbrel etanercept amgen pfizer 89 4 rituxan rituximab mabthera roche genentech biogen 86 5 remicade infliximab johnson johnson merck 78 6 revlimid lenalidomide celgene n 69 7 avastin bevacizumab roche genentech 68 8 herceptin trastuzumab roche genentech 68 9 lantus insulin glargine sanofi 61 10 prevnar 13 pneumococcal 13valent conjugate vaccine pfizer 57 11 xarelto rivaroxaban bayer johnson johnson n 54 12 eylea aflibercept bayerregeneron 50 13 lyricapregabalin pfizer n 49 14 neulasta pegfilgrastim amgen kyowa hakko kirin 47 15 advairfluticasone salmeterol glaxosmithkline n 43 source genetic engineering biotechnology news wwwgenengnewscom driven recent advance created much excitement industry eg nivolumab pembrolizumab atezolizumab ocrelizumab oncology remains sought therapeutic area followed immunotherapy expanding waistline across globe continue see growth segment antidiabetic drug attract research dollar past several year biologics made many new ground breaking treatment possible gained significant traction pharmaceutical industry novel biologic blockbuster continued enter market company increasingly focusing narrow patient population characterized large unmet need easier market access estimate evaluate pharma indicate sale biotechnology product stood 165 billion revenue 2013 likely go 337 billion 2022 comprise nearly 29 pharmaceutical market mentioned growth trend expected offset increased demand generic drug biosimilars defines biosimilars biotherapeutic product similar term quality safety efficacy already licensed reference biotherapeutic product given high cost biologic treatment coming year lower cost biosimilars instrumental expanding access population need therapy unable afford access analyst expect worldwide biosimilars market reach 25 billion 35 billion 2020 access affordability biological drug cost access advanced biologic therapy paid different channel across globe reimbursed market welldefined insurance payment mechanism government funded healthcare cash based outofpocket market access patient biologic treatment defined accordingly 130 ahead curve annual report 2017 biocon limited developed market success led united state reimbursement widely available private insurance medicare federal health insurance program people 65 older certain others followed eu even developed market access biologics uniform often patient struggle cope cost continued therapy emerging market biologics penetration suboptimal given varied nature payment mechanism drug coverage government emerging market country trending towards adoption universal healthcare promote wellbeing citizen reduce outofpocket cost drug provided may include biologics like human insulin available competitive price seldom include expensive drug treat cancer chronic inflammatory condition hence access biologics patient might severely limited market government unable afford higher priced branded biologic therapy biosimilars landscape biologics development long complex expensive resulting patient payer buying drug high cost resulted large unmet need affordable alternative form biosimilars made available patient different part world negate effect high pricing drug seen increase biosimilar development activity globally developed market focus area biologics manufacturer emerging market may attracted level attention developed market incurred biosimilar environment market poised drive long term growth company would require specific strategy successful segment key success vary based market chosen although country environment unique similarity trend across developed emerging market given need significant investment capital time required biosimilar development company need build right condition success able get fair return investment figure 2 biosimilar landscape summary crosscountry analysis access regulatory payer assessment prescriber patient biosimilars affordable environment access acceptance acceptance presence variable biologics presence engagement willingness patient attitude number ranked importance physical financial abbreviated advocacy prescribe biosimilar towards biosimilars approved ability receive dedicated pathway payer favour v reference biosimilars biologics biosimilars molecule market u large access development low low low 05 developed eu5 large access established high medium medium 10 japan large access established medium low low 10 brazil poor access established high medium medium 05 russia fragmented development low low medium 05 brics india poor access established low medium medium 10 china poor access development medium medium low 05 south africa poor access established high high medium 05 mexico fragmented established high low medium 05 indonesia poor access medium medium low 05 mist south korea fragmented established high medium medium 10 turkey fragmented established low medium medium 610 source deloitte winning biosimilars opportunity global market developed market per deloitte greatest biosimilar presence today figure 2 seen developed market led adoption seen eu country market u eu5 japan provide growth opportunity biosimilars aided availability better defined regulatory requirement registration biosimilar product payer pushing contain cost witnessed eu market adoption biosimilars largely payerdriven figure 2 given need contain public health expenditure market uptake product varied across eu early physician scepticism low patient awareness certain market especially southern europe payer include government many instance proactively promoting use biosimilars education patient encouraging doctor use lower cost alternative branded biologics biosimilar manufacturer tasted success recent success infliximab eu specifically penetration level seen nordic country 90 good example pricing discount varied based level penetration achieved various market discount 2530 seen eu5 country discount may higher eastern europe given higher unmet need due lack sophisticated reimbursement mechanism nordic country government promoted use biosimilars witnessed much steeper discount compared either eu5 eastern europe outcome government tender guaranteed volume physician willingness switch patient branded biologics biosimilars japan government pushing doctor incentivising pharmacy increase use generic biosimilars treat aging population thereby helping control spiralling drug cost japan traditionally branded market process adoption slow encouraging long term perspective united state market behind rest world adoption biosimilars still area regulatory policy evolving point include 1 standard interchangeability pharmaceutical substitution 2 extrapolation indication 3 traceability pharmacovigilance report naming convention permit differentiation product recent commentary action payer regulatory level increased political noise around drug pricing encouraging towards acceptance biosimilars currently two biosimilars one generic insulin glargine commercially available u biosimilar filgrastim achieved success launched market sep15 biosimilar management discussion analysis 131 infliximab launched nov16 initial report suggest generic insulin glargine launched dec16 also well accepted price discount launched product suggested range 1520 given providing rebate secure formulary access common u one would expect net discount higher given high cost development long developmental time inherent risk developer face includes change standard care delay due potential intellectual property lawsuit commercial challenge establish mainstream use drug therefore commercial strategy formulary placement physician education increased patient awareness coupled smart navigation intellectual property landscape needed company successful developed market notably u coming year analyst report suggest pace adoption may surprise industry advanced biosimilars current wave approved marketed united state emerging market company would want presence developed market considerable opportunity exists emerging market biosimilars market characterized poor physical financial access current highpriced branded biologics provide favourable long term growth opportunity biosimilar company figure 2 addition favourable macroeconomic factor improving gross domestic product gdp growth rate coupled growing middle class increasing healthcare spending strong focus containing cost increasing treatment access physician would increase prescription rate lower priced biosimilar alternative available many country biosimilar approval pathway place finalizing guideline many case intellectual property landscape market less troublesome biosimilar sponsor compared developed market historically emerging market seen high penetration generic drug similar trend could apply biosimilars well signalling strong growth attainable biosimilar manufacturer course next year market would require tailored approach due regional country local complexity key success would involve choosing right market right therapeutic area provide greatest impact local population keeping price competitive secure broad access partnering local company overcome local resource knowledge gap getting access local commercial capability distribution network distinctive understanding local stakeholder including prescribing physician figure 3 therefore biosimilar player would grow sale albeit lower margin developed market among increasing affluent health conscious population figure 3 key theme emerging market government pushing development patient cannot domestic pharmaceutical afford industry access high priced biologics shifting disease profile infectious disease physcians key chronic condition influencers deciders better treated large patient therapy often make molecule therapy decision brand v generic biosimilars based perceived ability pay source deloitte winning biosimilars opportunity global market conclusion regulatory framework governing requirement biosimilar development continues evolve globally requirement large expensive phase 3 trial currently mandated many geography could waived biosimilar sponsor able demonstrate biosimilarity address regulatory concern around residual risk using bioassay limited population pharmacokineticpharmacodynamics pkpd phase 1 trial technologically sophisticated analytical tool characterization seen eu guidance future development insulin product globally process becomes mainstream includes complex drug like monoclonal antibody would help reduce cost time associated biosimilar development benefitting patient healthcare system macro favourable ignore support requirement biosimilars effective tool bring healthcare cost provide increased access biologic therapy however risk cannot ignored highly fluid environment would require utmost focus dedication perseverance access large pool capital make opportunity would play next five year current set molecule development indian pharmaceutical industry indian pharmaceutical industry seen steady growth last decade backed increased export expanding indian pharma market ipm indian company revenue coming sale intermediate active pharmaceutical ingredient api formulation various global market include developed market like u europe japan semi developed market across world major indian pharma company global player generic vaccine biosimilars generating half sale outside country ipm highly 132 ahead curve annual report 2017 biocon limited fragmented 20000 player sale dominated branded generic top 10 player include indian well multinational firm accounting 40 market value past year indian company grown tremendously capitalizing major blockbuster losing patent protection paving way generic especially u market volume indian company supply 20 global generic however every passing year left fewer patented drug opportunity indian company launch new product market moving plain vanilla drug complex formulation delivery system thus indian pharma company stepped rd effort newer area company spending establish niche product portfolio future growth respiratory dermatology biosimilars sterile injectable product development major area focus regulatory challenge especially u fda impacted many player including major player u market resulting lower growth last two year complicated debate drug pricing impacted sentiment around industry economic growth increase disposable income india resulted greater affordability consumption healthcare service general particularly generic medicine growing burden account noncommunicable disease infectious disease india lifestyle disease diabetes cardiovascular disease stroke india become public health challenge estimate disease mostly preventable risk factor account 60 death significant morbidity india continue increase per caput consumption medicine country however access quality healthcare service equal country resulting inequitable outcome instance led catastrophic expenditure family one major contributor family discontinuing treatment thrust poverty central state government india taking step address problem recent national health policy nhp 2017 lay plan towards achieving universal health coverage india policy aim achieving universal health coverage delivering quality health care service affordable cost recommends prioritizing role government shaping health system dimension roadmap nhp predicated public spending 25 gdp phased manner provisioning public healthcare system comprehensive integrated accessible seek promote quality care focus emerging disease investment promotive preventive healthcare policy patient centric quality driven address health security promotes make india drug device private player strategic partner cro space contract research organization cro provide support pharmaceutical biotechnology related industry outsourced research development service span drug discovery preclinical research clinical research clinical trial management commercialization pharmacovigilance life science industry evolved matured company dedicating resource effort particular area value chain developed outsourcing relationship perform function incremental outsourcing additional process qualified contract research organization cro brought cost efficiency process improved quality control speed market increased spending drug development industry outsourcing increasing quantum service competitive vendor strong underlying pharmaceutical demand coupled increasing complexity regulatory burden created favourable environment cro helped change dynamic pharmaceutical biotechnology industry cro purely client vendor relationship strategic partnership company trying consolidate simplify supply chain concentrating sourcing among select number multiservice vendor increased outsourcing manufacturing service cro moderate manufacturing cost outsourcing lowcost global destination like india india emerged one leading economical quality pharmaceutical manufacturing hub number global player outsourcing india offer significant benefit mature pharmaceutical hub north america europe india become increasingly important global pharmaceutical supply chain hence incentivising engagement indian pharmaceutical player research related manufacture resulted contract research manufacturing service crams emerging one fastest growing segment country opportunity prospect outsourcing cro discovery service 2016 estimated usd 178 bn estimate exclude clinical research contract manufacturing outsourcing number estimated grow usd 29 bn 2022 source iq4i report increased outsourcing efficient low cost cro hub especially india china compared european american counterpart asiapacific therefore expected fastest growing region drug discovery outsourcing market time period space intentionally left blank management discussion analysis 133 company review biocon utilises core capability fermentation technology high end rd skill manufacturing biopharmaceuticals across small molecule apis large molecule biologics company currently front end presence india uae sell novel branded small molecule biologic product field force also address customer rd requirement various service provided publically listed research service arm syngene international company organized following reporting segment small molecule apis generic formulation b biologics biosimilars insulin mabs biologics novel biologics c branded formulation currently india uae research service syngene detailed analysis business segment indicated hereunder small molecule segment apis generic formulation small molecule segment comprises apis well generic formulation revenue segment currently derived sale api third party segment successful track record regulatory audit developed well emerging market regulator segment leverage strength manufacturing product high degree complexity case using fermentation preferred route include production various statin api various immunosuppressant api api contract manufacturing innovator fermentation space working towards entering oncology space near future investment towards enhancing development manufacturing capability key api product portfolio statin basket simvastatin pravastatin atorvastatin rosuvastatin fluvastatin b immunosuppressant basket tacrolimus sirolimus everolimus mycophenolate mofetil mmf mycophenolate sodium mpa c key product orlistat fidaxomicin leading supplier product leading company estimate global market share range 15 high 50 top10 molecule api portfolio product manufactured via fermentation process core strength biocon supplying customer high quality product many year resulted multiyear association client enabling high global market share biocon api space diversify address need changing landscape given limited number fermentation based api available generic opportunity decided move value chain ventured generic formulation focusing following disease segment metabolics oncology immunology auto immune indication strategy vertically integrated business model currently nascent pipeline product couple approved dossier u eu market working niche portfolio product complex expected limited competition aim leverage strength acquired characterization manufacturing complex protein business hence would targeting select opportunity would fit selection criterion vertically integrated believe could add value api business help sustain long term growth segment work greenfield generic oral solid dosage facility would key component vertical integration effort full swing facility expected commissioned fy18 propose use facility primarily potent product currently segment business contributes significant revenue 40 fy17 profit company cash generated business helped fund early biosimilar foray global market operationally fy17 good year small molecule segment growth 12 compared fy16 growth driven large extent supply rosuvastatin api customer targeting u generic market generic formulation side received approval rosuvastatin calcium anda usfda eu approval received fy16 biologics segment biosimilars novel biologics biocon ahead curve india focussing early innovation especially area biologic drug made significant investment building capability science technology courtesy highly talented team scientist novel process engineering drug substance drug product predictive toxicology adaptive clinical trial design data analytics outcome effort innovative product include antibody like biomabegfr nimotuzumab treatment head neck cancer alzumab itolizumab treating psoriasis addition capability also enabled approval canmab affordable trastuzumab biosimilar treating her2 breast cancer large scale development insulin insugen insulin analog basalog device system insupen made available global patient population biocons biologics segment comprises pipeline 10 biosimilar molecule includes human insulininsulin analogue monoclonal antibody biologics apart pipeline novel biologic product focus segment drug help patient fight diabetes cancer auto immune disease inflammation future segment identified management significant growth driver company early starter among peer india experience developing manufacturing selling product many market globally company confident making mark global scene enters developed market portfolio product year review built upon success fy16 multiple clinical regulatory milestone met business segment segment revenue grew 43 fy16 5793 mn 134 ahead curve annual report 2017 biocon limited biosimilars biocon possesses one largest global biosimilars portfolio spanning human insulininsulin analogue monoclonal antibody biologics addressable market size usd 61 bn 10 disclosed molecule pipeline nine molecule developed partnership mylan global generic major strategic partnership biocon mylan represents biocons strength biologics development manufacturing well mylans regulatory commercial strength globally received first developed market approval insulin glargine product japan partnership fujifilm pharma fy16 partner fujifilm pharma ffp launched product japan 15th july 2016 feedback product positive device appreciated ease use market insulin glargine japan small compared percentage insulin glargine sale globally however success getting product approved first pas selling product japanese market reinforces internal belief well positioned address insulin glargine opportunity developed market partnership mylan proposed biosimilar trastuzumab pegfilgrastim accepted review united state food drug administration usfda european medicine agency ema ema also reviewing proposed biosimilar insulin glargine targeted eu market expect receive marketing approval decision molecule second half fy18 filing generic insulin glargine usfda expected early fy18 proposed biosimilar adalimumab global clinical trial complete completed emerging market targeted indian clinical trial proposed biosimilar bevacizumab filed marketing authorization indian health regulator fy17 global phase 3 trial bevacizumab also initiated late fy17 work recombinant human insulin rhi product targeted u market two global program insulin analog insulin aspart insulin lispro continues table summarizes status global biosimilar portfolio march 31 2017 table status biocons global biosimilar portfolio category molecule status regular acting insulin recombinant human insulin preclinical u market marketed emerging market long acting insulin insulin glargine filed eu australia canada u filing h1 fy18 marketed japan since jul16 emerging market rapid acting insulin analog insulin aspart preclinical rapid acting insulin analog insulin lispro preclinical cancer trastuzumab filed u eu marketed emerging market neutropenia pegfilgrastim filed u eu canada australia emerging market autoimmune adalimumab global phase 3 completed cancer bevacizumab indiaemerging market phase 3 complete global phase 3 commenced neutropenia filgrastim early development autoimmune etanercept early development biocon achieved significant commercialization milestone first overseas facility malaysia subsidiary biocon sdn bhd malaysia awarded myr 300 million 4600 million three year contract supplying rhi cartridge reusable insulin pen malaysian government offtake agreement ota initiative large scale biopharmaceutical facility johor malaysia ota seek encourage local manufacturing new pharmaceutical product thus lowering country reliance import also enhancing export potential biocons rhi malaysia first locally manufactured biosimilar biologic product approved national pharmaceutical regulatory authority npra malaysia commercial sale country apart japanese malaysia milestone insulin portfolio saw increase licensing income fy17 income great extent result successful partnership outcome trastuzumab several large emerging market local partner receive regulatory approval market expect would result meaningfully contribution trastuzumab sale segment fy18 beyond larger emerging market given high unmet need drug see biosimilar trastuzumab meaningful opportunity developed market also emerging market developed market stand point partner mylan entered settlement agreement genentech la hoffman roche related intellectual property around trastuzumab remove legal uncertainty related timing launch product various market around world ability address market demand creating capacity reducing cost increasing operational efficiency key differentiator success biosimilar foray developed well emerging market biocon building manufacturing capacity phased manner fulfil market demand portfolio product malaysia insulin plant started commercial operation fy17 plan augment biologics manufacturing capacity monoclonal antibody line launch ramp supply product across globe expect break ground new monoclonal antibody facility bengaluru fy18 facility built two phase period three four year expansion malaysian insulin plant malaysia phase 2 also considered due course line movement portfolio molecule insulin lispro insulin aspart clinic regulatory commercial outcome insulin glargine product eu u market company continues work towards augmenting portfolio biosimilar candidate development name undisclosed market formation expected next decade current effort focused executing partnered pipeline expected commercialized next year novel biologics biocons novel biologics portfolio comprised therapeutic aim treating diabetes immunooncology autoimmune inflammatory disease therapeutic span across broad range platform including recombinant protein monoclonal antibody mabs novel fusion mabs small interfering rna sirna management discussion analysis 135 field diabetes biocons lead program insulin tregopil phase 2 ready firstinclass oral prandial insulin molecule postprandial glycaemic control january 2016 biocon announced successful result phase 1 study concluded fy16 study established target product profile molecule includes food effect drugdrug interaction pkpd profile data provide basis rd group continue development program type 1 type 2 diabetes patient population type 2 diabetes patient india pivotal phase 3 study expected start fy18 likewise type 1 diabetes patient population multiple ascending dose study planned fy18 combined study different diabetic population form foundation broad global program envisioned insulin tregopil autoimmuneinflammatory disease itolizumab humanized monoclonal cd6 antibody approved india psorasis fy17 bridging phase 1 pk safety study normal healthy volunteer initiated australia evaluate pharmacokinetics subcutaneous route administration itolizumab comparison intravenous route company marketing approval india stage 1 dosing completed subcutaneous route administration show good bioavailability drug plan initiate stage 2 dosing shortly biocon first global company biologically clinically validate cd6 target autoimmune disease qpi1007 novel sirna molecule treat nonarteritic ischemic optic neuropathy naion based quark pharma sirna technology platform licensed india related market qpi 1007 continues make good progress following initiation pivotal global phase 23 study partner quark pharma study initiated fy17 u includes patient randomized india immunooncology biocons lead program fmab2 preclinical development fusion protein efgr mab tgfβ rii ecd fusion antibody work concept preferentially delivering immune modulators tumour site enhancing efficacy delivering larger dos tgfβ tumour micro environment ind molecule planned fy18 currently ready pharmacology mechanism action moa established invitro invivo tumour model provides u potentially broad clinical opportunity multiple tumour type also 2nd generation humanized antibody targeting cd20 path ind mapped plan advance asset neuroinflammatory disease eg multiple sclerosis biocons focus innovation global market continues strengthened via increasing depth emphasis inhouse research capability including access novel ip therapeutic modality invivo invitro model toxicology study early regulatory filing academic collaboration etc development broader global advancement novel program asset likely driven via external collaboration fund larger study required bring market realize full value innovation branded formulation biocon branded formulation business focus regional market currently operational india uae clear strategy focused around leveraging strength biologics differentiated product chronic therapeutic area metabolics diabetes cardiovascular oncotherapeutics immunotherapy inflammation autoimmune nephrology dialysis transplant specialty provide worldclass quality product thousand patient india uae performance india business continued sluggish fy17 increased competition low priced biosimilar mabs introduction price cap key brand government loss key inlicensed oncology brand abraxane withdrawn licensor india uae market impacted growth working overcome challenge modernising tomarket approach focussed execution expanding reach adjacent market like sri lanka making organizational change year review company worked portfolio consolidation focused targeting segmenting operating market targeted licensing strategy focus therapy area repurposing resource high growth segment market anticipated drive growth fy18 idea increase reach key opinion leader kol augmented method digital strategy communicate detail also flattened organization structure brought outside talent rolled attractive reward recognition career path branded formulation india key area objective quicker decision making aim taking current execution notch higher ultimately deliver superior result company change hope deliver higher growth segment fy18 beyond fy17 branded formulation segment grew 24 5489 mn compared previous year attributable growth uae business biocon one strongest company india insulin space 12 16 prescription share human insulin glargine market respectively source cmarc oncology product novel biosimilars command high market share respective category top 10 brand contribute 74 sale india business grew 1 fy17 previous year primarily due impact price control key brand like insugen tacrograf insulin franchise grew 4 fy17 1589 mn uae branded business supported 27 brand sale well diversified across portfolio product top 10 brand contribute 73 sale grew 9 fy17 compared fy16 biocon brand ranked top 3 respective therapy segment uae market research service syngene subsidiary syngene biocon 745 shareholding one leading india based cro offering suite integrated endtoend drug discovery development service novel molecular entity nmes hundred client including startup company large pharma biotech agrochemical chemical nutrition animal health company u europe asia pacific including japan includes 093 held biocon research limited syngene amongst one listed drug discovery development company globally offer onestop solution organisation looking optimize rd expenditure right foundation conducting discovery hit candidate selection development including preclinical clinical study analytical bioanalytical evaluation formulation development stability study pilot manufacturing scaleup preclinical clinical supply one roof service offering discovery development cover multiple domain across small molecule large molecule 136 ahead curve annual report 2017 biocon limited antibodydrugs conjugate adc oligonucleotides unlike traditional business model service offered flexible time engagement model customized client requirement engagement range fulltime equivalent fte feeforservice ffs model combination based client requirement 3100 scientist laboratory base 132 million square foot currently service 290 client ranging multinational corporation startup including eight top ten global pharma company based rd spend besides number multiyear contract syngene five longduration multidisciplinary partnership dedicated research centre bristolmeyers squibb co bm amgen research development center sarc abbott laboratory singapore pte ltd abbott herbalife nutrition company baxter international inc baxter year review syngenes revenue grew 7 11604 mn driven business momentum across three vertical discovery service dedicated centre development manufacturing service notable achievement year includes 1 commissioning first phase syngene research centre 2 set stateofthe art viral testing facility 3 commissioning integrated multidisciplinary drug discovery development centre amgen syngene amgen research development centre capacity staff 100 highly qualified scientist 4 acquisition strand life science asset related system biology heptox pharma bioinformatics service 5 signing strategic partnership herbalife nutrition global nutrition company set first dedicated nutrition research development lab india 6 commissioning phase new formulation facility capable manufacturing clinical commercial supply small volume niche technology product complies regulatory requirement usfda emea authority december 2017 fire accident one syngenes research facility bangalore facility includes office lab space made approximately 20 total revenue fire caused due chemical reaction conducted facility injury loss life part business continuity plan client related project redeployed lab enhanced shift working introduced minimize impact revenue long term structural story business robust syngene continues investment expand service offering building capacity near term investment include forward integration commercialscale manufacturing nmes proven track record effective combination scientific talent global accredited system rd infrastructure continued focus protection client intellectual property syngene remains well positioned benefit expected growth cro industry operational performance year 2017 eventful one company made lot clinical progress diverse pipeline product also delivered better financial performance group overview financial performance company given next page form part mda resource review employee employee represent cornerstone success believe good employee culture translates individual performance success shareholder light steady growth ambitious plan attracting grooming retaining talent utmost importance detailed discussion human capital provided human resource section annual report group employ 9200 people including 500 individual outside india ipr one key focus area creation intellectual property ip generates competitive advantage also creates potential exponential enduring value patent ip portfolio biocon group company comprises 1286 patent application 1053 patent granted various jurisdiction trade mark biocon limited ip portfolio comprises 833 trade mark application 555 registered trademark different class various jurisdiction across world design biocon limited ip portfolio consists four design application three design registered management discussion analysis 137 financial performance overview april 1 2016 company adopted new indian accounting standard commonly referred ind based ifrs principle displayed financials classified based new accounting standard previous year number fy16 restated reflect change consolidated balance sheet following table highlight consolidated balance sheet march 31 2017 fy17 march 31 2016 fy16 table 1 figure million particular fy17 fy16 change asset noncurrent asset tangible intangible asset 44651 39887 12 investment associate joint venture 422 259 63 financial asset 2747 872 215 asset current tax net 895 852 5 deferred tax asset net 1975 715 176 noncurrent asset 2775 2287 21 53465 44872 19 current asset inventory 6353 5424 17 financial asset 32535 33633 3 current asset 1589 652 144 40477 39709 2 total 93942 84581 11 equity liability equity equity share capital 1000 1000 0 equity 47377 39338 20 noncontrolling interest 3761 2658 41 52138 42996 21 noncurrent liability financial liability 21145 20918 1 provision noncurrent liability 3876 4010 3 25021 24928 0 current liability financial liability 11693 12154 4 income tax liability net 964 965 0 provision current liability 4126 3538 17 16783 16657 1 total 93942 84581 11 noncurrent asset noncurrent asset grew 19 primarily due investment tangible asset malaysian facility research service syngene intangible capitalisation pertaining product development expense also continued invest research service business facility investment long term security mat credit also contributed increase noncurrent financial asset equity share capital equity share capital comprises 200000000 equity share face value 5 change equity capital company year equity equity majorly comprises share premium treasury share retained earnings reserve total equity company increased 20 fy17 compared fy16 due profit accumulation year net dividend distribution noncontrolling interest profit attributable minority shareholder increased 41 fy17 attributable accumulation profit current year 138 ahead curve annual report 2017 biocon limited noncurrent liability major movement noncurrent liability fy17 compared fy16 increase termloan obtained biocon sdn bhd offset reduction derivative liability release deferred revenue working capital current asset less current liability working capital march 31 2017 stood 23694 mn 3 compared fy16 line volume operation consolidated statement profit loss following table highlight key component statement profit loss fiscal year ended march 31 2017 fy17 march 31 2016 fy16 table 2 figure million particular fy17 fy16 change total revenue 40787 34602 18 expense cost material consumed 14466 12904 12 excise duty 305 336 9 employee benefit expense 7470 6101 22 depreciation amortisation expense 2772 2487 11 finance cost 260 293 11 expense 8463 8111 4 subtotal 33736 30232 12 less recovery product development cost codevelopment partner net 1283 1320 3 total expense 32453 28912 12 share profit joint venture 163 217 25 profit tax exceptional item 8497 5907 44 exceptional item 1606 100 profit tax 8497 7513 13 tax expense 1538 1299 18 tax exceptional item 78 123 37 profit tax 6881 6091 13 noncontrolling interest 760 587 29 profit year 6121 5504 11 comprehensive income attributable shareholder 764 58 1417 total comprehensive income attributable shareholder 6885 5446 26 revenue year review revenue grew 18 consolidated basis 34602 mn 40787 mn small molecule segment grew 12 driven strong sale rosuvastatin immunosuppressant biologics segment achieved annual growth 43 year year major contributor growth insulin sale malaysia trastuzumab sale emerging market including strong outlicencing opportunity also branded formulation segment showed growth 24 resulting total revenue 5489 mn 4409 mn previous fiscal due deconsolidation joint venture uae likeforlike basis however segment marginally contract research segment syngene reported turnover 11604 mn reflecting annual growth 7 total revenue composition fy17 fy16 detailed table 3 fy17 fy16 fy17 fy16 particular mn mn small molecule 16330 14546 40 42 biologics 5793 4046 14 12 branded formulation 5489 4409 13 13 research service 11604 10809 29 31 revenue operation 39216 33810 income 1571 792 4 2 total revenue 40787 34602 cost material consumed material cost comprised raw material packing material traded good change inventory fy17 material cost percentage overall revenue operation remained consistent fy16 management discussion analysis 139 employee benefit expense employee benefit expense comprise following item salary wage allowance bonus contribution provident fund contribution towards gratuity provision amortisation employee stock compensation expense welfare expense including employee insurance scheme expense increased 22 fy17 driven largely increased employee strength annual increment research development expense net rd expenditure fy17 reduced 3 2662 mn 2742 mn fy16 amount profit loss account represented 9 revenue exsyngene compared 11 previous year capitalized 1357 mn taking gross rd spend 4019 mn year compared 4267 mn fy16 decrease rd expense account reduced spends anda development program whereas expenditure inhouse novel program increased 38 fy17 estimate rd spends remain range 1215 revenue exsyngene coming year depreciation amortization fiscal depreciation amortization increased 2772 mn 2487 mn fy16 new facility research arm resulted additional depreciation current year finance cost finance cost fy17 260 mn contributed use foreign currency borrowing address routine operation total finance cost fy17 reduced 33 mn increase interest cost term loan new term obtained fy17 however fy17 exchange difference considered borrowing cost remained nil 67 mn fy16 exceptional item net year ended march 31 2017 biocon sa bsa biocon sdn bhd biocon malaysia entered assignment license agreement pursuant bsa transferred right interest obligation insulin analog ipr biocon malaysia consequent transfer bsa recorded net gain standalone book offered tax swiss tax law restructuring impact consolidated financial statement except tax cost 78 mn representing tax payable bsa locally included within income tax expense year ended march 31 2017 exceptional item previous year comprised following consequent agreement customer resulted change nature group future obligation rhinsulin program deferred revenue 2684 mn relating program recognized income consolidated financial result year ended march 31 2016 disclosed exceptional item b pursuant uncertainty respect ability group license product development commercialization certain territory biocon sa recorded impairment carrying value intangible asset amounting 1078 mn impairment recognized exceptional item consolidated financial result year ended march 31 2016 c gain arising sale equity share respect syngene net related expense cost equity share amounting 962 mn accounted exceptional gain standalone financial result year ended march 31 2016 year ended march 31 2016 company sold investment equity share biocon malaysia wholly owned subsidiary biocon biologics limited uk another wholly owned subsidiary company sum 811 mn gain arising sale equity share net cost equity share amounting 99 mn recorded exceptional item standalone financial result consequential tax 21 mn recorded gain tax expense tax expense fiscal stood 1538 mn comparison 1299 mn fy16 increase account higher profit comparison previous year comprehensive income comprehensive income includes remeasurement gainslosses defined benefit plan gainlosses hedging instrument cash flow hedge increase current year primarily account gain hedging instrument amounting 871 mn net tax arising research business group 140 ahead curve annual report 2017 biocon limited risk threat concern risk potential event nonevent occurrence nonoccurrence adversely affect objective strategy company global pharma industry bear striking resemblance financial service industry decade ago industry landscape affected product safety quality issue intellectual property tangle inappropriate marketing practice corruption thereby leading penalty product recall brand loss revenue loss regulatory landscape international pharma industry complex dynamic primary industry driver patient health safety even regulatory approach patient protection vary market market besides factor rapid change increased scrutiny sophisticated riskmonitoring technique coordination across agency region context imperative respond holistic risk mitigation framework company carved niche back steadfastness conducting business accordance applicable law regulation well manner consistent core organizational value established risk management framework address strategic operational legal financial compliance risk inherent pharma business impact strategic goal risk management coupled robust internal control framework help company emphasize qualitative consistency employee safety longterm sustainability global pharma business marked variety risk pharmaceutical company struggle globally enforce ip protection particularly emerging market enhanced regulatory scrutiny set backdrop increasing patient advocacy social medium affiliate marketing programme digitisation proliferation electronic medical record networked medical device mobile health application cloudbased technology datasharing among industry stakeholder increased complexity managing information asset particularly protected health information intellectual property success new product global pharmaceutical industry offset global pricing pressure supporting outlook change stable positive industry although comprehensive eradication risk associated business company unfeasible constant effort made mitigate adverse impact company implemented precise methodology entailing timely identification analysis assessment risk potential consequence formulation specific mitigation strategy seamless execution enterprisewide risk evaluation validation process conducted regularly reviewed risk management committee board director government investor public demand transparency life science company covering aspect like product commercialisation executive pay financial information accuracy manufacturing process clinical trial quality several highprofile incident particularly emerging market enhanced need transparency key development comprise indian government plan involve private sector rd across vaccine drug pharmaceutical brighter side drug approval process simplified authority approval time new facility drastically reduced onus company capitalise opportunity protecting risk addition key risk relating current operation include human capital risk loss key personnel timely non replenishment critical vacant role concentration reliance third party sole supplier service provider including regional supplier reliance risk arising codevelopment arrangement disruption operation natural disaster risk arising strategic project foreign exchange fluctuation changing global political regulatory landscape change company strategy etc internal control company responsible establishing maintaining adequate effective internal control preparation presentation financial statement including assertion internal financial control accordance broader criterion established company robust comprehensive internal control system prerequisite organisation function ethically commensuration ability objective established strong internal control system company comprised policy guideline procedure adopted company ensure orderly efficient business conduct including adherence policy asset safeguarding fraud cum error prevention detection accounting record accuracy completeness timely preparation presentation reliable financial information internal control system aimed providing assurance operational effectiveness efficiency compliance law regulation asset safeguarding reliability financial management reporting company staffed experienced qualified professional play important role designing implementing maintaining monitoring internal control environment independent firm chartered accountant perform periodic internal audit provide reasonable assurance internal control effectiveness advice industrywide best practice audit committee consisting independent director review important issue raised internal statutory auditor regular basis status rectification measure ensure risk mitigated appropriately timely basis outlook fiscal 201617 exciting year biocon marked beginning new growth journey company led biologics segment coupled commencement insulin glargine product sale japan followed initiation commercial supply recombinant human insulin malaysian insulin facility progress global biosimilar pipeline continued multiple filing across various developed market syngene continued make investment expand capacity service offering taking everything consideration beginning new growth journey provided good visibility u deliver long term growth shareholder management discussion analysis 141 corporate governance report company philosophy code governance biocon belief good corporate governance emerges application best management practice compliance law coupled highest standard integrity transparency accountability ethic business matter biocon also belief sound corporate governance critical enhance retain investor trust hence biocons business policy based ethical conduct health safety commitment building long term sustainable relationship relevant stakeholder company continues strengthen governance principle generate long term value stakeholder sustainable basis thus ensuring ethical responsible leadership board management level biocon also consider inherent responsibility disclose timely accurate information regarding financials performance well leadership governance company bioconites committed balanced corporate governance system provides framework attaining company objective encompassing practically every sphere management action plan internal control corporate disclosure company compliance requirement stipulated sebi listing obligation disclosure requirement regulation 2015 sebi lodr regard corporate governance also committed sound corporate governance principle practice constantly strives adopt emerging best corporate governance practice followed worldwide report compliance corporate governance provision prescribed sebi lodr given ii board director composition board company conformity regulation 17 sebi lodr chairperson managing director company though professional director individual capacity promoter number independent director onehalf total number director board company m kiran mazumdar shaw chairperson managing director mr john shaw vice chairman dr arun chandavarkar chief executive officer joint managing director executive director company prof ravi mazumdar non executive non independent director remaining director board company comprises six independent director march 31 2017 renowned professional drawn diverse field possessing requisite qualification experience general corporate management finance banking insurance economics science technology allied field enable contribute effectively company enhance quality board decision making process board aware fiduciary responsibility recognizes responsibility towards stakeholder uphold highest standard matter concerning company empowered responsible person implement broad policy guideline set adequate review process board provides strategic guidance affair company independent director provide independent objective judgement matter placed company day day affair managed chairperson vice chairman ceo assisted competent management team overall supervision board company commitment ethical lawful business conduct fundamental shared value board senior management employee board committed representing long term interest stakeholder providing effective governance company affair exercise reasonable business judgment affair company director elected based qualification experience varied field time induction director formal invitation join board sent director handbook comprising compendium role power duty performed given new director independent director annually provide certificate independence accordance applicable law taken record board board member encouraged meet interact management board member invited key meeting senior management strategic guidance advice composition board board company comprises ten director march 31 2017 name category director number directorship committee position held company given none director director 10 public limited company specified section 165 company act 2013 act act independent director 7 listed company 3 listed company case heshe serf wholetime director listed company specified regulation 25 sebi lodr none director board member 10 committee chairman 5 committee specified regulation 26 sebi lodr across indian public limited company heshe director 142 ahead curve annual report 2017 biocon limited name director category director total number directorship committee chairmanship identification membership public limited company number march 31 2017 directorship committee committee chairmanship membership m kiran mazumdarshaw promoter executive 00347229 8 mr john shaw promoter executive 00347250 4 dr arun chandavarkar executive 01596180 4 2 prof ravi mazumdar promoter nonexecutive 00109213 1 1 mr russell wall independent 03528496 5 4 2 m mary harney independent 05321964 1 mr daniel bradbury independent 06599933 2 1 2 dr vijay k kuchroo independent 07071727 3 1 dr jeremy levin independent 07071720 1 1 mr damodaran independent 02106990 5 2 5 excludes private limited company foreign company company registered section 8 act government body includes additional directorship directorship biocon limited committee considered audit committee stakeholder relationship committee including biocon limited m kiran mazumdar shaw chairperson managing director spouse mr john shaw vice chairman wholetime director sister prof ravi mazumdar non executive director b board procedure detailed agenda sent director least 7 day advance board committee meeting material information incorporated agenda facilitating meaningful focused discussion meeting practicable attach document agenda tabled meeting specific reference effect agenda special exceptional circumstance additional supplementary item agenda permitted enable board discharge responsibility effectively chairperson present every board meeting overall performance company board review strategy business plan annual operating capital expenditure budget investment exposure limit compliance report law applicable company well step taken company rectify instance noncompliance board also review major legal issue minute meeting various committee board subsidiary company significant transaction arrangement entered subsidiary company adoption financial result transaction pertaining purchase disposal property major accounting provision writeoffs corporate restructuring detail joint venture collaboration agreement material default financial obligation fatal serious accident material effluent pollution problem transaction involve substantial payment towards goodwill brand equity intellectual property issue involves possible public product liability claim substantial nature including judgement order may passed stricture conduct company quarterly detail foreign exchange exposure step taken management limit risk adverse exchange rate movement information recruitment senior officer board level key managerial personnel company secretary record minute proceeding board committee meeting draft minute circulated board committee member within 15 day meeting comment director communicate comment writing draft minute within seven day date circulation minute entered minute book within 30 day conclusion meeting signed chairperson subsequent meeting guideline board committee meeting facilitate effective post meeting followup review reporting process decision taken board committee thereof important decision taken board committee meeting communicated promptly concerned department division actiontaken report decisionsminutes previous meeting placed succeeding meeting board committee noting apart board member company secretary board committee meeting also attended chief financial officer wherever required head various corporate function c number board meeting attendance director meeting board annual general meeting agm year april 01 2016 march 31 2017 four board meeting held following date april 26 2016 july 21 2016 october 20 2016 january 24 2017 board met least every calendar quarter gap two meeting exceed one hundred twenty day meeting well attended 38th agm company held june 30 2016 corporate governance report 143 attendance director meeting director board meeting held board meeting attendance 38th agm fy 1617 attended m kiran mazumdarshaw 4 4 yes mr john shaw 4 4 yes dr arun chandavarkar 4 4 yes prof ravi mazumdar 4 4 mr russell wall 4 4 yes m mary harney 4 4 mr daniel bradbury 4 4 dr vijay k kuchroo 4 3 dr jeremy levin 4 4 mr damodaran 4 4 yes shareholding nonexecutive director detail company share held non executive director march 31 2017 director share held march 31 2017 prof ravi mazumdar 565014 mr russell wall nil m mary harney nil mr daniel bradbury nil dr vijay k kuchroo nil dr jeremy levin nil mr damodaran nil joint holding spouse e meeting independent director independent director company met year without presence nonindependent director member management meeting conducted informal flexible manner enable independent director inter alia discus matter pertaining review performance non independent director board whole review performance chairperson company taking account view executive nonexecutive director assess quality quantity timeliness flow information company management board necessary board effectively reasonably perform duty f detail familiarisation programme imparted independent director year independent director apprised frequent interval industry trend business model overview company operation senior management team various business unit head made presentation independent director periodic interval performance future strategy respective business unit independent director also regularly appraised regulatory policy change including role right responsibility presentation internal control financial reporting operational control financial reporting prevention insider trading regulation sebi lodr framework related party transaction etc made board member year company familiarisation policy detail programme attended hour spent independent director financial year 2016 17 available company website httpwwwbioconcomdocsfamiliarisation_programme_fy1617pdf iii committee board board constituted various committee focus specific area make informed decision within authority committee directed charter outline scope role responsibility power decision recommendation committee placed board approval company guideline relating board meeting applicable committee meeting far practicable committee authority engage outside expert advisor counsel extent considers appropriate assist function senior officer functional head company invited present various detail called committee meeting various committee board audit risk committee nomination remuneration committee stakeholder relationship committee corporate social responsibility committee 144 ahead curve annual report 2017 biocon limited audit risk committee brief description term reference power role term reference audit risk committee line provision section 177 act part c schedule ii sebi lodr audit risk committee discharge duty function generally indicated regulation 18 sebi lodr company act 2013 function may specifically assigned board time time company put place enterprise wide risk management framework overseen audit risk committee holistic approach provides assurance best capability company business unit identify assess mitigate risk could materially impact performance achieving stated objective committee ensures company taking appropriate measure achieve prudent balance risk reward ongoing new business activity review strategic decision company regular basis review company portfolio risk considering company risk appetite committee also recommend change appropriate risk management technique andor associated framework process practice company ii composition following director member committee 1 mr russell wall chairman 2 mr daniel bradbury 3 dr jeremy levin 4 mr damodaran member committee independent director committee member possess sound knowledge account finance audit governance legal matter senior staff account finance department representative statutory internal auditor attend audit risk committee meeting company secretary act secretary committee chairman audit risk committee mr russell wall present last annual general meeting held june 30 2016 iii meeting attendance year year committee met 4 time april 26 2016 july 21 2016 october 20 2016 january 24 2017 attendance meeting member meeting held attended mr russell wall 4 4 mr daniel bradbury 4 3 dr jeremy levin 4 4 mr damodaran 4 3 mr damodaran appointed member audit risk committee board meeting held april 26 2016 committee good governance practice also meet external auditor internal auditor chief financial officer company private know independent opinion performance company b stakeholder relationship committee brief description term reference term reference stakeholder relationship committee line provision section 178 act part schedule ii sebi lodr stakeholder relationship committee primarily responsible redressal shareholder investor security holder grievance including complaint related transfer share nonreceipt declared dividend annual report etc ii composition following director member committee 1 mr daniel bradbury chairman 2 mr russell wall 3 prof ravi mazumdar member committee nonexecutive director majority independent mr rajiv balakrishnan company secretary compliance officer company corporate governance report 145 iii meeting attendance year year committee met 4 time april 26 2016 july 21 2016 october 20 2016 january 24 2017 attendance meeting member meeting held attended mr daniel bradbury 4 3 mr russell wall 4 4 prof ravi mazumdar 4 4 year 103 complaint received resolved satisfaction investor march 31 2017 outstanding complaint investor quarterly statement investor complaint received disposed filed stock exchange within 21 day end quarter statement filed also placed subsequent meeting board director c corporate social responsibility committee brief description term reference term reference committee line provision section 135 act committee prime responsibility assist board discharging social responsibility way formulating monitoring implementing framework line corporate social responsibility policy company ii composition following director member committee 1 m mary harney chairperson 2 dr vijay k kuchroo 3 prof ravi mazumdar member committee nonexecutive director majority independent iii meeting attendance year year committee met twice april 26 2016 october 20 2016 attendance meeting member meeting held attended m mary harney 2 2 dr vijay k kuchroo 2 2 prof ravi mazumdar 2 2 nomination remuneration committee brief description term reference term reference nomination remuneration committee line provision section 178 act part schedule ii sebi lodr nomination remuneration committee vested authority inter alia recommend nomination board membership develop recommend policy respect composition board commensurate size nature business operation company establish criterion selection board member respect competency qualification experience track record integrity devise appropriate succession plan determine overall compensation policy company scope committee also includes review market practice decide remuneration package executive director lay performance parameter chairperson managing director executive director senior management key managerial personnel etc review addition committee role includes identifying person may appointed senior management accordance criterion laid recommending board appointment removal committee also formulates criterion determining qualification positive attribute independence director recommends board periodically policy relating remuneration director key managerial personnel employee committee also carry separate exercise evaluate performance individual director feedback sought way structured questionnaire covering various aspect board functioning adequacy composition board committee board culture execution performance specific duty obligation governance performance evaluation carried based response received director 146 ahead curve annual report 2017 biocon limited performance evaluation independent director based various criterion including experience expertise independent judgment ethic value adherence corporate governance norm interpersonal relationship attendance contribution meeting etc ii composition following director member committee 1 m mary harney chairperson 2 dr vijay k kuchroo 3 prof ravi mazumdar 4 m kiran mazumdar shaw majority member committee nonexecutive director half committee composition consist independent director iii meeting attendance year year committee met thrice april 26 2016 october 20 2016 january 24 2017 attendance meeting member meeting held attended m mary harney 3 3 dr vijay k kuchroo 3 3 prof ravi mazumdar 3 3 m kiran mazumdar shaw 3 1 m kiran mazumdar shaw appointed member nomination remuneration committee board meeting held april 27 2017 attended invitee iv remuneration director remuneration policy company welldefined policy remuneration director key managerial personnel employee policy furnished annexure iii board report element remuneration package executive director includes fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company executive director employee company subject service condition per company policy two month notice period period mutually agreed separate provision payment severance fee executive director non executive director independent director paid remuneration form commission apart sitting fee subject notice period severance fee b remuneration nonexecutive director pursuant approval granted shareholder company 35th agm held 26th july 2013 independent director paid commission upto maximum 1 net profit company financial year computed manner laid act subject limit independent director eligible commission outlined participation various meeting meeting various performance parameterscriteria including restricted participation contribution director commitment guidance provided senior management outside board committee meeting effective deployment knowledge expertise effective management relationship various stakeholder independence behaviour judgment etc set nomination remuneration committee sl particular amount usd 1 commission attending board meeting 5000 2 commission attending audit risk committee meeting chairman 6000 member 3000 3 commission attending nomination remuneration committee meeting chairman 2000 member 1000 4 commission attending corporate social responsibility committee meeting chairman 2000 member 1000 besides commission foreign independent director paid travel allowance usd 4000 case travel united state usd 3000 case travel country attending meeting non executive director paid consolidated sitting fee 100000 attending board committee meeting company also reimburses outofpocket expense incurred director attending meeting non executive director bring significant professional expertise rich experience across wide spectrum functional area marketing technology corporate strategy legal finance corporate function company seek expert advice various matter science corporate governance report 147 technology legal governance matter pecuniary relationship transaction nonexecutive director vi avis company financial year 201617 c remuneration executive director shareholder 37th agm appointed m kiran mazumdar shaw chairman managing director period five year effective april 01 2015 certain term condition including remuneration subject limit 5 net profit company remuneration includes fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company mr john shaw appointed whole time director designated vice chairman company shareholder 32nd agm certain term condition including remuneration comprising fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company shareholder 35th agm increased remuneration mr john shaw subject limit 5 net profit company dr arun chandavarkar appointed ceo joint managing director period five year effective april 24 2014 shareholder 36th agm certain term condition including remuneration comprising fixed variable salary performance bonus contribution provident fund superannuation gratuity perquisite allowance reimbursement expense etc applicable employee company detail remuneration paid director year ended march 31 2017 given amount million director salary perquisite others fixed pay bonus perquisite retiral benefit commission sitting fee total m kiran mazumdar shaw 194 003 098 2041 mr john shaw 172 003 1723 dr arun chandavarkar 317 003 127 3300 prof ravi mazumdar 04 04 mr russell wall 375 04 379 m mary harney 281 04 285 mr daniel bradbury 221 04 225 dr vijay k kuchroo 214 03 217 dr jeremy levin 322 04 326 mr damodaran 195 04 199 perquisite valued per income tax act 1961 dr arun chandavarkar granted 76500 restricted stock unit rsus company subsidiary syngene international limited april 2015 nil exercise price doesnt form part remuneration shown rsus shall vest period 4 year date grant year 201617 7650 rsus exercised dr arun chandavarkar option company esop plan granted executive nonexecutive director financial year 201617 v general body meeting annual general meeting date time location annual general meeting held last three year special resolution passed follows year date time venue special resolution passed 201314 july 25 2014 tyler jack auditorium biocon research centre 1approval enhancement borrowing limit creation 330 pm plot 3 biocon sez bommasandra jigani link road charge bengaluru 560 099 201415 july 24 2015 tyler jack auditorium biocon research centre 1 amendment article association company 330 pm plot 3 biocon sez bommasandra jigani link road 2 implementation esop plan esop trust bengaluru 560 099 3 acquisition share esop trust secondary market 20152016 june 30 2016 tyler jack auditorium biocon research centre 1 appointment statutory auditor 400 pm plot 3 biocon sez bommasandra jigani link road 2 approval new grant company esop plan bengaluru 560 099 special resolution passed postal ballot special resolution passed postal ballot fy 201617 board meeting held april 27 2017 proposes seek approval shareholder special resolution increasing authorised share capital company consequent amendment memorandum association way postal ballot none business proposed transacted ensuing agm requires passing special resolution postal ballot 148 ahead curve annual report 2017 biocon limited ii procedure postal ballot compliance provision section 108 110 act read applicable rule company provides electronic voting evoting facility member company engages service karvy computershare private limited karvy purpose providing evoting facility member member option vote either physical ballot evoting company dispatch postal ballot notice form along postage prepaid business reply envelope member whose name appear register member list beneficiary cutoff date postal ballot notice sent member electronic form email address registered depository participant case electronic shareholding registered address member case physical shareholding company also publishes notice newspaper declaring detail completion dispatch requirement mandated act applicable rule voting right reckoned paidup value share registered name member cutoff date member desiring exercise vote physical postal ballot form requested return form duly completed signed scrutinizer close voting period member desiring exercise vote electronic mode requested vote close business hour last date evoting scrutinizer submits report chairman completion scrutiny consolidated result voting postal ballot announced chairman director company company secretary result also displayed company website wwwbioconcom besides communicated stock exchange depository registrar share transfer agent date declaration postal ballot result shall date resolution would deemed passed approved requisite majority b mean communication quarterly result quarterly financial result published financial express vijayavani kannada edition also displayed company website www bioconcom ii news release presentation official news press release sent stock exchange displayed company website wwwbioconcom iii presentation institutional investor analyst presentation made institutional investor financial analyst quarterly financial result company presentation also uploaded company website wwwbioconcom sent stock exchange schedule meeting institutional investor financial analyst intimated advance stock exchange disclosed company website iv website company website wwwbioconcom contains separate dedicated section investor shareholder information available information press release notice board meeting outcome board meeting revision credit rating clipping newspaper publication etc uploaded website company annual report also uploaded website userfriendly downloadable form v nse electronic application processing system neap neap webbased application designed nse corporates periodical compliance filing like shareholding pattern corporate governance report medium release etc filed electronically neap vi bse corporate compliance listing centre listing centre bs listing centre webbased application designed corporates periodical compliance filing like shareholding pattern corporate governance report medium release etc filed electronically listing centre vii sebi complaint redress system score investor complaint processed centralized webbased complaint redressal system centralized database complaint received online upload action taken report atrs company online viewing investor action taken complaint current status updated resolved electronically sebi score system vi general shareholder information company registration detail company registered state karnataka india corporate identity number cin allotted company ministry corporate affair mca l24234ka1978plc003417 corporate governance report 149 b annual general meeting date time friday july 28 2017 400 pm venue tyler jack auditorium biocon research centre plot 3 biocon sez bommasandra jigani link road bengaluru 560 099 financial year april 01 march 31 dividend payment date creditdispatch dividend warrant approved member meeting would made july 28 2017 august 4 2017 date book closure saturday july 22 2017 friday july 28 2017 day inclusive financial result calendar 20172018 q1 fy 18 july 27 2017 q2 fy 18 october 26 2017 q3 fy 18 january 24 2018 q4 fy 18 april 26 2018 date tentative listed stock exchange national stock exchange india limited exchange plaza bandrakurla complex bandra e mumbai 400 051 bse limited p j tower dalal street mumbai 400 001 stock codesymbol nse biocon bse 532523 international security identification number ine 376g01013 payment annual listing fee stock exchange paid market price data 201617 monthly high low closing price volume share company april 1 2016 march 31 2017 given month bse nse high price low price volume equity high price low price volume equity share share apr16 58950 48245 2560625 58990 48215 22005012 may16 72135 58200 2208773 72180 58340 21269893 jun16 76600 68900 1691858 76500 68815 18200909 jul16 83730 68900 4073823 83720 68895 36117642 aug16 92350 76700 4043362 92400 81080 32982382 sep16 98800 87530 2303143 98475 87135 18928591 oct16 102000 89500 2021224 102000 89490 22441085 nov16 94685 80350 1304937 93690 80440 17164695 dec16 99205 88210 1361276 99000 88170 15784030 jan17 105205 93050 2107061 105175 92925 19298822 feb17 114420 99510 955671 114380 99510 9817612 mar17 116185 101500 1003262 116290 101755 12725905 ii performance comparison broad based index chart show performance company share price comparison broad based index bse sensex nse nifty biocon management caution stock price movement shown graph considered indicative potential future stock price performance 150 ahead curve annual report 2017 biocon limited biocon bse sensex share price movement april 1 2016 march 31 2017 250 200 150 100 50 0 6 6 6 16 7 16 7 6 6 6 7 6 1 1 1 1 1 r1 t1 1 1 1 v c p ay g ar b n n l ap oc de ju au se fe ju ja 1 1 1 1 1 1 1 1 1 1 1 1 biocon bse sensex close note share price biocon limited bse sensex indexed 100 april 1 2016 biocon p nifty share price movement april 1 2016 march 31 2017 250 200 150 100 50 0 6 6 6 16 7 16 7 6 6 16 17 6 1 1 1 1 1 r1 t1 l1 v c p n n ay g ar b ap oc de ju au se fe ju ja 1 1 1 1 1 1 1 1 1 1 1 1 biocon nse nifty close note share price biocon limited nse nifty indexed 100 april 1 2016 iii share transfer system share transfer processed share certificate duly endorsed returned within period fifteen day date receipt subject document valid complete respect stakeholder relationship committee delegated authority approving transfer transmission etc company security share transfer committee consisting m kiran mazumdar shaw chairperson managing director mr john shaw vice chairman wholetime director company summary transfertransmission security company approved share transfer committee placed every stakeholder relationship committee meeting company obtains company secretary practice halfyearly certificate compliance share transfer formality required sebi lodr file copy said certificate stock exchange iv dematerialization share liquidity 9977 equity share company electronic form march 31 2017 trading equity share company permitted dematerialized form company equity share actively traded nse bse substantial increase daily trading activity company equity share witnessed fy 201617 compared fy 2015 16 corporate governance report 151 v distribution shareholding category wise march 31 2017 category share equity promoter indian foreign 121360946 6068 foreign institutional investor 35427957 1771 mutual fund bank ifis 6725931 336 nris foreign national 2376919 119 corporate body 4099910 205 trust 7812176 391 indian public others 22196161 1110 total 200000000 10000 vi distribution shareholding number share march 31 2017 category holder holder share equity 1 1000 98420 9768 9145919 457 1001 2000 1029 102 1543058 077 2001 3000 343 034 872209 044 3001 4000 179 018 648380 032 4001 5000 132 013 622874 031 5001 10000 247 025 1845984 092 10001 20000 131 013 1904957 095 20001 30000 53 005 1355012 068 30001 40000 19 002 641159 032 40001 50000 30 003 1330520 067 50001 100000 62 006 4400966 220 100001 116 012 175688962 8784 total 100761 10000 200000000 10000 vii outstanding adrsgdrswarrants convertible instrument conversion date likely impact equity company issued adrsgdrs warrant convertible instrument viii commodity price risk foreign exchange risk hedging activity input pricing risk managed appropriate long term rate contract constant evaluation alternate support source key raw material company approved foreign exchange risk management policy accordingly year ended march 31 2017 company managed foreign exchange risk hedged extent considered necessary detail foreign currency exposure hedging disclosed note 39 standalone financial statement ix plant location 1 2 3 4 20th km hosur road biocon park plot 213215 plot 2 electronics city po plot 2 3 4 5 ida phaseii pashamylaram road 21 jn pharma city ida bengaluru 560 100 bommasandra jigani link road medak district 502307 parvada vishakapatnam 531021 bengaluru 560 099 andhra pradesh india x address correspondence financial disclosure medium corporate communication mr siddharth mittal m seema ahuja president finance chief financial officer head corporate communication tel 91 80 2808 2808 tel 91 80 2808 2808 email id siddharthmittalbioconcom email id seemaahujabioconcom investor relation institutional investor research analyst registrar share transfer agent mr saurabh paliwal karvy computershare private limited head investor relation unit biocon limited tel 91 80 2808 2808 plot 3132 karvy selenium tower b gachibowli financial district email id investorrelationsbioconcom nanakramguda hyderabad 500 032 email id einwardriskarvycom corporate governance compliance registered office mr rajiv balakrishnan biocon limited company secretary compliance officer 20th k hosur road tel 91 80 2808 2808 electronics city po bengaluru 560 100 email id cosecretarybioconcom 152 ahead curve annual report 2017 biocon limited company also designated cosecretarybioconcom exclusive email id purpose investor servicing registering complaint displayed company website c disclosure materially significant related party transaction financial year 201617 materially significant transaction arrangement entered company promoter management director relative subsidiary etc may potential conflict interest company large company formulated policy dealing related party transaction specify manner entering related party transaction policy also posted website company accessed web link httpwwwbioconcomdocspolicydocument_relatedpartytransaction_2015 pdf ii detail noncompliance last three year instance noncompliance company related capital market penalty stricture imposed company stock exchange sebi statutory authority company also complied requirement corporate governance report para 2 10 mentioned part c schedule v sebi lodr disclosed necessary information specified regulation 17 27 regulation 462 b appropriately annual report iii vigil mechanism whistle blower policy vigil mechanism envisaged act rule prescribed thereunder sebi lodr implemented company whistle blower policy provide adequate safeguard victimisation person use mechanism make provision direct access chairperson audit committee address chairman audit risk committee given policy employee director vendor supplier stakeholder associated company report matter concern whistle blower policy company available website company accessed web link httpwwwbioconcomdocsbiocon_group_integrity_whistle_blower_policypdf iv compliance nonmandatory requirement apart complying mandatory requirement prescribed sebi listing obligation disclosure requirement regulation 2015 company complied nonmandatory requirement year review audit qualification company financial statement company continues adopt best practice ensure regime unqualified financial statement post chairperson managing director chief executive officer separately held internal auditor report directly audit risk committee v material subsidiary company subsidiary board managed respective board right obligation manage company best interest stakeholder audit risk committee review financial statement particular investment made unlisted subsidiary company minute board meeting unlisted subsidiary company placed reviewed periodically company board statement containing significant transaction arrangement entered unlisted subsidiary company placed company board periodically company formulated policy determining material subsidiary defined regulation 16 sebi lodr policy also posted website company accessed web link httpwwwbioconcomdocspolicydocument_materialsubsidiarypdf vi disclosure respect demat suspense account unclaimed suspense account company security demat suspense accountunclaimed suspense account vii code conduct code conduct code board member senior management personnel adopted board comprehensive code applicable director senior management personnel code lay detail standard business conduct ethic strict governance norm board senior management personnel copy code put company website wwwbioconcomthe code circulated director senior management personnel compliance affirmed annually declaration signed company chief executive officer effect published report viii code prevention insider trading practice company formulated comprehensive code conduct prevention insider trading designated person compliance security exchange board india prohibition insider trading regulation 2015 amended time time director officer designated person connected person company governed code ix disclosure senior management personnel senior management company made disclosure board confirming material financial commercial transaction personal interest may potential conflict interest company large corporate governance report 153 x ceocfo certification chief executive officer ceo chief financial officer cfo company furnished board requisite compliance certificate regulation 178 sebi lodr financial year ended march 31 2017 declaration code conduct biocon group committed conducting business accordance applicable law rule regulation highest standard business ethic company adopted code ethic business conduct applicable director officer employee hereby certify board member senior management personnel company affirmed compliance code ethic business conduct year 201617 biocon limited sd bengaluru dr arun chandavarkar april 27 2017 chief executive officer space intentionally left blank 154 ahead curve annual report 2017 biocon limited auditor certificate corporate governance member biocon limited examined compliance condition corporate governance biocon limited year ended 31 march 2017 per regulation 17 27 clause b regulation 462 paragraph c e schedule v security exchange board india listing obligation disclosure requirement regulation 2015 listing regulation management responsibility company management responsible compliance condition corporate governance requirement stipulated listing regulation responsibility includes design implementation maintenance corporate governance process relevant compliance condition responsibility also includes collecting collating validating data designing implementing monitoring corporate governance process suitable ensuring compliance mentioned listing regulation auditor responsibility pursuant requirement mentioned listing regulation examination limited procedure implementation thereof adopted company ensuring compliance condition corporate governance neither audit expression opinion financial statement company conducted examination corporate governance compliance company per guidance note report certificate special purpose revised 2016 issued institute chartered accountant india icai guidance note requires comply ethical requirement code ethic issued icai complied relevant applicable requirement standard quality control sqc 1 quality control firm perform audit review historical financial information assurance related service engagement opinion opinion best information according explanation given u certify company complied condition corporate governance per regulation 17 27 clause b regulation 462 paragraph c e schedule v listing regulation applicable state compliance neither assurance future viability company efficiency effectiveness management conducted affair company restriction use certificate solely issued purpose complying aforesaid regulation may suitable purpose accordingly accept assume liability duty care purpose person report shown whose hand may come save expressly agreed prior consent writing b r co llp chartered accountant firm registration number 101248ww100022 sethuraman partner membership number 203491 place bengaluru date 27 april 2017 corporate governance report 155 business responsibility report pursuant regulation 342f security exchange board india listing obligation disclosure requirement regulation 2015 section general information company 1 corporate identity number cin company l24234ka1978plc003417 2 name company biocon limited 3 registered address 20th km hosur road electronic city bangalore 560100 4 website wwwbioconcom 5 email id cosecretarybioconcom 6 financial year reported 01042016 31032017 7 sector company engaged industrial activity codewise industrial group description 021 manufacture pharmaceutical medicinal chemical botanical product per national industrial classification ministry statistic programme implementation 8 list three key productsservices company manufacturesprovides balance sheet statin ii immunosuppressant iii insulin 9 total number location business activity undertaken company number international location 5 united state america switzerland united kingdom malaysia dubai b number national location 3 manufacturing location bengaluru hyderabad vishakhapatnam marketing office india 10 market served company localstatenationalinternational addition serving indian market company global footprint serf market 120 country section b financial detail company 1 paid capital 1000 million 2 total turnover 27172 million 3 total profit tax 5193 million 4 total spending corporate social responsibility csr percentage profit tax 2 5 list activity expenditure 4 incurred refer annexure 9 board report csr activity section c detail 1 company subsidiary company company yes company 10 subsidiary march 31 2017 2 subsidiary companycompanies participate br initiative parent company yes indicate number subsidiary company yes company subsidiary biocon academy participates br initiative company 3 entityentities eg supplier distributor etc company business participate br initiative company yes indicate percentage entityentities less 30 3060 60 per corporate risk governance process supplier distributor work closely supply chain several risk mitigation program including business continuity plan geographic risk mitigation reducing environmental burden using recycled solvent training user team inside company manage product functioning related hazard product specific product handling usage procedure set supplier required followed 156 ahead curve annual report 2017 biocon limited section br information 1 detail directordirectors responsible br detail directordirectors responsible implementation br policypolicies din number 01596180 ii name dr arun chandavarkar iii designation ceo joint managing director b detail br head particular detail 1 din number applicable 01596180 2 name dr arun chandavarkar 3 designation ceo joint managing director 4 telephone number 080 2808 2808 5 email id arunchandavarkarbioconcom 2 principlewise per nvgs br policypolicies p1 business conduct govern ethic transparency accountability p2 business provide good service safe contribute sustainability throughout life cycle p3 business promote wellbeing employee p4 business respect interest responsive towards stakeholder especially disadvantaged vulnerable marginalized p5 business respect promote human right p6 business respect protect make effort restore environment p7 business engaged influencing public regulatory policy responsible manner p8 business support inclusive growth equitable development p9 business engage provide value customer consumer responsible manner space intentionally left blank business responsibility report 157 detail compliance reply yn 158 question p1 p2 p3 p4 p5 p6 p7 p8 p9 ethic product wellbeing responsiveness respect environmental public support inclusive engagement transparency responsibility stakeholder human responsibility policy growth customer employee right advocacy 1 policy policy n 2 policy formulated n consultation relevant stakeholder 3 policy conform n n national international standard yes specify 50 word 4 policy approved n board yes signed md owner ceo appropriate board director 5 company n n specified committee board ahead curve annual report 2017 director official oversee implementation policy 6 indicate link policy refer refer refer httpwwwbiocon n httpwwwbiocon httpwwwbioconcom viewed online table table table combiocon_aboutus_ combiocon_csr_ biocon_invrelation_cor_ ehspolicyasp about_policyasp codeaspsublinkgover 7 policy formally n communicated relevant internal external stakeholder 8 company inhouse n structure implement policy policy policy uploaded local intranet 9 company n grievance redressal mechanism related policy policy address stakeholder grievance related policy policy 10 company carried n n n independent audit evaluation working policy internal external agency note 1 company doesnt formal stakeholder responsiveness policy however specific stakeholder engagement policy exist like biocon communication policy social medium policy internal external stakeholder also outline issue management crisis communication sop company practice upload policy biospace intranet site information implementation internal stakeholder note 2 public policy advocacy yet formulated however company play strong role public policy advocacy regular engagement specific external stakeholder including industry association government body regulatory department biocon limited principle 1 business conduct principle 3 business promote principle 5 business respect govern ethic transparency wellbeing employee promote human right accountability code conduct code conduct code conduct standing order employment policy standing order company practice upload policy intranet site information implementation internal stakeholder however code conduct integrity policy applicable internal external stakeholder available company website wwwbioconcom 3 governance related br indicate frequency board director committee board ceo meet assess br performance company within 3 month 36 month annually 1 year corporate social responsibility committee board meet interval six month assess br performance company ii company publish br sustainability report hyperlink viewing report frequently published maiden br report published annually part company annual report compliance provision sebi listing obligation disclosure requirement regulation 2015 hyperlink viewing report httpwwwbioconcombiocon_invrelation_annualreportsaspsublinkfinance section e principle wise performance principle 1 business conduct govern ethic transparency accountability 1 policy relating ethic bribery corruption cover company yes extend groupjoint venture supplier contractorsngos others extends groupjoint venturescontractors etc 2 many stakeholder complaint received past financial year percentage satisfactorily resolved management provide detail thereof 50 word closed 1 pending management review 1 yet commence investigation 2 total 4 received end march 2017 company hotline whistle blowing concern voiced complaint received addressed accordingly authorized official principle 2 business provide good service safe contribute sustainability throughout life cycle 1 list 3 product service whose design incorporated social environmental concern risk andor opportunity anticholesterol agent human insulin immunosuppresants 2 product provide following detail respect resource use energy water raw material etc per unit productoptional reduction sourcingproduction distribution achieved since previous year throughout value chain biocon belief behaviour practice throughout value chain contribute sustainability company prefers enter long term commitment supplier fulfil responsibility towards society well environment initiative taken improve awareness legal compliance enhance ecofriendly efficiency packaginglogistics improvement supplier end supplier transporter meet held periodical basis company engages encourages undertake sustainable practice across supply chain company drive distribution plan using erp enterprise resource planning system optimize freight cost approach add value manner product affordable accessible practice also sustainable equitable along spreading wellness product also work welfare neighbourhood economy sourcing local material labour wherever possible local sourcing also environmentally sustainable option decrease logistics significantly reduces carbon footprint business responsibility report 159 b reduction usage consumer energy water achieved since previous year company manufacture distributes world class manufacturing facility wide range small molecule biosimilars fermentation based product diverse product portfolio complex production process calculating environmental performance per product pose unique challenge however company taken several measure reduce consumption energy water biocon adopted principle natural resource conservation reuse reduce recycle waste minimization renewable energy manufacturing unit certified ohsas 18001 iso 14001 standard waste generated company operation either recycled disposed responsible way line legal requirement manufacturing facility zero discharge facility 100 wastewater recycled reused back process utility water consumption form important part agenda manufacturing unit across india effort continuously underway reduce fresh water consumption 3 company procedure place sustainable sourcing including transportation yes percentage input sourced sustainably also provide detail thereof 50 word yes company formulated operating procedure approve vendor material procured approved vendor local international quality assurance team company conduct periodic audit vendor especially supply key material various parameter towards evaluating business sustainability integrated scm function encompasses multiple product vertical manufacturing location revolves around meticulous planning smart sourcing disciplined monitoring initiative place sustainable sourcing sourcing vendor consolidation believe strategic supplier interest business best minimum touchpoints multiple level help driving common corporate message across without fly multiple channel towards sourcing strategy consolidated plant bengaluru headquarters strive achieve balance benefit centralization decentralization ii consolidating vendor also help u keeping transaction minimum thereby minimizing operational load consolidating requirement also help better planning effective negotiation b green supply chain biocon made tremendous stride moving animalorigin recombinant supply base key product portfolio includes insulin believe contributed significantly environment friendly initiative apart social cause ii sourcing team biocon focus use green solvent nonpetrochemicals based eg ethanol majority business unit thereby reducing dependency nonrenewable form energy iii deployment professional regulatory compliant logistics provider help consolidating solvent delivery help achieving reduction fuel cost per unit solvent consumed biocon c periodic vendor evaluation supplier small medium large periodically evaluated basis supply performance matrix used evaluate include otif ontime infull delivery number quality complaint ii conduct monthly review supply chain function address issue supplier iii also entrusted vendor evaluation 3rd party international agency like dun bradstreet 4 company taken step procure good service local small producer including community surrounding place work yes step taken improve capacity capability local small vendor yes biocon always strived work develop small medium enterprise around area operation company procures considerable part good avail service local small vendor particularly located around manufacturing location 1520 total supplier base small medium enterprise also strong corporate directive develop sourcing capability locally enables u achieving multiple benefit like shorter turnaround time delivery b quicker resolution issue pertaining material quality c contribute local economy thereby enhancing sustainability operation besides also help long term capacity planning vendor sharing forecast upto 12 month 160 ahead curve annual report 2017 biocon limited 5 company mechanism recycle product waste yes percentage recycling product waste separately 5 510 10 also provide detail thereof 50 word yes mechanism recycling product well waste place company since company zero liquid discharge facility 100 wastewater recycled reused back process utility stp treated water used gardening company premise thereby reducing usage fresh water hyderabad unit managed reduce water consumption around 30 100 used solvent recovered part reused internally reduce usage fresh solvent rest sent recycling authorized recyclers effort made strengthen recovery process biologics b small molecule c cross functional project drive reduction utility solvent novel technology platform help making significant progress towards long term reduction consumption fresh solvent principle 3 business promote wellbeing employee company committed promote diversity work place recognize right heard provide equal opportunity employee regardless race colour religion age gender sexual orientation national origin disability factor may covered local labour law child labour unpaid form involuntary labour encouraged employee right work environment free form discrimination considered harassing coercive disruptive particularly behaviour tantamount sexual harassment company ensures providing safe healthy clean working environment employee employee provided transport canteen facility subsidised price employee engagement activity conducted regularly maintain healthy work environment comprehensive health checkup mandatory employee annually company ensures timely fair payment wage accordance applicable law standard wellbeing employee priority company necessary step taken ensure 2 please indicate total number employee 4278 ii please indicate total number employee hired temporarycontractualcasual basis 1466 iii please indicate number permanent woman employee 505 iv please indicate number permanent employee disability 5 3 employee association recognized management 4 percentage permanent employee member recognized employee association na 5 please indicate number complaint relating child labour forced labour involuntary labour sexual child labour nil harassment last financial year pending end financial year forced labour nil involuntary labour nil sexual harassmentsh 7 sh pending closure 3 received mar 2017 6 percentage mentioned employee given safety skill upgradation training last year skill upgradation safety permanent employee 74 59 permanent woman employee 98 77 casualtemporarycontractual employee 2 100 employee disability 67 83 principle 4 business respect interest responsive towards stakeholder especially disadvantaged vulnerable marginalized 1 company mapped internal external stakeholder yesno yes stakeholder mapped key category government regulatory authority ii employee iii customer iv local community v investor shareholder vi supplier business responsibility report 161 2 company identified disadvantaged vulnerable marginalized stakeholder yes company identified disadvantaged marginalized stakeholder biocon foundation csr arm work marginalized underserved community promote social economic inclusion ensuring marginalized community equal access healthcare service educational opportunity 3 special initiative taken company engage disadvantaged vulnerable marginalized stakeholder provide detail thereof 50 word biocons csr initiative vision promote social economic inclusion ensuring marginalised community equal access healthcare service educational opportunity healthcare focused primary healthcare establishing e laj smart clinic ensure rural poor access efficient health management via competent clinical care generic medicine standard diagnostic test also provide service early detection prevention non communicable disease like cancer diabetes hypertension primary objective program eliminate health disparity among poor address social determinant health develop care pathway educate disseminate information health wellbeing education since education hold key progress biocon made concentrated effort empower rural indian youth aiming provide computer aided learning extracurricular activity life skill education english language skill rural child foundation spearheaded several education program chinnara ganitha seek strengthen learning basic math concept aata paata wadi afterschool resource center child local government school kelsa initiative try inexpensively reach lowincome staff biocons campus community development foundation also provides support infrastructure village like community centre primary health clinic proper sanitation safe drinking water rain water harvesting facility water purification system etc importantly biocon built new village resettle villager mangalgudda north karnataka washed away flood year ago company effort directed constructing 400 new house equipped toilet solar light house principle 5 business respect promote human right 1 policy company human right cover company extend groupjoint venture supplier contractor ngo others extends groupjoint venture contractor etc 2 many stakeholder complaint received past financial year percent satisfactorily resolved management received financial year 201617 2 resolved financial year 201617 2 percentage satisfactorily resolved 100 principle 6 business respect protect make effort restore environment 1 policy related principle 6 cover company extends groupjoint venture supplier contractorsngosothers yes biocon well defined environment health safety policy place motivate employee minimize environmental impact prevent injury ill health workplace cover internal external stakeholder extends group joint venture supplier contractor stakeholder like ngo work u policy communicated stakeholder ensure compliance policy adherence ehs policy emphasized stake holder top management well appropriate communication within company 2 company strategy initiative address global environmental issue climate change global warming etc yn yes please give hyperlink webpage etc yes commitment pertaining global warming climate change biodiversity clearly stressed company ehs policy relevant project initiative place hyperlink webpage httpwwwbioconcombiocon_aboutus_ehspolicyasp 3 company identify assess potential environmental risk yn yes aspect impact identification methodology place assess identify environmental risk activity new project modification 162 ahead curve annual report 2017 biocon limited 4 company project related clean development mechanism provide detail thereof 50 word also yes whether environmental compliance report filed date company project registered clean development mechanism cdm company various project related clean technology strive identify cdm potential project project line cdm methodology company switching piped natural gas fuel boiler instead conventional fossil fuel thus reducing ghg emission usage biogas generated effluent treatment unit anaerobic digester cofuel boiler usage solar energy water heating lighting purpose 35 power requirement sourced wind energy currently exploring opportunity registering cdm project near future 5 company undertaken initiative clean technology energy efficiency renewable energy etc yn yes please give hyperlink web page etc yes energy efficiency clean technology renewable energy project implemented site installation energy efficient centrifugal air compressor ii installation led lighting replace fluorescent lamp iii power trading indian energy exchange iv installation energy efficient air blower motor v reduction co2 emission using png piped natural gas steam generation vi 35 power requirement sourced wind energy vii installation solar powered lighting viii installation waste steam recovery system intranetlink httpsbionetinbioconcomceehsirbp_layouts15wopiframe2aspxsourcedocceehsirbpmanagement_review_report mrm 20report0620mrm2020160220mrm2020pdfpdfactiondefault 6 emissionswaste generated company within permissible limit given cpcbspcb financial year reported yes air emission waste generated company well within permissible limit prescribed environmental regulator reported last financial year 7 number show causelegal notice received cpcbspcb pending ie resolved satisfaction end financial year show causelegal notice received cpcbspcb pending end financial year 1617 principle 7 business engaged influencing public regulatory policy responsible manner 1 company member trade chamber association yes name major one business deal cii idma kdpma karnataka chamber commerce 2 advocatedlobbied association advancement improvement public good yesno yes specify broad area drop box governance administration economic reform inclusive development policy energy security water food security sustainable business principle others pioneering biotechnology company biocon engages various stakeholder including various government department facilitate progressive pragmatic policy address daunting healthcare challenge country biocons cmd kiran mazumdar shaw biotech pioneer well regarded globally passionate enabling affordable healthcare therefore contributes selflessly towards creating enabling ecosystem promotes science encourages startup enables access affordable universal healthcare biocons ceo also chairperson national cii committee biotechnology engages government enable creation optimal biotech ecosystem principle 8 business support inclusive growth equitable development 1 company specified programmesinitiativesprojects pursuit policy related principle 8 yes detail thereof biocon belief corporate social responsibility lie creating comprehensive integrated ecosystem deliver affordable effective healthcare less privileged among india rural urban population also support education initiative impart better learning underprivileged student rural school empower community providing proper infrastructure self sustained village health centre community centre school sanitation water source light business responsibility report 163 understand csr effort must collaborative concentrated comprehensive must integrate private public sector participation permeate social stratum expand radius reach grassroots level poorest underserved citizen primary healthcare service elaj based core principle integrated healthcare service biocon foundation introduced elaj smart clinic across karnataka rajasthan clinic state art diagnostic equipment clinic patient management software along doctor technician eclinics provide access preventive primary healthcare supported robust screening early detection program digital record patient case file elaj electronic medical record system multi parameter monitor mpm clinic collect following vitals blood pressure temperature random blood sugar spo2 pulse rate height weight preventive healthcare biocon foundation primary healthcare program well supported population based screening programme specialist clinic early detection prevention oral cancer mhealth program eighty percent burden oral cancer occurs lowresource setting due delayed presentation community approach ensure last mile reach critical making program impactful biocon foundation introduced mhealth approach mobile health connect specialist remote rural population implemented since 2011 program reached around 20000 people individually obtained risk profile image lesion electronically program empowered community health worker capable identifying oral lesion monitoring high risk group biocon running several pilot government karnataka gok facilitate integration government screening program detection prevention cervical cancer screening high incidence cervical cancer among indian woman growing public health concern biocon foundation addressed since may 2013 developing comprehensive program look towards preventive mechanism also provides support service free screening subsidized treatment program focus community information education b conducting monthly screening service includes pap smear pelvic breast bimanual examination c effective followup referral diagnosis andor treatment service tertiary care centre breast cancer screening biocon foundation introduced hand held device called intelligent breast exam ibe order conduct breast screening field practice area designed geography cancer case detected later stage limited access early detection breast cancer device accuracy detect clinically relevant breast lesion higher 85 device easily used healthworker doctor pain free process without radiation device helped health worker conduct house house breast cancer screening diabetes hypertension built successfully executed multipronged holistic strategy manage non communicable disease focus diabetes hypertension health promotion prevention strategy conducted community encourage healthy life style reduce incidence integrated risk factor addition incorporated psychosocial counselling meet emotional social mental health need patient conduct early diagnosis combination periodic opportunistic screening community provide handholding referral required balaspandana management malnutrition program support government anganwadis ensuring child severe acute malnutrition sam child receive regular health check ups prescribed medicine nutritional supplement program reached 1 25 000 malnourished child age 5 year bagalkot district karnataka education company spearheaded several education program chinnara ganitha seek strengthen learning basic math concept aata paata wadi afterschool resource centre child local government school kelsa initiative provides access internet connected computer encourages informal selfpaced learning program run support staff company community development community school sanitation line swachh bharat mission swachh vidyalaya program constructed toilet 5 government primary school 3 anekal taluk near bangalore 2 badami bagalkot district also built 1000 plus household toilet anekal bagalkot district karnataka 164 ahead curve annual report 2017 biocon limited project one project one community drinking water initiative program installed water purification system ro uv technology provide potable drinking water community serve system capacity purifying 500 litre water one hour provide drinking water community 5000 member installed community water point 3 location biocon nagar biocon nagar village consists 411 house built biocon foundation mangalgudda community displaced flood 2009 house solar light independent toilet foundation built clinic community provides medical consultation medicine diagnostic test school community centre also built girl hostel biocon foundation collaboration shri vr deshpande memorial trust established lady hostel economically weaker section society haliyal north karnataka hostel dormitory provision 65 woman young girl surrounding distant village come haliyal learn vocational skill hostel provides safe free accommodation biocon academy established biocon academy centre excellence advanced learning applied bio science platform provides industry oriented training program make student industry ready 2 programmesprojects undertaken inhouse teamown foundationexternal ngogovernment structuresany organization csr initiative primarily implemented house grant provided ngo impactful work foundation carried program domain healthcare education community development past 12 year also support ngo small grant implement project 3 done impact assessment initiative impact assessment conducted continuously program interval program primary healthcare program monitored assessed continuous basis live dashboard snapshot information dashboard annual patient footfall recorded 100000 across 14 clinic 8 biocon foundation clinic 5 government rajasthan primary health centre 1 government karnataka primary health centre disease profile community populated dashboard help public health planning developing better public health policy listing patient suffering disease also made available facilitate follow control rate non communicable disease ncds compliance medication progress illness monitored patient counselled frequently effective follow referral patient visiting clinic possible clinic created complete care pathway address health concern community accuracy elaj data data presentation elaj dashboard project evaluation also impact indicator project 4 company direct contribution community development project amount inr detail project undertaken refer annexure 8 board report corporate social responsibility 5 taken step ensure community development initiative successfully adopted community please explain 50 word yes step taken ensure program successfully adopted community illustrated example increase patient footfall clinic show community using service tried strengthen preventive primary health service reduce burden larger tertiary centre reduce number patient regular awareness sensitization program conducted beneficiary dedicated team health worker last mile reach community use iec material train educate health worker create awareness amongst beneficiary disease screening program doctor consultation lab test medicine provided subsidized cost noncommunicable disease health promotion prevention strategy conducted community encourage healthy life style reduce incidence integrated risk factor introduced diabetes educator counsellor help patient key selfcare point diet exercise drug compliance optimal management blood sugar behaviour change education given care giver malnourished child health camp regular growth monitoring nourished child facilitated upward growth trend child business responsibility report 165 rigorous training care giver malnourished child providing nutritional supplement growth monitoring nourished child health camp reduced outlier cancer screening low resource setting quality care referral encouraged individual participate screening process follow referral required increased patient footfall clinic training operation maintenance school sanitation unit helped maintaining toilet facility introducing subscription mechanism drinking water project one helped community maintain water purification system principle 9 business engage provide value customer consumer responsible manner 1 percentage customer complaintsconsumer case pending end financial year customer complaintsconsumer case pending end financial year 2 company display product information product label mandated per local law yesnonaremarks additional information since company product biopharmaceuticals product information approved regulatory authority displayed product label 3 case filed stakeholder company regarding unfair trade practice irresponsible advertising andor anticompetitive behaviour last five year pending end financial year provide detail thereof 50 word nil 4 company carry consumer survey consumer satisfaction trend however company process conducting formal survey financial year 201718 space intentionally left blank 166 ahead curve annual report 2017 biocon limited independent auditor report member biocon limited report standalone indian accounting standard ind financial statement audited accompanying standalone ind financial statement biocon limited company comprise balance sheet 31march 2017 statement profit loss including comprehensive income statement cash flow statement change equity year ended summary significant accounting policy explanatory information herein referred standalone ind financial statement management responsibility standalone ind financial statement company board director responsible matter stated section 1345 company act 2013 act respect preparation standalone ind financial statement give true fair view financial position financial performance including comprehensive income cash flow change equity company accordance accounting principle generally accepted india including ind prescribed section 133 act read relevant rule issued thereunder responsibility also includes maintenance adequate accounting record accordance provision act safeguarding asset company preventing detecting fraud irregularity selection application appropriate accounting policy making judgment estimate reasonable prudent design implementation maintenance adequate internal financial control operating effectively ensuring accuracy completeness accounting record relevant preparation presentation standalone ind financial statement give true fair view free material misstatement whether due fraud error auditor responsibility responsibility express opinion standalone ind financial statement based audit taken account provision act accounting auditing standard matter required included audit report provision act rule made thereunder conducted audit accordance standard auditing specified section 14310 act standard require comply ethical requirement plan perform audit obtain reasonable assurance whether standalone ind financial statement free material misstatement audit involves performing procedure obtain audit evidence amount disclosure standalone ind financial statement procedure selected depend auditor judgment including assessment risk material misstatement standalone ind financial statement whether due fraud error making risk assessment auditor considers internal financial control relevant company preparation standalone ind financial statement give true fair view order design audit procedure appropriate circumstance audit also includes evaluating appropriateness accounting policy used reasonableness accounting estimate made company director well evaluating overall presentation standalone ind financial statement believe audit evidence obtained sufficient appropriate provide basis audit opinion standalone ind financial statement opinion opinion best information according explanation given u aforesaid standalone ind financial statement give information required act manner required give true fair view conformity accounting principle generally accepted india including ind financial position company 31 march 2017 financial performance including comprehensive income cash flow change equity year ended date matter comparative financial information company year ended 31 march 2016 transition date opening balance sheet 1 april 2015 included standalone ind financial statement based previously issued statutory financial statement prepared accordance company accounting standard rule 2006 audited predecessor auditor whose report year ended 31 march 2016 31 march 2015 dated 26 april 2016 29 april 2015 respectively expressed unmodified opinion standalone financial statement adjusted difference accounting principle adopted company transition ind audited u opinion modified respect matter report legal regulatory requirement 1 required company auditor report order 2016 order issued central government india term section 14311 act give annexure statement matter specified paragraph 3 4 order 2 required section 1433 act report sought obtained information explanation best knowledge belief necessary purpose audit financial report 167 b opinion proper book account required law kept company far appears examination book c balance sheet statement profit loss statement cash flow statement change equity dealt report agreement book account opinion aforesaid standalone ind financial statement comply indian accounting standard specified section 133 act read relevant rule issued thereunder e basis written representation received director 31 march 2017 taken record board director none director disqualified 31 march 2017 appointed director term section 1642 act f respect adequacy internal financial control financial reporting company operating effectiveness control refer separate report annexure b g respect matter included auditor report accordance rule 11 company audit auditor rule 2014 opinion best information according explanation given u company disclosed impact pending litigation financial position standalone ind financial statement refer note 36 standalone ind financial statement ii provision made financial statement required applicable law accounting standard material foreseeable loss longterm contract including derivative contract refer note 39 standalone ind financial statement iii delay transferring amount required transferred investor education protection fund company iv company provided requisite disclosure standalone ind financial statement holding well dealing specified bank note period 8 november 2016 30 december 2016 based audit procedure relying management representation report disclosure accordance book account maintained company produced u management refer note 37 standalone ind financial statement b r co llp chartered accountant firm registration number 101248ww100022 sethuraman partner membership number 203491 place bengaluru date 27 april 2017 168 ahead curve annual report 2017 biocon limited annexure independent auditor report annexure referred independent auditor report member company standalone ind financial statement biocon limited year ended 31 march 2017 report company maintained proper record showing full particular including quantitative detail situation property plant equipment b company regular programme physical verification property plant equipment property plant equipment verified phased manner period three year opinion periodicity physical verification reasonable regard size company nature asset accordance programme certain property plant equipment verified year material discrepancy noticed verification c according information explanation given u basis examination record company title deed immovable property held name company except one immovable property amounting 35 million 31 march 2017 company process obtaining registration ii inventory apart good transit inventory lying outside party physically verified management year discrepancy noticed verification physical stock book record material opinion frequency verification reasonable inventory lying outside party substantially confirmed yearend material discrepancy noticed respect confirmation iii company granted loan company covered register maintained section 189 company act 2013 act opinion rate interest term condition loan granted company listed register maintained section 189 act prima facie prejudicial interest company b case loan granted covered register maintained section 189 act borrower regular payment principal interest stipulated c overdue amount respect loan granted company covered register maintained section 189 act iv opinion according information explanation given u company complied provision section 185 186 act respect loan given investment made guarantee security given v company accepted deposit public vi broadly reviewed book account maintained company pursuant company cost record audit rule 2014 amended prescribed central government section 148 act opinion prima facie prescribed account record made maintained however made detailed examination record vii according information explanation given u basis examination record company amount deducted accrued book account respect undisputed statutory due including provident fund employee state insurance incometax sale tax value added tax duty custom excise duty service tax cess material statutory due regularly deposited year appropriate authority according information explanation given u undisputed amount payable respect provident fund employee state insurance income tax sale tax value added tax duty custom excise duty service tax cess material statutory due arrears 31 march 2017 period six month date became payable b according information explanation given u due income tax sale tax value added tax service tax duty custom duty excise deposited appropriate authority account dispute following due name statute nature due amount amount paid period amount forum dispute disputed protest relates pending million million incometax act 1961 income tax 4 4 199697 supreme court incometax act 1961 income tax 1207 111 200910 201213 201314 commissioner appeal incometax act 1961 income tax 1053 117 200809 201011 201112 income tax appellate tribunal itat incometax act 1961 income tax 4 4 199798 high court finance act 1994 service tax 54 march 2010 commissioner appeal april 2009 march 2013 march 2009 december 2011 july 2009 march 2013 finance act 1994 service tax 91 may 2006 september 2010 custom excise october 2010 march 2011 service tax appellate march 2006 march 2010 tribunal cestat 200708 financial report 169 name statute nature due amount amount paid period amount forum dispute disputed protest relates pending million million finance act 1994 service tax 1 january 2009 may 2012 additional commissioner june 2010 june 2012 finance act 1994 service tax 11 april 2014 march 2015 principal commissioner ltu value added tax act value added tax 1 200607 commissioner appeal 2005 central excise act excise duty 361 53 april 2005 march 2008 cestat 1944 200607 200809 200910 201213 central excise act excise duty 1 200910 201213 commissioner appeal 1944 central excise act excise duty 15 200708 201112 commissioner appeal 1944 september 2013 october 2013 custom act 1962 custom duty 4 3 1994 till 2008 cestat custom act 1962 custom duty 4 4 2005 till 2011 commissioner appeal viii opinion according information explanation given u company defaulted repayment due bank financial institution government company borrowing year way debenture ix according information explanation given u company raised money way public issue public offer including debt instrument year term loan raised company applied purpose raised x according information explanation given u fraud company company officer employee noticed reported year xi according information explanation given u based examination record company company paid provided managerial remuneration accordance requisite approval per provision section 197 read schedule v act xii opinion according information explanation given u company nidhi company xiii according information explanation given u based examination record company transaction related party compliance section 177 188 act applicable detail transaction disclosed standalone ind financial statement required applicable accounting standard xiv according information explanation given u based examination record company company made preferential allotment private placement share fully partly convertible debenture year accordingly para 3 xiv order applicable xv according information explanation given u based examination record company company entered noncash transaction director person connected xvi according information explanation given u company required registered section 45ia reserve bank india act 1934 b r co llp chartered accountant firm registration number 101248ww100022 sethuraman partner membership number 203491 place bengaluru date 27 april 2017 170 ahead curve annual report 2017 biocon limited annexure b independent auditor report even date standalone financial statement biocon limited report internal financial control clause subsection 3 section 143 company act 2013 act audited internal financial control financial reporting biocon limited company 31 march 2017 conjunction audit standalone ind financial statement company year ended date management responsibility internal financial control company management responsible establishing maintaining internal financial control based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting guidance note issued institute chartered accountant india icai responsibility include design implementation maintenance adequate internal financial control operating effectively ensuring orderly efficient conduct business including adherence company policy safeguarding asset prevention detection fraud error accuracy completeness accounting record timely preparation reliable financial information required company act 2013 auditor responsibility responsibility express opinion company internal financial control financial reporting based audit conducted audit accordance guidance note audit internal financial control financial reporting guidance note standard auditing issued icai deemed prescribed section 14310 company act 2013 extent applicable audit internal financial control applicable audit internal financial control issued institute chartered accountant india standard guidance note require comply ethical requirement plan perform audit obtain reasonable assurance whether adequate internal financial control financial reporting established maintained control operated effectively material respect audit involves performing procedure obtain audit evidence adequacy internal financial control system financial reporting operating effectiveness audit internal financial control financial reporting included obtaining understanding internal financial control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk procedure selected depend auditor judgment including assessment risk material misstatement financial statement whether due fraud error believe audit evidence obtained sufficient appropriate provide basis audit opinion company internal financial control system financial reporting meaning internal financial control financial reporting company internal financial control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statement external purpose accordance generally accepted accounting principle company internal financial control financial reporting includes policy procedure 1 pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company 2 provide reasonable assurance transaction recorded necessary permit preparation financial statement accordance generally accepted accounting principle receipt expenditure company made accordance authorisation management director company 3 provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition company asset could material effect ind financial statement inherent limitation internal financial control financial reporting inherent limitation internal financial control financial reporting including possibility collusion improper management override control material misstatement due error fraud may occur detected also projection evaluation internal financial control financial reporting future period subject risk internal financial control financial reporting may become inadequate change condition degree compliance policy procedure may deteriorate opinion opinion company material respect adequate internal financial control system financial reporting internal financial control financial reporting operating effectively 31 march 2017 based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting issued institute chartered accountant india b r co llp chartered accountant firm registration number 101248ww100022 sethuraman partner membership number 203491 place bengaluru date 27 april 2017 financial report 171 balance sheet march 31 2017 amount indian rupee million except share data per share data unless otherwise stated note march 31 2017 march 31 2016 april 01 2015 asset noncurrent asset property plant equipment 3 8649 8596 8527 capital workinprogress 3 2408 1723 576 investment property 4 439 439 459 intangible asset 5 292 342 156 financial asset investment 6 33635 32106 32492 ii loan 7 1923 1584 2447 iii financial asset 8a 243 670 373 incometax asset net 414 428 415 deferred tax asset net 18 1054 noncurrent asset 9a 1847 1382 1471 total noncurrent asset 50904 47270 46916 current asset inventory 10 5396 5046 4359 financial asset investment 11 5247 5983 1018 ii trade receivables 12 7982 5038 5033 iii cash cash equivalent 13 3416 2903 3219 iv bank balance iii 13 413 3527 3383 v financial asset 8b 983 990 607 current asset 9b 348 224 194 total current asset 23785 23711 17813 total 74689 70981 64729 equity liability equity equity share capital 14a 1000 1000 1000 equity 64411 58966 56341 total equity 65411 59966 57341 noncurrent liability financial liability borrowing 15 1324 1365 114 ii financial liability 16a 2 7 6 provision 17a 133 95 deferred tax liability net 18 9 282 noncurrent liability 19a 767 913 905 total noncurrent liability 2226 2389 1307 current liability financial liability borrowing 20 2255 561 ii trade payable 21 4505 3944 3008 iii financial liability 16b 663 910 1385 provision 17b 320 285 325 incometax liability net 777 729 584 current liability 19b 787 503 218 total current liability 7052 8626 6081 total 74689 70981 64729 accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 172 ahead curve annual report 2017 biocon limited statement profit loss year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated note year ended year ended march 31 2017 march 31 2016 income revenue operation 22 26184 23354 income 23 988 1731 total income 27172 25085 expense cost raw material packing material consumed 24 9915 9479 purchase traded good 902 760 change inventory traded good finished good workinprogress 25 465 364 excise duty 305 336 employee benefit expense 26 3650 3219 finance cost 27 38 19 depreciation amortisation expense 28 1506 1397 expense 29 5963 5754 21814 20600 less recovery product development cost codevelopment partner net 30 4 48 total expense 21810 20552 profit tax exceptional item 5362 4533 exceptional item net 33 1061 profit tax 5362 5594 tax expense 35 current tax 1269 2175 less mat credit entitlement 1172 deferred tax 72 267 total tax expense 169 1908 profit year 5193 3686 comprehensive income expense item reclassified subsequently profit loss remeasurement defined benefit plan 27 16 income tax effect 9 6 18 10 ii item reclassified subsequently profit loss effective portion gainslosses hedging instrument cash flow hedge 149 income tax effect 47 102 comprehensive income expense year net tax 84 10 total comprehensive income year 5277 3676 earnings per share 32 basic 2645 1878 diluted 2627 1876 accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 financial report 173 statement change equity year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated equity share capital march 31 march 31 2017 2016 opening balance 1000 1000 change equity share capital closing balance 1000 1000 b equity particular security revaluation general retained sez share treasury cash flow item total premium reserve reserve earnings investment based share hedging reserve reserve payment reserve comprehensive equity reserve income balance april 01 2015 2788 9 3458 50180 328 427 5 56341 profit year 3686 3686 comprehensive income 10 10 net tax transaction recorded directly equity dividend including dividend 1107 1107 distribution tax purchase treasury share 150 150 share based payment 107 107 exercise share option 99 99 balance march 31 2016 2788 9 3458 52858 435 577 5 58966 profit year 5193 5193 comprehensive income 102 18 84 net tax transaction recorded directly equity share based payment 125 125 purchase treasury share 150 150 transfer special economic 162 162 zone sez reinvestment reserve transfer sez reinvestment 162 162 reserve utilization exercise share option 120 193 120 193 balance march 31 2017 2908 9 3458 58244 440 727 102 23 64411 accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 174 ahead curve annual report 2017 biocon limited statement cash flow year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated march 31 2017 march 31 2016 cash flow operating activity profit year 5193 3686 adjustment reconcile profit year net cash flow depreciation amortisation expense 1506 1397 unrealised foreign exchange gainloss 213 55 sharebased compensation expense 125 107 provisionreversal provision doubtful debt 16 43 bad debt written 8 interest expense 38 19 interest income 669 727 net gain financial asset measured fair value profit loss 69 dividend income 13 618 net gain sale investment 39 1077 tax expense 169 1908 operating profit working capital change 6470 4715 movement working capital decreaseincrease inventory 350 687 decreaseincrease trade receivables 3077 165 decreaseincrease asset 736 1123 increasedecrease trade payable liability provision 758 1397 cash generated operation 3065 4137 direct tax paid net refund 1207 2052 net cash flow generated operating activity 1858 2085 ii cash flow investing activity purchase tangible asset 2276 2202 acquisition intangible asset 31 232 proceeds sale fixed asset 2 7 loan given subsidiary 957 1979 recovery loan subsidiary 1162 3707 purchase investment 28008 34350 proceeds sale investment 25007 35254 investment bank deposit inter corporate deposit 3250 6944 redemptionmaturity bank deposit inter corporate deposit 8679 2395 interest received 763 515 dividend received 13 618 net cash flow generated fromused investing activity 1104 3211 iii cash flow financing activity purchase treasury share 150 150 proceeds exercise share option 193 99 proceeds longterm borrowing 1324 repayment longterm borrowing 75 140 proceedsrepayment shortterm borrowing net 2312 1716 dividend paid equity share including tax thereon 2107 interest paid 39 12 net cash flow generated fromused financing activity 2383 730 financial report 175 statement cash flow year ended march 31 2017 contd amount indian rupee million except share data per share data unless otherwise stated march 31 2017 march 31 2016 iv net increasedecrease cash cash equivalent ii iii 579 396 v effect exchange difference cash cash equivalent held foreign currency 64 78 vi cash cash equivalent beginning year 2901 3219 vii cash cash equivalent end year iv v vi 3416 2901 reconciliation cash cash equivalent per statement cash flow cash cash equivalent note 13 balance bank current account 3410 2653 unpaid dividend account 6 10 deposit original maturity less 3 month 240 3416 2903 bank overdraftscash credit note 20 2 balance per statement cash flow 3416 2901 company utilize balance towards settlement respective unpaid dividend liability accompanying note integral part standalone financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 space intentionally left blank 176 ahead curve annual report 2017 biocon limited note standalone financial statement year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated 1 company overview 11 reporting entity biocon limited biocon company engaged manufacture biotechnology product research service company public limited company incorporated domiciled india registered office bengaluru karnataka india company share listed bombay stock exchange bse national stock exchange nse india 12 basis preparation financial statement statement compliance standalone financial statement prepared accordance indian accounting standard ind per company indian accounting standard rule 2015 notified section 133 company act 2013 act relevant provision act company standalone financial statement year ended march 31 2016 prepared accordance company accounting standard rule 2006 notified section 133 act read together paragraph 7 company account rule 2014 previous gaap company first standalone financial statement prepared accordance indian accounting standard ind ind 101 firsttime adoption indian accounting standard applied explanation transition ind affected previously reported financial position financial performance cash flow company provided note 41 standalone financial statement prepared company going concern basis relevant ind effective company annual reporting date march 31 2017 standalone financial statement authorised issuance company board director april 27 2017 detail company accounting policy included note 2 b functional presentation currency standalone financial statement presented indian rupee inr also functional currency company amount roundedoff nearest million unless otherwise indicated c basis measurement standalone financial statement prepared historical cost basis except following item certain financial asset liability including derivative instrument measured fair value net defined benefit assetsliability measured fair value plan asset less present value defined benefit obligation use estimate judgement preparation financial statement conformity ind requires management make estimate judgement assumption estimate judgement assumption affect application accounting policy reported amount asset liability disclosure contingent asset liability date financial statement reported amount revenue expense period accounting estimate could change period period actual result could differ estimate appropriate change estimate made management becomes aware change circumstance surrounding estimate change estimate reflected financial statement period change made material effect disclosed note standalone financial statement judgement information judgement made applying accounting policy significant effect amount recognised financial statement included following note note 12b assessment functional currency note 2a 39 financial instrument note 2b 2c 2d useful life property plant equipment intangible asset investment property note 38 asset obligation relating employee benefit note 31 share based payment note 2l 35 provision income tax related tax contingency evaluation recoverability deferred tax asset 13 assumption estimation uncertainty information assumption estimation uncertainty significant risk resulting material adjustment year ending march 31 2018 included following note note 18 35 recognition deferred tax asset availability future taxable profit tax loss carried forward used note 39 impairment financial asset note 17 36 recognition measurement provision contingency key assumption likelihood magnitude outflow resource financial report 177 14 measurement fair value number company accounting policy disclosure require measurement fair value financial nonfinancial asset liability fair value categorised different level fair value hierarchy based input used valuation technique follows level 1 quoted price unadjusted active market identical asset liability level 2 input quoted price included level 1 observable asset liability either directly ie price indirectly ie derived price level 3 input asset liability based observable market data unobservable input measuring fair value asset liability company us observable market data far possible input used measure fair value asset liability fall different level fair value hierarchy fair value measurement categorised entirety level fair value hierarchy lowest level input significant entire measurement company recognises transfer level fair value hierarchy end reporting period change occurred information assumption made measuring fair value included following note note 31 share based payment arrangement note 4 investment property note 2a 39 financial instrument 2 significant accounting policy financial instrument recognition initial measurement trade receivables debt security issued initially recognised originated financial asset financial liability initially recognised company becomes party contractual provision instrument financial asset financial liability initially measured fair value plus item fair value profit loss fvtpl transaction cost directly attributable acquisition issue ii classification subsequent measurement financial asset initial recognition financial asset classified measured amortised cost fvoci debt investment fvoci equity investment fvtpl financial asset reclassified subsequent initial recognition except period company change business model managing financial asset financial asset measured amortised cost meet following condition designated fvtpl asset held within business model whose objective hold asset collect contractual cash flow contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding debt investment measured fvoci meet following condition designated fvtpl asset held within business model whose objective achieved collecting contractual cash flow selling financial asset contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding initial recognition equity investment held trading company may irrevocably elect present subsequent change investment fair value oci designated fvoci equity investment election made investment investment basis financial asset classified measured amortised cost fvoci described measured fvtpl includes derivative financial asset initial recognition company may irrevocably designate financial asset otherwise meet requirement measured amortised cost fvoci fvtpl eliminates significantly reduces accounting mismatch would otherwise arise 178 ahead curve annual report 2017 biocon limited financial asset subsequent measurement gain loss financial asset fvtpl asset subsequently measured fair value net gain loss including interest dividend income recognised statement profit loss however see note 39 derivative designated hedging instrument financial asset amortised cost asset subsequently measured amortised cost using effective interest method amortised cost reduced impairment loss interest income foreign exchange gain loss impairment recognised statement profit loss gain loss derecognition recognised statement profit loss debt investment fvoci asset subsequently measured fair value interest income effective interest method foreign exchange gain loss impairment recognised statement profit loss net gain loss recognised oci derecognition gain loss accumulated oci reclassified statement profit loss equity investment fvoci asset subsequently measured fair value dividend recognised income statement profit loss unless dividend clearly represents recovery part cost investment net gain loss recognised oci reclassified statement profit loss financial liability classification subsequent measurement gain loss financial liability classified measured amortised cost fvtpl financial liability classified fvtpl classified held trading derivative designated initial recognition financial liability fvtpl measured fair value net gain loss including interest expense recognised statement profit loss financial liability subsequently measured amortised cost using effective interest method interest expense foreign exchange gain loss recognised statement profit loss gain loss derecognition also recognised statement profit loss iii derecognition financial asset company derecognises financial asset contractual right cash flow financial asset expire transfer right receive contractual cash flow transaction substantially risk reward ownership financial asset transferred company neither transfer retains substantially risk reward ownership retain control financial asset company enters transaction whereby transfer asset recognised balance sheet retains either substantially risk reward transferred asset transferred asset derecognised financial liability company derecognises financial liability contractual obligation discharged cancelled expire company also derecognises financial liability term modified cash flow modified term substantially different case new financial liability based modified term recognised fair value difference carrying amount financial liability extinguished new financial liability modified term recognised statement profit loss iv offsetting financial asset financial liability offset net amount presented balance sheet company currently legally enforceable right set amount intends either settle net basis realise asset settle liability simultaneously v derivative financial instrument hedge accounting company hold derivative financial instrument hedge foreign currency interest rate risk exposure embedded derivative separated host contract accounted separately host contract financial asset certain criterion met derivative initially measured fair value subsequent initial recognition derivative measured fair value change therein generally recognised statement profit loss company designates certain derivative hedging instrument hedge variability cash flow associated highly probable forecast transaction arising change foreign exchange rate interest rate inception designated hedging relationship company document risk management objective strategy undertaking hedge company also document economic relationship hedged item hedging instrument including whether change cash flow hedged item hedging instrument expected offset cash flow hedge derivative designated cash flow hedging instrument effective portion change fair value derivative recognised oci accumulated equity effective portion cash flow hedge effective portion change fair value derivative recognised oci limited cumulative change fair value hedged item determined present value basis inception hedge ineffective portion change fair value derivative recognised immediately statement profit loss hedge longer meet criterion hedge accounting hedging instrument sold expires terminated exercised hedge accounting discontinued prospectively hedge accounting cash flow hedge discontinued amount accumulated financial report 179 equity remains hedge transaction resulting recognition nonfinancial item included nonfinancial item cost initial recognition cash flow hedge reclassified profit loss period period hedged expected future cash flow affect profit loss hedged future cash flow longer expected occur amount accumulated equity immediately reclassified statement profit loss vi treasury share company created employee welfare trust ewt providing sharebased payment employee equity instrument reacquired treasury share recognised cost deducted equity treasury share issued employee ewt amount received recognised increase equity resultant gain loss transferred security premium vii cash cash equivalent cash cash equivalent balance sheet comprise cash bank hand shortterm deposit original maturity three month less subject insignificant risk change value purpose statement cash flow cash cash equivalent consist cash shortterm deposit defined net outstanding bank overdraft considered integral part company cash management cash dividend equity holder company recognises liability make cash equity holder distribution authorised distribution longer discretion company per corporate law india distribution authorised approved shareholder corresponding amount recognised directly equity interim dividend recorded liability date declaration company board director b property plant equipment recognition measurement item property plant equipment measured cost less accumulated depreciation accumulated impairment loss cost selfconstructed item property plant equipment comprises cost material direct labor cost directly attributable bringing item working condition intended use estimated cost dismantling removing item restoring site located significant part item property plant equipment different useful life accounted separate item major component property plant equipment gain loss disposal item property plant equipment recognised statement profit loss subsequent expenditure capitalised probable future economic benefit associated expenditure flow company ii depreciation depreciation calculated cost item property plant equipment less estimated residual value estimated useful life using straightline method asset acquired finance lease depreciated shorter lease term useful life unless reasonably certain company obtain ownership end lease term freehold land depreciated estimated useful life item property plant equipment current comparative period follows asset management estimate useful life per schedule ii useful life building 25 year 30 year road 5 year 5 year plant equipment including electrical installation lab equipment 911 year 820 year computer server 3 year 36 year office equipment 5 year 5 year research development equipment 9 year 510 year furniture fixture 6 year 10 year vehicle 6 year 610 year leasehold improvement 5 year lease period whichever lower depreciation method useful life residual value reviewed financial yearend adjusted appropriate based technical evaluation consequent advice management belief estimate useful life given best represent period management expects use asset depreciation addition disposal provided prorata basis ie upto date asset ready use disposed c intangible asset internally generated research development expenditure research activity recognised statement profit loss incurred development expenditure capitalised part cost resulting intangible asset expenditure measured reliably product process technically commercially feasible future economic benefit probable company intends sufficient 180 ahead curve annual report 2017 biocon limited resource complete development use sell asset otherwise recognised statement profit loss incurred subsequent initial recognition asset measured cost less accumulated amortisation accumulated impairment loss others intangible asset initially measured cost subsequently intangible asset measured cost less accumulated amortization accumulated impairment loss subsequent expenditure subsequent expenditure capitalised increase future economic benefit embodied specific asset relates expenditure including expenditure internally generated goodwill brand recognised statement profit loss incurred ii amortisation goodwill amortised tested impairment annually intangible asset amortised straight line basis estimated useful life follows computer software 35 year marketing manufacturing right 510 year customer related intangible 5 year amortisation method useful life residual value reviewed end financial year adjusted appropriate investment property investment property property held either earn rental income capital appreciation sale ordinary course business use production supply good service administrative purpose upon initial recognition investment property measured cost subsequent initial recognition investment property measured cost less accumulated depreciation accumulated impairment loss based technical evaluation consequent advice management belief period 25 year representing best estimate period investment property quite similar expected used accordingly company depreciates investment property period 25 year straightline basis useful life estimate 25 year different indicative useful life relevant type building mentioned part c schedule ii act ie 30 year gain loss disposal investment property recognised statement profit loss e business combination accordance ind 103 business combination company account business combination acquisition date using acquisition method control transferred company see note 42 cost acquisition measured fair value asset given equity instrument issued liability incurred assumed date exchange cost acquisition also includes fair value contingent consideration deferred consideration goodwill arises tested annually impairment gain bargain purchase recognised oci accumulated equity capital reserve exists clear evidence underlying reason classifying business combination resulting bargain purchase otherwise gain recognised directly equity capital reserve transaction cost expensed incurred f inventory inventory measured lower cost net realisable value cost inventory based firstin firstout formula includes expenditure incurred acquiring inventory production conversion cost cost incurred bringing present location condition case manufactured inventory workinprogress cost includes appropriate share fixed production overhead based normal operating capacity net realisable value estimated selling price ordinary course business less estimated cost completion selling expense net realisable value workinprogress determined reference selling price related finished product raw material component supply held use production finished product written cost except case material price declined estimated cost finished product exceed net realisable value comparison cost net realisable value made itembyitem basis g impairment impairment financial asset accordance ind 109 company applies expected credit loss ecl model measurement recognition impairment loss following financial asset measured amortised cost financial asset measured fvoci debt investment loss allowance trade receivables significant financing component measured amount equal lifetime expected credit loss financial asset ecl measured amount equal 12month ecl unless significant increase credit risk initial recognition case measured lifetime ecl loss allowance financial asset measured amortised cost deducted gross carrying amount asset debt security fvoci loss allowance charged statement profit loss recognised oci financial report 181 ii impairment nonfinancial asset company assess reporting date whether indication carrying amount may recoverable indication exists asset recoverable amount estimated impairment loss recognised carrying amount asset cgu exceeds estimated recoverable amount statement profit loss goodwill tested annually impairment purpose impairment testing goodwill arising business combination allocated cgus group cgus expected benefit synergy combination company nonfinancial asset inventory deferred tax asset reviewed reporting date determine whether indication impairment indication exists asset recoverable amount estimated impairment testing asset generate independent cash inflow grouped together cashgenerating unit cgus cgu represents smallest group asset generates cash inflow largely independent cash inflow asset cgus impairment loss recognised respect cgu allocated first reduce carrying amount goodwill allocated cgu reduce carrying amount asset cgu group cgus pro rata basis impairment loss respect goodwill subsequently reversed respect asset impairment loss recognised prior period company review reporting date whether indication loss decreased longer exists impairment loss reversed change estimate used determine recoverable amount reversal made extent asset carrying amount exceed carrying amount would determined net depreciation amortisation impairment loss recognised h employee benefit gratuity company provides gratuity defined benefit plan gratuity plan covering eligible employee company gratuity plan provides lumpsum payment vested employee retirement death incapacitation termination employment amount based respective employee salary tenure employment company liability regard gratuity plan determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method defined benefit plan administered trust formed purpose company gratuity scheme company recognises net obligation defined benefit plan liability balance sheet gain loss remeasurement net defined benefit liability recognised comprehensive income reclassified profit loss subsequent period actual return portfolio plan asset excess yield computed applying discount rate used measure defined benefit obligation recognised comprehensive income effect plan amendment recognised statement profit loss ii provident fund eligible employee company receive benefit provident fund defined contribution plan eligible employee company make monthly contribution government administered provident fund scheme equal specified percentage eligible employee salary amount collected provident fund plan deposited government administered provident fund company obligation plan beyond monthly contribution iii compensated absence company policy compensated absence accumulating nonaccumulating nature expected cost accumulating compensated absence determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method additional amount expected paidavailed result unused entitlement accumulated balance sheet date expense nonaccumulating compensated absence recognised period absence occur iv sharebased compensation grant date fair value equity settled sharebased payment award granted employee recognised employee expense corresponding increase equity period employee unconditionally become entitled award amount recognised expense based estimate number award related service nonmarket vesting condition expected met amount ultimately recognised expense based number award meet related service nonmarket vesting condition vesting date provision employee benefit provision recognised result past event company present legal constructive obligation estimated reliably probable outflow economic benefit required settle obligation provision determined discounting expected future cash flow representing best estimate expenditure required settle present obligation balance sheet date pre tax rate reflects current market assessment time value money risk specific liability unwinding discount recognised finance cost expected future operating loss provided onerous contract contract considered onerous expected economic benefit derived company contract lower unavoidable cost meeting obligation contract provision onerous contract measured present value lower expected cost terminating contract expected net cost continuing contract provision made company recognises impairment loss asset associated contract j revenue sale good revenue recognised significant risk reward ownership transferred buyer recovery consideration probable associated cost possible return good estimate reliably continuing management involvement 182 ahead curve annual report 2017 biocon limited good amount revenue measured reliably timing transfer risk reward varies depending individual term sale revenue sale good includes excise duty measured fair value consideration received receivable net return sale tax applicable trade discount allowance ii milestone payment licensing arrangement company enters certain dossier sale licensing supply arrangement certain instance include certain performance obligation based evaluation whether obligation inconsequential perfunctory recognise defer upfront payment received arrangement deferred revenue recognised standalone statement operation period complete remaining performance obligation arrangement typically also consist subsequent payment dependent achieving certain milestone accordance term prescribed agreement milestone payment contingent achieving certain clinical milestone recognised revenue either achievement milestone milestone considered substantive period continuing performance obligation milestone considered substantive milestone payment creditable future royalty payment milestone deferred released period royalty anticipated paid iii sale return allowance company account sale return recording allowance sale return concurrent recognition revenue time product sale allowance based company estimate expected sale return estimate sale return determined primarily company historical experience market company operates iv dividend dividend recognised company right receive payment established generally shareholder approve dividend v rental income rental income investment property recognised statement profit loss straightline basis term lease except rental structured increase line expected general inflation lease incentive granted recognised integral part total rental income term lease vi contribution received customerscodevelopment partner towards plant equipment contribution received customerscodevelopment partner towards item property plant equipment require obligation supply good customer future recognised credit deferred revenue contribution received recognised revenue operation useful life asset company capitalises gross cost asset company control asset k government grant company recognises government grant reasonable assurance condition attached complied grant received government grant received relation asset presented reduction carrying amount related asset grant related income deducted reporting related expense l income tax income tax comprises current deferred income tax income tax expense recognised statement profit loss except extent relates item recognised directly equity case recognised comprehensive income current income tax current year prior period recognised amount expected paid recovered tax authority using tax rate law enacted substantively enacted balance sheet date deferred income tax asset liability recognised temporary difference arising tax base asset liability carrying amount financial statement except taxable temporary difference arising initial recognition goodwill temporary difference arising initial recognition asset liability transaction business combination affect neither accounting taxable profit loss time transaction temporary difference related investment subsidiary associate joint arrangement extent company able control timing reversal temporary difference probable reverse foreseeable future deferred tax asset reviewed reporting date reduced extent longer probable related tax benefit realised deferred income tax asset liability measured using tax rate law enacted substantively enacted balance sheet date expected apply taxable income year temporary difference expected recovered settled effect change tax rate deferred income tax asset liability recognised income expense period includes enactment substantive enactment date deferred income tax asset recognised extent probable future taxable income available deductible temporary timing difference tax loss utilised company offset incometax asset liability legally enforceable right set recognised amount intends either settle net basis realise asset settle liability simultaneously borrowing cost borrowing cost interest cost including exchange difference relating foreign currency borrowing extent regarded adjustment interest cost incurred connection borrowing fund borrowing cost directly attributable acquisition construction asset necessarily take substantial period time get ready intended use capitalised part cost asset borrowing cost recognised expense period incurred n earnings per share basic earnings per share computed using weighted average number equity share outstanding period adjusted treasury share held diluted earnings per share computed using weightedaverage number equity dilutive equivalent share outstanding period using treasury stock method option warrant except result would antidilutive financial report 183 3 property plant equipment capital workinprogress land building leasehold plant research furniture vehicle total capital improvement equipment development workin equipment fixture progress refer note refer note refer note b e gross carrying amount april 01 2015 346 3440 6 11973 1148 393 44 17350 576 addition 130 381 832 15 43 6 1407 2554 disposal 77 6 83 1407 march 31 2016 476 3821 6 12728 1163 436 44 18674 1723 addition 88 89 1164 66 42 11 1460 2145 disposal 1 10 2 5 18 1460 march 31 2017 564 3909 6 13882 1229 476 50 20116 2408 accumulated depreciation april 01 2015 879 1 6966 745 215 17 8823 depreciation year 149 1040 86 50 6 1331 disposal 74 2 76 march 31 2016 1028 1 7932 831 265 21 10078 depreciation year 158 1109 78 54 6 1405 disposal 9 2 5 16 march 31 2017 1186 1 9032 909 317 22 11467 net carrying amount april 01 2015 346 2561 5 5007 403 178 27 8527 576 march 31 2016 476 2793 5 4796 332 171 23 8596 1723 march 31 2017 564 2723 5 4850 320 159 28 8649 2408 land includes land held leasehold basis gross carrying amount nil march 31 2016 236 net carrying amount nil march 31 2016 236 b plant equipment include computer office equipment c addition property plant equipment includes addition related research development amounting 250 march 31 2016 35 year ended march 31 2016 company acquired business pharmaceutical manufacturing unit m acacia lifesciences private limited located vishakhapatnam effect october 01 2015 also refer note 42 e capital workinprogress mainly comprises new biopharmaceutical manufacturing unit constructed india f detail security certain property plant equipment refer note 15b space intentionally left blank 184 ahead curve annual report 2017 biocon limited 4 investment property gross carrying amount april 01 2015 533 addition march 31 2016 533 addition 20 march 31 2017 553 accumulated depreciation april 01 2015 74 depreciation year 20 march 31 2016 94 depreciation year 20 march 31 2017 114 net carrying amount april 01 2015 459 march 31 2016 439 march 31 2017 439 year company recognised rental income 109 march 31 2016 107 depreciation charge 20 march 31 2016 20 statement profit loss investment property fair value investment property march 31 2017 479 march 31 2016 495 april 1 2015 510 5 intangible asset intellectual computer marketing customer total property right software manufacturing related right intangible refer note refer note b gross carrying amount april 01 2015 81 163 193 437 addition 54 101 77 232 march 31 2016 81 218 294 77 669 addition 31 31 march 31 2017 81 249 294 77 700 accumulated amortisation april 01 2015 81 59 141 281 amortisation year 27 12 8 46 march 31 2016 81 86 153 8 327 amortisation year 39 27 15 81 march 31 2017 81 125 180 23 408 net carrying amount april 01 2015 104 52 156 march 31 2016 132 141 69 342 march 31 2017 124 114 54 292 pursuant asset purchase agreement customer executed year ended march 31 2016 company acquired marketing manufacturing right product sum 101 b also refer note 42 acquisition customer related intangible part business acquired m acacia lifesciences private limited financial report 185 march 31 2017 march 31 2016 april 01 2015 6 noncurrent investment quoted equity instrument subsidiary company cost syngene international limited 145217843 march 31 2016 145217843 april 01 2015 nil 27591 27591 equity share 10 refer note 33 total quoted noncurrent investment 27591 27591 ii unquoted equity instrument subsidiary company cost syngene international limited nil march 31 2016 nil april 01 2015 167217843 equity 31771 share 10 refer note 33 biocon research limited 500000 march 31 2016 500000 april 01 2015 500000 equity 1 1 1 share 1 biocon sa switzerland 100000 march 31 2016 100000 april 01 2015 100000 equity 4 4 4 share chf 1 biocon sdn bhd malaysia nil march 31 2016 nil april 01 2015 4853734 equity share 712 rm 10 refer note 33 biocon fz llc uae 150 march 31 2016 150 april 01 2015 nil equity share aed 1000 3 3 biocon pharma limited 12050000 march 31 2016 5050000 april 01 2015 50000 equity 121 51 1 share 10 biocon biologics limited uk 47183101 march 31 2016 47183101 april 01 2015 nil 4453 4453 equity share gbp 1 biocon academy 50000 march 31 2016 50000 april 01 2015 50000 equity share 1 1 1 10 joint venture company neobiocon fz llc uae 147 march 31 2016 153 april 01 2015 153 equity share aed 2 2 2 1000 others energon kn wind power private limited 38500 march 31 2016 nil april 01 2015 nil equity 1 share 10 less provision decline temporary value non current investment 1 total unquoted investment equity instrument 4585 4515 32492 iii unquoted preference share associate company iatrica inc usa 4285714 march 31 2016 4285714 april 01 2015 4285714 series 139 139 139 preferred stock u 070 par value u 000001 less provision decline temporary value noncurrent investment 139 139 139 total unquoted investment preference share associate company others vaccinex inc usa 2722014 march 31 2016 2722014 april 01 2015 2722014 series b1 186 186 186 preferred convertible stock u 155 par value u 0001 vaccinex inc usa 217972 march 31 2016 217972 april 01 2015 217972 series b2 32 32 32 preferred convertible stock u 310 par value u 0001 less provision decline temporary value noncurrent investment 218 218 218 energon kn wind power private limited 14666 march 31 2016 nil april 01 2015 nil 1 compulsorily convertible preference share par value 100 less provision decline temporary value non current investment 1 total unquoted investment preference share iv unquoted debenture bond others lic housing finance co ltd 700 march 31 2016 nil april 01 2015 nil 751 bond 701 1001120 par value 1000000 hdfc ltd 75 march 31 2016 nil april 01 2015 nil 815 bond 10090700 par 758 value 10000000 total unquoted investment debenture bond 1459 total noncurrent investment 33635 32106 32492 aggregate book value quoted investment 27591 27591 aggregate market value quoted investment 75622 55800 aggregate value unquoted investment 6403 4872 32849 aggregate amount impairment value investment 359 357 357 company invested national saving certificate unquoted disclosed since amount rounded rupee million 186 ahead curve annual report 2017 biocon limited march 31 2017 march 31 2016 april 01 2015 7 loan unsecured considered good loan subsidiary refer note 34 1923 1584 2447 1923 1584 2447 loan related party comprise loan following subsidiary biocon research limited 1923 1455 2447 maximum amount outstanding year 1965 4799 3053 ii biocon pharma limited 129 maximum amount outstanding year 260 179 8 financial asset noncurrent fair value hedging instrument 14 16 26 interest accrued due 26 deposit 179 173 166 receivables related party refer note 34 50 455 181 243 670 373 b current fair value hedging instrument 128 23 143 interest accrued due 173 241 55 unbilled revenue 108 receivables related party refer note 34 670 705 285 others 12 21 16 983 990 607 9 asset noncurrent capital advance 409 430 274 duty drawback receivable 329 313 326 balance statutorygovernment authority 1101 631 858 prepayment 8 8 13 1847 1382 1471 b current prepayment 348 224 194 348 224 194 10 inventory raw material including goodsinbond 988 1166 957 packing material 386 323 209 workinprogress 2494 1569 1316 finished good 1305 1726 1628 traded good 223 262 249 5396 5046 4359 includes good intransit nil march 31 2016 151 april 01 2015 nil writedown inventory net realisable value amounted 3 march 31 2016 3 recognised expense year included change inventory traded good finished good workinprogress statement profit loss space intentionally left blank financial report 187 march 31 2017 march 31 2016 april 01 2015 11 current investment unquoted investment mutual fund birla sun life short term fund growth 14572296 unit march 31 2016 nil unit april 01 907 2015 nil unit dhfl pramerica banking psu debt fund gr 6602593 unit march 31 2016 nil unit april 93 01 2015 nil unit axis liquid fund daily dividend reinvestment nil unit march 31 2016 nil unit april 01 98 2015 98005 unit dws banking psu debt fund weekly dividend reinvestment nil unit march 31 2016 724 70409716 unit april 01 2015 nil unit edelweiss banking psu debt fund regular plan growth 20407166 unit march 31 2016 nil 276 unit april 01 2015 nil unit hdfc liquid fund daily dividend reinvestment nil unit march 31 2016 nil unit 138 april 01 2015 13566785 unit hdfc medium term opportunity fund regular plan growth 27762046 unit march 31 2016 503 nil unit april 01 2015 nil unit hdfc short term opportunity fund regular plan growth 22489571 unit march 31 2016 405 nil unit april 01 2015 nil unit idfc cash fund daily dividend regular plan nil unit march 31 2016 nil unit april 01 2015 159 158344 unit jp morgan banking psu debt fund weekly dividend reinvestment option nil unit march 31 258 2016 24569495 unit april 01 2015 nil unit reliance banking psu debt fund weekly dividend plan nil unit march 31 2016 46064513 465 unit april 01 2015 nil unit reliance banking psu debt fund growth 72201894 unit march 31 2016 nil unit april 851 01 2015 nil unit reliance liquidity fund daily dividend reinvestment option nil unit march 31 2016 nil unit 135 april 01 2015 135112 unit sbi premier liquid fund regular plan daily dividend nil unit march 31 2016 73826 unit 74 april 01 2015 nil unit tata fixed maturity plan series 47 scheme c plan growth nil unit march 31 2016 nil unit 150 april 01 2015 15000000 unit tata liquid fund plan daily dividend nil unit march 31 2016 nil unit april 01 2015 163 146580 unit uti treasury advantage fund institutional plan daily dividend reinvestment 91862 unit march 31 2016 41818 unit april 01 2015 175000 unit 92 42 175 3127 1563 1018 others inter corporate deposit financial institution 2120 4420 5247 5983 1018 aggregate value unquoted investment 5247 5983 1018 space intentionally left blank 188 ahead curve annual report 2017 biocon limited march 31 2017 march 31 2016 april 01 2015 12 trade receivables unsecured considered good also refer note 34 7982 5038 5033 doubtful 58 42 85 8040 5080 5118 allowance credit loss 58 42 85 7982 5038 5033 includes due narayana hrudayalaya limited nhl formerly known narayana hrudayalaya private 4 8 5 limited director company member board director nhl company exposure credit currency risk loss allowance disclosed note 39 13 cash bank balance cash cash equivalent balance bank current account 3410 2653 3213 unpaid dividend account 6 10 6 deposit original maturity less 3 month 240 total cash cash equivalent 3416 2903 3219 bank balance deposit maturity less 12 month 410 3524 3380 margin money deposit refer note 3 3 3 total bank balance 413 3527 3383 3829 6430 6602 margin money deposit carrying amount 3 march 31 2016 3 april 01 2015 3 subject first charge bank guarantee obtained b company cash hand disclosed since amount rounded rupee million space intentionally left blank financial report 189 march 31 2017 march 31 2016 april 01 2015 14a equity share capital authorised 220000000 march 31 2016 220000000 april 01 2015 220000000 equity share 5 march 31 2016 5 april 01 2015 5 1100 1100 1100 issued subscribed fully paidup 200000000 march 31 2016 200000000 april 01 2015 200000000 equity share 5 march 31 2016 5 april 01 2015 5 1000 1000 1000 reconciliation share outstanding beginning end reporting year equity share march 31 2017 march 31 2016 million million beginning year 200000000 1000 200000000 1000 issued year outstanding end year 200000000 1000 200000000 1000 ii termsrights attached equity share company one class equity share par value 5 per share holder equity share entitled one vote per share company declares pay dividend indian rupee dividend proposed board director subject approval shareholder ensuing annual general meeting event liquidation company holder equity share entitled receive remaining asset company distribution preferential amount distribution proportion number equity share held shareholder iii detail shareholder holding 5 share company march 31 2017 march 31 2016 holding holding equity share 5 fully paid dr kiran mazumdarshaw 79287564 3964 79287564 3964 glentec international limited 39535194 1977 39535194 1977 per record company including register shareholdersmembers shareholding represents legal beneficial ownership share iv share reserved issue option detail share reserved issue employee stock option plan esop company refer note 31 14b equity security premium reserve security premium used record premium received issue share utilised accordance provision company act 2013 general reserve general reserve used time time transfer profit retained earnings appropriation purpose retained earnings amount distributed company dividend equity shareholder sez reinvestment reserve sez reinvestment reserve created profit eligible sez unit term provision section 10aa1ii incometax act 1961 reserve utilised acquiring new plant machinery purpose business term section 10aa2 incometax act 1961 share based payment reserve company established various equity settled share based payment plan certain category employee company also refer note 31 detail plan treasury share equity instrument reacquired treasury share recognised cost deducted equity cash flow hedging reserve cash flow hedging reserve represents cumulative effective portion gain loss net tax arising change fair value designated portion hedging instrument entered cash flow hedge 190 ahead curve annual report 2017 biocon limited march 31 2017 march 31 2016 april 01 2015 15 longterm borrowing deferred sale tax liability unsecured refer note 65 195 loan bank secured term loan refer note b 1296 1326 loan advance unsecured nmitli csir loan refer note c 1 1 1 financial assistance dsir refer note 3 6 10 financial assistance dst refer note e 35 42 48 1335 1440 254 less amount disclosed head current financial liability refer note 16b 11 75 140 1324 1365 114 amount includes secured borrowing 1296 1326 unsecured borrowing 39 114 254 amount disclosed head current financial liability refer note 16b 11 75 140 net amount 1324 1365 114 february 9 2000 company obtained order karnataka sale tax authority allowing interest free deferment sale tax including turnover tax period upto 12 year respect sale hebbagodi manufacturing facility amount exceeding 649 interest free liability amount repayable 10 equal half yearly instalment 65 starting february 2012 loan repaid year b year ended march 31 2016 company obtained external commercial borrowing facility usd 20 million bank term loan facility secured first priority paripassu charge plant machinery proposed expanded facility line existing facility carrying amount 1410 longterm loan repayable 4 equal quarterly instalment usd 5 million commencing december 31 2018 carry interest rate libor 095 pa year ended march 31 2016 company entered interest rate swap convert floating rate fixed rate c march 31 2005 company entered agreement council scientific industrial research csir unsecured loan 3 carrying part research development project new millennium indian technology leadership initiative nmitli scheme loan repayable 10 equal annual instalment 03 starting april 2009 carry interest rate 3 pa march 31 2009 department scientific industrial research dsir sanctioned financial assistance sum 17 company part financing one research project assistance repayable form royalty payment three year post commercialisation project five equal annual instalment 3 starting april 1 2013 e august 25 2010 department science technology dst drug pharmaceutical research programme dprp sanctioned financial assistance sum 70 company financing one research project loan repayable 10 annual instalment 7 starting july 1 2012 carry interest rate 3 pa f respect financial assistance received aforesaid programme refer note c e company required utilise fund specified project required obtain prior approval said authority disposal assetsintellectual property right acquired developed programme company exposure liquidity interest rate currency risk disclosed note 39 space intentionally left blank financial report 191 march 31 2017 march 31 2016 april 01 2015 16 financial liability noncurrent fair value hedging instrument 4 interest accrued due 2 3 6 2 7 6 b current current maturity longterm borrowing refer note 15 11 75 140 unpaid dividend 6 10 6 payable capital good 646 748 239 interim dividend equity share 1000 fair value hedging instrument 77 663 910 1385 17 provision noncurrent provision employee benefit gratuity refer note 38 133 95 133 95 b current provision employee benefit gratuity refer note 38 88 73 121 compensated absence 96 82 74 provision sale return 136 130 130 320 285 325 movement provision gratuity compensated sale return absence opening balance 168 82 130 provision recognisedreversed year 53 14 6 closing balance 221 96 136 march 31 2017 march 31 2016 april 01 2015 18 deferred tax liabilityassets net deferred tax liability property plant equipment investment property intangible asset 523 558 609 derivative asset 46 48 gross deferred tax liability 569 558 657 deferred tax asset employee benefit obligation 110 86 67 allowance doubtful debt 20 14 29 disallowable expense 169 145 80 deferred revenue 162 69 mat credit entitlement 1194 22 22 derivative liability 1 others 130 119 108 gross deferred tax asset 1623 549 375 net deferred tax liabilityassets 1054 9 282 19 liability noncurrent deferred revenue 767 913 905 767 913 905 b current deferred revenue 113 116 97 advance customer 82 58 32 book overdraft 501 252 statutory tax due payable 91 77 89 787 503 218 192 ahead curve annual report 2017 biocon limited march 31 2017 march 31 2016 april 01 2015 20 shortterm borrowing banksfinancial institution packing credit foreign currency loan unsecured refer note ii iii 2253 561 cash credit secured refer note iv 2 2255 561 amount includes secured borrowing 2 unsecured borrowing 2253 561 year ended march 31 2016 company obtained unsecured foreign currency denominated loan 597 usd 9 million april 01 2015 nil usd nil carrying interest rate libor 020 pa bank facility repayable within 120 day date origination repaid current year ii year ended march 31 2016 company obtained unsecured foreign currency denominated loan 1656 usd 25 million april 01 2015 nil usd nil carrying interest rate libor 010 pa bank facility repayable within 180 day date origination repaid current year iii year ended march 31 2015 company obtained foreign currency denominated loan 561 usd 9 million carrying interest rate libor 035 pa bank facility repayable within 180 day date origination repaid year ended march 31 2016 iv company working capital facility various bank carrying interest rate ranging 97 13 pa facility repayable demand secured paripassu first charge inventory trade receivables march 31 2017 march 31 2016 april 01 2015 21 trade payable trade payable refer note note 34 4505 3944 3008 disclosure required clause 22 micro small medium enterprise development msmed act 2006 principal amount interest due thereon remaining unpaid supplier end year principal amount due micro small enterprise 120 102 77 interest due 3 1 ii amount interest paid buyer term section 16 msmed act 2006 328 317 312 along amount payment made supplier beyond appointed day accounting year iii amount interest due payable period delay making payment paid beyond appointed day year without adding interest specified msmed act 2006 iv amount interest accrued remaining unpaid end accounting year v amount interest remaining due payable even succeeding year 31 25 23 date interest due actually paid small enterprise purpose disallowance deductible expenditure section 23 msmed act 2006 disclosure provided company based information available company respect registration status vendorssuppliers b trade payable current company exposure currency liquidity risk related trade payable disclosed note 39 space intentionally left blank financial report 193 march 31 2017 march 31 2016 22 revenue operation sale product finished good 22174 19861 traded good 1583 1679 sale service licensing development fee 329 93 operating revenue sale process waste 127 129 others refer note 1971 1592 revenue operation 26184 23354 others include processing charge rental cross charge power facility sez developer sez unit company 23 income interest income deposit bank financial institution 523 397 others 146 330 dividend income subsidiary 487 current investment 13 131 net gain sale current investment 39 16 net gain financial asset measured fair value profit loss 69 foreign exchange gain net 160 nonoperating income 198 210 988 1731 24 cost raw material packing material consumed inventory beginning year 1489 1166 add purchase 9800 9802 less inventory end year 1374 1489 cost raw material packing material consumed 9915 9479 25 change inventory traded good finished good workinprogress inventory beginning year traded good 262 249 finished good 1726 1628 workinprogress 1569 1316 3557 3193 inventory end year traded good 223 262 finished good 1305 1726 workinprogress 2494 1569 4022 3557 465 364 26 employee benefit expense salary wage bonus 3091 2740 contribution provident fund 134 115 gratuity refer note 38 39 31 share based compensation expense refer note 31 125 107 staff welfare expense 261 226 3650 3219 27 finance cost interest expense financial liability measured amortised cost 38 9 fair value change interest rate swap 10 38 19 194 ahead curve annual report 2017 biocon limited march 31 2017 march 31 2016 28 depreciation amortisation expense depreciation tangible asset refer note 3 4 1425 1351 amortisation intangible asset refer note 5 81 46 1506 1397 29 expense royalty technical fee 36 56 rent 16 17 communication expense 38 40 travelling conveyance 292 335 professional charge 257 383 payment auditor refer note 6 6 director fee including commission 19 20 power fuel 1456 1551 insurance 27 30 rate tax fee 197 180 lab consumables 327 373 repair maintenance plant machinery 502 368 building 107 90 others 324 280 selling expense freight outwards clearing charge 243 284 sale promotion expense 474 423 commission brokerage sole selling agent 247 253 bad debt written 8 provisionreversal doubtful debt net 16 43 foreign exchange fluctuation net 239 printing stationery 35 26 research development expense refer note 30 920 902 csr expenditure refer note 45 90 81 miscellaneous expense 95 91 5963 5754 payment auditor auditor statutory audit fee 3 3 tax audit fee 1 1 limited review 1 2 capacity service certification fee refer note b 1 reimbursement outofpocket expense refer note b 6 6 payment year ended march 31 2016 represents fee reimbursement paid predecessor auditor b amount presented since amount rounded rupee million 30 research development expense research development expense 920 902 research development expense included head account salary wage bonus 201 182 contribution provident fund 9 7 staff welfare expense 2 2 lab consumables 324 373 travelling conveyance 4 14 professional charge 1 b 541 578 ab 1461 1480 less recovery product development cost codevelopment partner net 4 48 1457 1432 financial report 195 31 employee stock compensation biocon esop plan september 27 2001 biocons board director approved biocon employee stock option plan esop plan 2000 grant stock option employee company subsidiariesjoint venture company nomination remuneration committee remuneration committee administers plan trust established specifically purpose called biocon india limited employee welfare trust esop trust esop trust shall make additional purchase equity share company using proceeds loan obtained company cash inflow allotment share employee esop plan shall subscribe allotted number share necessary transferring employee esop trust may also receive share promoter purpose issuance employee esop plan remuneration committee shall determine exercise price less face value share grant iv july 2006 company approved grant 3478200 option face value share 5 employee existing esop plan 2000 option grant would vest employee 25 35 40 total grant end first second third year date grant existing employee end 3rd 4th 5th year date grant new employee exercise period 3 year grant condition number option granted include service term performance grade employee option exercisable discount 20 market price company share date grant detail grant iv particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 3500 231 61625 187 granted year forfeited year exercised year 2500 231 55250 179 expired year 1000 231 2875 154 outstanding end year 3500 231 exercisable end year 3500 231 weighted average remaining contractual life year 03 range exercise price outstanding option end year 231 grant v april 2008 company approved grant employee existing esop plan 2000 option grant would vest employee 25 35 40 total grant end first second third year date grant existing employee end 3rd 4th 5th year date grant new employee exercise period 3 year grant condition number option granted include service term performance grade employee option exercisable market price company share date grant detail grant v particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 791875 343 1151975 336 granted year forfeited year 74625 344 269087 324 exercised year 221388 307 91013 303 expired year outstanding end year 495862 357 791875 343 exercisable end year 135175 312 220638 310 weighted average remaining contractual life year 25 46 range exercise price outstanding option end year 221471 197531 196 ahead curve annual report 2017 biocon limited grant vi july 2014 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 1185839 470 1346152 470 granted year 95000 477 forfeited year 61600 470 160313 470 exercised year 258001 471 expired year outstanding end year 961238 471 1185839 470 exercisable end year 125026 470 116750 470 weighted average remaining contractual life year 23 33 weighted average fair value option granted 156 range exercise price outstanding option end year 470493 470 grant vii july 2014 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 1275500 461 293000 452 granted year 200000 605 1077500 461 forfeited year 238500 392 95000 472 exercised year 16800 457 expired year outstanding end year 1220200 482 1275500 461 exercisable end year 9450 457 weighted average remaining contractual life year 52 60 weighted average fair value option granted 251 185 range exercise price outstanding option end year 415741 415518 grant viii july 2015 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange last day month preceding month first grant space intentionally left blank financial report 197 particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 312500 459 granted year 55000 457 312500 459 forfeited year 105000 457 exercised year 1000 457 expired year outstanding end year 261500 460 312500 459 exercisable end year 16750 457 weighted average remaining contractual life year 38 46 weighted average fair value option granted 149 154 range exercise price outstanding option end year 457481 457481 grant ix june 2016 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable 50 closing price per national stock exchange preceding day date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year 472500 495 forfeited year 5000 467 exercised year expired year outstanding end year 467500 496 exercisable end year weighted average remaining contractual life year 89 weighted average fair value option granted 617 range exercise price outstanding option end year 415566 grant x june 2016 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable 50 closing price per national stock exchange preceding day date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year 255000 388 forfeited year 51250 373 exercised year expired year outstanding end year 203750 392 exercisable end year weighted average remaining contractual life year 43 weighted average fair value option granted 442 range exercise price outstanding option end year 371467 assumption used determination fair value stock option black scholes model follows 198 ahead curve annual report 2017 biocon limited particular march 31 2017 march 31 2016 weighted average exercise price 388605 459461 expected volatility 295 334 29 345 life option granted vesting exercise period year 3065 3065 average riskfree interest rate 712 765 expected dividend rate 110 110 expected volatility based historical volatility market price company publicly traded equity share expected term option grant b rsu plan 2015 march 11 2015 biocons remuneration committee approved biocon restricted stock unit rsus syngene rsu plan 2015 grant rsus employee company subsidiary syngene remuneration committee administers plan trust established specifically purpose called biocon limited employee welfare trust rsu trust purpose march 31 2015 company transferred 2000000 equity share syngene rsu trust april 2015 company approved grant employee rsu plan 2015 rsus grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee exercise price rsus nil particular march 31 2017 march 31 2016 number weighted number weighted unit average unit average exercise price exercise price outstanding beginning year 1231803 granted year 193454 1364148 forfeited year 117963 132345 exercised year 10742 expired year outstanding end year 1296552 1231803 exercisable end year 92320 weighted average remaining contractual life year 41 48 weighted average fair value option granted 468 162 assumption used determination fair value stock option black scholes model follows particular march 31 2017 march 31 2016 weighted average exercise price expected volatility 2992 4431 2992 life option granted vesting exercise period year 5065 5065 average riskfree interest rate 712 765 expected dividend rate 030 030 summary movement respect share held esop trust follows march 31 2017 march 31 2016 opening balance 3876828 3674928 add share purchased esop trust 152731 348163 less share exercised employee 499689 146263 closing balance 3529870 3876828 option granted eligible exercise end year 286401 340888 option granted eligible exercise end year 3323649 3228326 summary movement respect equity share syngene held rsu trust follows opening balance 2000000 2000000 less share exercised employee 10742 closing balance 1989258 2000000 financial report 199 32 earnings per share eps march 31 2017 march 31 2016 earnings profit year 5193 3686 share basic outstanding share 200000000 200000000 less weighted average share held esop trust 3702196 3697436 weighted average share used computing basic eps 196297804 196302564 add effect dilutive option granted yet exercisednot yet eligible exercise 1376487 167870 weighted average share used computing diluted eps 197674291 196470434 earnings per share basic 2645 1878 diluted 2627 1876 33 exceptional item net march 31 2017 march 31 2016 gain sale share subsidiary net refer note b 1061 1061 year ended march 31 2016 company sold investment equity share biocon sdn bhd wholly owned subsidiary biocon biologics limited uk sum 811 gain arising sale equity share amounting 99 net cost equity share recorded exceptional gain standalone financial statement consequential tax 21 recorded gain b year ended march 31 2016 syngene international limited syngene completed initial public offering ipo offer sale 22000000 equity share 10 company gain arising sale equity share net related expense cost equity share amounting 962 recorded exceptional gain standalone financial statement consequential tax 1042 recorded gain included within income tax expense mat credit transaction recorded previous year due uncertainty utilization current year pursuant change income tax law business restructuring company belief able utilize mat credit entitlement accordingly year ended march 31 2017 company recorded mat credit entitlement 1042 included within income tax expense current year space intentionally left blank 200 ahead curve annual report 2017 34 related party transaction related party control exists related party transaction taken place year listed sl name related party relationship description transaction april 1 balance april 1 balance balance 2016 2015 march 31 march 31 march 31 march 31 april 1 2017 2017 2016 2016 2015 income payable income payable payable expense receivable expense receivable receivable transaction transaction remuneration paid key management personnel refer note g 1 kiran mazumdarshaw chairperson managing director salary perquisite 20 16 2 john shaw vicechairman director salary perquisite 17 16 3 arun chandavarkar joint managing director ceo salary perquisite 33 31 4 siddharth mittal president finance chief salary perquisite 20 16 financial officer 5 kiran kumar company secretary salary perquisite 7 6 upto dec 15 2016 6 rajiv balakrishnan company secretary salary perquisite 1 wef jan 24 2017 b others 7 syngene international limited subsidiary power facility charge recovered refer note b 466 454 rent income refer note b 47 50 dividend income 145 expense incurred behalf related party refer 49 58 note sale goodsother product 4 4 research service received 89 107 ipo expense incurred behalf company 45 receivables 125 91 150 trade payable 53 16 30 guarantee given behalf related party custom 148 148 242 excise department ced guarantee given related party ced behalf 500 500 500 company 8 biocon research limited whollyowned subsidiary rent income refer note b 42 37 power facility charge recovered refer note b 63 66 cross charge towards lab consumables 673 expense research service received 243 sale good 6 40 receivables 50 431 181 royalty expense 16 27 interest loan related party 121 316 expense incurred behalf related party 26 financial report refer note trade payable 63 loan related party net 468 1923 992 1455 2447 201 biocon limited sl name related party relationship description transaction april 1 balance april 1 balance balance 2016 2015 202 march 31 march 31 march 31 march 31 april 1 2017 2017 2016 2016 2015 income payable income payable payable expense receivable expense receivable receivable transaction transaction 9 biocon sa whollyowned subsidiary cross charge towards facility expense 197 50 expense incurred related party behalf 25 company trade receivable 157 receivable 51 94 10 biocon sdnbhd whollyowned subsidiary expense incurred behalf related party refer 8 15 biocon biologics limited note sale good 64 69 purchase good 218 operating income 9 guarantee income 29 trade payable 274 ahead curve annual report 2017 trade receivables 125 81 30 receivables 505 560 41 guarantee given company bank behalf 12330 10760 8096 related party loan facility 11 neobiocon fz llc jointventure sale good 39 35 dividend income 342 receivables 3 trade receivables 2 30 29 12 glentec international enterprise owned key rent expense 1 1 1 limited management personnel 13 biocon pharma limited whollyowned subsidiary investment equity share 70 50 expense incurred behalf related party refer 7 21 note interest loan related party 4 4 loan related party net 129 129 129 receivables 5 24 guarantee given company bank behalf 1296 1362 related party loan facility 14 biocon biologics limited whollyowned subsidiary investment equity share 4453 sale noncurrent investment share biocon 811 sdn bhd refer note 33 sale good 522 73 cross charge towards expense 1093 royalty expense 5 trade receivables 1746 71 trade payable 5 5 sl name related party relationship description transaction april 1 balance april 1 balance balance 2016 2015 march 31 march 31 march 31 march 31 april 1 2017 2017 2016 2016 2015 income payable income payable payable expense receivable expense receivable receivable transaction transaction 15 biocon fz llc whollyowned subsidiary investment equity share 3 sale good 1 trade receivables 1 16 biocon pharma inc whollyowned subsidiary expense incurred behalf related party 35 biocon pharma limited receivables 35 17 biocon academy whollyowned subsidiary csr expenditure 30 29 18 biocon foundation trust key management csr expenditure 60 52 personnel board trustee 19 narayana hrudayalaya enterprise director sale good 41 51 limited formerly known company member trade receivables 4 8 5 narayana hrudayalaya private board director limited expense incurred behalf related party include recharge software license fee amount paid behalf vendor b company sez developer division entered agreement lease land provide certain facility power utility etc sez unit biocon research limited syngene international limited respect company recovers rent facility usage charge c company purchased consumables mazumdar farm proprietary firm relative director disclosed since amount rounded rupee million year transaction biocon india limited employee welfare trust trust key management personnel board trustee e disclosure include related party per ind 24 related party disclosure company act 2013 f remuneration key management personnel doesnt include provision made gratuity compensated absence obtained actuarial basis company whole g share based compensation expense allocable key management personnel 5 march 31 2016 10 included remuneration disclosed h transaction related party priced arm length basis none balance secured space intentionally left blank financial report 203 biocon limited 35 tax expense march 31 2017 march 31 2016 amount recognised statement profit loss current tax 1269 2175 mat credit entitlement 1172 deferred tax expenseincome related origination reversal temporary difference 72 267 tax expense year 169 1908 b reconciliation effective tax rate profit tax 5362 5594 less exceptional item net 1061 profit tax exceptional item 5362 4533 tax statutory income tax rate 3461 march 31 2016 3461 1856 1569 tax effect amount deductibletaxable calculating taxable income weighted deduction research development expenditure 520 432 exempt income deduction 254 372 nondeductible expense 74 65 tax exceptional item 1042 1063 basis difference reverse tax holiday period 22 27 others 33 12 income tax expense 169 1908 c tax loss unused tax loss deferred tax asset recognised 238 70 potential tax impact 36 11 expiry date financial year 202223 202223 202324 recognised deferred tax asset liability following movement deferred tax assetsliabilities presented balance sheet year ended opening recognised recognised closing march 31 2017 balance profit loss oci balance deferred tax liability property plant equipment investment property intangible asset 558 35 523 derivative asset 46 46 gross deferred tax liability 558 35 46 569 deferred tax asset defined benefit obligation 86 15 9 110 allowance doubtful debt 14 6 20 disallowable expense 145 24 169 deferred revenue 162 162 mat credit entitlement 22 1172 1194 derivative liability 1 1 others 119 11 130 gross deferred tax asset 549 1066 8 1623 9 1101 38 1054 year ended opening recognised recognised closing march 31 2016 balance profit loss oci balance deferred tax liability property plant equipment investment property intangible asset 609 51 558 derivative asset 48 48 gross deferred tax liability 657 99 558 deferred tax asset defined benefit obligation 67 13 6 86 allowance doubtful debt 29 15 14 disallowable expense 80 65 145 deferred revenue 69 93 162 mat credit entitlement 22 22 derivative liability 1 1 others 108 11 119 gross deferred tax asset 375 168 6 549 282 267 6 9 204 ahead curve annual report 2017 biocon limited 36 contingent liability commitment extent provided march 31 2017 march 31 2016 april 01 2015 contingent liability claim company acknowledged debt 2893 3041 1241 includes direct taxation 1950 2050 297 ii indirect taxation includes matter pertaining dispute central excise custom 550 594 552 duty service tax iii litigation 393 397 392 company involved taxation dispute lawsuit proceeding etc including patent commercial matter arise time time ordinary course business management view claim tenable material adverse effect company financial position result operation march 31 2017 march 31 2016 april 01 2015 b guarantee corporate guarantee given favour central excise department respect certain performance obligation subsidiary syngene international limited 148 148 242 ii corporate guarantee given favour bank towards loan obtained subsidiary stepdown subsidiary biocon research limited 685 biocon sdn bhd 12330 10760 8096 biocon pharma limited 1296 1362 13626 12122 8781 iii guarantee given bank behalf company contractual obligation 18 18 63 company necessary term condition complied liability arisen ii commitment estimated amount contract remaining executed capital account provided net advance 401 1114 824 b operating lease commitment company lessee vehicle company taken vehicle certain employee operating lease expire period upto january 2020 gross rental expense year aggregate 16 march 31 2016 16 committed lease rental future follows march 31 2017 march 31 2016 april 01 2015 later one year 19 15 12 later one year later five year 22 26 24 c march 31 2016 2015 company committed provide financial support biocon research limited regard operation company 37 disclosure specified bank note sbns year company specified bank note denomination note defined mca notification gsr 308e dated march 30 2017 detail specified bank note sbn held transacted period november 8 2016 december 30 2016 denomination wise sbns note per notification given amount particular sbns total denomination note closing cash hand november 8 2016 130500 148761 279261 permitted receipt 604105 604105 permitted payment 499419 499419 amount deposited bank 130500 130500 closing cash hand december 30 2016 253447 253447 purpose clause term specified bank note shall meaning provided notification government india ministry finance department economic affair number 3407e dated november 8 2016 financial report 205 38 employee benefit plan company defined benefit gratuity plan per payment gratuity act 1972 legislation employee completed five year service entitled specific benefit level benefit provided depends employee length service salary retirement termination age gratuity plan funded plan company make contribution recognised fund india based actuarial valuation obtained respect following table set status gratuity plan amount recognised company financial statement balance sheet date defined benefit fair value net defined obligation plan asset benefit assetliability balance april 01 2016 229 61 168 current service cost 27 27 interest expenseincome 17 5 12 amount recognised statement profit loss 44 5 39 remeasurements return plan asset excluding amount included interest expenseincome 2 2 actuarial gainloss arising demographic assumption 3 3 financial assumption 9 9 experience adjustment 23 23 amount recognised comprehensive income 29 2 27 employer contribution 13 13 benefit paid 23 23 balance march 31 2017 279 58 221 balance april 01 2015 193 72 121 current service cost 23 23 interest expenseincome 15 7 8 amount recognised statement profit loss 38 7 31 remeasurements return plan asset excluding amount included interest expenseincome 1 1 actuarial gainloss arising demographic assumption financial assumption 5 5 experience adjustment 12 12 amount recognised comprehensive income 17 1 16 employer contribution benefit paid 19 19 balance march 31 2016 229 61 168 march 31 2017 march 31 2016 april 01 2015 noncurrent 133 95 current 88 73 121 221 168 121 ii assumption used gratuity valuation march 31 2017 march 31 2016 april 01 2015 interest rate 69 75 88 discount rate 69 75 79 expected return plan asset 69 75 79 salary increase 90 90 90 attrition rate 14 30 7 26 7 26 retirement age year 58 58 58 assumption regarding future mortality experience set accordance published statistic mortality table weighted average duration defined benefit obligation 8 year march 31 2016 8 year defined benefit plan expose company actuarial risk longevity interest rate risk iii sensitivity analysis sensitivity defined benefit obligation change weighted principal assumption particular march 31 2017 march 31 2016 increase decrease increase decrease discount rate 13 14 9 10 salary increase 14 13 10 9 attrition rate 2 3 1 2 sensitivity significant actuarial assumption computed varying one actuarial assumption used valuation defined benefit obligation one percentage keeping actuarial assumption constant although analysis take account full distribution cash flow expected plan provide approximation sensitivity assumption shown 206 ahead curve annual report 2017 biocon limited march 31 2017 march 31 2016 plan asset invested insurer managed fund expected contribution fund year ending march 31 2018 approximately 51 march 31 2017 73 maturity profile defined benefit obligation particular million 1st following year 51 2nd following year 30 3rd following year 29 4th following year 39 5th following year 27 year 6 10 106 39 financial instrument fair value risk management accounting classification fair value carrying amount fair value march 31 2017 fvtpl fvtoci amortised total level 1 level 2 level 3 total cost financial asset noncurrent investment 1459 1459 loan 1923 1923 current investment 3127 2120 5247 3127 3127 trade receivables 7982 7982 cash bank balance 3829 3829 financial asset 142 1084 1226 142 142 3127 142 18397 21666 3127 142 3269 financial liability borrowing 1324 1324 trade payable 4505 4505 financial liability 665 665 6494 6494 march 31 2016 fvtpl fvtoci amortised total level 1 level 2 level 3 total cost financial asset loan 1584 1584 current investment 1563 4420 5983 1563 1563 trade receivables 5038 5038 cash bank balance 6430 6430 financial asset 39 1621 1660 39 39 1563 39 19093 20695 1563 39 1602 financial liability borrowing 3620 3620 trade payable 3944 3944 financial liability 71 10 836 917 81 81 71 10 8400 8481 81 81 april 01 2015 fvtpl fvtoci amortised total level 1 level 2 level 3 total cost financial asset loan 2447 2447 current investment 1018 1018 1018 1018 trade receivables 5033 5033 cash bank balance 6602 6602 financial asset 169 811 980 169 169 1018 169 14893 16080 1018 169 1187 financial liability borrowing 675 675 trade payable 3008 3008 financial liability 1391 1391 5074 5074 financial report 207 b measurement fair value fair value liquid mutual fund based quoted price derivative financial instrument valued based quoted price similar asset liability active market input directly indirectly observable market place sensitivity analysis fair value forward contract foreign currency reasonably possible change reporting date one significant observable input holding input constant would following effect significant observable input march 31 2017 march 31 2016 profit loss profit loss increase decrease increase decrease spot rate foreign currency 1 movement 31 31 1 1 interest rate 100 bps movement 38 38 27 27 c financial risk management company exposure following risk arising financial instrument credit risk liquidity risk market risk risk management framework company risk management carried treasury department policy approved board director board provides written principle overall risk management well policy covering specific area foreign exchange risk interest rate risk credit risk use derivative nonderivative financial instrument investment excess liquidity credit risk credit risk risk counterparty meet obligation financial instrument customer contract leading financial loss credit risk arises principally operating activity primarily trade receivables financing activity including deposit bank financial institution financial instrument customer credit risk managed business unit subject company established policy procedure control relating customer credit risk management audit risk management committee established credit policy new customer analysed individually creditworthiness company standard payment delivery term condition offered company review includes external rating available publicly available financial information outstanding customer receivables regularly monitored shipment major customer generally covered letter credit form credit insurance company establishes allowance impairment represents estimate expected loss respect trade receivables maximum exposure credit risk reporting date primarily trade receivables amounting 7982 march 31 2016 5038 april 01 2015 5033 movement allowance impairment respect trade receivables year follows allowance impairment march 31 2017 march 31 2016 opening balance 42 85 impairment loss recognisedreversed 16 43 closing balance 58 42 single customer accounted 10 trade receivable march 31 2017 2016 significant concentration credit risk credit risk cash cash equivalent derivative limited company generally transacts bank financial institution high credit rating assigned international domestic credit rating agency investment primarily include investment liquid mutual fund unit bond non convertible debenture ii liquidity risk liquidity risk risk company encounter difficulty meeting obligation associated financial liability settled delivering cash another financial asset company approach managing liquidity ensure far possible sufficient liquidity meet liability due normal stressed condition without incurring unacceptable loss risking damage company reputation company belief working capital sufficient meet current requirement accordingly liquidity risk perceived addition company maintains following line credit cash credit facility bank carrying interest rate ranging 97 13 pa facility repayable demand secured paripassu charge inventory trade receivables b unsecured foreign currency denominated loan bank amounting nil march 31 2016 2253 carrying interest ranging nil march 31 2016 libor 010 020 pa facility repayable within 180 day origination 208 ahead curve annual report 2017 biocon limited table provides detail regarding undiscounted contractual maturity significant financial liability march 31 2017 particular less 1 year 12 year 25 year 57 year total longterm borrowing 11 655 669 1335 shortterm borrowing trade payable 4505 4505 financial liability 652 2 654 total 5168 657 669 6494 table provides detail regarding undiscounted contractual maturity significant financial liability march 31 2016 particular less 1 year 12 year 25 year 57 year total longterm borrowing 75 11 1347 7 1440 shortterm borrowing 2255 2255 trade payable 3944 3944 financial liability 835 7 842 total 7109 18 1347 7 8481 table provides detail regarding undiscounted contractual maturity significant financial liability april 01 2015 particular less 1 year 12 year 25 year 57 year total longterm borrowing 140 76 24 14 254 shortterm borrowing 561 561 trade payable 3008 3008 financial liability 1245 6 1251 total 4954 82 24 14 5074 iii market risk market risk risk fair value future cash flow financial instrument fluctuate change market price foreign exchange rate interest rate equity price foreign currency risk company operates internationally major portion business transacted several currency consequently company exposed foreign exchange risk operating borrowing activity foreign currency company hold derivative instrument foreign exchange forward interest rate swap option contract mitigate risk change exchange rate foreign currency exposure currency profile financial asset financial liability march 31 2017 march 31 2016 march 31 2017 usd eur others total financial asset loan trade receivables 4916 259 5175 cash cash equivalent 2800 188 19 3007 noncurrent financial asset current financial asset 539 539 financial liability longterm borrowing 1296 1296 shortterm borrowing trade payable 620 81 4 705 current financial liability 154 99 30 283 net assetsliabilities 6185 267 15 6437 march 31 2016 usd eur others total financial asset loan trade receivables 2696 222 2918 cash cash equivalent 2062 302 14 2378 noncurrent financial asset current financial asset 600 600 financial liability longterm borrowing 1326 1326 shortterm borrowing 2253 2253 trade payable 951 86 10 1047 current financial liability 117 6 123 net assetsliabilities 711 438 2 1147 financial report 209 sensitivity analysis sensitivity profit loss change exchange rate arises mainly foreign currency denominated financial instrument impact component equity arises foreign exchange forwardoption contract designated cash flow hedge particular impact profit loss impact component equity march 31 2017 march 31 2016 march 31 2017 march 31 2016 usd sensitivity inrusd increase 1 62 7 31 6 inrusd decrease 1 62 7 31 6 eur sensitivity inreur increase 1 3 4 3 4 inreur decrease 1 3 4 3 4 derivative financial instrument following table give detail respect outstanding foreign exchange forward option contract particular march 31 2017 march 31 2016 million foreign exchange forward contract buy usd 25 inr 1656 european style option contract periodical maturity date usd 44 usd 59 inr 2844 inr 3903 european style option contract periodical maturity date eur 6 eur 12 inr 434 inr 899 cash flow fair value interest rate risk company main interest rate risk arises longterm borrowing variable rate expose company cash flow interest rate risk year ended march 31 2017 march 31 2016 company borrowing variable rate mainly denominated usd interest rate risk exposure exposure company borrowing interest rate change end reporting period follows particular march 31 2017 march 31 2016 april 01 2015 variable rate borrowing 1296 3579 561 fixed rate borrowing 36 45 49 total borrowing 1332 3624 610 b sensitivity company policy maintain borrowing fixed rate using interest rate swap achieve necessary therefore subject interest rate risk defined ind 107 since neither carrying amount future cash flow fluctuate change market interest rate 40 capital management key objective company capital management ensure maintains stable capital structure focus total equity uphold investor creditor customer confidence ensure future development business company focused keeping strong total equity base ensure independence security well high financial flexibility potential future borrowing required without impacting risk profile company company goal continue able return excess liquidity shareholder continuing distribute annual dividend future period amount future dividend equity share balanced effort continue maintain adequate liquidity status capital structure march 31 2017 2016 follows particular march 31 2017 march 31 2016 total equity attributable equity shareholder company 65411 59966 percentage total capital 98 94 longterm borrowing 1335 1440 shortterm borrowing 2255 total borrowing 1335 3695 percentage total capital 2 6 total capital equity borrowing 66746 63661 210 ahead curve annual report 2017 biocon limited 41 firsttime adoption ind standalone financial statement prepared accordance ind purpose transition previous gaap ind company followed guidance prescribed ind 101 first time adoption indian accounting standard ind 101 effect april 01 2015 transition date preparing ind balance sheet april 1 2015 presenting comparative information year ended march 31 2016 group adjusted amount reported previously financial statement prepared accordance previous gaap note explains transition previous gaap ind affected company balance sheet financial performance optional exemption availed mandatory exception preparing standalone financial statement company applied mentioned optional exemption mandatory exception optional exemption availed 1 deemed cost investment subsidiary per ind 101 entity may elect use fair value investment subsidiary date transition deemed cost accordingly company recognised fair value subsidiary deemed cost date transition 2 business combination ind 101 provides option apply ind 103 business combination prospectively transition date specific date prior transition date company elected apply ind 103 prospectively business combination occurring transition date business combination occurring prior transition date restated 3 share based payment ind 102 share based payment applied equity instrument share based payment transaction vested april 1 2014 cash settled share based payment transaction company applied ind 102 liability settled april 1 2014 mandatory exemption availed 1 estimate per ind 101 entity estimate accordance ind date transition ind shall consistent estimate made date accordance previous gaap unless objective evidence estimate error company estimate ind consistent requirement key estimate considered preparation financial statement required previous gaap listed fair valuation financial instrument carried fvtpl fvoci impairment financial asset based expected credit loss model determination discounted value financial instrument carried amortised cost 2 classification measurement financial asset ind 101 requires entity assess classification financial asset basis fact circumstance existing date transition standard permit measurement financial asset accounted amortised cost based fact circumstance existing date transition retrospective application impracticable accordingly company determined classification financial asset based fact circumstance exist date transition measurement financial asset accounted amortised cost done retrospectively except impracticable 3 hedge accounting hedge accounting applied prospectively transition date transaction satisfy hedge accounting criterion ind 109 financial instrument date transition hedging relationship cannot designated retrospectively supporting documentation cannot created retrospectively result hedging relationship satisfied hedge accounting criterion date transition reflected hedge consolidated financial statement ind space intentionally left blank financial report 211 b reconciliation following reconciliation provides effect transition ind previous gaap accordance ind 101 firsttime adoption ind reconciliation equity april 01 2015 previous gaap adjustment ind asset noncurrent asset property plant equipment 8986 459 8527 capital workinprogress 576 576 investment property 459 459 intangible asset 157 1 156 financial asset investment 804 31688 32492 ii loan 2447 2447 iii financial asset 1032 659 373 incometax asset net 462 47 415 noncurrent asset 1465 6 1471 total noncurrent asset 15929 30987 46916 current asset inventory 4063 296 4359 financial asset investment 843 175 1018 ii trade receivables 5551 518 5033 iii cash cash equivalent 3159 60 3219 iv bank balance iii 3053 330 3383 v financial asset 494 113 607 current asset 196 2 194 total current asset 17359 454 17813 total 33288 31441 64729 equity liability equity equity share capital 1000 1000 equity 24844 31497 56341 total equity 25844 31497 57341 noncurrent liability financial liability borrowing 114 114 ii financial liability 6 6 provision deferred tax liability net 326 44 282 noncurrent liability 1358 453 905 total noncurrent liability 1804 497 1307 current liability financial liability borrowing 561 561 ii trade payable 3008 3008 iii financial liability 1385 1385 provision 195 130 325 incometax liability net 273 311 584 current liability 218 218 total current liability 5640 441 6081 total 33288 31441 64729 space intentionally left blank 212 ahead curve annual report 2017 biocon limited ii reconciliation equity march 31 2016 previous gaap adjustment ind asset noncurrent asset property plant equipment 9035 439 8596 capital workinprogress 1723 1723 investment property 439 439 intangible asset 342 342 financial asset investment 4587 27519 32106 ii loan 1584 1584 iii financial asset 1307 637 670 incometax asset net 462 34 428 noncurrent asset 1384 2 1382 total noncurrent asset 20424 26846 47270 current asset inventory 4675 371 5046 financial asset investment 5941 42 5983 ii trade receivables 5731 693 5038 iii cash cash equivalent 2860 43 2903 iv bank balance iii 3103 424 3527 v financial asset 990 990 current asset 224 224 total current asset 23524 187 23711 total 43948 27033 70981 equity liability equity equity share capital 1000 1000 equity 31885 27081 58966 total equity 32885 27081 59966 noncurrent liability financial liability borrowing 1365 1365 ii financial liability 4 3 7 provision 95 95 deferred tax liability net 255 246 9 noncurrent liability 1236 323 913 total noncurrent liability 2955 566 2389 current liability financial liability borrowing 2255 2255 ii trade payable 3943 1 3944 iii financial liability 901 9 910 provision 155 130 285 incometax liability net 351 378 729 current liability 503 503 total current liability 8108 518 8626 total 43948 27033 70981 space intentionally left blank financial report 213 iii reconciliation statement profit loss year ended march 31 2016 previous gaap adjustment ind income revenue operation 23236 118 23354 income 1841 110 1731 total income 25077 8 25085 expense cost raw material packing material consumed 9478 1 9479 purchase traded good 760 760 change inventory traded good finished good workinprogress 288 76 364 excise duty 336 336 employee benefit expense 3187 32 3219 finance cost 9 10 19 expense 5754 5754 depreciation amortisation expense 1310 87 1397 20210 390 20600 less recovery product development cost codevelopment partner net 48 48 total expense 20162 390 20552 profit tax exceptional item 4915 382 4533 exceptional item net 5230 4169 1061 profit tax 10145 4551 5594 tax expense current tax 2128 47 2175 deferred tax 71 196 267 total tax expense 2057 149 1908 profit year 8088 4402 3686 comprehensive incomeexpense item reclassified subsequently profit loss remeasurement defined benefit plan 16 16 income tax effect 6 6 10 10 ii item reclassified subsequently profit loss effective portion gainslosses hedging instrument cash flow hedge income tax effect comprehensive incomeexpense year net tax 10 10 total comprehensive income year 8088 4412 3676 space intentionally left blank 214 ahead curve annual report 2017 biocon limited iv reconciliation total equity note march 31 2016 april 01 2015 equity previous gaap attributable shareholder company 32885 25844 adjustment difference account revenue recognition net related cost 802 571 impact derivative accounting ii 2 126 consolidation esop trust vii 475 526 fair valuation investment subsidiary transition date 27519 31688 adjustment iii 24 14 income tax adjustment correction earlier year iv 133 286 total adjustment 27081 31497 equity ind attributable shareholder company 59966 57341 v reconciliation net profit net profit reconciliation note march 31 2016 net profit attributable shareholder company per previous gaap 8088 adjustment difference account revenue recognition net related cost 230 impact derivative accounting ii 130 adjustment iii 23 income tax impact adjustment correction earlier year iv 150 impact profit sale syngene share net tax v 4169 total adjustment b 4402 profit year c ab 3686 comprehensive income oci actuarial loss defined benefit obligation gratuity vi 10 subtotal 10 total comprehensive income year c 3676 note reconciliation difference account revenue recognition net related cost primarily due difference timing revenue recognition ind compared previous gaap deferral licensing income account continuing obligation ii impact due derivative accounting accordance ind 109 iii adjustment account employee benefit expense share based payment actuarial gainslosses mark market adjustment mutual fund guarantee income iv represents income tax impact ind adjustment including correction earlier year v reduction profit sale syngene share primarily account fair valuation investment syngene subsidiary ind transition date deemed cost vi actuarial loss defined benefit obligation gratuity taken comprehensive income ind compared statement profit loss previous gaap vii impact consolidation esop trust 42 business combination year ended march 31 2016 company acquired business pharmaceutical manufacturing unit m acacia lifesciences private limited located vishakhapatnam effect october 01 2015 going concern basis consideration 531 paid cash transaction accounted ind 103 business combination business combination purchase price allocated identifiable asset liability fair value following table present allocation purchase price particular amount net tangible asset 454 customer related intangible 77 total purchase price 531 financial report 215 43 segmental information accordance ind 108 operating segment segment information provided consolidated financial statement company therefore separate disclosure segment information given standalone financial statement 44 note company entered transaction sale product private company year ended march 31 2013 2012 amounting 28 17 respectively required prior approval central government section 297 company act 1956 transaction entered prevailing market price approved board director company year ended march 31 2014 company filed application central government approval transaction compounding noncompliance pending central government march 31 2017 b company paid dividend distribution tax nil march 31 2016 107 interim dividend reducing amount dividend received company subsidiary 45 corporate social responsibility per section 135 company act 2013 company meeting applicability threshold need spend least 2 average net profit immediately preceding three financial year corporate social responsibility csr activity gross amount required spent company year 90 b amount spent year sl particular cash yet paid total cash constructionacquisition asset ii purpose 90 90 46 event reporting period april 27 2017 board director company approved issue bonus share proportion 21 ie 2 two bonus equity share 5 every 1 one fully paidup equity share held record date subject approval shareholder company postal ballot b april 27 2017 board director company proposed final dividend 3 per equity share prebonus share basis proposed dividend subject approval shareholder annual general meeting per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 216 ahead curve annual report 2017 biocon limited subsidiary independent auditor report member biocon limited report consolidated indian accounting standard ind financial statement audited accompanying consolidated ind financial statement biocon limited holding company subsidiary joint venture collectively referred company group comprise consolidated balance sheet 31 march 2017 consolidated statement profit loss including comprehensive income consolidated statement cash flow consolidated statement change equity year ended summary significant accounting policy explanatory information hereinafter referred consolidated ind financial statement management responsibility consolidated ind financial statement holding company board director responsible preparation consolidated ind financial statement term requirement company act 2013 hereinafter referred act give true fair view consolidated financial position consolidated financial performance including comprehensive income consolidated cash flow consolidated change equity group accordance accounting principle generally accepted india including ind prescribed section 133 act read relevant rule issued thereunder respective board director company included group responsible maintenance adequate accounting record accordance provision act safeguarding asset group preventing detecting fraud irregularity selection application appropriate accounting policy making judgment estimate reasonable prudent design implementation maintenance adequate internal financial control operating effectively ensuring accuracy completeness accounting record relevant preparation presentation consolidated ind financial statement give true fair view free material misstatement whether due fraud error used purpose preparation consolidated ind financial statement director holding company aforesaid auditor responsibility responsibility express opinion consolidated ind financial statement based audit conducting audit taken account provision act accounting auditing standard matter required included audit report provision act rule made thereunder conducted audit accordance standard auditing specified section 14310 act standard require comply ethical requirement plan perform audit obtain reasonable assurance whether consolidated ind financial statement free material misstatement audit involves performing procedure obtain audit evidence amount disclosure consolidated ind financial statement procedure selected depend auditor judgment including assessment risk material misstatement consolidated ind financial statement whether due fraud error making risk assessment auditor considers internal financial control relevant holding company preparation consolidated ind financial statement give true fair view order design audit procedure appropriate circumstance audit also includes evaluating appropriateness accounting policy used reasonableness accounting estimate made holding company board director well evaluating overall presentation consolidated ind financial statement believe audit evidence obtained u sufficient appropriate provide basis audit opinion consolidated ind financial statement opinion opinion best information according explanation given u based consolidation report auditor separate financial statement subsidiary joint venture group noted aforesaid consolidated ind financial statement give information required act manner required give true fair view conformity accounting principle generally accepted india including ind consolidated financial position group 31 march 2017 consolidated financial performance including comprehensive income consolidated cash flow consolidated change equity year ended matter comparative financial information group year ended 31 march 2016 transition date opening balance sheet 1 april 2015 included consolidated ind financial statement based previously issued statutory financial statement prepared accordance company accounting standard rule 2006 audited predecessor auditor whose report year ended 31 march 2016 31 march 2015 dated 26 april 2016 29 april 2015 respectively expressed unmodified opinion consolidated financial statement adjusted difference accounting principle adopted company transition ind audited u b audit financial statement financial information subsidiary joint venture incorporated outside india included consolidated ind financial statement group subsidiary account 5 million net profit 998 million revenue year ended 31 march 2017 21856 million total asset 31 march 2017 consolidated ind financial statement also include group share net profit 163 million year ended 31 march 2017 respect joint venture financial statement subsidiary joint venture incorporated outside india audited auditor whose report furnished u opinion financial report 217 consolidated ind financial statement far relates subsidiary joint venture based aforesaid report auditor opinion consolidated ind financial statement report legal regulatory requirement modified respect matter respect reliance work done report auditor report legal regulatory requirement 1 required section 1433 act based audit consideration report auditor separate financial statement subsidiary company joint venture incorporated outside india noted matter paragraph report extent applicable sought obtained information explanation best knowledge belief necessary purpose audit aforesaid consolidated ind financial statement b opinion proper book account required law relating preparation aforesaid consolidated ind financial statement kept far appears examination book report auditor c consolidated balance sheet consolidated statement profit loss consolidated statement cash flow consolidated statement change equity dealt report agreement relevant book account maintained purpose preparation consolidated ind financial statement opinion aforesaid consolidated ind financial statement comply indian accounting standard prescribed section 133 act read relevant rule issued thereunder e basis written representation received director group company incorporated india 31 march 2017 taken record respective board director group company incorporated india none director group company incorporated india disqualified 31 march 2017 appointed director company term section 1642 act f respect adequacy internal financial control financial reporting group operating effectiveness control refer separate report annexure g respect matter included auditor report accordance rule 11 company audit auditor rule 2014 opinion best information according explanation given u based consideration report auditor separate financial statement financial information subsidiary company joint venture noted matter paragraph consolidated ind financial statement disclose impact pending litigation consolidated financial position group refer note 35 consolidated ind financial statement ii provision made consolidated ind financial statement required applicable law accounting standard material foreseeable loss longterm contract including derivative contract refer note 38 consolidated ind financial statement iii delay transferring amount required transferred investor education protection fund holding company subsidiary company incorporated india iv company provided requisite disclosure consolidated ind financial statement holding well dealing specified bank note period 8 november 2016 30 december 2016 based audit procedure relying management representation report disclosure accordance book account maintained company produced u management refer note 33 consolidated ind financial statement b r co llp chartered accountant firm registration number 101248ww100022 sethuraman partner membership number 203491 place bengaluru date 27 april 2017 218 ahead curve annual report 2017 biocon limited subsidiary annexure independent auditor report even date consolidated financial statement biocon limited report internal financial control clause subsection 3 section 143 company act 2013 act conjunction audit consolidated ind financial statement group year ended 31 march 2017 audited internal financial control financial reporting biocon limited holding company subsidiary company company incorporated india date management responsibility internal financial control respective board director holding company subsidiary company company incorporated india responsible establishing maintaining internal financial control based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting guidance note issued institute chartered accountant india icai responsibility include design implementation maintenance adequate internal financial control operating effectively ensuring orderly efficient conduct business including adherence company policy safeguarding asset prevention detection fraud error accuracy completeness accounting record timely preparation reliable financial information required company act 2013 auditor responsibility responsibility express opinion company internal financial control financial reporting based audit conducted audit accordance guidance note audit internal financial control financial reporting guidance note issued icai standard auditing issued icai deemed prescribed section 14310 company act 2013 extent applicable audit internal financial control issued institute chartered accountant india standard guidance note require comply ethical requirement plan perform audit obtain reasonable assurance whether adequate internal financial control financial reporting established maintained control operated effectively material respect audit involves performing procedure obtain audit evidence adequacy internal financial control system financial reporting operating effectiveness audit internal financial control financial reporting included obtaining understanding internal financial control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk procedure selected depend auditor judgment including assessment risk material misstatement ind financial statement whether due fraud error believe audit evidence obtained sufficient appropriate provide basis audit opinion company internal financial control system financial reporting meaning internal financial control financial reporting company internal financial control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statement external purpose accordance generally accepted accounting principle company internal financial control financial reporting includes policy procedure 1 pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company 2 provide reasonable assurance transaction recorded necessary permit preparation financial statement accordance generally accepted accounting principle receipt expenditure company made accordance authorisation management director company 3 provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition company asset could material effect ind financial statement inherent limitation internal financial control financial reporting inherent limitation internal financial control financial reporting including possibility collusion improper management override control material misstatement due error fraud may occur detected also projection evaluation internal financial control financial reporting future period subject risk internal financial control financial reporting may become inadequate change condition degree compliance policy procedure may deteriorate opinion opinion holding company subsidiary company company incorporated india material respect adequate internal financial control system financial reporting internal financial control financial reporting operating effectively 31 march 2017 based internal control financial reporting criterion established company considering essential component internal control stated guidance note audit internal financial control financial reporting issued icai b r co llp chartered accountant firm registration number 101248ww100022 sethuraman partner membership number 203491 place bengaluru date 27 april 2017 financial report 219 consolidated balance sheet march 31 2017 amount indian rupee million except share data per share data unless otherwise stated note march 31 2017 march 31 2016 april 01 2015 asset noncurrent asset property plant equipment 3 35529 16811 15982 capital workinprogress 3 5327 20597 15582 investment property 4 8 9 11 goodwill 5 264 264 264 intangible asset 5 458 408 228 intangible asset development 5 3065 1798 1718 investment associate joint venture 42c 422 259 384 financial asset investment 6 1458 ii derivative asset 1092 614 874 iii financial asset 7a 197 258 193 incometax asset net 895 852 890 deferred tax asset net 8 1975 715 320 noncurrent asset 9a 2775 2287 2123 total noncurrent asset 53465 44872 38569 current asset inventory 10 6353 5424 4756 financial asset investment 11 10650 8747 2478 ii trade receivables 12 8832 7145 6833 iii cash cash equivalent 13 7102 7613 4575 iv bank balance 13 3341 7773 4629 v derivative asset 1059 511 350 vi financial asset 7b 1551 1844 468 current asset 9b 1589 652 661 total current asset 40477 39709 24750 total 93942 84581 63319 equity liability equity equity share capital 14a 1000 1000 1000 equity 47377 39338 31622 equity attributable owner company 48377 40338 32622 noncontrolling interest 42b 3761 2658 1121 total equity 52138 42996 33743 noncurrent liability financial liability borrowing 15 21082 20724 7671 ii derivative liability 61 191 174 iii financial liability 16a 2 3 6 provision 17a 360 299 150 noncurrent liability 18a 3516 3711 5601 total noncurrent liability 25021 24928 13602 current liability financial liability borrowing 19 972 3949 2610 ii trade payable 20 7397 6098 4126 iii derivative liability 63 143 128 iv financial liability 16b 3261 1964 4416 provision 17b 468 374 398 income tax liability net 964 965 609 current liability 18b 3658 3164 3687 total current liability 16783 16657 15974 total 93942 84581 63319 accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 220 ahead curve annual report 2017 biocon limited subsidiary consolidated statement profit loss year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated note year ended year ended march 31 2017 march 31 2016 income revenue operation 21 39216 33810 income 22 1571 792 total income 40787 34602 expense cost raw material packing material consumed 23 13224 12549 purchase traded good 1932 760 change inventory traded good finished good workinprogress 24 690 405 excise duty 305 336 employee benefit expense 25 7470 6101 finance cost 26 260 293 depreciation amortisation expense 27 2772 2487 expense 28 8463 8111 33736 30232 less recovery product development cost codevelopment partner net 29 1283 1320 total expense 32453 28912 profit tax share profit joint venture exceptional item tax 8334 5690 share profit joint venture 163 217 profit tax exceptional item 8497 5907 exceptional item net 32 1606 profit tax 8497 7513 tax expense 41 current tax 2082 1813 less mat credit entitlement 369 166 deferred tax 97 225 total tax expense 1616 1422 profit year 6881 6091 space intentionally left blank financial report 221 consolidated statement profit loss year ended march 31 2017 contd amount indian rupee million except share data per share data unless otherwise stated note year ended year ended march 31 2017 march 31 2016 comprehensive income item reclassified subsequently profit loss remeasurement defined benefit plan 57 39 income tax effect 15 9 42 30 ii item may reclassified subsequently profit loss effective portion gain loss hedging instrument cash flow hedge 1293 21 income tax effect 263 5 1030 26 comprehensive income expense year net tax 988 56 total comprehensive income year 7869 6035 profit attributable shareholder company 6121 5504 noncontrolling interest 760 587 profit year 6881 6091 comprehensive income expense attributable shareholder company 764 58 noncontrolling interest 224 2 comprehensive income expense year 988 56 total comprehensive income attributable shareholder company 6885 5446 noncontrolling interest 984 589 total comprehensive income year 7869 6035 earnings per share 31 basic 3118 2804 diluted 3097 2801 accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 222 ahead curve annual report 2017 consolidated statement change equity year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated equity share capital march 31 march 31 2017 2016 opening balance 1000 1000 change equity share capital closing balance 1000 1000 b equity particular attributable owner company non total security revaluation capital general retained sez share treasury foreign cash flow item total controlling premium reserve reserve reserve earnings investment based share currency hedging comprehensive interest reserve reserve payment translation reserve income equity reserve reserve balance april 01 2015 2788 9 801 3459 24054 462 427 494 18 31622 1121 32743 profit year 5504 5504 587 6091 comprehensive income 163 32 26 105 2 107 net tax transaction owner directly recorded equity dividend including dividend 1148 53 1201 distribution tax 1148 share based payment 186 186 186 gain sale share 3160 3160 939 4099 subsidiary net tax refer note 32 purchase treasury share 150 150 150 exercise share option 99 40 59 62 121 balance march 31 2016 2788 9 801 3459 31669 608 577 657 32 44 39338 2658 41996 financial report 223 biocon limited subsidiary consolidated statement change equity year ended march 31 2017 contd 224 amount indian rupee million except share data per share data unless otherwise stated b equity contd particular attributable owner company non total security revaluation capital general retained sez share treasury foreign cash flow item total controlling premium reserve reserve reserve earnings investment based share currency hedging comprehensive interest reserve reserve payment translation reserve income equity reserve reserve balance march 31 2016 2788 9 801 3459 31669 608 577 657 32 44 39338 2658 41996 profit year 6121 6121 760 6881 comprehensive income 118 800 36 646 224 870 net tax transfer special economic 162 162 zone sez reinvestment reserve transfer sez reinvestment 162 162 reserve utilisation ahead curve annual report 2017 transaction owner directly recorded equity share based payment 266 266 266 tax benefit related gain 1042 1042 1042 sale share subsidiary refer note 32 purchase treasury share 150 150 150 exercise share option 120 193 199 114 119 233 balance march 31 2017 2908 9 801 3459 39025 675 727 539 768 80 47377 3761 51138 accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 biocon limited subsidiary consolidated statement cash flow year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated march 31 2017 march 31 2016 cash flow operating activity profit year 6881 6091 adjustment reconcile profit year net cash flow depreciation amortisation 2772 2487 tax expense 1616 1422 unrealised foreign exchange gainloss 311 18 sharebased compensation expense 266 186 provisionreversal provision doubtful debt 34 47 bad debt written 6 8 interest expense 260 226 interest income 1115 428 dividend income 156 191 net gain financial asset measured fair value profit loss 132 net gain sale investment 39 16 proceeds insurance company towards loss tangible asset 159 share profit joint venture 163 217 exceptional item net 1606 operating profit working capital change 10700 7933 movement working capital decreaseincrease inventory 929 668 decreaseincrease trade receivables 1883 654 decreaseincrease asset 1125 2019 increasedecrease trade payable liability provision 1667 1579 cash generated operation 8430 6171 direct tax paid net refund 2030 2465 net cash flow generated operating activity 6400 3706 ii cash flow investing activity purchase tangible asset 6084 6180 acquisition intangible asset 1537 1857 proceeds sale fixed asset 2 9 purchase investment 38689 39668 proceeds sale investment 33182 42964 investment bank deposit inter corporate deposit 17337 11190 redemptionmaturity bank deposit inter corporate deposit 24083 3710 interest received 1239 262 dividend received 156 533 net cash flow generated fromused investing activity 4985 11417 iii cash flow financing activity purchase treasury share 150 150 proceeds exercise share option 193 99 proceeds longterm borrowing 2002 12620 repayment longterm borrowing 264 541 proceeds repayment shortterm borrowing net 2970 1350 dividend paid equity share including tax thereon 2201 interest paid 586 501 net cash flow generated fromused financing activity 1775 10676 financial report 225 consolidated statement cash flow year ended march 31 2017 contd amount indian rupee million except share data per share data unless otherwise stated march 31 2017 march 31 2016 iv net increasedecrease cash cash equivalent ii iii 360 2965 v effect exchange difference cash cash equivalent held foreign currency 113 35 vi cash cash equivalent beginning year 7575 4575 vii cash cash equivalent end year iv v vi 7102 7575 reconciliation cash cash equivalent per statement cash flow cash cash equivalent note 13 balance bank current account 7096 7063 unpaid dividend account 6 10 deposit original maturity less 3 month 540 7102 7613 bank overdraft cash credit note 19 38 balance per statement cash flow 7102 7575 group utilize balance towards settlement respective unpaid dividend liability accompanying note integral part consolidated financial statement per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 space intentionally left blank 226 ahead curve annual report 2017 biocon limited subsidiary note consolidated financial statement year ended march 31 2017 amount indian rupee million except share data per share data unless otherwise stated 1 company overview 11 reporting entity biocon limited biocon parent company company together subsidiary joint venture associate collectively group engaged manufacture biotechnology product research service company public limited company incorporated domiciled india registered office bengaluru karnataka india company share listed bombay stock exchange bse national stock exchange nse india 12 basis preparation financial statement statement compliance consolidated financial statement prepared accordance indian accounting standard ind per company indian accounting standard rule 2015 notified section 133 company act 2013 act relevant provision act group consolidated financial statement year ended march 31 2016 prepared accordance company accounting standard rule 2006 notified section 133 act read together paragraph 7 company account rule 2014 previous gaap group first consolidated financial statement prepared accordance indian accounting standard ind ind 101 firsttime adoption indian accounting standard applied explanation transition ind affected previously reported financial position financial performance cash flow group provided note 40 consolidated financial statement prepared group going concern basis relevant ind effective company annual reporting date march 31 2017 consolidated financial statement authorised issuance company board director april 27 2017 detail group accounting policy included note 2 b functional presentation currency consolidated financial statement presented indian rupee inr also functional currency parent company amount roundedoff nearest million unless otherwise indicated respect subsidiary associate whose operation selfcontained integrated functional currency determined currency primary economic environment entity operates c basis measurement consolidated financial statement prepared historical cost basis except following item certain financial asset liability including derivative instrument measured fair value net defined benefit assetsliability measured fair value plan asset less present value defined benefit obligation use estimate judgement preparation financial statement conformity ind requires management make estimate judgement assumption estimate judgement assumption affect application accounting policy reported amount asset liability disclosure contingent asset liability date financial statement reported amount revenue expense period accounting estimate could change period period actual result could differ estimate appropriate change estimate made management becomes aware change circumstance surrounding estimate change estimate reflected financial statement period change made material effect disclosed note consolidated financial statement judgement information judgement made applying accounting policy significant effect amount recognised financial statement included following note note 12b assessment functional currency note 2c 38 financial instrument note 2d 2e 2f useful life property plant equipment intangible asset investment property note 36 asset obligation relating employee benefit note 30 share based payment note 2n 8 41 provision income tax related tax contingency evaluation recoverability deferred tax asset e assumption estimation uncertainty information assumption estimation uncertainty significant risk resulting material adjustment year ending march 31 2018 included following note financial report 227 note 2n 8 41 recognition deferred tax asset availability future taxable profit tax loss carried forward used note 38 impairment financial asset note 36 measurement defined benefit obligation key actuarial assumption note 17 35 recognition measurement provision contingency key assumption likelihood magnitude outflow resource f measurement fair value number group accounting policy disclosure require measurement fair value financial nonfinancial asset liability fair value categorised different level fair value hierarchy based input used valuation technique follows level 1 quoted price unadjusted active market identical asset liability level 2 input quoted price included level 1 observable asset liability either directly ie price indirectly ie derived price level 3 input asset liability based observable market data unobservable input measuring fair value asset liability group us observable market data far possible input used measure fair value asset liability fall different level fair value hierarchy fair value measurement categorised entirety level fair value hierarchy lowest level input significant entire measurement group recognises transfer level fair value hierarchy end reporting period change occurred information assumption made measuring fair value included following note note 30 sharebased payment arrangement note 4 investment property note 2c 38 financial instrument 2 significant accounting policy basis consolidation subsidiary subsidiary entity controlled group group control entity exposed right variable return involvement entity ability affect return power entity financial statement subsidiary included consolidated financial statement date control commences date control cease financial statement group consolidated linebyline basis intragroup transaction balance unrealised gain arising intragroup transaction eliminated unrealised loss eliminated extent evidence impairment temporary difference arise elimination profit loss resulting intragroup transaction recognised per ind 12 income tax purpose preparing consolidated financial statement accounting policy subsidiary changed necessary align policy adopted company noncontrolling interest nci nci measured proportionate share acquirees net identifiable asset date acquisition change group equity interest subsidiary result loss control accounted equity transaction ii loss control group loses control subsidiary derecognises asset liability subsidiary related nci component equity interest retained former subsidiary measured fair value date control lost resulting gain loss recognised statement profit loss iii associate joint arrangement equity accounted investees group interest equity accounted investees comprise interest associate joint venture associate entity group significant influence control joint control financial operating policy joint venture arrangement group joint control right net asset arrangement rather right asset obligation liability interest associate joint venture accounted using equity method initially recognised cost includes transaction cost subsequent initial recognition consolidated financial statement include group share profit loss oci equity accounted investees date significant influence joint control cease 228 ahead curve annual report 2017 biocon limited subsidiary b foreign currency foreign currency transaction transaction foreign currency translated respective functional currency company exchange rate date transaction average rate average rate approximates actual rate date transaction monetary asset liability denominated foreign currency translated functional currency exchange rate reporting date nonmonetary asset liability measured fair value foreign currency translated functional currency exchange rate fair value determined nonmonetary asset liability measured based historical cost foreign currency translated exchange rate date transaction exchange difference recognised statement profit loss except exchange difference arising translation qualifying cash flow hedge extent hedge effective recognised oci previous gaap exchange difference arising restatement longterm foreign currency monetary item related acquisition depreciable asset added todeducted cost depreciable asset accordance ind 101 first time adoption indian accounting standard group continues accounting treatment respect longterm foreign currency monetary item recognised financial statement march 31 2016 ii foreign operation asset liability foreign operation subsidiary associate joint arrangement including goodwill fair value adjustment arising acquisition translated inr functional currency group exchange rate reporting date income expense foreign operation translated inr exchange rate date transaction average rate average rate approximates actual rate date transaction foreign currency translation difference recognised oci accumulated equity exchange difference translating financial statement foreign operation except extent exchange difference allocated nci c financial instrument recognition initial measurement trade receivables debt security issued initially recognised originated financial asset financial liability initially recognised group becomes party contractual provision instrument financial asset financial liability initially measured fair value plus item fair value profit loss fvtpl transaction cost directly attributable acquisition issue ii classification subsequent measurement financial asset initial recognition financial asset classified measured amortised cost fvoci debt investment fvoci equity investment fvtpl financial asset reclassified subsequent initial recognition except period group change business model managing financial asset financial asset measured amortised cost meet following condition designated fvtpl asset held within business model whose objective hold asset collect contractual cash flow contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding debt investment measured fvoci meet following condition designated fvtpl asset held within business model whose objective achieved collecting contractual cash flow selling financial asset contractual term financial asset give rise specified date cash flow solely payment principal interest principal amount outstanding initial recognition equity investment held trading group may irrevocably elect present subsequent change investment fair value oci designated fvoci equity investment election made investment investment basis financial asset classified measured amortised cost fvoci described measured fvtpl includes derivative financial asset initial recognition group may irrevocably designate financial asset otherwise meet requirement measured amortised cost fvoci fvtpl eliminates significantly reduces accounting mismatch would otherwise arise financial report 229 financial asset subsequent measurement gain loss financial asset fvtpl asset subsequently measured fair value net gain loss including interest dividend income recognised statement profit loss however see note 38 derivative designated hedging instrument financial asset amortised cost asset subsequently measured amortised cost using effective interest method amortised cost reduced impairment loss interest income foreign exchange gain loss impairment recognised statement profit loss gain loss derecognition recognised statement profit loss debt investment fvoci asset subsequently measured fair value interest income effective interest method foreign exchange gain loss impairment recognised statement profit loss net gain loss recognised oci derecognition gain loss accumulated oci reclassified statement profit loss equity investment fvoci asset subsequently measured fair value dividend recognised income statement profit loss unless dividend clearly represents recovery part cost investment net gain loss recognised oci reclassified profit loss financial liability classification subsequent measurement gain loss financial liability classified measured amortised cost fvtpl financial liability classified fvtpl classified held trading derivative designated initial recognition financial liability fvtpl measured fair value net gain loss including interest expense recognised statement profit loss financial liability subsequently measured amortised cost using effective interest method interest expense foreign exchange gain loss recognised statement profit loss gain loss derecognition also recognised statement profit loss iii derecognition financial instrument financial asset group derecognises financial asset contractual right cash flow financial asset expire transfer financial asset transfer qualifies derecognition ind 109 financial liability part financial liability de recognised group balance sheet obligation specified contract discharged cancelled expires financial liability group derecognises financial liability contractual obligation discharged cancelled expire group also derecognises financial liability term modified cash flow modified term substantially different case new financial liability based modified term recognised fair value difference carrying amount financial liability extinguished new financial liability modified term recognised statement profit loss iv derivative financial instrument hedge accounting group hold derivative financial instrument hedge foreign currency interest rate risk exposure embedded derivative separated host contract accounted separately host contract financial asset certain criterion met derivative initially measured fair value subsequent initial recognition derivative measured fair value change therein generally recognised statement profit loss group designates certain derivative hedging instrument hedge variability cash flow associated highly probable forecast transaction arising change foreign exchange rate interest rate inception designated hedging relationship group document risk management objective strategy undertaking hedge group also document economic relationship hedged item hedging instrument including whether change cash flow hedged item hedging instrument expected offset cash flow hedge derivative designated cash flow hedging instrument effective portion change fair value derivative recognised oci accumulated equity effective portion cash flow hedge effective portion change fair value derivative recognised oci limited cumulative change fair value hedged item determined present value basis inception hedge ineffective portion change fair value derivative recognised immediately statement profit loss hedge longer meet criterion hedge accounting hedging instrument sold expires terminated exercised hedge accounting discontinued prospectively hedge accounting cash flow hedge discontinued amount accumulated equity remains hedge transaction resulting recognition nonfinancial item included nonfinancial item cost initial recognition cash flow hedge reclassified profit loss period period hedged expected future cash flow affect profit loss 230 ahead curve annual report 2017 biocon limited subsidiary hedged future cash flow longer expected occur amount accumulated equity immediately reclassified profit loss v treasury share group created employee welfare trust ewt providing sharebased payment employee equity instrument reacquired treasury share recognised cost deducted equity treasury share issued employee ewt amount received recognised increase equity resultant gain loss transferred security premium vi offsetting financial asset financial liability offset net amount presented balance sheet group currently legally enforceable right set amount intends either settle net basis realise asset settle liability simultaneously vii cash cash equivalent cash cash equivalent balance sheet comprise cash bank hand shortterm deposit original maturity three month less subject insignificant risk change value purpose statement cash flow cash cash equivalent consist cash shortterm deposit defined net outstanding bank overdraft considered integral part group cash management viii cash dividend equity holder group recognises liability make cash distribution equity holder distribution authorised distribution longer discretion group per corporate law india distribution authorised approved shareholder corresponding amount recognised directly equity interim dividend recorded liability date declaration company board director property plant equipment recognition measurement item property plant equipment measured cost less accumulated depreciation accumulated impairment loss cost selfconstructed item property plant equipment comprises cost material direct labour cost directly attributable bringing item working condition intended use estimated cost dismantling removing item restoring site located significant part item property plant equipment different useful life accounted separate item major component property plant equipment gain loss disposal item property plant equipment recognised statement profit loss subsequent expenditure capitalised probable future economic benefit associated expenditure flow group ii depreciation depreciation calculated cost item property plant equipment less estimated residual value estimated useful life using straightline method asset acquired finance lease depreciated shorter lease term useful life unless reasonably certain group obtain ownership end lease term freehold land depreciated estimated useful life item property plant equipment current comparative period follows asset management estimate useful life per useful life schedule ii building 2530 year 30 year road 5 year 5 year plant equipment including electrical installation lab equipment 915 year 820 year computer server 3 year 36 year office equipment 5 year 5 year research development equipment 9 year 510 year furniture fixture 6 year 10 year vehicle 6 year 610 year leasehold improvement 5 year lease period whichever lower depreciation method useful life residual value reviewed financial yearend adjusted appropriate based technical evaluation consequent advice management belief estimate useful life given best represent period management expects use asset depreciation addition disposal provided prorata basis ie upto date asset ready use disposed financial report 231 e goodwill intangible asset goodwill measurement goodwill arises business combination refer note 37 subsequent measurement cost less accumulated impairment loss ii intangible asset internally generated research development expenditure research activity recognised statement profit loss incurred development expenditure capitalised part cost resulting intangible asset expenditure measured reliably product process technically commercially feasible future economic benefit probable group intends sufficient resource complete development use sell asset otherwise recognised statement profit loss incurred subsequent initial recognition asset measured cost less accumulated amortisation accumulated impairment loss others intangible asset initially measured cost subsequently intangible asset measured cost less accumulated amortization accumulated impairment loss iii subsequent expenditure subsequent expenditure capitalised increase future economic benefit embodied specific asset relates expenditure including expenditure internally generated goodwill brand recognised statement profit loss incurred iv amortisation goodwill amortised tested impairment annually intangible asset amortised straight line basis estimated useful life follows computer software 35 year marketing manufacturing right 510 year customer related intangible 5 year amortisation method useful life residual value reviewed end financial year adjusted appropriate f investment property investment property property held either earn rental income capital appreciation sale ordinary course business use production supply good service administrative purpose upon initial recognition investment property measured cost subsequent initial recognition investment property measured cost less accumulated depreciation accumulated impairment loss based technical evaluation consequent advice management belief period 25 year representing best estimate period investment property quite similar expected used accordingly group depreciates investment property period 25 year straightline basis useful life estimate 25 year different indicative useful life relevant type building mentioned part c schedule ii act ie 30 year gain loss disposal investment property recognised statement profit loss g business combination accordance ind 103 business combination group account business combination acquisition date using acquisition method control transferred company see note 37 cost acquisition measured fair value asset given equity instrument issued liability incurred assumed date exchange cost acquisition also includes fair value contingent consideration deferred consideration goodwill arises tested annually impairment gain bargain purchase recognised oci accumulated equity capital reserve exists clear evidence underlying reason classifying business combination resulting bargain purchase otherwise gain recognised directly equity capital reserve transaction cost expensed incurred h inventory inventory measured lower cost net realisable value cost inventory based firstin firstout formula includes expenditure incurred acquiring inventory production conversion cost cost incurred bringing present location condition case manufactured inventory workinprogress cost includes appropriate share fixed production overhead based normal operating capacity net realisable value estimated selling price ordinary course business less estimated cost completion selling expense net realisable value workinprogress determined reference selling price related finished product raw material component supply held use production finished product written cost except case material price declined estimated cost finished product exceed net realisable value 232 ahead curve annual report 2017 biocon limited subsidiary comparison cost net realisable value made itembyitem basis impairment impairment financial asset accordance ind 109 group applies expected credit loss ecl model measurement recognition impairment loss following financial asset measured amortised cost financial asset measured fvoci debt investment loss allowance trade receivables significant financing component measured amount equal lifetime expected credit loss financial asset ecl measured amount equal 12month ecl unless significant increase credit risk initial recognition case measured lifetime ecl loss allowance financial asset measured amortised cost deducted gross carrying amount asset debt security fvoci loss allowance charged statement profit loss recognised oci ii impairment nonfinancial asset group assesses reporting date whether indication carrying amount may recoverable indication exists asset recoverable amount estimated impairment loss recognised carrying amount asset cgu exceeds estimated recoverable amount statement profit loss goodwill tested annually impairment purpose impairment testing goodwill arising business combination allocated cgus group cgus expected benefit synergy combination group nonfinancial asset inventory deferred tax asset reviewed reporting date determine whether indication impairment indication exists asset recoverable amount estimated impairment testing asset generate independent cash inflow grouped together cashgenerating unit cgus cgu represents smallest group asset generates cash inflow largely independent cash inflow asset cgus impairment loss recognised respect cgu allocated first reduce carrying amount goodwill allocated cgu reduce carrying amount asset cgu group cgus pro rata basis impairment loss respect goodwill subsequently reversed respect asset impairment loss recognised prior period group review reporting date whether indication loss decreased longer exists impairment loss reversed change estimate used determine recoverable amount reversal made extent asset carrying amount exceed carrying amount would determined net depreciation amortisation impairment loss recognised j employee benefit gratuity group provides gratuity defined benefit plan gratuity plan covering eligible employee company indian subsidiary gratuity plan provides lumpsum payment vested employee retirement death incapacitation termination employment amount based respective employee salary tenure employment group liability regard gratuity plan determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method defined benefit plan administered trust formed purpose group gratuity scheme group recognises net obligation defined benefit plan liability balance sheet gain loss measurement net defined benefit liability recognised comprehensive income reclassified profit loss subsequent period actual return portfolio plan asset excess yield computed applying discount rate used measure defined benefit obligation recognised comprehensive income effect plan amendment recognised statement profit loss ii provident fund eligible employee company indian subsidiary receive benefit provident fund defined contribution plan eligible employee respective company make monthly contribution government administered provident fund scheme equal specified percentage eligible employee salary amount collected provident fund plan deposited government administered provident fund company obligation plan beyond monthly contribution iii compensated absence group policy compensated absence accumulating nonaccumulating nature expected cost accumulating compensated absence determined actuarial valuation performed independent actuary balance sheet date using projected unit credit method additional amount expected paidavailed result unused entitlement accumulated balance sheet date expense nonaccumulating compensated absence recognised period absence occur financial report 233 iv sharebased compensation grant date fair value equity settled sharebased payment award granted employee recognised employee expense corresponding increase equity period employee unconditionally become entitled award amount recognised expense based estimate number award related service nonmarket vesting condition expected met amount ultimately recognised expense based number award meet related service nonmarket vesting condition vesting date k provision employee benefit provision recognised result past event group present legal constructive obligation estimated reliably probable outflow economic benefit required settle obligation provision determined discounting expected future cash flow representing best estimate expenditure required settle present obligation balance sheet date pretax rate reflects current market assessment time value money risk specific liability unwinding discount recognised finance cost expected future operating loss provided onerous contract contract considered onerous expected economic benefit derived group contract lower unavoidable cost meeting obligation contract provision onerous contract measured present value lower expected cost terminating contract expected net cost continuing contract provision made group recognises impairment loss asset associated contract l revenue sale good revenue recognized significant risk reward ownership transferred buyer recovery consideration probable associated cost possible return good estimate reliably continuing management involvement good amount revenue measured reliably timing transfer risk reward varies depending individual term sale revenue sale good includes excise duty measured fair value consideration received receivable net return sale tax applicable trade discount allowance ii milestone payment licensing arrangement company enters certain dossier sale licensing supply arrangement certain instance include certain performance obligation based evaluation whether obligation inconsequential perfunctory recognise defer upfront payment received arrangement deferred revenue recognised consolidated statement operation period complete remaining performance obligation arrangement typically also consist subsequent payment dependent achieving certain milestone accordance term prescribed agreement milestone payment contingent achieving certain clinical milestone recognized revenue either achievement milestone milestone considered substantive period continuing performance obligation milestone considered substantive milestone payment creditable future royalty payment milestone deferred released period royalty anticipated paid iii contract research manufacturing service income respect contract involving research service case time material contract contract research fee recognised service rendered accordance term contract revenue relating fixed price contract recognised based percentage completion method determined based effort expended proportion total estimated effort group monitor estimate total contract revenue cost routine basis throughout contract period cumulative impact change estimate contract revenue cost reflected period change become known event loss anticipated particular contract provision made estimated loss respect contract involving sale compound arising contract research service separate invoice raised revenue recognised significant risk reward ownership compound passed buyer comprise amount invoiced compound sold respect service group collect service tax applicable behalf government therefore economic benefit flowing group hence excluded revenue iv sale return allowance group account sale return recording allowance sale return concurrent recognition revenue time product sale allowance based group estimate expected sale return estimate sale return determined primarily group historical experience market group operates v dividend dividend recognised group right receive payment established generally shareholder approve dividend 234 ahead curve annual report 2017 biocon limited subsidiary vi rental income rental income investment property recognised statement profit loss straightline basis term lease except rental structured increase line expected general inflation lease incentive granted recognised integral part total rental income term lease vii contribution received customerscodevelopment partner towards plant equipment contribution received customerscodevelopment partner towards item property plant equipment require obligation supply good customer future recognised credit deferred revenue contribution received recognised revenue operation useful life asset group capitalises gross cost asset group control asset government grant group recognizes government grant reasonable assurance condition attached complied grant received government grant received relation asset presented reduction carrying amount related asset grant related income deducted reporting related expense n income tax income tax comprises current deferred income tax income tax expense recognised statement profit loss except extent relates item recognised directly equity case recognised comprehensive income current income tax current year prior period recognised amount expected paid recovered tax authority using tax rate law enacted substantively enacted balance sheet date deferred income tax asset liability recognised temporary difference arising tax base asset liability carrying amount financial statement except taxable temporary difference arising initial recognition goodwill temporary difference arising initial recognition asset liability transaction business combination affect neither accounting taxable profit loss time transaction temporary difference related investment subsidiary associate joint arrangement extent group able control timing reversal temporary difference probable reverse foreseeable future deferred tax asset reviewed reporting date reduced extent longer probable related tax benefit realized deferred income tax asset liability measured using tax rate law enacted substantively enacted balance sheet date expected apply taxable income year temporary difference expected recovered settled effect change tax rate deferred income tax asset liability recognised income expense period includes enactment substantive enactment date deferred income tax asset recognised extent probable future taxable income available deductible temporary timing difference tax loss utilized deferred income tax provided undistributed earnings subsidiary expected earnings subsidiary distributed foreseeable future group offset incometax asset liability legally enforceable right set recognised amount intends either settle net basis realise asset settle liability simultaneously borrowing cost borrowing cost interest cost including exchange difference relating foreign currency borrowing extent regarded adjustment interest cost incurred connection borrowing fund borrowing cost directly attributable acquisition construction asset necessarily take substantial period time get ready intended use capitalised part cost asset borrowing cost recognised expense period incurred p earnings per share basic earnings per share computed using weighted average number equity share outstanding period adjusted treasury share held diluted earnings per share computed using weightedaverage number equity dilutive equivalent share outstanding period using treasury stock method option warrant except result would antidilutive q operating segment operating segment component group engages business activity may earn revenue incur expense including revenue expense relate transaction group component discrete financial information available operating segment reported manner consistent internal reporting provided chief operating decision maker chairperson managing director company responsible allocating resource assessing performance operating segment accordingly identified chief operating decision maker codm operating segment operating result reviewed regularly codm make decision resource allocated segment assess performance financial report 235 3 property plant equipment capital workinprogress land building leasehold plant research furniture vehicle total capital work improvement equipment development inprogress equipment fixture refer note refer note c refer note f gross carrying amount april 01 2015 1362 5926 5 19986 2028 552 59 29918 15582 addition 130 657 2254 60 83 6 3190 7291 disposal 85 8 93 3190 adjustment foreign currency translation 59 24 15 98 914 march 31 2016 1551 6607 5 22170 2088 635 57 33113 20597 addition 663 6288 14806 113 218 20 22108 6728 disposal 99 1753 58 7 1917 22108 adjustment foreign currency translation 22 4 9 35 110 march 31 2017 2192 12792 5 35214 2201 795 70 53269 5327 accumulated depreciation april 01 2015 1386 4 11006 1184 337 19 13936 depreciation year 249 1971 155 68 6 2449 disposal 80 4 84 adjustment foreign currency translation 1 1 march 31 2016 1635 4 12898 1339 405 21 16302 depreciation year 282 2176 142 85 10 2695 disposal 36 1158 52 7 1253 adjustment foreign currency translation 1 3 4 march 31 2017 1880 4 13913 1481 438 24 17740 net carrying amount april 01 2015 1362 4540 1 8980 844 215 40 15982 15582 march 31 2016 1551 4972 1 9272 749 230 36 16811 20597 march 31 2017 2192 10912 1 21301 720 357 46 35529 5327 land includes land held leasehold basis gross carrying amount nil march 31 2016 236 net carrying amount nil march 31 2016 236 b year ended march 31 2016 group acquired business pharmaceutical manufacturing unit m acacia lifesciences private limited located vishakhapatnam effect october 01 2015 also refer note 37 c plant equipment include computer office equipment foreign exchange gain 169 march 31 2016 21 long term foreign currency monetary liability relating acquisition depreciable capital asset adjusted cost asset depreciated balance life asset e addition property plant equipment includes addition related research development amounting 297 march 31 2016 80 f capital workinprogress march 31 2017 mainly comprises new biopharmaceutical manufacturing unit constructed india g detail security certain property plant equipment refer note 15b e f space intentionally left blank 236 ahead curve annual report 2017 biocon limited subsidiary 4 investment property gross carrying amount april 01 2015 34 march 31 2016 34 march 31 2017 34 accumulated depreciation april 01 2015 23 depreciation year 2 march 31 2016 25 depreciation year 1 march 31 2017 26 net carrying amount april 01 2015 11 march 31 2016 9 march 31 2017 8 year company recognised rental income 20 march 31 2016 20 depreciation charge 1 march 31 2016 2 statement profit loss investment property fair value investment property march 31 2017 8 march 31 2016 9 april 01 2015 11 5 intangible asset goodwill intangible asset intangible asset development marketing ip customer total product marketing total intangible manufacturing commercialisation related right asset right intangible development refer note refer note b refer note 37 gross carrying amount april 01 2015 264 264 64 81 409 670 1048 1718 addition 72 101 77 250 1082 1082 adjustment impairment refer note 32 1078 1078 foreign currency 46 30 76 translation march 31 2016 264 336 165 81 77 659 1798 1798 addition 169 169 1342 1342 adjustment foreign currency 75 75 translation march 31 2017 264 505 165 81 77 828 3065 3065 accumulated amortisation april 01 2015 88 12 81 181 amortisation year 50 12 8 70 march 31 2016 138 24 81 8 251 amortisation year 77 27 15 119 march 31 2017 215 51 81 23 370 net carrying amount april 01 2015 264 176 52 228 670 1048 1718 march 31 2016 264 198 141 69 408 1798 1798 march 31 2017 264 290 114 54 458 3065 3065 group acquired intellectual property right system biology pharma service practice along team data scientist strand life science private limited sum 120 effect august 1 2016 b pursuant asset purchase agreement customer executed year ended march 31 2016 group acquired marketing manufacturing right product sum 101 financial report 237 6 noncurrent investment march 31 2017 march 31 2016 april 01 2015 unquoted equity instrument others energon kn wind power private limited 38500 march 31 2016 nil april 01 2015 nil equity 1 share 10 less provision decline temporary value noncurrent investment 1 total unquoted investment equity instrument ii unquoted preference share associate company iatrica inc usa 4285714 march 31 2016 4285714 april 01 2015 4285714 series 131 131 131 preferred stock u 070 par value u 000001 less provision decline temporary value noncurrent investment 131 131 131 others vaccinex inc usa 2722014 march 31 2016 2722014 april 01 2015 2722014 series b1 186 186 186 preferred convertible stock u 155 par value u 0001 vaccinex inc usa 217972 march 31 2016 217972 april 01 2015 217972 series b2 32 32 32 preferred convertible stock u 310 par value u 0001 less provision decline temporary value noncurrent investment 218 218 218 energon kn wind power private limited 14666 march 31 2016 nil april 01 2015 nil 1 compulsorily convertible preference share par value 100 less provision decline temporary value noncurrent investment 1 total unquoted investment preference share iii unquoted debenture bond others lic housing finance co ltd 700 march 31 2016 nil april 01 2015 nil 751 bond 701 1001120 par value 1000000 hdfc ltd 75 march 31 2016 nil april 01 2015 nil 815 bond 10090700 par 757 value 10000000 total unquoted investment debenture bond 1458 total noncurrent investment 1458 aggregate value unquoted investment 1809 349 349 aggregate amount impairment value investment 351 349 349 company invested national saving certificate unquoted disclosed since amount rounded rupee million 7 financial asset march 31 2017 march 31 2016 april 01 2015 noncurrent interest accrued due 26 deposit 197 232 193 197 258 193 b current interest accrued due 173 241 98 unbilled revenue 243 679 296 receivables 1135 924 74 1551 1844 468 238 ahead curve annual report 2017 biocon limited subsidiary 8 deferred tax asset net march 31 2017 march 31 2016 april 01 2015 deferred tax liability property plant equipment investment property intangible asset 685 686 692 derivative asset 201 48 others 30 gross deferred tax liability 916 686 740 deferred tax asset employee benefit obligation 182 168 237 allowance doubtful debt 20 14 29 disallowable expense 169 145 80 deferred revenue 162 69 mat credit entitlement 2113 702 536 derivative liability 91 tax loss 262 others 145 119 109 gross deferred tax asset 2891 1401 1060 net deferred tax asset 1975 715 320 9 asset noncurrent capital advance 516 852 588 duty drawback receivable 329 313 326 balance statutory government authority 1589 951 965 prepayment 341 171 244 2775 2287 2123 b current balance statutory government authority 241 157 242 prepayment 1348 495 419 1589 652 661 10 inventory raw material including goodsinbond 1531 1354 1206 packing material 386 324 209 traded good 223 262 249 finished good 1747 1773 1656 workinprogress 2466 1711 1436 6353 5424 4756 includes good intransit nil march 31 2016 151 april 01 2015 nil writedown inventory net realisable value amounted 3 march 31 2016 3 recognised expense year included change inventory traded good finished good workinprogress statement profit loss space intentionally left blank financial report 239 march 31 2017 march 31 2016 april 01 2015 11 current investment unquoted investment mutual fund birla sun life short term fund growth 14572296 march 31 2016 nil april 01 2015 nil unit 907 dhfl pramerica banking psu debt fund gr 6602593 march 31 2016 nil april 01 2015 nil unit 93 axis liquid fund daily dividend reinvestment nil march 31 2016 nil april 01 2015 98005 98 unit dws banking psu debt fund weekly dividend reinvestment nil march 31 2016 70409716 724 april 01 2015 nil unit edelweiss banking psu debt fund regular plan growth 20407166 march 31 2016 nil 276 april 01 2015 nil unit hdfc liquid fund daily dividend reinvestment nil march 31 2016 nil april 01 2015 138 13566785 unit hdfc medium term opportunity fund regular plan growth 27762046 march 31 2016 nil 503 april 01 2015 nil unit hdfc short term opportunity fund regular plan growth 22489571 march 31 2016 nil 405 april 01 2015 nil unit idfc cash fund daily dividend regular plan nil march 31 2016 nil april 01 2015 158344 unit 159 jp morgan banking psu debt fund weekly dividend reinvestment option nil unit march 31 258 2016 24569495 unit april 01 2015 nil unit reliance banking psu debt fund weekly dividend plan nil march 31 2016 46064513 april 465 01 2015 nil unit reliance banking psu debt fund growth 72201894 unit march 31 2016 nil unit april 851 01 2015 nil unit reliance liquidity fund daily dividend reinvestment option nil march 31 2016 nil april 01 135 2015 135112 unit sbi premier liquid fund regular plan daily dividend nil march 31 2016 154313 april 01 155 2015 nil unit tata fixed maturity plan series 47 scheme c plan growth nil march 31 2016 nil april 01 150 2015 15000000 unit tata liquid fund plan daily dividend nil march 31 2016 nil april 01 2015 229233 unit 255 uti treasury advantage fund institutional plan daily dividend reinvestment 91862 march 31 92 42 175 2016 41818 april 01 2015 175000 unit uti treasury advantage fund 122052 march 31 2016 nil april 01 2015 nil unit 274 reliance money manager fund 69072 march 31 2016 nil april 01 2015 nil unit 155 kotak treasury advantage fund 7932353 march 31 2016 nil april 01 2015 nil unit 207 hdfc floating rate income fund 27436866 march 31 2016 nil april 01 2015 nil unit 776 franklin india ultra short bond fund super institutional plan 27293310 march 31 2016 nil 208 april 01 2015 nil unit idfc ultra short term fund 26359631 march 31 2016 nil april 01 2015 nil unit 607 hdfc floating rate income fund 1828193 march 31 2016 nil april 01 2015 nil unit 52 franklin india ultra short bond fund super institutional plan 9353355 march 31 2016 nil april 608 01 2015 nil unit birla saving fund 2431913 march 31 2016 nil april 01 2015 nil unit 775 icici prudential flexible income fund 1947431 march 31 2016 nil april 01 2015 nil unit 606 baroda pioneer liquid fund plan daily dividend nil march 31 2016 40637 april 01 2015 nil unit 41 axis liquid fund daily dividend nil march 31 2016 200433 april 01 2015 nil unit 201 utitreasury advantage fund daily dividend reinvestment nil march 31 2016 252021 april 253 01 2015 nil unit birla sun life saving fund daily dividend regular plan 5303556 march 31 2016 5016970 533 503 253 april 01 2015 2521502 unit birla sun life cash plus daily dividend direct plan nil march 31 2016 nil april 01 2015 9 93857 unit birla sun life cash plus daily dividend nil march 31 2016 nil april 01 2015 748871 unit 75 icici fmp series 78 95 plan k dividend nil march 31 2016 13003654 april 01 2015 nil unit 130 icici prudential flexible income daily dividend 5706959 march 31 2016 4689806 april 01 602 496 253 2015 2391423 unit icici prudential liquid regular plan daily dividend nil march 31 2016 nil april 01 2015 70 699774 unit 240 ahead curve annual report 2017 biocon limited subsidiary march 31 2017 march 31 2016 april 01 2015 jp morgan liquid fund daily dividend nil march 31 2016 nil april 01 2015 4033108 unit 40 tata floater fund plan daily dividend nil march 31 2016 nil april 01 2015 125068 unit 126 hdfc liquid fund direct plan daily dividend nil march 31 2016 nil april 01 2015 1013825 10 unit hdfc liquid fund regular plan daily dividend nil march 31 2016 nil april 01 2015 266017 3 unit hdfc liquid fund daily dividend reinvestment nil march 31 2016 171988 april 01 2015 175 nil unit hdfc floating rate income fund short term dividend reinvestment nil march 31 2016 496 142 49241163 april 01 2015 14034587 unit kotak liquid scheme plan direct plan daily dividend nil march 31 2016 nil april 01 2015 22 18308 unit kotak liquid fund plan regular plan daily dividend nil march 31 2016 nil april 01 2015 122 99734 unit reliance money manager fund daily dividend plan nil march 31 2016 151044 april 01 2015 152 nil unit reliance liquid fund regular plan daily dividend nil march 31 2016 154108 april 01 2015 236 193 125892 unit reliance liquid fund cash plan daily dividend nil march 31 2016 nil april 01 2015 45147 50 unit 8530 4327 2478 others inter corporate deposit financial institution 2120 4420 10650 8747 2478 aggregate value unquoted investment 10650 8747 2478 12 trade receivables unsecured considered good 8832 7145 6833 doubtful 90 56 90 8922 7201 6923 allowance credit loss 90 56 90 8832 7145 6833 includes due narayana hrudayalaya limited nhl formerly known narayana hrudayalaya private 4 8 5 limited director company member board director nhl group exposure credit currency risk loss allowance disclosed note 38 13 cash bank balance cash cash equivalent balance bank current account 7096 7063 4569 unpaid dividend account 6 10 6 deposit original maturity less 3 month 540 total cash cash equivalent 7102 7613 4575 bank balance deposit maturity less 12 month 3338 7770 4626 margin money deposit refer note 3 3 3 total bank balance 3341 7773 4629 total cash bank balance 10443 15386 9204 margin money deposit carrying amount 3 march 31 2016 3 april 01 2015 3 subject first charge bank guarantee obtained b group cash hand disclosed since amount rounded rupee million financial report 241 march 31 2017 march 31 2016 april 01 2015 14a equity share capital authorised 220000000 march 31 2016 220000000 april 01 2015 220000000 equity share 5 1100 1100 1100 march 31 2016 5 april 01 2015 5 issued subscribed fully paidup 200000000 march 31 2016 200000000 april 01 2015 200000000 equity share 5 1000 1000 1000 march 31 2016 5 april 01 2015 5 reconciliation share outstanding beginning end reporting period equity share march 31 2017 march 31 2016 million million beginning year 200000000 1000 200000000 1000 issued year outstanding end year 200000000 1000 200000000 1000 ii termsrights attached equity share company one class equity share par value 5 per share holder equity share entitled one vote per share company declares pay dividend indian rupee dividend proposed board director subject approval shareholder ensuing annual general meeting event liquidation company holder equity share entitled receive remaining asset company distribution preferential amount distribution proportion number equity share held shareholder iii detail shareholder holding 5 share company march 31 2017 march 31 2016 holding holding equity share 5 fully paid dr kiran mazumdarshaw 79287564 3964 79287564 3964 glentec international limited 39535194 1977 39535194 1977 per record company including register shareholder member shareholding represents legal beneficial ownership share iv share reserved issue option detail share reserved issue employee stock option plan esop company refer note 30 14b equity security premium reserve security premium used record premium received issue share utilised accordance provision company act 2013 general reserve general reserve used time time transfer profit retained earnings appropriation purpose retained earnings amount distributed company dividend equity shareholder determined based standalone financial statement company also considering requirement act thus amount reported distributable entirety sez reinvestment reserve sez reinvestment reserve created profit eligible sez unit term provision section 10aa1ii incometax act 1961 reserve utilised acquiring new plant machinery purpose business term section 10aa2 incometax act 1961 share based payment reserve group established various equity settled sharebased payment plan certain category employee group also refer note 30 detail plan treasury share equity instrument reacquired treasury share recognised cost deducted equity foreign currency translation reserve exchange difference relating translation result net asset group foreign operation functional currency group reporting currency ie accumulated foreign currency translation reserve cash flow hedging reserve cash flow hedging reserve represents cumulative effective portion gain loss net tax arising change fair value designated portion hedging instrument entered cash flow hedge 242 ahead curve annual report 2017 biocon limited subsidiary 15 longterm borrowing march 31 2017 march 31 2016 april 01 2015 deferred sale tax liability unsecured refer note 65 195 loan bank secured term loan refer note b e f 21403 20090 8097 buyer credit refer note c 611 624 186 loan advance unsecured nmitli csir loan refer note g 1 1 1 financial assistance dsir refer note h 3 6 10 financial assistance dst refer note 35 42 48 22053 20828 8537 less amount disclosed head current financial liability refer note 16b 971 104 866 21082 20724 7671 amount includes secured borrowing 22014 20714 8283 unsecured borrowing 39 114 254 amount disclosed head current financial liability refer note 16b 971 104 866 net amount 21082 20724 7671 february 9 2000 company obtained order karnataka sale tax authority allowing interest free deferment sale tax including turnover tax period upto 12 year respect sale hebbagodi manufacturing facility amount exceeding 649 interest free liability amount repayable 10 equal half yearly instalment 65 starting february 2012 loan repaid year b year ended march 31 2016 company obtained external commercial borrowing facility usd 20 million bank term loan facility secured first priority paripassu charge plant machinery proposed expanded facility line existing facility longterm loan repayable 4 equal quarterly instalment usd 5 million commencing december 31 2018 carry interest rate libor 095 pa company entered interest rate swap convert floating rate fixed rate also refer note 38 c syngene international limited syngene obtained foreign currency denominated long term secured buyer credit loan 611 usd 941 million march 31 2016 624 usd 941 million april 01 2015 186 usd 3 million hsbc bank mauritius limited carry interest rate range libor 060 libor 080 pa loan guaranteed hong kong shanghai banking corporation limited india hsbc bank mauritius limited credit facility provided hong kong shanghai banking corporation limited india secured pari passu charge current asset movable fixed asset syngene loan repayable end 960 day 1079 day date origination syngene entered external commercial borrowing agreement hong kong shanghai banking corporation limited agent citibank na hsbc bank mauritius limited lead arranger dated march 30 2016 borrow 6628 usd 100 million comprising usd 50 million term loan facility facility b usd 50 million term loan facility facility b facility borrowed incur capital expenditure bangalore mangalore premise syngene ii facility 3241 usd 50 million carry interest rate libor 104 pa repayable two installment usd 125 million march 2019 usd 375 million march 2020 facility b 3240 usd 50 million carry interest rate libor 130 pa repayable march 2021 iii facility provided secured first priority pari passu charge fixed asset second charge current asset syngene e year ended march 31 2016 biocon pharma limited bpl obtained external commercial borrowing usd 20 million bank carrying interest libor 175 pa loan payable 11 unequal quarterly instalment commencing june 28 2019 loan secured first priority paripassu charge plant machinery facility manufacture pharmaceutical bpl entered interest rate swap convert floating rate fixed rate f biocon sdn bhd malaysia biocon malaysia obtained term loan facility usd 130 million consortium bank year ended march 31 2016 biocon sdn bhd refinanced existing term loan standard chartered bank hong kong limited loan repayable quarterly installment commencing march 2017 july 6 2015 biocon sdn bhd entered new term loan agreement standard chartered bank hong kong limited amount usd 70 million loan repayable quarterly installment commencing march 2017 term loan denominated usd carry interest rate libor 325 pa term loan secured fixed floating charge present future asset charge freehold property biocon malaysia g march 31 2005 company entered agreement council scientific industrial research csir unsecured loan 3 carrying part research development project new millennium indian technology leadership initiative nmitli scheme loan repayable 10 equal annual instalment 03 starting april 2009 carry interest rate 3 pa financial report 243 h march 31 2009 department scientific industrial research dsir sanctioned financial assistance sum 17 company part financing one research project assistance repayable form royalty payment three year post commercialisation project five equal annual instalment 3 starting april 1 2013 august 25 2010 department science technology dst drug pharmaceutical research programme dprp sanctioned financial assistance sum 70 company financing one research project loan repayable 10 annual instalment 7 starting july 1 2012 carry interest rate 3 pa j respect financial assistance received aforesaid programme refer note g company required utilise fund specified project required obtain prior approval said authority disposal asset intellectual property right acquired developed programme k group exposure liquidity interest rate currency risk disclosed note 38 march 31 2017 march 31 2016 april 01 2015 16 financial liability noncurrent interest accrued due 2 3 6 2 3 6 b current current maturity longterm borrowing refer note 15 971 104 866 unpaid dividend 6 10 6 payable capital good 2284 1850 2544 interim dividend equity share 1000 3261 1964 4416 17 provision noncurrent provision employee benefit gratuity refer note 36 360 299 150 360 299 150 b current provision employee benefit gratuity refer note 36 131 77 124 compensated absence 201 167 144 provision sale return 136 130 130 468 374 398 movement provision gratuity compensated sale return absence opening balance 376 167 130 provision recognised reversed year 115 34 6 closing balance 491 201 136 march 31 2017 march 31 2016 april 01 2015 18 liability noncurrent deferred revenue 3516 3711 5601 3516 3711 5601 b current deferred revenue 273 267 1245 advance customer 2340 2427 2208 book overdraft 824 255 90 statutory tax due payable 221 215 144 3658 3164 3687 244 ahead curve annual report 2017 biocon limited subsidiary march 31 2017 march 31 2016 april 01 2015 19 shortterm borrowing banksfinancial institution packing credit foreign currency loan unsecured refer note ii iii iv v 648 2253 2610 packing credit foreign currency loan secured refer note vi vii 324 1658 cash credit secured refer note viii 2 bank overdraft unsecured refer note ix 36 972 3949 2610 amount includes secured borrowing 324 1660 unsecured borrowing 648 2289 2610 year ended march 31 2016 company obtained unsecured foreign currency denominated loan 597 usd 9 million april 01 2015 nil usd nil carrying interest rate libor 020 pa bank facility repayable within 120 day date origination repaid year ii year ended march 31 2016 company obtained unsecured foreign currency denominated loan 1656 usd 25 million april 01 2015 nil usd nil carrying interest rate libor 010 pa bank facility repayable within 180 day date origination repaid year iii year ended march 31 2015 company obtained foreign currency denominated loan 561 usd 9 million carrying interest rate libor 035 pa bank facility repayable within 180 day date origination repaid year ended march 31 2016 iv biocon research limited brl obtained foreign currency denominated loan 685 usd 11 million carrying interest rate libor 035 050 pa bank april 01 2015 repaid year ended march 31 2016 v syngene obtained foreign currency denominated short term unsecured preshipment credit loan 648 usd 10 million march 31 2016 nil hdfc bank limited carry interest rate libor 142 pa loan repayable end 6 month date origination vi syngene obtained foreign currency denominated short term secured preshipment credit loan 324 usd 5 million march 31 2016 nil hong kong shanghai banking corporation limited carry interest rate libor 142 pa loan repayable end 6 month date origination facility provided secured pari passu charge current asset movable fixed asset syngene vii syngene obtained foreign currency denominated short term secured preshipment credit loan 1658 usd 25 million march 31 2016 royal bank scotland n v carried interest rate libor 010 pa loan repayable end 6 month date origination facility provided secured charge fixed asset current asset syngene loan fully repaid current year ended march 31 2017 viii company working capital facility bank carrying interest rate ranging 97 13 pa facility repayable demand secured paripassu first charge inventory trade receivables ix bpl obtained unsecured overdraft facility bank carrying interest rate 925 pa march 31 2017 march 31 2016 april 01 2015 20 trade payable trade payable 7397 6098 4126 7397 6098 4126 trade payable current group exposure currency liquidity risk related trade payable disclosed note 38 space intentionally left blank financial report 245 march 31 2017 march 31 2016 21 revenue operation sale product finished good 22193 19908 traded good 3741 1647 sale service licensing development fee 1451 631 contract research manufacturing service income 11378 10730 operating revenue sale process waste 147 151 others 306 743 revenue operation 39216 33810 22 income interest income deposit bank financial institution 994 398 others 121 30 dividend income current investment 156 191 net gain sale current investment 39 16 net gain financial asset measured fair value profit loss 132 nonoperating income 129 157 1571 792 23 cost raw material packing material consumed inventory beginning year 1678 1415 add purchase 13463 12812 less inventory end year 1917 1678 cost raw material packing material consumed 13224 12549 24 change inventory traded good finished good workinprogress inventory beginning year traded good 262 249 finished good 1773 1656 workinprogress 1711 1436 3746 3341 inventory end year traded good 223 262 finished good 1747 1773 workinprogress 2466 1711 4436 3746 690 405 25 employee benefit expense salary wage bonus 6502 5314 contribution provident fund 264 221 gratuity refer note 36 82 66 sharebased compensation expense refer note 30 266 186 staff welfare expense 356 314 7470 6101 26 finance cost interest expense financial liability measured amortised cost 260 196 fair value change interest rate swap 30 exchange difference extent considered adjustment borrowing cost 67 260 293 246 ahead curve annual report 2017 biocon limited subsidiary march 31 2017 march 31 2016 27 depreciation amortisation expense depreciation tangible asset refer note 3 4 2696 2451 amortisation intangible asset refer note 5 119 70 2815 2521 less expense capitalised tangible asset 43 34 2772 2487 28 expense royalty technical fee 20 24 rent 34 29 communication expense 59 62 travelling conveyance 516 470 professional charge 566 525 payment auditor refer note 12 19 director fee including commission 33 33 power fuel 1564 1847 insurance 72 57 rate tax fee 222 194 lab consumables 734 614 repair maintenance plant machinery 691 535 building 212 143 others 530 478 selling expense freight outwards clearing charge 270 303 sale promotion expense 548 446 commission brokerage sole selling agent 256 259 bad debt written 6 8 provision reversal doubtful debt net 34 47 foreign exchange fluctuation net 23 95 printing stationery 69 57 research development expense refer note 29 2724 2655 clinical trial development expense 134 80 csr expenditure refer note 46 131 112 miscellaneous expense 369 285 9829 9283 less adjustment product development expense deferred revenue 152 less expense capitalised intangible asset 1366 1020 8463 8111 payment auditor auditor statutory audit fee 6 6 tax audit fee 2 2 limited review 2 3 capacity service certification fee 1 audit limited review fee relation ipo syngene 6 reimbursement outofpocket expense 1 2 12 19 payment year ended march 31 2016 represents fee reimbursement paid predecessor auditor 29 research development expense research development expense 2724 2655 research development expense included head b 2587 2579 ab 5311 5234 less recovery product development cost codevelopment partner net 1283 1320 adjustment product development expense deferred revenue 152 product development cost capitalised 1366 1020 2662 2742 financial report 247 30 employee stock compensation biocon esop plan september 27 2001 biocons board director approved biocon employee stock option plan esop plan 2000 grant stock option employee company subsidiary joint venture company nomination remuneration committee remuneration committee administers plan trust established specifically purpose called biocon india limited employee welfare trust esop trust esop trust shall make additional purchase equity share company using proceeds loan obtained company cash inflow allotment share employee esop plan shall subscribe allotted number share necessary transferring employee esop trust may also receive share promoter purpose issuance employee esop plan remuneration committee shall determine exercise price less face value share grant iv july 2006 company approved grant 3478200 option face value share 5 employee existing esop plan 2000 option grant would vest employee 25 35 40 total grant end first second third year date grant existing employee end 3rd 4th 5th year date grant new employee exercise period 3 year grant condition number option granted include service term performance grade employee option exercisable discount 20 market price company share date grant detail grant iv particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 3500 231 61625 185 granted year forfeited year adjustment issuance bonus share year exercised year 2500 231 55250 179 expired year 1000 231 2875 154 outstanding end year 3500 231 exercisable end year 3500 231 weighted average remaining contractual life year 03 range exercise price outstanding option end year 231 grant v april 2008 company approved grant employee existing esop plan 2000 option grant would vest employee 25 35 40 total grant end first second third year date grant existing employee end 3rd 4th 5th year date grant new employee exercise period 3 year grant condition number option granted include service term performance grade employee option exercisable market price company share date grant detail grant v particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 791875 343 1151975 336 granted year forfeited year 74625 344 269087 324 adjustment issuance bonus share year exercised year 221388 307 91013 303 expired year outstanding end year 495862 357 791875 343 exercisable end year 135175 312 220638 310 weighted average remaining contractual life year 25 46 range exercise price outstanding option end year 221471 197531 248 ahead curve annual report 2017 biocon limited subsidiary grant vi july 2014 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 1185839 470 1346152 470 granted year 95000 477 forfeited year 61600 470 160313 470 exercised year 258001 471 expired year outstanding end year 961238 471 1185839 470 exercisable end year 125026 470 116750 470 weighted average remaining contractual life year 23 33 weighted average fair value option granted 156 range exercise price outstanding option end year 470493 470 grant vii july 2014 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing market price company share existing date preceding date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 1275500 461 293000 452 granted year 200000 605 1077500 461 forfeited year 238500 392 95000 472 exercised year 16800 457 expired year outstanding end year 1220200 482 1275500 461 exercisable end year 9450 457 weighted average remaining contractual life year 52 60 weighted average fair value option granted 251 185 range exercise price outstanding option end year 415741 415518 grant viii july 2015 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable closing price per national stock exchange last day month preceding month first grant space intentionally left blank financial report 249 particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 312500 459 granted year 55000 457 312500 459 forfeited year 105000 457 exercised year 1000 457 expired year outstanding end year 261500 460 312500 459 exercisable end year 16750 457 weighted average remaining contractual life year 38 46 weighted average fair value option granted 149 154 range exercise price outstanding option end year 457481 457481 grant ix june 2016 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable 50 closing price per national stock exchange preceding day date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year 472500 495 forfeited year 5000 467 exercised year expired year outstanding end year 467500 496 exercisable end year weighted average remaining contractual life year 89 weighted average fair value option granted 617 range exercise price outstanding option end year 415566 grant x june 2016 company approved grant employee existing esop plan 2000 option grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee option exercisable 50 closing price per national stock exchange preceding day date grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year granted year 255000 388 forfeited year 51250 373 exercised year expired year outstanding end year 203750 392 exercisable end year weighted average remaining contractual life year 43 weighted average fair value option granted 442 range exercise price outstanding option end year 371467 250 ahead curve annual report 2017 biocon limited subsidiary assumption used determination fair value stock option black scholes model follows particular march 31 2017 march 31 2016 weighted average exercise price 388605 459461 expected volatility 295 334 29 345 historical volatility 3432 3418 life option granted vesting exercise period year 3065 3065 expected dividend per share 500 500 average riskfree interest rate 712 765 expected dividend rate 110 110 expected volatility based historical volatility market price company publicly traded equity share expected term option grant b rsu plan 2015 march 11 2015 biocons remuneration committee approved biocon restricted stock unit rsus syngene rsu plan 2015 grant rsus employee company subsidiary syngene remuneration committee administers plan trust established specifically purpose called biocon limited employee welfare trust rsu trust purpose march 31 2015 company transferred 2000000 equity share syngene rsu trust april 2015 company approved grant employee rsu plan 2015 rsus grant would vest employee 10 20 30 40 total grant end first second third fourth year date grant respectively exercise period ending one year end last vesting vesting condition include service term performance grade employee exercise price rsus nil particular march 31 2017 march 31 2016 number weighted number weighted unit average unit average exercise price exercise price outstanding beginning year 1231803 granted year 193454 1364148 forfeited year 117963 132345 exercised year 10742 expired year outstanding end year 1296552 1231803 exercisable end year 92320 weighted average remaining contractual life year 41 48 weighted average fair value option granted 468 162 assumption used determination fair value stock option black scholes model follows particular march 31 2017 march 31 2016 weighted average exercise price expected volatility 2992 4431 2992 historical volatility 4431 2992 life option granted vesting exercise period year 5065 5065 expected dividend per share 1 1 average riskfree interest rate 712 765 expected dividend rate 030 030 expected volatility based historical volatility market price syngenes publicly traded equity share expected term option grant c syngene esop plan july 20 2012 syngene employee welfare trust trust created welfare benefit employee director syngene board director approved employee stock option plan syngene october 31 2012 trust subscribed 1875000 equity share face value 5 per share syngene using proceeds interest free loan 150 obtained syngene march 31 2017 trust hold 4513525 march 31 2016 5919219 march 31 2015 6680000 equity share face value 10 adjusted consolidation share bonus issue march 31 2017 trust transferred 2166475 march 31 2016 760781 march 31 2015 nil equity share employee exercise stock option financial report 251 grant pursuant scheme syngene granted option eligible employee syngene syngene employee stock option plan 2011 option entitles one equity share option grant vest employee 25 35 40 total grant end second third fourth year date grant respectively exercise period three year grant vesting condition include service term performance employee option exercisable exercise price 2250 per share face value 10 per share detail grant particular march 31 2017 march 31 2016 number weighted number weighted option average option average exercise price exercise price outstanding beginning year 4942835 225 5057100 225 granted year 166000 225 930583 225 forfeited year 68684 225 284067 225 exercised year 1405694 225 760781 225 outstanding end year 3634457 225 4942835 225 exercisable end year 668492 225 434494 225 weighted average remaining contractual life year 14 30 weighted average fair value option granted 4846 3720 weighted average share price date exercise 5094 3672 assumption used determination fair value stock option black scholes model follows particular march 31 2017 march 31 2016 dividend yield 03 03 exercise price 2250 2250 volatility 342 291 life option granted vesting exercise period 615 569 average riskfree interest rate 67 75 march 31 2017 march 31 2016 summary movement respect share held esop trust follows opening balance 3876828 3674928 add share purchased esop trust 152731 348163 less share exercised employee 499689 146263 closing balance 3529870 3876828 option granted eligible exercise end year 286401 340888 option granted eligible exercise end year 3323649 3228326 summary movement respect equity share syngene held rsu trust follows opening balance 2000000 2000000 less share exercised employee 10742 closing balance 1989258 2000000 march 31 2017 march 31 2016 31 earnings per share eps earnings profit year attributable shareholder company 6121 5504 share basic outstanding share 200000000 200000000 less weighted average share held esop trust 3702196 3697436 weighted average share used computing basic eps 196297804 196302564 add effect dilutive option granted yet exercised yet eligible exercise 1376487 167870 weighted average share used computing diluted eps 197674291 196470434 earnings per share basic 3118 2804 diluted 3097 2801 252 ahead curve annual report 2017 biocon limited subsidiary march 31 2017 march 31 2016 32 exceptional item net impairment loss intangible asset refer note 1078 recognition deferred revenue refer note b 2684 loss account fire refer note 795 less recoverable insurance company 795 1606 pursuant uncertainty respect ability group license product development commercialization certain territory biocon sa recorded impairment carrying value intangible asset amounting 1078 b consequent agreement customer resulted change nature group future obligation rhinsulin program deferred revenue 2684 relating program recognised income consolidated financial statement year ended march 31 2016 c year ended march 31 2016 syngene international limited syngene completed initial public offering ipo offer sale 22000000 equity share 10 company gain arising sale equity share net related expense cost equity share amounting 3160 recorded credit equity consolidated financial statement net consequential tax 1042 gain mat credit transaction recorded previous year due uncertainty utilisation current year pursuant change income tax law business restructuring company belief able utilize mat credit entitlement accordingly year ended march 31 2017 company recorded mat credit entitlement 1042 included income tax expense standalone financial statement however consolidated financial statement entitlement recognised credit equity along underlying dilution gain sale equity stake syngene impact group control pursuant fire incident december 12 2016 certain fixed asset inventory content one building syngene damaged syngene lodged initial estimate loss insurance company survey currently ongoing year ended march 31 2017 syngene written net book value asset aggregating 795 recognised minimum insurance claim receivable equivalent amount current year group received initial disbursement 200 insurance company adjusted amount recoverable insurance company addition group process determining claim business interruption accordingly recorded claim arising therefrom stage e current year biocon sa bsa biocon sdn bhd biocon malaysia entered assignment license agreement pursuant bsa transferred right interest obligation insulin analog ipr biocon malaysia consequent transfer bsa recorded net gain standalone book offered tax swiss tax law restructuring impact consolidated financial statement except exceptional tax cost 78 representing tax payable bsa locally included within income tax expense year ended march 31 2017 33 disclosure specified bank note sbns year group specified bank note denomination note defined mca notification gsr 308e dated march 30 2017 detail specified bank note sbn held transacted period november 8 2016 december 30 2016 denomination wise sbns note per notification given amount particular sbns total denomination note closing cash hand november 8 2016 523000 1398946 1921946 permitted receipt 1956642 1956642 permitted payment 2556809 2556809 amount deposited bank 523000 523000 closing cash hand december 30 2016 798779 798779 purpose clause term specified bank note shall meaning provided notification government india ministry finance department economic affair number 3407e dated november 8 2016 financial report 253 34 related party transaction 254 related party control exists related party transaction taken place year listed sl name related party relationship description april 1 2016 balance april 1 2015 balance balance transaction march 31 2017 march 31 2017 march 31 2016 march 31 2016 april 01 2015 incomeexpenses payable incomeexpenses payable payable transaction receivable transaction receivable receivable remuneration paid key management personnel refer note 1 kiran mazumdarshaw chairperson managing director salary perquisite 20 16 2 john shaw vicechairman director salary perquisite 17 16 3 arun chandavarkar joint managing director ceo salary perquisite 33 31 4 siddharth mittal president finance chief salary perquisite 20 16 financial officer 5 kiran kumar company secretary salary perquisite 7 6 upto dec 15 2016 6 rajiv balakrishnan company secretary salary perquisite 1 wef jan 24 2017 b others 7 glentec international enterprise owned key rent expense paid 1 1 1 ahead curve annual report 2017 limited management personnel 8 biocon foundation trust key management csr expenditure 101 93 personnel board trustee 9 narayana hrudayalaya enterprise director sale good 41 52 limited formerly known company member trade receivables 4 8 5 narayana hrudayalaya board director private limited remuneration key managerial personnel include provision made gratuity compensated absence obtained actuarial basis company whole b sharebased compensation expense allocable key management personnel 5 march 31 2016 10 included remuneration disclosed c disclosure include related party per ind 24 related party disclosure company act 2013 year transaction biocon india limited employee welfare trust trust key management personnel board trustee e transaction related party priced arm length basis none balance secured f group purchased consumables mazumdar farm proprietary firm relative director disclosed since amount rounded rupee million space intentionally left blank biocon limited subsidiary march 31 2017 march 31 2016 april 01 2015 35 contingent liability commitment extent provided contingent liability claim company acknowledged debt 5272 5197 2840 includes direct taxation 4304 4132 1838 ii indirect taxation includes matter pertaining dispute central excise custom duty 575 668 610 service tax iii litigation 393 397 392 group involved taxation dispute lawsuit proceeding etc including patent commercial matter arise time time ordinary course business management view claim tenable material adverse effect group financial position result operation b guarantee corporate guarantee given central excise department 648 648 742 ii guarantee given bank behalf group contractual obligation group 20 60 65 ii commitment estimated amount contract remaining executed capital account provided net advance 1925 2131 3313 b operating lease commitment company lessee vehicle company taken vehicle certain employee operating lease expire period upto january 2020 gross rental expense year aggregate 22 march 31 2016 19 committed lease rental future follows later one year 26 19 15 later one year later five year 36 33 27 space intentionally left blank financial report 255 36 employee benefit plan group defined benefit gratuity plan per payment gratuity act 1972 employee india legislation employee completed five year service entitled specific benefit level benefit provided depends employee length service salary retirementtermination age based actuarial valuation obtained respect following table set status gratuity plan amount recognised group financial statement balance sheet date defined benefit fair value net defined obligation plan asset benefit assetliability balance april 01 2016 439 63 376 current service cost 54 54 interest expenseincome 33 5 28 amount recognised statement profit loss 87 5 82 remeasurements return plan asset excluding amount included interest expense income 2 2 actuarial gainloss arising demographic assumption 3 3 financial assumption 19 19 experience adjustment 43 43 amount recognised comprehensive income 59 2 57 employer contribution 24 24 benefit paid 34 34 balance march 31 2017 551 60 491 defined benefit fair value net defined obligation plan asset benefit asset liability balance april 01 2015 353 79 274 current service cost 44 44 interest expense income 28 6 22 amount recognised statement profit loss 72 6 66 remeasurements return plan asset excluding amount included interest expense income actuarial gain loss arising demographic assumption financial assumption 10 10 experience adjustment 29 29 amount recognised comprehensive income 39 39 employer contribution 3 3 benefit paid 25 25 balance march 31 2016 439 63 376 march 31 2017 march 31 2016 april 01 2015 noncurrent 360 299 150 current 131 77 124 491 376 274 space intentionally left blank 256 ahead curve annual report 2017 biocon limited subsidiary ii assumption used gratuity valuation march 31 2017 march 31 2016 april 01 2015 interest rate 69 75 88 discount rate 69 75 79 expected return plan asset 69 75 79 salary increase 90 90 90 attrition rate 7 30 7 26 7 26 retirement age year 58 58 58 assumption regarding future mortality experience set accordance published statistic mortality table weighted average duration defined benefit obligation 8 year march 31 2016 8 year defined benefit plan expose group actuarial risk longevity interest rate risk iii sensitivity analysis sensitivity defined benefit obligation change weighted principal assumption particular march 31 2017 march 31 2016 increase decrease increase decrease discount rate 26 29 18 20 salary increase 28 26 20 18 attrition rate 4 5 2 3 sensitivity significant actuarial assumption computed varying one actuarial assumption used valuation defined benefit obligation one percentage keeping actuarial assumption constant although analysis take account full distribution cash flow expected plan provide approximation sensitivity assumption shown march 31 2017 march 31 2016 plan asset invested insurer managed fund expected contribution fund year ending march 31 2018 approximately 95 march 31 2017 77 maturity profile defined benefit obligation particular million 1st following year 95 2nd following year 68 3rd following year 61 4th following year 67 5th following year 51 year 6 10 211 37 business combination year ended march 31 2016 group acquired business pharmaceutical manufacturing unit m acacia lifesciences private limited located vishakhapatnam effect october 01 2015 going concern basis consideration 531 paid cash transaction accounted ind 103 business combination business combination purchase price allocated identifiable asset liability fair value following table present allocation purchase price particular amount net tangible asset 454 customer related intangible 77 total purchase price 531 space intentionally left blank financial report 257 38 financial instrument fair value risk management accounting classification fair value carrying amount fair value march 31 2017 fvtpl fvtoci amortised total level 1 level 2 level 3 total cost financial asset noncurrent investment 1458 1458 derivative asset 71 2080 2151 2151 2151 current investment 8530 2120 10650 8530 8530 trade receivables 8832 8832 cash cash equivalent 7102 7102 bank balance 3341 3341 financial asset 1748 1748 8601 2080 24601 35282 8530 2151 10681 financial liability borrowing 22054 22054 trade payable 7397 7397 derivative liability 124 124 124 124 financial liability 3263 3263 124 32714 32838 124 124 march 31 2016 fvtpl fvtoci amortised total level 1 level 2 level 3 total cost financial asset derivative asset 332 793 1125 1125 1125 current investment 4327 4420 8747 4327 4327 trade receivables 7145 7145 cash cash equivalent 7613 7613 bank balance 7773 7773 financial asset 2102 2102 4659 793 29053 34505 4327 1125 5452 financial liability borrowing 24673 24673 trade payable 6098 6098 derivative liability 71 263 334 334 334 financial liability 1967 1967 71 263 32738 33072 334 334 april 01 2015 fvtpl fvtoci amortised total level 1 level 2 level 3 total cost financial asset derivative asset 403 821 1224 1224 1224 current investment 2478 2478 2478 2478 trade receivables 6833 6833 cash cash equivalent 4575 4575 bank balance 4629 4629 financial asset 661 661 2881 821 16698 20400 2478 1224 3702 financial liability borrowing 10281 10281 trade payable 4126 4126 derivative liability 302 302 302 302 financial liability 4422 4422 302 18829 19131 302 302 258 ahead curve annual report 2017 biocon limited subsidiary b measurement fair value fair value liquid mutual fund based quoted price derivative financial instrument valued based quoted price similar asset liability active market input directly indirectly observable market place sensitivity analysis fair value forward contract foreign currency reasonably possible change reporting date one significant observable input holding input constant would following effect march 31 2017 march 31 2016 profit loss profit loss significant observable input increase decrease increase decrease spot rate foreign currency 1 movement 222 223 173 187 interest rate 100 bps movement 312 312 215 215 c financial risk management group exposure following risk arising financial instrument credit risk liquidity risk market risk risk management framework group risk management carried treasury department policy approved board director board provides written principle overall risk management well policy covering specific area foreign exchange risk interest rate risk credit risk use derivative nonderivative financial instrument investment excess liquidity credit risk credit risk risk counterparty meet obligation financial instrument customer contract leading financial loss credit risk arises principally operating activity primarily trade receivables financing activity including deposit bank financial institution financial instrument customer credit risk managed business unit subject group established policy procedure control relating customer credit risk management audit risk management committee respective company established credit policy new customer analysed individually creditworthiness group standard payment delivery term condition offered group review includes external rating available publicly available financial information outstanding customer receivables regularly monitored shipment major customer generally covered letter credit form credit insurance group establishes allowance impairment represents estimate expected loss respect trade receivables maximum exposure credit risk reporting date primarily trade receivables amounting 8832 march 31 2016 7145 april 01 2015 6833 movement allowance impairment respect trade receivables year follows allowance credit loss march 31 2017 march 31 2016 opening balance 56 90 allowance credit loss recognised reversed 34 34 closing balance 90 56 single customer accounted 10 trade receivables march 31 2017 2016 significant concentration credit risk credit risk cash cash equivalent derivative limited group generally transacts bank financial institution high credit rating assigned international domestic credit rating agency investment primarily include investment liquid mutual fund unit bond nonconvertible debenture ii liquidity risk liquidity risk risk group encounter difficulty meeting obligation associated financial liability settled delivering cash another financial asset group approach managing liquidity ensure far possible sufficient liquidity meet liability due normal stressed condition without incurring unacceptable loss risking damage company reputation financial report 259 group belief working capital sufficient meet current requirement accordingly liquidity risk perceived addition group maintains following line credit syngene obtained long term secured buyer credit loan 611 usd 941 million march 31 2016 624 usd 941 million march 31 2017 carrying interest rate range libor 060 pa libor 080 pa repayable end 960 day 1079 day date origination b syngene obtained short term secured preshipment credit loan 324 usd 5 million march 31 2016 nil carry interest rate libor 142 pa repayable end 6 month date origination c syngene obtained short term unsecured preshipment credit loan 648 usd 10 million march 31 2016 nil carry interest rate libor 142 pa repayable end 6 month date origination cash credit facility bank carrying interest rate ranging 97 13 pa facility repayable demand secured paripassu charge inventory trade receivables e bpl obtained unsecured overdraft facility bank carrying interest rate 925 pa table provides detail regarding undiscounted contractual maturity significant financial liability march 31 2017 particular less 1 year 12 year 25 year 57 year total longterm borrowing 971 3418 15230 2434 22053 shortterm borrowing 972 972 trade payable 7397 7397 financial liability 2353 63 2416 total 11693 3481 15230 2434 32838 table provides detail regarding undiscounted contractual maturity significant financial liability march 31 2016 particular less 1 year 12 year 25 year 57 year total longterm borrowing 104 871 14773 5080 20828 shortterm borrowing 3949 3949 trade payable 6098 6098 financial liability 2003 194 2197 total 12154 1065 14773 5080 33072 table provides detail regarding undiscounted contractual maturity significant financial liability april 01 2015 particular less 1 year 12 year 25 year 57 year total longterm borrowing 866 1435 4692 1544 8537 shortterm borrowing 2610 2610 trade payable 4126 4126 financial liability 3680 178 3858 total 11282 1613 4692 1544 19131 iii market risk market risk risk fair value future cash flow financial instrument fluctuate change market price foreign exchange rate interest rate equity price foreign currency risk group operates internationally major portion business transacted several currency consequently group exposed foreign exchange risk operating borrowing activity foreign currency group hold derivative instrument foreign exchange forward option contract mitigate risk change exchange rate foreign currency exposure space intentionally left blank 260 ahead curve annual report 2017 biocon limited subsidiary currency profile financial asset financial liability march 31 2017 march 31 2016 march 31 2017 usd eur others total financial asset trade receivables 4098 299 279 4676 cash cash equivalent 4075 196 83 4354 financial asset 1051 23 276 1350 financial liability noncurrent borrowing 21054 21054 current borrowing 972 972 derivative liability 124 124 trade payable 1528 527 983 3038 financial liability 2069 221 53 2343 net financial asset liability 16523 230 398 17151 march 31 2016 usd eur others total financial asset trade receivables 4517 395 11 4923 cash cash equivalent 2996 306 60 3362 financial asset 1589 32 1621 financial liability noncurrent borrowing 20685 20685 current borrowing 3911 3911 derivative liability 236 236 trade payable 1733 393 414 2540 financial liability 616 8 18 642 net financial asset liability 18079 332 361 18108 sensitivity analysis sensitivity profit loss change exchange rate arises mainly foreign currency denominated financial instrument impact component equity arises foreign exchange forwardoption contract designated cash flow hedge particular impact profit loss impact component equity march 31 2017 march 31 2016 march 31 2017 march 31 2016 usd sensitivity inrusd increase 1 165 181 387 354 inrusd decrease 1 165 181 388 368 eur sensitivity inreur increase 1 2 3 2 3 inreur decrease 1 2 3 2 3 derivative financial instrument following table give detail respect outstanding foreign exchange forward option contract particular march 31 2017 march 31 2016 million foreign exchange forward contract buy usd 30 usd 34 inr 1946 inr 2722 european style option contract periodical maturity date usd 320 usd 386 inr 20703 inr 25581 european style option contract periodical maturity date usd 2 usd 8 conversion myr inr 97 inr 530 european style option contract periodical maturity date eur 6 eur 12 inr 434 inr 899 financial report 261 cash flow fair value interest rate risk company main interest rate risk arises longterm borrowing variable rate expose company cash flow interest rate risk year ended march 31 2017 march 31 2016 company borrowing variable rate mainly denominated usd interest rate risk exposure exposure company borrowing interest rate change end reporting period follows particular march 31 2017 march 31 2016 april 01 2015 variable rate borrowing 22989 24732 11098 fixed rate borrowing 36 45 49 total borrowing 23025 24777 11147 b sensitivity company policy maintain borrowing fixed rate using interest rate swap achieve necessary therefore subject interest rate risk defined ind 107 since neither carrying amount future cash flow fluctuate change market interest rate 39 capital management key objective group capital management ensure maintains stable capital structure focus total equity uphold investor creditor customer confidence ensure future development business group focused keeping strong total equity base ensure independence security well high financial flexibility potential future borrowing required without impacting risk profile group company goal continue able return excess liquidity shareholder continuing distribute annual dividend future period amount future dividend equity share balanced effort continue maintain adequate liquidity status capital structure march 31 2017 2016 follows particular march 31 2017 march 31 2016 total equity attributable owner company 48377 40338 percentage total capital 68 62 longterm borrowing 22053 20828 shortterm borrowing 972 3949 total borrowing 23025 24777 percentage total capital 32 38 total capital equity borrowing 71402 65115 40 firsttime adoption ind consolidated financial statement prepared accordance ind purpose transition previous gaap ind group followed guidance prescribed ind 101 first time adoption indian accounting standard ind 101 effect april 01 2015 transition date preparing ind balance sheet april 1 2015 presenting comparative information year ended march 31 2016 group adjusted amount reported previously financial statement prepared accordance previous gaap note explains transition previous gaap ind affected group balance sheet financial performance optional exemption availed mandatory exception preparing consolidated financial statement group applied mentioned optional exemption mandatory exception optional exemption availed 1 deemed cost joint venture per ind 101 changing proportionate consolidation method equity method entity may measure investment joint venture date transition aggregate carrying amount asset liability entity previously proportionately consolidated including goodwill arising acquisition resultant amount regarded deemed cost investment joint venture initial recognition group opted avail exemption 2 business combination ind 101 provides option apply ind 103 business combination prospectively transition date specific date prior transition date 262 ahead curve annual report 2017 biocon limited subsidiary group elected apply ind 103 prospectively business combination occurring transition date business combination occurring prior transition date restated 3 share based payment ind 102 sharebased payment applied equity instrument sharebased payment transaction vested april 1 2014 cashsettled sharebased payment transaction group applied ind 102 liability settled april 1 2014 mandatory exemption availed 1 estimate per ind 101 entity estimate accordance ind date transition ind shall consistent estimate made date accordance previous gaap unless objective evidence estimate error group estimate ind consistent requirement key estimate considered preparation financial statement required previous gaap listed fair valuation financial instrument carried fvtpl fvoci impairment financial asset based expected credit loss model determination discounted value financial instrument carried amortised cost 2 classification measurement financial asset ind 101 requires entity assess classification financial asset basis fact circumstance existing date transition standard permit measurement financial asset accounted amortised cost based fact circumstance existing date transition retrospective application impracticable accordingly group determined classification financial asset based fact circumstance exist date transition measurement financial asset accounted amortised cost done retrospectively except impracticable 3 hedge accounting hedge accounting applied prospectively transition date transaction satisfy hedge accounting criterion ind 109 financial instrument date transition hedging relationship cannot designated retrospectively supporting documentation cannot created retrospectively result hedging relationship satisfied hedge accounting criterion date transition reflected hedge consolidated financial statement ind space intentionally left blank financial report 263 b reconciliation following reconciliation provides effect transition ind previous gaap accordance ind 101 firsttime adoption ind previous gaap adjustment ind reconciliation equity april 01 2015 asset noncurrent asset property plant equipment 15807 175 15982 capital workinprogress 14938 644 15582 investment property 11 11 goodwill 264 264 intangible asset 228 228 intangible asset development 1828 110 1718 investment associate joint venture 384 384 financial asset derivative asset 1143 269 874 ii financial asset 303 110 193 incometax asset net 935 45 890 deferred tax asset net 142 178 320 noncurrent asset 2123 2123 total noncurrent asset 37711 858 38569 current asset inventory 4527 229 4756 financial asset investment 2303 175 2478 ii trade receivables 7705 872 6833 iii cash cash equivalent 4626 51 4575 iv bank balance 4749 120 4629 v derivative asset 561 211 350 vi financial asset 532 64 468 current asset 623 38 661 total current asset 25626 876 24750 total 63337 18 63319 equity liability equity equity share capital 1000 1000 equity 31706 84 31622 equity attributable owner company 32706 84 32622 noncontrolling interest 1722 601 1121 total equity 34428 685 33743 noncurrent liability financial liability borrowing 7696 25 7671 ii derivative liability 174 174 iii financial liability 6 6 provision 150 150 noncurrent liability 5510 91 5601 total noncurrent liability 13362 240 13602 current liability financial liability borrowing 2610 2610 ii trade payable 4293 167 4126 iii derivative liability 128 128 iv financial liability 4323 93 4416 provision 284 114 398 income tax liability net 298 311 609 current liability 3739 52 3687 total current liability 15547 427 15974 total 63337 18 63319 264 ahead curve annual report 2017 biocon limited subsidiary previous gaap adjustment ind ii reconciliation equity march 31 2016 asset noncurrent asset property plant equipment 16539 272 16811 capital workinprogress 19989 608 20597 investment property 9 9 goodwill 264 264 intangible asset 423 15 408 intangible asset development 1886 88 1798 investment associate joint venture 259 259 financial asset derivative asset 823 209 614 ii financial asset 340 82 258 incometax asset net 906 54 852 deferred tax asset net 379 336 715 noncurrent asset 2489 202 2287 total noncurrent asset 44038 834 44872 current asset inventory 5114 310 5424 financial asset investment 8705 42 8747 ii trade receivables 8229 1084 7145 iii cash cash equivalent 7944 331 7613 iv bank balance 7349 424 7773 v derivative asset 650 139 511 vi financial asset 1789 55 1844 current asset 652 652 total current asset 40432 723 39709 total 84470 111 84581 equity liability equity equity share capital 1000 1000 equity 39556 218 39338 equity attributable owner company 40556 218 40338 noncontrolling interest 3112 454 2658 total equity 43668 672 42996 noncurrent liability financial liability borrowing 20724 20724 ii derivative liability 191 191 iii financial liability 5 2 3 provision 299 299 noncurrent liability 3498 213 3711 total noncurrent liability 24526 402 24928 current liability financial liability borrowing 3949 3949 ii trade payable 6300 202 6098 iii derivative liability 143 143 iv financial liability 1881 83 1964 provision 270 104 374 income tax liability net 607 358 965 current liability 3269 105 3164 total current liability 16276 381 16657 total 84470 111 84581 financial report 265 previous gaap adjustment ind iii reconciliation statement profit loss year ended march 31 2016 income revenue operation 34854 1044 33810 income 845 53 792 total income 35699 1097 34602 expense cost raw material packing material consumed 12549 12549 purchase traded good 1070 310 760 increase decrease inventory finished good traded good workinprogress 318 87 405 excise duty 336 336 employee benefit expense 6363 262 6101 finance cost 102 191 293 depreciation amortisation net 2423 64 2487 expense 8310 199 8111 30499 267 30232 less recovery product development cost codevelopment partner net 1320 1320 total expense 29179 267 28912 profit tax share profit exceptional item 6520 830 5690 share net profit joint venture 217 217 profit tax exceptional item 6520 613 5907 exceptional item net 5754 4148 1606 profit tax 12274 4761 7513 tax expense current tax 2806 993 1813 less mat credit entitlement 166 166 deferred tax 71 154 225 total tax expense 2569 1147 1422 profit year 9705 3614 6091 comprehensive income item subsequently reclassified profit loss remeasurement gainslosses defined benefit plan 39 39 income tax effect 9 9 30 30 ii item may subsequently reclassified profit loss net movement cash flow hedge 21 21 income tax effect 5 5 26 26 total comprehensive income year net tax 56 56 total comprehensive income year 9705 3670 6035 iv reconciliation total equity note march 31 2016 april 01 2015 equity previous gaap attributable shareholder company 40556 32706 adjustment difference account revenue recognition net related cost 752 552 impact derivative accounting translation adjustment exchange gainloss ii viii 297 171 impact borrowing cost iii 152 consolidation esop trust x 475 526 adjustment iv 24 47 income tax adjustment correction earlier year vi 62 182 total adjustment 218 84 equity ind attributable shareholder company 40338 32622 266 ahead curve annual report 2017 biocon limited subsidiary v reconciliation net profit net profit reconciliation note year ended march 31 2016 net profit attributable owner company per previous gaap 8961 adjustment difference account revenue recognition net related cost 230 impact derivative accounting exchange gainloss ii 3 impact borrowing cost iii 152 adjustment iv 59 impact profit sale syngene share net tax v 3106 income tax impact adjustment correction earlier year vi 87 total adjustment b 3457 profit year c ab 5504 comprehensive income oci actuarial loss defined benefit obligation gratuity vii 30 effective portion cash flow hedge viii 26 noncontrolling interest ix 2 subtotal 58 total comprehensive income year c 5446 note reconciliation difference account revenue recognition net related cost primarily due difference timing revenue recognition ind compared previous gaap deferral licensing income account continuing obligation ii impact due derivative accounting per ind 109 exchange gain loss account change functional currency subsidiary iii impact account restructuring debt iv adjustment account employee benefit expense share based payment actuarial gainslosses mark market adjustment mutual fund v profit sale syngene share recognised credit equity impact group control vi income tax impact adjustment correction earlier year vii actuarial loss defined benefit obligation gratuity taken comprehensive income ind compared statement profit loss previous gaap viii effective portion cash flow hedge taken comprehensive income ix impact ind adjustment noncontrolling interest x group consolidated esop trust deconsolidated neobiocon fz llc pursuant ind 110 consolidated financial statement space intentionally left blank financial report 267 41 tax expense march 31 2017 march 31 2016 amount recognised statement profit loss current tax 2082 1813 mat credit entitlement 369 166 deferred tax expense income related origination reversal temporary difference 97 225 tax expense year 1616 1422 b reconciliation effective tax rate profit tax 8497 7513 less exceptional item net 1606 profit tax exceptional item 8497 5907 tax statutory income tax rate 3461 march 31 2016 3461 2941 2044 tax effect amount deductibletaxable calculating taxable income difference overseas tax rate 203 26 weighted deduction research development expenditure 520 432 exempt income deduction 1020 1086 nondeductible expense 123 82 tax loss 237 499 tax exceptional item 78 123 share profit joint venture 56 75 others 104 293 income tax expense 1616 1422 c tax loss unused tax loss deferred tax asset recognised 1809 2519 potential tax impact 350 647 expiry date financial year 202223 202223 202324 202324 tax loss never expire 166 space intentionally left blank 268 ahead curve annual report 2017 biocon limited subsidiary recognised deferred tax asset liability following movement deferred tax asset liability presented consolidated balance sheet year ended opening recognised recognised recognised closing march 31 2017 balance profit loss oci equity balance deferred tax liability property plant equipment investment property 686 1 685 intangible asset derivative asset 201 201 others 30 30 gross deferred tax liability 686 29 201 916 deferred tax asset defined benefit obligation 168 1 15 182 allowance doubtful debt 14 6 20 disallowable expense 145 24 169 deferred revenue 162 162 mat credit entitlement 702 369 1042 2113 derivative liability 91 29 62 tax loss 262 262 others 119 26 145 gross deferred tax asset 1401 495 47 1042 2891 715 466 248 1042 1975 year ended opening recognised recognised recognised closing march 31 2016 balance profit loss oci equity balance deferred tax liability property plant equipment investment property 692 6 686 intangible asset derivative asset 48 48 gross deferred tax liability 740 54 686 deferred tax asset defined benefit obligation 237 78 9 168 allowance doubtful debt 29 15 14 disallowable expense 80 65 145 deferred revenue 69 93 162 mat credit entitlement 536 166 702 derivative liability 96 5 91 tax loss others 109 10 119 gross deferred tax asset 1060 337 4 1401 320 391 4 715 space intentionally left blank financial report 269 42 interest entity subsidiary group subsidiary march 31 2017 set unless otherwise stated share capital consisting solely equity share held group proportion ownership interest held equal voting right held group country incorporation registration also principal place business name entity country ownership interest held ownership interest held principal activity incorporation group noncontrolling interest march march april 01 march march april 01 31 2017 31 2016 2015 31 2017 31 2016 2015 syngene international limited india 735 735 845 265 265 155 research service biocon research limited india 1000 1000 1000 research development biocon pharma limited india 1000 1000 1000 biopharmaceutical manufacturing biocon biologics india limited india 1000 nil nil biopharmaceutical manufacturing biocon academy india 1000 1000 1000 profit organisation biocon sa switzerland 1000 1000 1000 research development biocon sdn bhd malaysia 1000 1000 1000 biopharmaceutical manufacturing biocon biologics limited united 1000 1000 nil sale biosimilar product kingdom biocon pharma inc united state 1000 1000 nil sale pharmaceutical product biocon fz llc dubai 1000 1000 nil trading biopharmaceutical product b noncontrolling interest summarised financial information syngene international limited noncontrolling interest material group amount disclosed subsidiary intercompany elimination summarised balance sheet particular march 31 2017 march 31 2016 april 01 2015 noncurrent asset 12507 10208 8145 current asset 15231 13347 5535 total asset 27738 23555 13680 noncurrent liability 7614 7968 971 current liability 5993 5340 4752 total liability 13607 13308 5723 net asset 14131 10247 7957 accumulated noncontrolling interest 3761 2658 1121 summarised statement profit loss particular march 31 2017 march 31 2016 revenue operation 12009 11070 profit year 2873 2408 comprehensive income 848 6 total comprehensive income 3721 2414 total comprehensive income allocated noncontrolling interest 984 589 dividend paid noncontrolling interest 53 summarised statement cash flow particular march 31 2017 march 31 2016 cash flow used operating activity 3977 3081 cash flow used investing activity 4691 7512 cash flow used financing activity 808 7161 net increase decrease cash cash equivalent 1522 2730 270 ahead curve annual report 2017 biocon limited subsidiary c interest joint venture group one joint venture name neobiocon fz llc neobiocon incorporated dubai march 31 2017 holding 49 march 31 2016 51 equity stake accounted using equity method opinion director material group neobiocon share capital solely consisting equity share held directly ownership interest proportion voting right held summarised balance sheet neobiocon follows particular march 31 2017 march 31 2016 april 01 2015 noncurrent asset 14 20 7 current asset 1266 878 1032 total asset 1280 898 1039 noncurrent liability 34 25 16 current liability 299 235 204 total liability 333 260 220 net asset 947 638 819 percentage ownership interest 49 51 51 accumulated group share net asset 422 259 384 summarised statement profit loss neobiocon particular march 31 2017 march 31 2016 revenue operation 1250 1196 profit year 333 425 comprehensive income total comprehensive income 333 425 share profit joint venture 163 217 dividend received 342 space intentionally left blank financial report 271 43 segment reporting based management approach defined ind 108 chief operating decision maker codm evaluates group performance based analysis various performance indicator business segment geographic segment accordingly information presented along business segment geographic segment accounting principle used preparation financial statement consistently applied record revenue expenditure individual segment set significant accounting policy business segment group primarily enterprise small molecule smv biologics branded formulation bf research service research april 1 2016 march 31 2017 particular smv biologics bf research unallocated elimination total revenue external revenue 16330 5793 5489 11604 39216 intersegment revenue 75 1225 321 1621 total revenue 16405 7018 5489 11925 1621 39216 cost segment cost 11511 4641 3886 7849 27887 intersegment cost 321 1300 1621 result corporate expense 1534 1534 income including interest 707 864 1571 operating profit 11366 depreciation amortisation 752 659 3 1143 215 2772 finance cost 175 85 260 share profit joint venture 163 163 segment result 4142 1397 463 3465 970 8497 income tax current deferred 1616 1616 noncontrolling interest 760 760 profit tax 6121 information segment asset 16116 34111 2386 27738 80351 unallocable corporate asset 13591 13591 total asset 93942 segment liability 3548 8251 1650 13607 27056 unallocable corporate liability 14748 14748 noncontrolling interest 3761 3761 total liability 45565 space intentionally left blank 272 ahead curve annual report 2017 biocon limited subsidiary april 1 2015 march 31 2016 particular smv biologics bf research unallocated elimination total revenue external revenue 14546 4046 4409 10809 33810 intersegment revenue 37 1250 261 1548 total revenue 14583 5296 4409 11070 1548 33810 cost segment cost 11387 3654 2534 7266 24841 intersegment cost 261 1287 1548 result corporate expense 1303 1303 income including interest 63 741 804 operating profit 8470 depreciation amortisation 690 617 1 973 206 2487 finance cost 84 209 293 share profit joint venture 217 217 segment result 2506 764 804 2810 977 5907 exceptional item 1606 1606 income tax current deferred 1422 1422 noncontrolling interest 587 587 profit tax 5504 information segment asset 14831 28758 1698 23555 68842 unallocable corporate asset 15739 15739 total asset 84581 segment liability 2906 5527 601 13308 22342 unallocable corporate liability 19243 19243 noncontrolling interest 2658 2658 total liability 44243 geographical segment revenue net april 01 2016 april 01 2015 march 31 2017 march 31 2016 india 11799 11649 united state america 8997 9331 rest world 18420 12830 total 39216 33810 noncurrent asset march 31 2017 march 31 2016 india 26823 22808 malaysia 20031 18423 rest world 1889 2054 total 48743 43285 note noncurrent asset excludes financial instrument deferred tax significant client customer individually account 10 revenue year ended march 31 2017 march 31 2016 segment revenue result expense directly attributable allocated business segment reasonable basis shown unallocated corporate expense segment asset liability segment asset include operating asset used business segment consist principally fixed asset current asset segment liability comprise liability directly allocated respective segment asset liability allocated segment shown part unallocated corporate asset liability respectively financial report 273 44 additional information required schedule iii act enterprise consolidated subsidiaryassociatesjoint venture 274 name entity net asset share profit loss share comprehensive share total comprehensive march 31 2017 year ended income year ended income year ended march 31 2017 march 31 2017 march 31 2017 amount amount amount amount consolidated consolidated consolidated consolidated total net asset profit loss comprehensive comprehensive income income holding company biocon limited 71 65411 56 5193 8 85 51 5278 subsidiary indian syngene international limited 11 10370 23 2113 63 624 27 2737 biocon research limited 213 7 661 2 6 659 biocon pharma limited 131 4 3 27 31 biocon biologics india limited biocon academy foreign biocon sa 5 4436 7 684 7 684 ahead curve annual report 2017 biocon sdn bhd 4 3531 5 3 30 35 biocon biologics limited 5 4229 2 189 2 189 biocon pharma inc 8 1 98 1 98 biocon fz llc 15 21 21 joint venture foreign neobiocon fz llc 422 2 163 2 163 associate foreign iatrica inc usa noncontrolling interest 4 3761 8 760 23 224 10 984 gross total 100 92055 100 9275 100 988 100 10263 adjustment arising consolidation 39917 2394 2394 total 52138 6881 988 7869 44 additional information required schedule iii act enterprise consolidated subsidiaryassociatesjoint venture contd name entity net asset share profit loss share comprehensive share total comprehensive march 31 2016 year ended income year ended income year ended march 31 2016 march 31 2016 march 31 2016 amount amount amount amount consolidated consolidated consolidated consolidated total net asset profit loss comprehensive comprehensive income income holding company biocon limited 74 59966 46 3686 18 10 46 3676 subsidiary indian syngene international limited 9 7589 23 1821 7 4 23 1825 biocon research limited 1 873 10 832 4 2 10 830 biocon pharma limited 30 22 2 1 21 biocon biologics india limited biocon academy foreign biocon sa 5 3858 15 1228 15 1228 biocon sdn bhd 4 2756 4 332 91 51 5 383 biocon biologics limited 6 4513 1 71 1 71 biocon pharma inc 23 3 3 biocon fz llc 5 3 3 joint venture foreign neobiocon fz llc 259 2 217 3 217 associate foreign iatrica inc usa noncontrolling interest 3 2658 7 587 4 2 7 589 gross total 88 80784 100 8088 100 56 100 8032 adjustment arising consolidation 37788 1997 1997 total 42996 6091 56 6035 financial report 275 biocon limited subsidiary 45 note company entered transaction sale product private company year ended march 31 2013 2012 amounting 28 17 respectively required prior approval central government section 297 company act 1956 transaction entered prevailing market price approved board director company year ended march 31 2014 company filed application central government approval transaction compounding noncompliance pending central government march 31 2017 46 corporate social responsibility per section 135 company act 2013 company meeting applicability threshold need spend least 2 average net profit immediately preceding three financial year corporate social responsibility csr activity gross amount required spent company year 131 b amount spent year sl particular cash yet paid total cash construction acquisition asset ii purpose 131 131 47 event reporting period april 27 2017 board director company approved issue bonus share proportion 21 ie 2 two bonus equity share 5 every 1 one fully paidup equity share held record date subject approval shareholder company postal ballot b april 27 2017 board director company proposed final dividend 3 per equity share prebonus share basis proposed dividend subject approval shareholder annual general meeting per report even date attached b r co llp behalf board director biocon limited chartered accountant firm registration number 101248ww100022 sethuraman kiran mazumdarshaw arun chandavarkar partner managing director joint managing director ceo membership 203491 din 00347229 din 01596180 siddharth mittal rajiv balakrishnan president finance chief company secretary financial officer membership f6326 bengaluru bengaluru april 27 2017 april 27 2017 space intentionally left blank 276 ahead curve annual report 2017 forward looking statement biocon fy17 annual report annual report disclosed forwardlooking information enable investor comprehend prospect take informed investment decision report statement written oral periodically make contain forward looking statement set anticipated result based management plan assumption tried wherever possible identify statement using word anticipates estimate expects project intends plan belief word similar substance connection discussion future performance market data ranking used various chapter based several published report internal company assessment cannot guarantee forward looking statement realized although believe prudent assumption achievement result subject risk uncertainty even inaccurate assumption known unknown risk uncertainty materialize underlying assumption prove inaccurate actual result could vary materially anticipated estimated projected reader bear mind undertake obligation publicly update forwardlooking statement whether result new information future event otherwise conceptualized developed team corporate communication biocon seemaahujabioconcom trisys communication infotrisyscomcom biocon limited 20th km hosur road electronic city bangalore 560 100 india 91 80 2808 2808 e corporatecommunicationsbioconcom w wwwbioconcom